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Intracranial Hyper-and Hypotension
Jan Hoffmann
The Journal of Headache and Pain 2017, 18(Suppl 1):S1
Headache is one of the most prominent symptoms during a change
in intracranial pressure. As in these disorders headache is frequently
unspecific, highly variable in its clinical presentation and may occa-
sionally even mimic primary headaches including migraine, diagnosis
may in some cases be challenging.
The clinical syndrome of idiopathic intracranial hypertension results
from an increase in intracranial pressure without an identifiable
cause. Patients suffer from an unspecific headache, which in most
cases presents as a daily and bilateral headache without accompany-
ing symptoms. However, an aggravation upon physical exercise,
coughing and sneezing as well as nausea and photophobia may
occur. In addition to the headache patients commonly suffer from a
papilledema that leads to a progressive visual deficit which, if un-
treated, may results in a complete and irreversible visual loss. In
addition patients may suffer from cranial nerve palsies, cognitive
deficits, a pulsatile tinnitus and olfactory deficits adding to the sig-
nificant loss in quality of life. Given the severity and potential irrever-
sibility of these symptoms, a quick and accurate diagnosis as well as
an early initiation of treatment is mandatory. Treatment usually con-
sists of a combination of weight reduction and a pharmacological
treatment with carbonic anhydrase inhibitors such as acetazolamide
and topiramate. Invasive treatments should only be considered in ex-
ceptional therapy-resistant cases as long-term data regarding the
safety and long-term benefit of these procedures is scarce.
In contrast to a chronic elevation in intracranial pressure which may
be primary (idiopathic intracranial hypertension) or secondary, spon-
taneous intracranial hypotension is in almost all cases secondary to a
meningeal rupture with a resulting leak of cerebrospinal fluid. The
leaks are commonly localized in the cervicothoracic junction or along
the thoracic spine. The clinical picture is dominated by an orthostatic
headache which develops in temporal relation to a decrease in intra-
cranial pressure. However, the time course of the orthostatic aggra-
vation may vary substantially and with increasing disease duration
may even disappear completely. The pain is thought to result from a
slight downward displacement of the brain creating a painful traction
of the dura mater. In many cases treatment is not necessary as the
leak commonly heals within a few days or weeks causing a complete
remission of the symptoms. If the leak persists and treatment be-
comes necessary an epidural blood patch should be the first step. If
a spontaneous remission does not occur and repeated blood or fibrin© The Author(s). 2017 Open Access This article
International License (http://creativecommons.o
reproduction in any medium, provided you giv
the Creative Commons license, and indicate ifsealant patches do not lead to a complete remission a surgical inter-
vention may be considered.
S2
Emerging non CGRP drug targets
Messoud Ashina
The Journal of Headache and Pain 2017, 18(Suppl 1):S2
There is a huge unmet need for new specific acute and preventive
drugs in migraine. Development of therapies to treat migraine has pre-
viously been hampered by a lack of biomarkers and predictive animal
models. This situation has dramatically changed over the last couple of
decades, not least as a consequence of the increasing use of a human
migraine provocation model that demonstrates the importance of nat-
urally occurring signaling molecules in migraine. New highly specific
mechanisms have been discovered and because of this progress, new
drug targets are in different stages of clinical development.
S3
Emergency headaches
Luigi Titomanlio
The Journal of Headache and Pain 2017, 18(Suppl 1):S3
Headache is one of the most common reasons for consultation in
the pediatric emergency department (ED). Triage systems have been
developed and adapted to the pediatric population to differentiate
urgent from nonurgent patients, allowing appropriate and efficient
management.In children with certain brain disorders, headache can
be associated with focal neurologic signs or symptoms; these chil-
dren represent a true diagnostic challenge to physicians, owing to
the possibility of severe underlying disease. The differential diagnosis
in children with headache and focal neurologic signs includes pri-
mary etiologies, such as migraine with aura, and secondary etiolo-
gies, such as trauma, infection, and vascular, neoplastic, and epileptic
disorders. Achieving a diagnosis in children can be challenging at
times; important reasons for this include poor description of pain by
children and several childhood periodic syndromes that can be com-
mon precursors of migraine.
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Hypothalamic Regulation in Headache
Arne May (a.may@uke.de)
University Clinic of Hamburg, Dept. of Systems Neuroscience
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The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 2 of 151Migraine is a multiphasic disorder and understanding of its patho-
physiology starts with the acknowledgment that migraine is not sim-
ply a disease of intermittently occurring pain, but that it involves
processes that affect the brain over time. If one wants to interpret
the most recent findings in migraine pathophysiology it is important
to again discuss the clinical presentation of all phases of a migraine
attack. There are three clinical features of migraine which point to-
wards the limbic system and hypothalamus as attack generating
brain structures. The first one is that almost all symptoms of the pre-
monitory phase including yawning, tiredness and mood changes
already point towards hypothalamic involvement. Secondly, the circa-
dian rhythmicity of attacks and thirdly the association of attacks with
hormonal status and the menstrual cycle. The hypothalamus has vari-
ous neuroanatomical connections to pain modulating systems and
also to the spinal trigeminal nuclei. The orexinergic system, which is
known to regulate arousal and nociceptive processing as well as
thermoregulation and autonomic functions, has only recently be-
come a site of interest in migraine research. Another neurotransmit-
ter system involving the hypothalamus is the central dopaminergic
system. Recent neuroimaging studies in migraine patients undermine
hypothalamic involvement in the premonitory and acute pain phase
of migraine. Most recently one migraine patient went into the scan-
ner daily over a whole month which included 3 spontaneous un-
treated headache attacks. Increased hypothalamic activation was
seen in the prodromal phase (within the last 24 h before migraine
headache onset) as compared to the interictal state. More import-
antly, the pain-related hypothalamic functional connectivity between
the hypothalamus and the spinal trigeminal nuclei was significantly
increased during the preictal phase as compared to the interictal
phase. These data strongly suggest that the hypothalamus plays a
crucial role in generating premonitory symptoms but also the mi-
graine attack itself. Moreover, using a recently developed protocol
for high resolution brainstem imaging of standardized trigeminal
nociceptive stimulation, the anterior right hypothalamus (HT) was
significantly stronger activated in CM as compared to healthy con-
trols. These data corroborate a crucial role of the HT for migraine
chronification but also as for the sustainment of acute migraine pain.
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CGRP CNS models in headache
U. Reuter
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The Journal of Headache and Pain 2017, 18(Suppl 1):S5
Immunohistological studies show widespread distribution of CGRP
within the CNS, but the role and function of this neuropeptides in
the brain and spinal cord are largely unknown. There is also increas-
ing interest whether CGRP antagonists penetrate the blood brain
barrier and abort migraine headaches in part via central mechanisms.
As migraine is a CNS disorder a central abortive or preventative
mechanisms is suspected for several years. In this lecture, we will
evaluate the information derived from experimental CGRP studies
within the CNS. We will analyze the role of CGRP in central
sensitization as CGRP most likely facilitates nociceptive transmission.
The contribution of CGRP to vasodilation in the CNS will also bediscussed, and we look into imaging data of CGRP receptor antago-
nists in humans. Finally, we will illustrate the contribution of CGRP in
an animal model of photophobia.
S6
The classification of headache disorders has improved over the
years
Henrik Schytz
The Journal of Headache and Pain 2017, 18(Suppl 1):S6
The classification of headache disorders has improved over the years,
but further work is needed to develop and improve headache diag-
nosis within headache subtypes. The lecture presents laboratory tests
that might be useful in phenotyping and/or diagnosis of long-lasting
headache disorders such as migraine, tension-type headache, trigem-
inal autonomic cephalalgias, trigeminal neuralgia and persisting sec-
ondary headaches.
S7
CGRP PNS models in headache
A. Maassen van den Brink
Div. of Pharmacology, Dept. of Internal Medicine, Erasmus MC
Rotterdam, The Netherlands
The Journal of Headache and Pain 2017, 18(Suppl 1):S7
Calcitonin gene-related peptide (CGRP) is considered to be one of
the main molecules in the pathophysiology of migraine. Currently,
several drugs that target either the CGRP peptide or its receptor are
in clinical studies for the prophylactic as well as the acute treatment
of migraine. While CGRP is expressed abundantly in the central ner-
vous system, it also plays an important role in the peripheral nervous
system. Most antimigraine drugs that are currently in clinical devel-
opment and target CGRP or its receptor (for example, the monoclo-
nal antibodies) are not able to cross the blood brain barrier and thus
do not reach the central nervous system, highlighting the import-
ance of CGRP and its receptors at sites not protected by the blood
brain barrier. These sites include the trigeminal ganglion, but also
perivascular sensory afferents that may be involved in the patho-
physiology of migraine as well as in the development of potential
side effects. During the lecture, models and mechanisms important
for the understanding of the role of CGRP in the peripheral nervous
system will be discussed.
S8
Understanding the non-pain phases of migraine: premonitory and
postdromal
Peter J Goadsby
NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College
London, UK
The Journal of Headache and Pain 2017, 18(Suppl 1):S8
Migraine is the most common cause of neurological disability world-
wide [1]; it is a disorder of the brain with pan-sensory dysfunction
[2]. Migraine has, in essence, three phases, prior to the canonical at-
tack- the premonitory or prodromal phase, the attack itself, headache
with or without aura, and the period after canonical attack, the
postdrome.
The premonitory phase can occur from hours to days before the ca-
nonical attack. The symptoms include: neck discomfort, yawning,
tiredness, concentration impairment, mood change, polyuria/polydip-
sia, or food cravings [3]. The symptoms can be seen in children, as
they are in adults [4]. Moreover, there is evidence from functional im-
aging of activation in the region of the hypothalamus during the pre-
monitory phase [5].
The postdrome phase occurs after the headache phase of the canon-
ical attack is settling; it is typically settled in about half of patients in
six hours. The most common symptoms are: feeling tired/weary, con-
centration impairment and neck discomfort [6]. Remarkably there is
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 3 of 151widespread reduction in brain blood flow in the postdrome [7],
which reflects the phenotype well.
Understanding the non-pain phases of migraine will lead to be a bet-
ter formulation of the pathophysiology of migraine and eventually to
better treatment.
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The Eurolight Project 2017
Christian Lampl
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The Journal of Headache and Pain 2017, 18(Suppl 1):S9
The Eurolight project, supported by the EC European Agency for
Health and Consumers of the European Commission, was a data-
gathering exercise undertaken primarily to inform health policy on
headache disorders in the European Union (EU). This very large and
complex study involved multiple collaborating partners (academic
and lay) in ten countries, representing 60% of the adult population
of the EU. The project took the form of surveys by structured ques-
tionnaire, conducted from November 2008 to August 2009. Question-
naires were analysed from 8,271 participants (58% female, mean age
43.4 y). Unadjusted lifetime prevalence of any headache was 91.3%.
Gender-adjusted 1-year prevalences were 35.3% for migraine, 38.2%
for TTH and 7.2% for headache on ≥ 15 d/mo. Personal impact was
high, and included ictal symptom burden, interictal burden, cumula-
tive burden and impact on others (partners and children). Mean per-
person annual costs were €1,222 for migraine, €303 for tension-type
headache. We confirmed that depression and especially anxiety are
comorbid more than by chance with migraine. The level of this im-
pact and its pervasiveness taken together with estimates of huge fi-
nancial cost, have important implications for health policy in Europe.
Eurolight 2017 should proceed with focusing on cluster headache
and headache in the elderly.
S10
Multidisciplinary approach to head pain
Rigmor Hoejland Jensen
Danish Headache Center, Rigshospitalet-Glostrup, University of
Copenhagen, Denmark
The Journal of Headache and Pain 2017, 18(Suppl 1):S10
Background: Despite the very high prevalence of headaches, multi-
disciplinary headache clinics are still few and better documentation
of their content and efficacy is needed.Objective: To describe the structure of a multidisciplinary approach
and to characterize the patients and treatment results from existing
centres. Further to describe the proposed organization of headache
care in Europe.
The collaboration between European Headache Federation and Lift-
ing The Burden has proposed a three-tiered structure for Headache
Care in Europe. It is organised with the majority of patients (90%)
treated in primary care, the more complex migraine and tension-type
headache patients (7-8%) in secondary care with a headache special-
ist and a nurse whereas the most complex patients i.e. medication
overuse headache, comorbidity, chronicity or rare headache disor-
ders(2-3%) should be referred to a tertiary headache centre. At this
level headache specialists and a multidisciplinary team should con-
duct more complex treatment, initiate research and education. The
composition of the multidisciplinary team may vary, however and
here there is no international consensus. Most centres include nurses,
psychologists and in some countries also sports-therapists or
physiotherapists.
A systematic review of 1300 patients from the tertiary Danish Head-
ache Centre revealed that patients had a mean age of 43.7 years and
the male/female ratio was 3/7. In total, headache frequency was re-
duced from 20 to 11 days (p<0.001) and the absence rate 5 to 2
days/month (p<000.1) after treatment. Predictors for good outcome
was female gender, migraine, triptan overuse and a mean headache
frequency of 10 days/month. In recent years more evidence from
other centres has been provided and the positive outcome was con-
firmed, also in so called refractory patients.
Conclusion: Treatments strategies to the complicated headache pa-
tients need individualization but the present evidence provide hope
for the patients and a strong support for a multidisciplinary approach
in a tertiary headache centre. The existing treatment strategies will
be presented. Further discussion and evaluation of the elements and
the outcome predictors are important for future planning.
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GWAS studies in migraine
Arn M.J.M. van den Maagdenberg
Departments of Human Genetics & Neurology, Leiden University Medical
Center, Leiden, The Netherlands
The Journal of Headache and Pain 2017, 18(Suppl 1):S11
Migraine is a common debilitating brain disorder characterized by se-
vere headache attacks with various associated neurological symp-
toms. About one-third of migraine patients experience an aura
preceding the headache phase: hence migraine with and without
aura. Many migraine patients also suffer from comorbid neurological
disorders, such as epilepsy, depression and stroke. Migraine is a gen-
etic disease with both environmental and genetic factors determin-
ing the susceptibility to attacks. Recent technological advances in
genetic analysis, which allowed simultaneous testing of hundreds of
thousands of single nucleotide polymorphisms (SNPs) in tens of
thousands of migraine patients in genome-wide association studies
(GWAS), made it feasible to identify robust gene variants for the
common forms of migraine. Whereas GWAS performed in various mi-
graine subtypes yielded different top hits for the different subtypes,
additional analyses seem to point to a shared genetic underpinning
in migraine. Identified gene variants point towards various molecular
pathways, e.g. neuronal dysfunction, vascular integrity and function,
and pain signaling. GWAS data sets, to some extent, can also been
used to identify the type of brain cell involved in pathology. GWAS
also enable the identification of (shared) genetic factors for diseases
comorbid with migraine. Unlike gene mutations in monogenic mi-
graine subtypes, the effect size of gene variants in common migraine
is small, thus complicating direct translation to diagnostic tests,
pathogenetic mechanisms, and treatment targets. In fact, strategies
to properly address the biological role of these variants are still being
developed. Further technological advances in genetic research, com-
monly labelled by “next generation sequencing” (NGS), make it feas-
ible to identify gene variants/mutations at the DNA level at an
unprecedented scale. The coming years will show the true impact of
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 4 of 151these combined genetic approaches on the identification of genes,
pathological mechanisms, and diagnosis of patients in migraine.
S12
Diagnostic tests for assessing patients with neuropathic pain
A Truini
Department of Neurology and Psychiatry, University Sapienza, Rome,
Italy
The Journal of Headache and Pain 2017, 18(Suppl 1):S12
Research has devised various techniques for investigating nocicep-
tive and non-nociceptive somatosensory pathways in patients with
neuropathic pain. The most widely agreed tools in use today include
neurophysiological techniques and skin biopsy.
The standard neurophysiological techniques such as nerve conduc-
tion studies, trigeminal reflexes and somatosensory evoked potentials
are mediated by large non-nociceptive afferent fibres (Aβ-fibres), and
are widely used for assessing peripheral and central nervous system
diseases.
Laser Evoked Potentials (LEPs) are the easiest and most reliable
neurophysiological technique for assessing nociceptive pathway
function. Laser-generated radiant heat pulses selectively excite free
nerve endings in the superficial skin layers and activate Aδ and C
nociceptors and evoke scalp potentials. In diseases associated with
nociceptive-pathway damage, LEPs can be absent, reduced in ampli-
tude or delayed in latency.
Skin biopsy is a reliable and minimally invasive tool for investigation
of nociceptive fibres in human epidermis and dermis. Researchers
have used this technique for assessing epidermal nerve fibres quali-
tatively and quantitatively. Skin biopsy can be done at any site of the
body, with a disposable punch, using a sterile technique, and under
local anaesthesia. Many investigators have used skin biopsy to inves-
tigate epidermal nerve fibres in various peripheral nerve diseases,
such as diabetic neuropathy, infectious and inflammatory neuropa-
thies and neuropathies associated with systemic diseases. In all stud-
ies, epidermal nerve fibre density was significantly lower in patients
with neuropathy than in controls.
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Neuromodulation and Headache. Future perspectives
Massimo Leone (Massimo.Leone@istituto-besta.it)
Neuroalgology Department, Fondazione I.R.C.C.S. Istituto Neurologico
Carlo Besta, Milan, 20133, Italy
The Journal of Headache and Pain 2017, 18(Suppl 1):S13
Patients suffering from chronic headaches challange health care sys-
tems. They are estimated to affect 3% of general population and
carry a considerable disease burden. A proportion of chronic head-
ache patients does not properly respond to prophylactic treatments
or shows low tolerability profile and remains in need for alternative
therapeutic strategies and options.
The improved understanding of head pain pathophysiology has fo-
cused attention on the role of neural structures both at peripheral
and central nervous system level. Thus in the attempt to improve
chronic intractable neurovascular headache (migraine and cluster
headache) patients a number of neuromodulation procedures target-
ing peripheral and central nervous system structures have been
tried.
So far, efficacy and safety of various non-invasive and invasive stimu-
lation procedures and devices have been investigated. Vagus nerve
stimulation, supraorbital stimulation and single-pulse transcranial
magnetic stimulation are considered non invasive neurostimulation
options. While invasive procedures are occipital nerve stimulation,
sphenopalatine ganglion stimulation and hypothalamic deep brain
stimulation. Years after their introduction there is still debate about
their use and place in clinical practice.
Results from open label series and few controlled trials suggest the
need of further investigations.Criteria employed to define intractable headaches were given more
than ten years ago (1). An ad hoc European Headache Federation ex-
pert board has reviewed these aspects (2). A still unsolved issue is
the lack of adequate placebo to properly design randomized con-
trolled trials in neurostimulation studies. In patients with chronic pain
conditions interpretation of placebo effect is a challange particularly
for headache specialists.In chronic migraine and chronic cluster
headache patients occurrence of psychiatric comorbidities is fre-
quently encountered. Also, occurrence of medication overuse head-
ache – seen as an addiction behavior - is frequently observed both
in chronic migraine and chronic cluster headache. The role of psy-
chosocial factors driving drug overuse/addiction behavior in chronic
headaches is undisputable. These factors are often a barrier when
selecting patients for neurostimulation procedures.
Long term experience with deep brain stimulation of the posterior
hypothalamic area in chronic cluster headache has suggested that
the generator of the attacks is not there (3). Similarly other neurosti-
mulation procedures tried in migraine and cluster headache have
shown poor, unsatisfactory ability to stop ongoing attacks. These ob-
servations suggest either that these stimulation procedures are not
able to switch off the attack generator or that there are multiple mi-
graine/cluster pain generators.
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What we should in the future
T.J. Nurmikko
The Walton Centre NHS Foundation trust
The Journal of Headache and Pain 2017, 18(Suppl 1):S14
An underlying concept in the new ICHD-3 classification of trigeminal
neuralgia is the postulation that clinical presentations matter because
they reflect distinct pathophysiological mechanisms. Previous at-
tempts to establish the connection between the two have yielded
uncertain results as the authors have paid limited attention to indi-
vidual clinical symptoms and signs. Yet, the relatively strict criteria
for trigeminal neuralgia and its subgroups yield homogenous popula-
tions that allow advantage to be taken of the advances in neuro-
physiological and imaging methods. It is now possible to conduct
subgroup-specific pathophysiological studies aimed at biomarkers
that pave the way for precision diagnosis of TN and individualised
therapy. An example of how this might be done comes from recent
studies based on sensory profiling of peripheral neuropathic pain. In
a large group of patients with three different diagnoses, cluster ana-
lysis of detailed sensory testing revealed three main sensory pheno-
types [1], with the potential to allocate individual patients to these
sensory groups [2]. For TN, a stratification based on the new classifi-
cation and linked to patients’ symptoms, somatosensory profiles, and
neurophysiological and neuroimaging data provides a unique oppor-
tunity to explore clinical questions that are even more ambitious
than those for other neuropathic pains. In my presentation I will sug-
gest a pathway as to how to accomplish this. I will start by arguing
that the existing data are sufficient to recommend preferred treat-
ment in selected cases. I will then highlight a number of clinically
relevant research questions that can be answered by large-
population multi-centre studies applying established methods ran-
ging from QST and evoked potentials to structural and functional
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 5 of 151neuroimaging of the trigeminal system and linking them with clinical
signs and symptoms. Alongside this, I will discuss the challenges of
phenotype profiling that could guide pharmacotherapy with, e.g.,
Nav 1.7 channel blockers or identifying genes that could make a sub-
ject susceptible to the development of TN.
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Posttraumatic headache in children and adolescents
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Headache is a common problem in children and adolescents with a
prevalence of about 60%. Head injuries are also relatively common
with an estimated incidence of 3/1000 children per year with 80-90%
of cases are considered as minor injuries (Glasgow Coma Score 13-
15). Mild head injury is associated with good recovery in most pa-
tients, but with a small risk of poor outcomes. Headache is the most
common complication that occurs as an isolated symptom or can be
a part of the post-concussion syndrome which can also include dizzi-
ness, fatigue, reduced ability to concentrate, psychomotor slowing,
mild memory problems, insomnia, anxiety, personality changes and
irritability Following head injuries, children may develop headache
for the first time or have their previously experienced headache get-
ting worse in severity or frequency. Post head injury headache is re-
ferred to as acute posttraumatic headache if it evolves within one
week of the injury and resolves within 3 months and it is called
chronic posttraumatic headache (CPTH) if it persisted for over 3
months.
Systematic review of the occurrence of headache after head injury
shows that up to 40% of children complain of any type of headache
following head injury and around 7% have CPTH as defined by the
ICHD-2 and 3beta.
The pathophysiology of posttraumatic headache is not well under-
stood, but likely to involve several mechanisms and factors. It is sug-
gested that even minor head injury may cause a widespread
stretching or shearing injuries to the axonal network. Psychosocial
factors may also play a role in the pathogenesis of CPTH.
The clinical features of CPTH are similar to primary headache disor-
ders phenotypes with the majority of children presenting with
migraine-like headache and probable tension-type headache. Some
children may have mixed or unclassified headache disorders. In the
majority of children no investigations are necessary. However, neuro-
imaging and other investigations may be necessary in children with
red flags or abnormal findings on neurological examination.
The management of children with CPTH should include reassurances,
adequate pain relief and preventative treatment as appropriate.
Multidisciplinary approach is necessary and should include support
from clinical psychology and education to help the child achieve nor-
mal school attendance and education.
The prognosis of CPTH is generally good, but long term data are
needed.
S16
Contraception in Women with Seizure Disorder
György Bártfai
Department of Gynaecology and Obstetrics, University of Szeged
The Journal of Headache and Pain 2017, 18(Suppl 1):S16One third of women with epilepsy (WWE) are in reproductive age,
and nearly 50% of their pregnancy are unplanned because of using
an inappropriate method or failure of combined oral hormonal con-
traceptives (COCs). The interaction between enzyme inductive anti-
epileptics (EiAED) like carbamazepine, phenytoin, primidone,
phenobarbitone, rufinamide, lamotrigine, topiramate and COCs is
well-known. Therefore, while taking this medication, the risk of
contraceptive failure is quite high.
The mechanism of action of enzyme-inductors is to modify the me-
tabolism of the sexual steroids in the liver. Moreover, ethinylestradiol
(EE) might modify the metabolism of certain antiepileptic drugs (glu-
curonization of lamotrigine). Therefore, the gynaecologist has to be
careful when prescribing the pill or administering other types of hor-
monal contraceptives for WWE.
Knowing the interaction between antiepileptics and contraceptives is
important to find the most effective medication with fewer side ef-
fects. The consequence of interaction between EiAED and COC as
well as EE and AED (lamotrigine) may be: a) unwanted pregnancy; b)
teratogenicity; negative effect on the cognitive and psychomotor
functions of the child; and/or c) changes in seizure activity.
Nowadays, women with epilepsy do not always get the right infor-
mation; thus, it is necessary to improve the cooperation and consult-
ation between the epileptologist and the gynaecologist. The first
meeting with the epileptologist or gynaecologist is equally important
in choosing the right antiepileptic drugs and/or contraceptive
method. The information is also needed even if the patient is sexu-
ally inactive.
S17
CSD evolution in 2017
H. Bolay
The Journal of Headache and Pain 2017, 18(Suppl 1):S17
Migraine is a complex neuronal disorder where the cortex has a key
importance and characteristic headache attack is associated with
multiple sensorial disturbances. A cerebral cortical phenomenon
known as cortical spreading depression (CSD) was linked to latera-
lized headache. CSD is an intrinsic brain phenomenon to a noxious
stimulus such as high potassium or trauma, and manifests as an ex-
treme excitability state of the gray matter with massive
depolarization of neuronal and glial membranes and redistribution of
ions. Initial depolarization is replaced by a long-term depression in
the neuronal activity which traverses whole hemisphere in case of lis-
sencephalic brain with a rate at 3–6 mm/min. Propagating
depolarization in the brain parenchyma leads to a release of various
vasoactive and nociceptive ions and molecules. Vascular compart-
ment reacts with initial hyperemia followed by long-term oligemia. It
occurs in many species from rodents to primates, though it is hard
to initiate and sustain its propagation in gyrencephalic brains.
Spreading depression wave involves neuronal, glial and vascular cells,
and leads remarkable effects on those compartments and overlying
meningeal membranes with capability of triggering peripheral tri-
geminal fibers and second order trigeminal neurons in the brainstem
nucleus, though its effect on subcortical structures are less known.
CSD is implicated in the development of inflammatory response and
releasing CGRP and nitric oxide from trigeminal nerve endings.
Animal studies investigating the mechanisms of migraine and CSD
are usually conducted under anesthesia, despite the fact that pain is
a conscious experience. Anesthesia have profound effects on the
mechanisms by which CSD is initiated and propagated, and clearly
prevents observation of any associated behavioral response. There-
fore CSD studies in awake animals are crucial for translational mi-
graine research. CSD in freely moving lissencephalic animals, led to
reduced locomotor activity, freezing & grooming episodes and pain
calls (Akcali et al, 2010).
Cerebral cortex and thalamus are inseparable in sensory processing
and thalamic reticular nucleus (TRN) is the gatekeeper of sensory out-
flow to the cortex. CSD was shown to activate thalamic reticular
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cographic recordings demonstrated the direct propagation of CSD
waves in to thalamic reticular nucleus. Activation of TRN was unilat-
eral and ipsilateral to CSD and TNC. It was dependent on full con-
scious experience and highly vulnerable to anesthetics. CSD
selectively activated visual sector of TRN, though other six TRN sec-
tors of auditory, gustatory, visceral, somatosensoriyal, motor and lim-
bic TRN were not affected by CSD. CGRP receptor antagonist MK-
8825, reversed CSD induced freezing, grooming, wet dog shake be-
havior, reductions in von Frey thresholds and c-fos induction in TNC
and TRN. However, MK-8825 did not block CSD waves and accom-
panied rCBF response (Filiz et al, 2017). MK-8825 did not exert any ef-
fect on CSD induced amygdala activation and anxiety behavior.
TRN is also involved in discrimination of sensory stimulus and transi-
ent disruption of sensorial perception during migraine headache
attacks was reported (Boran et al, 2016). Disruption of temporal dis-
crimination of two consecutive sensorial stimuli seems specific to mi-
graine headache attacks (Vurallı et al, 2016, Vurallı et al, 2017).
Involvement of a strategic subcortical thalamic structure by a cortical
event is important to explain several clinical features of migraine
such as 1) Dysfunction of the GABAergic neurons in TRN would result
in enhanced transmission of sensory information to the cortex and
disruption of sensory discrimination 2) Photophobia and visual hallu-
cinations of aura may reflect dysregulation of visual stimuli by the
TRN, 3) TRN could play a role in either termination or initiation of an
attack as sleep is closely related with migraine, attacks are often as-
sociated with the circadian cycle and are typically relieved by sleep,
4) Thalamo-cortical gating could be a novel target in migraine as val-
proate, triptans and CGRP antagonists MK-8825 suppressed CSD in-
duced TRN activation.
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In this discussion, we will review the differential diagnosis of Trigemi-
nal Neuralgia (TN) vis-à-vis other facial pains that may mimic TN’s fea-
tures. Common misdiagnoses for TN include dental pathology, other
regional neuralgias, short-lasting neuralgiform headaches with auto-
nomic signs (SUNHA), cluster headache and theoretically an atypical
(shorter) cluster-tic syndrome (CTS). More rarely there may be more
sinister underlying disorders (tumors, multiple sclerosis) that induce
TN-like syndromes. We will outline and highlight the salient features
across disorders that will ensure correct diagnosis.
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Trigeminal neuralgia (TN) is a neurological disease which is peculiar
under several respects. The diagnosis of TN, in its typical presenta-
tion, in unmistakable on clinical grounds alone. Pain manifests with
intense bursts that occur and end abruptly and usually last few sec-
onds only. This type of pain is paradigmatic of what pain scholars call
paroxysmal pain. The most common verbal descriptors are electric-
shock like or stabbing. Unique to TN is the trigger mechanism. The
attacks are evoked by innocuous stimuli in tiny zones of the extra- or
intraoral trigeminal territories. The most frequent trigger maneuvers
include activities of the daily life such as washing, cleaning, brushing
the teeth or talking. Although the trigger zones shared by most pa-
tients are confined between the nostril and the lateral perioral re-
gion, any area innervated by the trigeminal nerve may do.
One aspect of pathophysiology is supported by established neuro-
physiologic, neuroimaging, and histologic evidence: the primary
mechanism is focal demyelination of primary afferents near the entry(extra- or intra-axial) of the trigeminal root into the pons. A second
pathophysiologic theory, admittedly more debatable, is that hyperex-
citable primary afferents, in the area of focal demyelination, become
a source of ectopic generation of impulses and ephaptic transmission
(cross talk) from close, healthy nerve fibers. More supported by evi-
dence from animal models is the generation of high-frequency dis-
charges. A third potential step, with so far almost no sound evidence
at all, is that the hyperactivity of primary afferents secondarily in-
duces central sensitization of wide dynamic range neurons in the
spinal trigeminal nucleus or even more central changes.
Finally, TN is unique also for its pharmacological and surgical treat-
ment. TN is highly sensitive to voltage-gated, frequency-dependent
sodium-channels blockers (and almost nothing else), and is the
neuropathic pain condition that respond best to surgical lesions of
the postganglionic primary sensory afferents.
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The HUNT Studies
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The Nord-Trøndelag Health study (HUNT), ongoing in Norway since
1984, is one of the worlds’ largest longitudinal epidemiological stud-
ies collecting comprehensive data on headache disorders. The
speaker will present an overview of the methodological potentials
and challenges of the HUNT survey. Results will be displayed regard-
ing prevalences of the common headache disorders and their trends
over time.
Most importantly, the HUNT-survey enables risk factor analyses. Find-
ings will be reviewed for factors of life such as physical activity, sub-
stance use, head traumas, insomnia, and mortality. Also, associations
between headache and women’s issues such as contraceptives, hor-
mone replacement, pregnancy, and menarche have been studied
and will be discussed. Finally, associations between intracranial ab-
normalities and headache disorders are now beginning to be pub-
lished from a neuroimaging sub-study (HUNT MRI).
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Spreading depression (SD) is a wave of simultaneous and near-
complete depolarization of virtually all cells in brain tissue associated
with a transient “depression” of all spontaneous or evoked electrical
activity in the brain. SD is widely accepted as the pathophysiological
event underlying migraine aura, and may play a role in headache
pathogenesis in secondary headache disorders such as ischemic
stroke, subarachnoid or intracerebral hemorrhage, traumatic brain in-
jury, and epilepsy. Here, we provide an overview of the pathogenic
mechanisms and propose plausible hypotheses on the involvement
of SD in primary and secondary headache disorders. SD can activate
downstream trigeminovascular nociceptive pathways to explain the
cephalgia in migraine, and possibly in secondary headache disorders
as well. In healthy, well-nourished tissue (such as migraine), the in-
tense transmembrane ionic shifts, the cell swelling, and the meta-
bolic and hemodynamic responses associated with SD do not cause
tissue injury; however, when SD occurs in metabolically compro-
mised tissue (e.g. in ischemic stroke, intracranial hemorrhage, or trau-
matic brain injury), it can lead to irreversible depolarization, injury
and neuronal death. Recent non-invasive technologies to detect SDs
in human brain injury may aid in the investigation of SD in headache
disorders in which invasive recordings are not possible. SD explains
migraine aura and progression of neurological deficits associated
with other neurological disorders. Studying the nature of SD in head-
ache disorders might provide pathophysiological insights for disease
and lead to targeted therapies in the era of precision medicine.
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The proportion of adult patients reporting non-traumatic headache
as their major complaint at ER access ranges from 0.5 to 4.5%.The
main objective is to identify the patients who require urgent investi-
gations besause of a suspected serious secondary cause. Serious con-
ditions are disclosed in 5-10% of the cases; the remaining patients
have benign secondary headaches, or more frequently, primary
headaches.
The crucial step in the diagnosis is the initial interview. Most patients
presenting with headache as the chief complaint have a primary
headache disorder, such as migraine or tension-type headache, the
diagnosis of which relies on strict diagnostic criteria in the absence
of any objective marker. Secondary headache disorders manifest as
new-onset headaches that arise in close temporal association with
the underlying cause.Secondary headache should be suspected in
any patient without a history of primary headache who reports a
new onset headache and in any patient with a new unusual head-
ache that is clearly distinct from their usual primary headache
attacks. Since many serious disorders, such as subarachnoid haemor-
rhage, can present with isolated headache and a normal clinical
examination, diagnosis is reliant on clinical investigation.
Subarachnoid hemorrhage should be suspected in anyone with a
sudden or a thunderclap headache. Diagnosis is based on plain brain
computed tomography and, if tomogram is normal, on lumbar punc-
ture. Reversible cerebral vasoconstriction syndrome should be sus-
pected in anyone with recurrent thunderclap headaches over a few
days. Cervical artery dissection, cerebral venous thrombosis, revers-
ible cerebral vasoconstriction syndrome and pituitary apoplexy may
present with isolated headache and normal physical examination,
normal cerebral computed tomography and normal cerebrospinal
fluid. When computed tomography and lumbar puncture are normal,
other investigations are needed, including cervical and cerebral vas-
cular imaging and brain magnetic resonance imaging.
Treatment of headaches in the ER should be based on the etiology.
A severe migraine attack can be treated by SC sumatriptan, intraven-
ous non-steroidal anti-inflammatory drugs and/or dopamine antago-
nists. The treatment of secondary headaches requires the treatment
of the underlying cause and a symptomatic treatment based on
intravenous acetaminophen or on opiates depending on the pain
intensity.
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Progestin-only contraception and beneficial effects on migraine
Gabriele S. Merki-Feld
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In women migraine prevalence peaks during reproductive years.
Menstruation is a significant risk factor for migraine with attacks
most likely to occur between 2 days before the onset of menstru-
ation and the first three days of bleeding. The pathophysiology of
menstrual attacks involves estrogen withdrawal and potentially ab-
normal release of prostaglandins triggered by the end-cycle drop in
estrogen level. Reproductive year are the life span during which
many women require effective contraception.
Migraine with aura (MA) and to a lesser extent migraine without aura
(MO) increase the risk for cardiovascular events, especially for stroke.
There is a substantial elevation of these risks in migraineurs using
combined contraceptive pills (COC). In additon it has been shown
that COC can initiate migraine, worsen the course of migraine and in-
duce a change from MO to MA. Several clinical trials report improve-
ments in migraine frequency and intensity in users of the progestin-
only pill (POP) with desogestrel 75microgram. Both, inhibition of
ovulation and ist continous use contribute to reduce hormone flucu-
tations during ist use. In contrast to COC, POP are not associatedwith an increased risk for stroke. The positive impact of this pill has
been shown in MA and MO patients. In women with chronic mi-
graine, the reduction in pain medications used contributes to pre-
vent medication overuse headaches.
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Chapter 13 sets out a classification system for painful lesions of the
cranial nerves and other facial pains based on a consensus between
the International Headache Society (IHS) and the International Associ-
ation for the Study of Pain (IASP).
The existing nosology of cranial-nerve pains does not fully portray
the subtle differences between various conditions. However, rather
than abandoning many long-established diagnostic terms, this classi-
fication retains them, providing detailed definitions for differential
diagnoses and their types, subtypes and subforms.
There are several axes of classification: a) syndomology (neuralgia vs.
neuropathy), b) location (central vs. peripheral neuropathic pain) and
c) aethiology (classical, idiopathic or secondary).
The authors of the classification tried to incorporate the existing lit-
erature into the IHS classification system.
The current version defines the trigeminal neuralgia and trigeminal
neuropathy. Trigeminal neuralgia is subdivided into classical (due to
nerve-vascular compression, not purely a nerve vascular contact),
idiopathic (unknown cause or nerve vascular contact, because the
value of a nerve vascualr contact is unclear) and secondary (due to
other disease). Base don the clinical presentation it is further charac-
terised as TN with and without concomitant facial pain indicating
pure response to treatment.
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Headache following the trauma or so called post-traumatic headache
is on of if not the most common secondary headache disorder,
reaching approximately 4 % of all secondary headaches. According
to the International Classification of Headache Disorders, 3rd edition
(beta version) headache attributed to trauma or injury to the head
and/or neck is divided into acute and persistent headache for each
separate trauma mechanism – injury to the head, whiplash or crani-
otomy (performed for reasons other than traumatic head injury) [1].
The cut-line for distinguishing between an acute and persistent
headache is defined to be 3 months: resolution of headache within
this period complies with an acute, persistence for the longer time –
with a persistent headache. Headache attributed to the injury to the
head is further subclassified based on the severity of preceding
trauma. Probably one of the most debated diagnostic criterions of
this chapter is the time of onset of headache after a traumatic event.
For the main classification it is agreed that causative relation be-
tween trauma and development of headache should be within 7
days after the trauma. However based on a data derived from reports
of everyday clinical practice alternative criteria published under the
Appendix allow the delayed onset of headache, reaching up to 30
days following the injury. Clinical phenotypes of post-traumatic head-
ache are varying from mild tension-type-like to severe migrainous.
Pathophysiological mechanisms of post-traumatic headaches remain
largely unclear as a reason to the epidemiological data suggesting,
that mild injury to the head represents a greater risk of developing
persistent headache. The latter one causes a considerable reduction
of health related quality of life and frequently is challenging in terms
of treatment, requiring pharmacological (preventative medications)
and non-pharmacological (cognitive behavioural treatment, physical
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interventional procedures, usage of onabotulinum toxin A and neuro-
stimulation have been reported to be potentially effective.
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Within person variation in headache days in persons with migraine
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Objective
To determine persistence of and transitions between episodic mi-
graine (EM) and chronic migraine (CM) and to describe and model
the natural variability of self-reported frequency of headache days
Background
Relatively little is known about the stability of headache days per
month in persons with EM or CM over time. Within person variability
in headache day frequency has implications for the diagnosis of CM,
assessing treatment in clinical practice and for the design and inter-
pretation of clinical trials.
Methods
The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study is
a longitudinal survey of a systematic sample of US adults with EM
and CM identified by a web-questionnaire. A validated questionnaire
was used to classify respondents with EM (<15 headache days/
month) or CM (≥15 headache days/month) every 3 months for a total
of 5 assessments. We modelled longitudinal transitions between EM
and CM and, separately, headache day frequency per month using
negative binomial repeated measures regression models (NBRMR).
The NBRMR was parameterized using polynomial mixed effects to
better account for cyclic variation.
Results
Among the 5,464 respondents with EM at baseline providing 4 or 5
waves of data, 5,048 (92.4%) had EM in all waves and 416 (7.6%) had
CM in at least one wave. Among 526 respondents with CM at base-
line providing 4 or 5 waves of data, 140 had CM in every wave
(26.6%) and 386 (73.4%) had EM for at least one wave. Individual
plots revealed striking within-person variations in headache days per
month. The polynomial mixed effect NBRMR model revealed that the
rate of headache days increased across waves of observation 19%
more per wave for CM compared to EM (rate ratio [RR], 1.19; 95% CI,
1.13 – 1.26). The inclusion of a comprehensive covariate pool in the
fully adjusted model increased this difference to a 26% increase per
wave (RR, 1.26; 95% CI, 1.2 – 1.33).
Conclusions
Follow-up at 3 month intervals reveals a high level of short-term vari-
ability in headache days per month. As a consequence many individ-
uals cross the arbitrary CM diagnostic boundary of ≥15 headache
days per month over the course of one year. Nearly three forths of
persons with CM at baseline drop below this diagnostic boundary at
least once over the course of a year. These findings my influence
case definitions of migraine subtypes, the design and interpretation
of epidemiologic studies and clinical trials as well as the interpret-
ation of change in headache days in clinical practice.
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Impairment of brain solute clearance through the recently described
glymphatic system has been linked with traumatic brain injury, sleep
deprivation, and aging. This lecture will summarize new data show-
ing that cortical spreading depression (CSD), the neural correlate of
migraine aura, closes the paravascular space and impairs glymphatic
flow. This closure holds the potential to define a novel mechanism
for regulation of glymphatic flow. It also implicates the glymphaticsystem in altered cortical and endothelial functioning of the migraine
brain, which can explain the increased risk of stroke among migraine
aura patients.
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Many patients report that their need to avoid light is driven mainly
by how unpleasant it makes them feel. This lecture will attempt to
explain why is light unpleasant. The data presented will show that
during migraine, light can trigger the perception of (a) hypothalamic-
mediated autonomic responses such as chest tightness, throat tight-
ness, shortness of breath, fast breathing, faster than usual heart rate,
light-headedness, dizziness, nausea, vomiting, dry mouth, salivation,
rhinorrhea, stuffy sinuses and lacrimation; (b) hypothalamic mediated
non-autonomic responses such as thirst, hunger drowsiness, tired-
ness, sleepiness, fatigue, and yawning; (c) negative emotions such as
intense, irritable, angry, nervous, hopeless, needy, agitated, sad,
scared, cranky, upset, depressed, disappointed, jittery, worried,
stressed, anxious, panic and fear; and (d) positive emotions such as
happy, relaxing, soothing, and calming. The data presented will also
show that retinal axons converge on dopaminergic/noradrenergic,
histaminergic, orexinergic, MCHergic, oxytocinergic and vasopressi-
nergic hypothalamic neurons that regulate autonomic functions and
emotions. By defining better the aversive nature of light, the findings
suggest that the retina and hypothalamus play a critical role in
migraine-type photophobia and that photophobia may not depend
on hyperexcitable visual cortex, as traditionally thought.
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The Gymphatic System
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We have recently described a macroscopic pathway in the central
nervous system – the glymphatic system that facilitates the clearance
of interstitial waste products from neuronal metabolism. Glymphatic
clearance of macromolecules is driven by cerebrospinal fluid (CSF)
that flows in along para-arterial spaces and through the brain paren-
chyma via support from astroglial aquaporin-4 water channels. The
glymphatic circulation constitutes a complete anatomical pathway;
para-arterial CSF exchanges with the interstitial fluid, solutes collect
along para-venous spaces, then drain into the vessels of the lymph-
atic system for ultimate excretion from the kidney or degradation in
the liver. As such, this may after circulation represent a novel and un-
explored target for prevention and treatment of neurodegenerative
diseases.
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Population (adults 18-70 years old) in Greece. A quantitative study,
using the form of computer-assisted telephone interviews (C.A.T.I.)
was designed. A draft questionnaire consisting of 37 questions was
delivered in 145 headache sufferers in a pre-study work to evaluate
the diagnosis of the primary headache disorder according to ICH-
3beta diagnostic criteria. After the analysis of this questionnaire the
specific 37-item questionnaire was decided. In total, N=10,008 inter-
views, representative of the population of Greece in terms of gender,
age, and area, based on the most recent census (ELSTAT, 2011) were
performed using the structured evaluated questionnaire. Based on
the above contacts, n=1,197 respondents (12% of the sample) were
found to suffer from headaches that reduce their performance. The
one-year prevalence of Migraine that reduces activity was 8.2%
(n=0.6m population) of Tension-Type Headache (TTH) 3.8% (n=0.28m
of population) and of Cluster Headache 0.01% (n=0.74K of popula-
tion). Chronic migraine one-year prevalence was 1% (n=0.7K of popu-
lation). Females tend to suffer more from migraines and TTH as well
as ages 35-54. The average patients has been suffering from head-
aches for 12 years. Headaches typically occur once a month or more
frequently, 8 days per month on average. Although patients rarely
misss work due to headaches, they do report headache-induced re-
ductions in performance around 3 days per month. Slighly less than
half patients have felt bad/ humiliated because of headaches, while
social/family obligations are affected 3 days per month on average.
About one fifth of patients seek professional treatment for head-
aches, most of them in the private sector. The most popular specialty
for headache treatment is neurologist, followed by internist. Regard-
ing both prophylactic and acute treatment, patients prefer oral medi-
cation to injection, even if the former is administered more
frequently. They also prefer oral medication/ injection to a stimula-
tion device. The stimulation device seems to be more attractive to
males. Painkillers also are by far the most common acute treatment
for headaches and the vast majority of patients have never taken
prophylaxis for headaches. Only a small fraction have stopped taking
a prophylactic treatment due to adverse effects. Interstingly, patients
would be willing to spend 20€ on average per month for headache
treatment, on average.
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Calcitonin gene-related peptide (CGRP), a neuropeptide previously
known only by specialists interested in neurogenic inflammation, is
now discussed throughout the communities of migraine researchers,
headache therapists and even migraine patients. The reason for this
surprising career of CGRP awareness is evident. CGRP is the main
neuropeptide of a major part of nociceptive trigeminal afferents and
is released upon their activation. Thus CGRP release is characteristic,
though in no way specific, for the trigeminovascular system, which is
regarded as the structural basis for headache generation. In fact,
CGRP has been found at elevated concentrations in the cranial out-
flow during attacks of migraine and some trigemino-autonomic
headaches; infusion of CGRP into patients suffering from primary
headaches can cause head pain mimicking their spontaneous head-
ache attacks; inhibiting CGRP or its receptors or its release can be
preventive or therapeutic in those types of primary headaches. How-
ever, looking behind the curtain of impressive significance of this
biomarker, broad gaps in our knowledge are visible concerning the
sites of CGRP release, its flow through the meningeal compartments,
the sites and mechanisms of actions and its elimination. With preclin-
ical experiments we are only at the beginning to study these issues,
which are increasingly important in the light of new pharmacological
developments targeting CGRP and its receptors by antagonists or
monoclonal antibodies, and keeping in mind possible risks of a long-term treatment with these substances. Trigeminal activity controlled
by CGRP receptor activation could indeed be a pivot point in head-
ache generation and therapy. However, measurable circulating con-
centrations of CGRP are far too low to explain any receptor effects,
while it is difficult to assess its real concentrations near the likely re-
lease sites, namely the meningeal terminals of trigeminal afferents,
the trigeminal ganglion and the central terminals in the trigemino-
cervical brainstem complex. The central effects of CGRP as a synaptic
neuromodulator could explain neuronal CGRP effects to some extent
but big molecules like monoclonal antibodies are unlikely to pass the
blood-brain barrier and may not be able to act there. Peripheral ef-
fects of CGRP are largely confined to its well-known vascular func-
tions, while fast neuronal effects are not established so far in the
trigeminal system. The trigeminal ganglion is a possible point of
CGRP action but only few experiments have shown an impact on the
signalling or metabolic changes of ganglion neurons. Therefore new
experimental approaches are needed to uncover the secrets of the
nociceptive CGRP signalling system and its therapeutic control.
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Medical management of headache disorders, for the vast majority of
people affected by them, can and should be carried out in primary
care. It does not require specialist skills. Nonetheless, it is recognised
that non-specialists throughout Europe may have received limited
training in the diagnosis and treatment of headache.
This publication, in the Journal of Headache and Pain, provides a
combination of educational materials and practical management
aids. It is a product of the Global Campaign against Headache, a
programme of action for the benefit of people with headache con-
ducted by the UK-registered non-governmental organization Lifting
The Burden (LTB) in official relations with the World Health
Organization. It updates the first edition [1], published 10 years ago.
The content has been put together by a writing group of experts
convened by Lifting The Burden in collaboration with the European
Headache Federation (EHF). It has undergone review by a wider con-
sultation group of headache experts, including representatives of the
member national societies of EHF, primary-care physicians from eight
countries of Europe, and lay advocates from the European Headache
Alliance. While the focus is Europe, the inclusion in the consultation
group of members from all six world regions has aimed for cross-
cultural relevance of all content so that it is useful to a much wider
population.
The European principles of management of headache disorders in pri-
mary care, laid out in 11 sections, are the core of the content. Each
of these is more-or-less stand-alone, in order to act as practical
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additional practical management aids. An abbreviated version of the
International Classification of Headache Disorders, 3rd edition (ICHD-
3), provides diagnostic criteria for the few headache disorders rele-
vant to primary care. A headache diary further assists diagnosis and
a headache calendar assists follow-up. A measure of headache im-
pact (the HALT-90 index) can be employed in pre-treatment assess-
ment of illness severity, and an outcome measure (the HURT
questionnaire) is a guide to follow-up and need for treatment-review.
Five patient information leaflets are included, which may be offered
to patients to improve their understanding of their headache disor-
ders and their management.
LTB and EHF offer these aids freely available for use without restric-
tion. We hope for benefits for both physicians and patients.
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Several data indicate that migraine, especially migraine with aura, is
associated with an increased risk of ischemic stroke and other vascu-
lar events. Of concern is whether the risk of ischemic stroke in
migraineurs is magnified by the use of hormonal contraceptives
(HCs). As migraine prevalence is high in women of reproductive age,
it is common to face the issue of migraine and HC use in clinical
practice.
To improve decision-making on the use of HCs in women with mi-
graine, a selected group of representatives from the European Head-
ache Federation (EHF) and the European Society of Contraception
and Reproductive Health (ESC) developed a Consensus Statement on
this topic. The document pointed out that evidence addressing the
risk of ischemic stroke associated with the use of HCs is generally
poor. All information relies on observational data, which may carry
the risk of potential bias. Available studies had different settings and
used different groups for comparing risks, limiting reliable compari-
son of studies as a pooled analysis of data. Most of the available
studies were published several years ago and used compounds
which are different from those available today. Additionally, in most
studies not enough information is available regarding the type of HC
considered and in most cases results are not provided according to
migraine type. Despite those limitations, available data pointed to-
ward an increased risk of ischemic stroke associated with the use of
HCs in women with migraine. Literature indicated that, whereas com-
bined HCs carry a certain risk of arterial ischemic events this does
not happen for progestogens-only HCs which are considered safe in
terms of cardiovascular risk even in the presence of associated risk
factors. Considering those data, and unless studies will prove safety
of the use of combined HCs in women with migraine, the recom-
mendations from the Consensus Group gave priority to safety and
suggested several limitations in the use of combined HCs in women
with migraine. There are alternative methods to combined HCs
which provide similar contraceptive benefits but that are much safer
in terms of risks. Further research is need to address safety of newer
compounds in women with migraine.
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Neuropathic pain is pain caused by a lesion or disease of the som-
atosensory nervous system. The term lesion is refers to nervous sys-
tem damage demonstrated by imaging, neurophysiology, biopsies or
surgical evidence. The term disease is used when the nervous system
damage is due to a neurological disorder such as stroke or peripheral
diabetes neuropathy. In peripheral neuropathic pain there is usually
a mixture of damaged and undamaged axons within the peripheral
nerve, leading to the clinical presentation with ongoing pain, sensory
loss and sensory gain (hyperalgesia, allodynia). The clinical presenta-
tion in central neuropathic pain is similar, but the mechanisms are
less well understood. Mechanisms of peripheral neuropathic pain in-
clude ectopic impulse generation, peripheral sensitization of undam-
aged nerve fibers, and central sensitization; the latter includes
altered signal processing in the CNS due to changes in descending
pain modulation. Neuropathic pain is included in the upcoming ICD-
11 coding system, but not in the currently used classifications ICD-10
and ICD-9. For this reason the exact prevalence of neuropathic pain
is not yet known, but is expected to be high due to the high preva-
lence of the underlying neurological disorders.
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A range of clinical neurophysiological and functional imaging studies
have suggested that migraine might be associated with cerebellar
dysfunction. These studies all had methodological short-comings to a
greater or lesser extent. Therefore, it is still uncertain whether mi-
graine is associated with cerebellar dysfunction, and, if so, to what
extent and why. Is this presumed cerebellar dysfunction due to the
increased prevalence of cerebellar ischemic lesions in migraine pa-
tients or is there a more functional explanation similar to what’s seen
in familial hemiplegic migraine type 1 (FHM1)? Recent anatomical
studies demonstrated that the output of the cerebellum targets mul-
tiple non-motor areas in the prefrontal and posterior parietal cortex.
Neuro-anatomy and functions of the cerebellum will be reviewed as
well as the evidence of cerebellar infarcts in migraineurs. In detail re-
sults of the population-based CAMERA II (Cerebral Abnormalities in
Migraine, an Epidemiological Risk Analysis Cohort) study specific on
cerebellar ischemia and cerebellar function will be discussed.
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During the last decades, the methods of neurophysiology proved to
be very effective in disclosing subtle functional abnormalities of the
brain of patients affected by primary headache disorders. These
methods received several refinements during the last years, further
improving our understanding of headaches pathophysiology. Abnor-
mal increased responsivity was several times revealed with almost all
the sensory modalities of stimulation in migraine between attacks,
with its normalization during the attacks. Recently, authors observed
that the degree of some neurophysiological abnormalities might de-
pends on the distance from the last attack, i.e. on the point where
the patient is recorded during the migraine cycle. Thalamic/thalamo-
cortical drives were found to be less active interictally, but normally
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terhemispheric inhibition were altered in migraine, and may contrib-
ute to cortical hyperresponsivity and clinical features.
Cluster headache patients are characterized by a deficient habitu-
ation of the brainstem blink reflex during the bout, outside of at-
tacks, on the affected side. Evidence for sensitization of pain
processing was disclosed by studying temporal summation threshold
of the nociceptive withdrawal reflex, which was less modulated by
supraspinal descending inhibitory controls.
In conclusion, much has been discovered and much more needs to
be investigated to better understand what causes, how it triggers,
keeps and runs out recurrent primary headaches. Clarifying some of
these mechanisms might help in the identification of new thera-
peutic targets.
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In this rejoinder to “Photophobia and Hypothalamus”, I will speculate
on how the diverse collection of neuropeptides, including CGRP, in
the hypothalamus might increase sensitivity to light. Within the
brain, neuropeptides can modulate the strength of synaptic signaling
even at a relatively large distance from their site of release. Given
the evidence for CGRP in migraine and potential roles for other
hypothalamic peptides, it seems likely that altered neuropeptide ac-
tions may be a general theme underlying the heightened sensory
state of migraine. Towards this point, I will briefly discuss our preclin-
ical CGRP and optogenetic studies using light aversive behavior in
mouse models as a surrogate for migraine-associated photophobia. I
will describe how both the brain and the periphery are susceptible
to elevated CGRP and how CGRP appears to act by distinct mecha-
nisms in these sites. In the CNS, we have identified the posterior thal-
amus as a likely site of CGRP action, which is in agreement with
Burstein’s evidence that this region is a convergent relay point from
the retina and dura. These ideas will be tied together in a speculative
model that integrates peripheral and central CGRP actions in
photophobia.
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Background
Classical trigeminal neuralgia (TN) is a unique neuropathic facial pain
disorder. As there are no diagnostic tests to confirm the diagnosis, it
relies on a thorough history and exam. MRI is used to exclude symp-
tomatic trigeminal neuralgia, not to confirm the diagnosis of TN.
Knowing how to interpret MRI findings is of importance with respect
to surgical treatment options and their expected chance of a suc-
cessful outcome.
Results
TN is characterized by paroxysms of unilateral intense pain usually in
the 2nd and 3rd trigeminal branch. The pain quality is stabbing and
the pain is typically evoked by sensory stimuli like light touch, brush-
ing teeth, cold wind or eating. Up to half of the patients also have
concomitant persistent pain. A smaller proportion of patients may
have sporadic autonomic symptoms. The average age of disease on-
set is in the early fifties and TN is slightly more prevalent in women
than in men.
As a general rule, the neurological exam is normal in TN patients. As
objective signs of TN, patients may wince at pain paroxysms and
may avoid shaving or brushing their teeth on the affected side. Some
studies argue that a proportion of TN patients have subtle sensory
abnormalities at bedside exam, primarily hypoesthesia. Studies using
quantitative sensory testing also documented sensory changes in TN.Rather than indicating nerve damage, the findings may be explained
by functional changes of the nervous system in response to severe
pain.
There is widespread consensus that TN is associated to a neurovascu-
lar contact between the trigeminal nerve and a blood vessel in the
prepontine course of the nerve. Emerging advanced imaging studies
confirms that at the site of a neurovascular contact on the ipsilateral
side of pain, there is of demyelination – a process that seems to be
reversible in some patients after successful surgery. Imaging studies
also consistently show that TN is strongly associated to a neurovas-
cular contact with morphological changes of the trigeminal nerve, i.e.
dislocation, distortion or atrophy of the trigeminal nerve. Meanwhile,
only half of TN patients have morphological changes of the trigemi-
nal nerve and there may be other unknown etiological factors caus-
ing TN.
Conclusions
The talk discusses the clinical features and the clinical and MRI find-
ings of TN. The pearls and pitfalls of TN diagnosis and neuroimaging
is discussed from both a clinical and a scientific perspective.
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Background
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a mem-
ber of the vasoactive intestinal polypeptide (VIP)/secretin/growth
hormone-releasing hormone/glucagon neuropeptide superfamily,
widely expressed in vertebrate tissues [1]. The first evidence for po-
tential role of PACAP in pathomechanism of migraine was the intra-
venous administration of PACAP-38 caused headache and
vasodilatation in healthy subjects as well as in migraineurs, and lead
to delayed-type migraine-like attacks [2]
Materials and methods
A systematic literature search was conducted to identify preclinical
and clinical publications in the field of PACAP and migraine in the
database of MEDLINE/PubMed up to 31 May 2017.
Results
Preclinical experiments revealed that both PACAP-27 and PACAP-38
were found elevated in the trigeminal nucleus caudalis of rats follow-
ing electrical stimulation of the trigeminal ganglion or chemical
stimulation by nitroglycerin of the trigeminovascular system [3]. A
magnetic resonance imaging (MRI) angiographic study demonstrated
that PACAP-38-induced headache was associated with prolonged
dilatation of the middle meningeal arteries, but not of the middle
cerebral arteries in healthy volunteers [4]. Another MRI trial con-
cluded that PACAP-38-induced vasodilatation was longer lasting
compared to VIP in migraineurs [5]. The recent functional imaging
study pointed that intravenous PACAP-38-induced migraine attacks
was associated with alterations in brain network connectivity [6]
Clinical investigation provided evidence of a clear association be-
tween migraine phases (during a spontaneous migraine attack versus
pain-free period) and the alteration of plasma PACAP-38 level [7].
Conclusions
The activation and sensitization of the trigeminovascular system by
vasoactive neuropeptides might be crucial factors of the migraine
pathogenesis [8]. The recent preclinical and clinical studies suggest
the importance of PACAP as a future biomarker of migraine
headache.
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Several studies are found a relationship between headache and psy-
chiatric comorbidity in both children and adolescents [1-3]. The most
frequently described comorbidities include anxiety, mood disorders
[1], sleep disorder [2] and attention hyperactive disorder [3]. The as-
sociation between headache and comorbidities has been interpreted
in the light of different possible causal pathways. Psychiatric comor-
bidity may represent the consequence of a link between neurotrans-
mitter systems involved in migraine and psychiatric disorder, such as
depression and anxiety [4]. A central role is thought to be played by
serotonergic receptors, adrenergic and dopaminergic D2 receptor
genotype, that seem to be associated with migraine, major depres-
sion, generalized anxiety disorder, panic attacks and phobia [5]. It
has been suggested that the patient's vulnerability to anxiety disor-
ders and affective disorders as well as migraine might be attributed
to the dysregulation of the serotonergic system [6]. Furthermore, it is
possible that each disorder increases the risk of the other [4;7]. Twin
studies have shown that the genetic liability related to migraine
amounts to 40-60%, while the contribution of non-shared environ-
mental factors has to be weighed in a range between 35 and 55%
[8]. Therefore, the relevance of other mediating factors for the co-
occurrence of headache and psychiatric comorbidity has to be taken
into consideration. Recent research found that an insecure attach-
ment may be a risk factor for an outcome of poor adaptation that in-
cludes chronic pain [9] and that pain perception may change in
relation with specific attachment styles.
The ambivalent attachment seems to be the most common style
among patients reporting high attack frequency and severe pain in-
tensity and in children with this attachment style there is a relation-
ship between high attack frequency and high anxiety levels [10].
Barone et al. [11] showed that higher is the attachment security,lower is the association between maternal stress and children’s be-
havioural problems in children and adolescents with headache. Al-
though more studies are needed in order to detect the biological,
genetic and environmental mechanisms underlying the relationship
between headache and comorbidities, attachment styles can be
regarded as one of the factors mediating this association [12].
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Background. Metabolic syndrome and overweight are highly preva-
lent among migraineurs and the weight-loss was suggested as a
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Among different approaches to achieve a rapid weight loss, in the
last years the very low-calorie diets (VLCDs), characterized by a dra-
matic caloric restriction (<800 Kcal/day), are gaining large dietician
approval. Recently, we have observed that a particular version of
VLCD characterized by very low-carbohydrate intake and Ketone
bodies (KBs) production, named very low-calorie ketogenic diet
(VLCKD), was able to induce a rapid improvement of headache in
migraineurs. To assess if the favorable outcome on migraine was due
to the caloric restriction, instead of KBs, we performed a double blind
crossover study to compare headache modifications during a VLCD
and a VLCKD in a population of overweighed and obese migraineurs.
Methods. Among patients referred to the Sapienza University Obes-
ity Clinic, a neurologist specializing in headache recruited 35 migrai-
neurs. After one month of headache diary recording, they started a
4-month weight-loss program characterized by the alternation of two
VLCD protocols named “red” and “blue”; one of them was a VLCKD,
the other a non-ketogenic VLCD. Randomly patients started with one
of the two diets according to the following scheme: first VLCD, transi-
tion diet (progressive increase of calorie, up to 1200 Kcal/day), the
other VLCD, and the second transition diet (Fig. 1). To verify varia-
tions in headache frequency, we used as baseline the month before
the first VLCD and the first transition diet.
Results. Out 35 enrolled patients, six dropped at the first month of
diet: all followed the “blue” diet; 29 completed the study. The pri-
mary endpoint was the responder rate (number of patients with a
headache frequency reduction ≤50%): 26 of 29 patients (74.28% of
intention to treat (ITT) patients) responded to the “red diet”, only 2
(5.7% of ITT patients) responded to the “blue diet”. When the blind
was broken, we found out that the “red diet” was the ketogenic diet
and the “blue diet” was the non-ketogenic.
Conclusions. Our results are suggestive for an outstanding protective
effect of VLCKD in migraineurs. This positive outcome could be due
to the KBs GABAergic, anti-inflammatory, and energetic properties.
The 17% of dropout rate is in line with other similar studies and it is
interesting to highlight that all the patients that drops did it during
the first month of non-ketogenic VLCKD.Fig. 1 (abstract S41). See text for descriptionS42
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Headaches are one of the most disabling disorders [1]. The 3rd edi-
tion of the International Classification of Headache Disorders (ICHD-
III) describes the diagnostic criteria of primary, secondary and other
headache disorder types. Interestingly, Migraine and Cervicogenic
Headache (CGH) , Tension Type Headache (TTH), Headache attributed
to temporo-mandibular disorder (TMD), Headache attributed to cer-
vical myofascial pain and Occipital Neuralgia share similarities in
some criteria and clinical presentation. Moreover, Neck Pain associ-
ated disorders (NAD) and Temporo-Mandibular Disorders (TMD) are a
very common presentation in primary headache population asMigraine and Tension Type Headache [2, 3]. Moreover, recent know-
ledge have suggested that physical examination for provocative pro-
cedures should be done on each patient with side- locked
headaches as many of these headaches may closely mimic primary
headaches [4]. There have been identified eleven physical tests to
properly assess cervical disorders. When these dysfunctions are
present, they support a reciprocal interaction between the trigeminal
and the cervical systems as a trait symptom in migraine [6, 7]. The
ICHD-III also does recommend the use of diagnostic criteria evolved
by the International RDC/TMD Consortium Network and Orofacial
Pain Special Interest Group to assess disorder involving structures in
the temporomandibular region contributing to primary headache [8,
9]. In this presentation, an evidence based physical protocol of spe-
cific tests it will be provided by a physiotherapist to assess musculo-
skeletal disorders in the most common primary headaches as
Migraine and Tension Type Headache. Moreover, the integration of
this examination in a multidisciplinary team it will be discussed.
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Headache represents the most common neurological symptom in
pediatric age. Among the primary headaches, migraine is far
more prevalent than tension-type headache and cluster head-
ache. Though extremely rare at this age, also trigeminal auto-
nomic cephalgias have been reported. The most frequent causes
of pediatric secondary headaches are represented by respiratory
tract infections, while potentially life-threatening diseases, such as
brain tumors, are less common. However, especially in the emer-
gency setting, the possibility that a headache attack is due to a
brain tumor must be always considered. To avoid missing these
cases, some headache characteristics (red flags) have been identi-
fied [1]. In pediatric age, as in adulthood, the diagnosis of
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Headache Disorders III-beta version (ICHD-IIIb). However, while
the most recent ICHD criteria improved the possibility to classify
some patients, such as children with migraine with aura [2], they
turned out to be unsuitable for others, such as young patients
with primary headache. In particular, we have showed that more
than 50% of children up to 6 years of age have a headache dur-
ation shorter than 30 minutes, thus they could not be classified
either in migraine or in tension-type headache [3]. Several studies
have shown the primary role played by psychological factors in
determining the severity of migraine in children [4]. Therefore, a
psychological examination is often mandatory, as part of the ini-
tial assessment of the patient. Lastly, when assessing a child with
primary headache, possible comorbidities should be never forgot-
ten, since addressing them can represent a crucial point for the
treatment [5].
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Whether medication-overuse headache (MOH) represents a dis-
tinct biological entity within the concept of chronic daily head-
ache with specific neurobiological and genetic background is still
a matter of debate. A great deal of interest has been directed at
understanding the neurophysiological mechanisms that underlie
MOH pathogenesis. Currently, two main, non-mutually exclusive
hypotheses have been proposed. The first, stems from the appar-
ent compulsive use of headache medications by MOH patients,
and considers this disorder a sort of addiction to symptomatic
remedies. The second shifts the focus from drug addiction to
neural sensitization, claiming that triptan overuse triggers adapta-
tions of the trigeminovascular system, thereby facilitating pain
transmission and leading to a state of latent sensitization. How-
ever, whether the effects of triptans are shared by all symptom-
atic headache medications as a sort of signature of the complex
neurophysiologic rearrangements occurring in MOH is still un-
known, as well as the extent of neurotransmitter/neuromodulators
involved. Answering these questions might be relevant to better
understand the neurochemical mechanisms prompted by acute
headache medications that underlie the pathophysiology of MOH
and of chronic headache in general.In this presentation, preclinical data will be presented showing that
chronic exposure to eletriptan or indomethacin alter trigeminal gan-
glion gene expression patterns broadly and to a similar extend. Re-
markably, qualitative transcriptomic analysis reveals that prolonged
exposure to the two different symptomatic drugs triggers almost
identical, increased expression of various genes coding for proteins
involved in headache pathogenesis such as neuropeptides, their cog-
nate receptors, TRP channels, prostanoid and NO synthesizing en-
zymes. These findings will be correlated with the clinical aspects of
MOH.
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Background
The very low calorie diet (VLCD) is a dietetic regimen character-
ized by a daily energetic intake < 800 Kcal/day, also called “simu-
lated fasting”. The dramatic caloric restriction promotes the fat
metabolism, mimicking the starvation, even if meals replacements
ad hoc developed accounts for essential nutrients, avoiding the
malnutrition. Because of the extreme caloric restriction, this type
of diet is very effective in weight loss, however, that characteris-
tic also is the main limit of VLCD, since it is possible to follow
this kind of dietetic regimen for a very limited period (usually 3-
12 weeks).
Materials and methods
According to macronutrients intake, it is possible to divide all the
VLCDs in two sub-groups: ketogenic (VLCKD) and non-ketogenic
diets. The VLCKD is characterized by low-carbohydrate (about 30
g/day carbohydrates), low-fat (fixed 15 g lipids), and slightly high-
protein (1.0–1.4 g/kg of ideal body weight), divided in four daily
meals consisting of dietary products developed ad hoc and nutra-
ceutical integrators (Table 1). Salads are allowed ad libitum
dressed with a spoonful of olive oil. The non-ketogenic VLCD is
characterized by a slightly limited carbohydrate intake (≅100 g/
day carbohydrates), low-fat (≅10 g lipids), and normal-protein
(≅0.8 g/kg of ideal body weight). Also in this kind of diet, there
are 4-5 meals per day, mainly consisting in meal replacement
products. Both in VLCD and VLCKD lipids are usually provided by
olive oil or omega-3.
Results
There is a growing interest in the ketogenic form of the VLCD be-
cause several studies have shown a higher compliance of patients
with this diet. The reason of this higher adherence to the diet is still
under scrutiny but several reasons are called in cause: an appetite
suppression induced by proteins and (maybe) by ketone bodies
(KBs), or a modification in hormone secretion (insulin, glucagon,
ghrelin, adipokines).
Conclusion
The real impact of ketogenic diets in weight loss is still disputed;
in fact, on the long period there are not differences between
low-carb and low-fat diets in terms of weight reduction and re-
gain of lost weight after the diet. However, thanks to the higher
compliance and the drastic caloric restriction, the VLCKDs seem
to be a promising approach in the early management of obesity
and in the preparation phase for patients that must undergo to
bariatric or other types of surgical procedures.
Table 1 (abstract S45). See text for description
Daily dose RDA
Vit A 800 mcg 100% RDA
Vit B1 1.4 mg 100% RDA
Vit B2 1.6 mg 100% RDA
Vit B3 18 mg 100% RDA
Vit B5 6 mg 100% RDA
Vit B6 2 mg 100% RDA
Vit B8 150 mcg 100% RDA
Vit B9 200 mcg 100% RDA
Vit B12 1 mcg 100% RDA
Vit C 60 mg 100% RDA
Vit D 5 mcg 100% RDA
Vit E 10 mg 100% RDA
Ca 800 mg 100% RDA
Cr 7.5 mcg 15% RDA
Cu 0.6 mg 50% RDA
Mg 90 mg 30% RDA
Mn 1.75 mg RDA 1-10 mg
Zn 7.5 mg 50% RDA
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 15 of 151S46
Headache and temporomandibular disorders: association or
causality? The bio-psychosocial model applied to the clinical
reasoning
Marco Testa
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics,
Maternal and Child Health, University of Genova – Campus of Savona,
17100 Savona - Italy
The Journal of Headache and Pain 2017, 18(Suppl 1):S46
Temporomandibular disorders (TMD) represent the main cause of
orofacial pain of non-dental origin and comprehend several distur-
bances of the masticatory system characterized by myofascial pain of
masticatory muscles or articular pain localized in the pre-auricular
area. Moreover, TMD patients show temporomandibular joint sounds
and deviation or limitation of the opening of the mouth.
Myofascial pain is a probable consequence of central nervous system
mechanisms of convergence and activation of second order neurons
with enlargement of the receptive field, reduced pain threshold and
allodinia. Often there are accompanying symptoms like facial pain
and headaches.
Headache is the most prevalent neurologic disorder, third most dif-
fused health disturbance and the seventh cause of disability in the
world. It can be primary, without apparent organic cause, or second-
ary to other pathologies.
Some epidemiological studies indicates that headache is more preva-
lent in TMD patients and TMD is more prevalent in subjects affected
by headache. A stronger association exists between TMD and chronic
migraine in comparison with other types of headache. Myofascial
TMD is more frequently associated to headache than articular TMD.
Nevertheless the methodological quality of the available studies is
not optimal and many of them classify patients with anamnestic
questionnaire that tend to overestimate the values of prevalence.
A growing body of literature suggests that the association between
headache and TMD may be a manifestation of a central sensitization
mechanism. Temporomandibular joint and muscles receive the sensi-
tive innervation of the trigeminal nerve that supply also the cranial
vascular structures likely involved in the etiology of the headache.
The sensitization of the trigeminal caudate nucleus by the TMD
symptoms can favor the triggering of migraine episode.Beside the epidemiological studies and the neurophysiologic hypoth-
esis, there are some initial clinical evidence that show how severity
of TMD symptoms parallels an increase of frequency and intensity of
migraine and the simultaneous treatment of both conditions results
in better outcomes.
From a clinical perspective, a comprehensive assessment based on a
biopsychosocial approach can provide relevant information to plan a
contemporaneous treatment of TMD and headache, together with an
intervention targeted to the reduction of psychosocial conditions
that can elicit and maintain mechanisms of central sensitization likely
responsible of the comorbidity of TMD and headache.
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Tension-type headache (TTH) is the most common headache, with a
lifetime prevalence ranging between 30% and 78% in the general
population, and with a high socio-economic impact [1].
The exact pathophysiology is still unknown, but evidence supporting
both peripheral and central mechanisms (i.e. central sensitization) is
increasing [2,3].
In fact, the frequency of headache attacks has found to be related to
the level of central sensitization [4].
However, not all TTH patients present with the same level of central
sensitization and clinical presentation, but subgroups need to be
identified in order to offer specific therapeutic programs [5].
Prolonged peripheral nociceptive input from the pericranial, neck,
and shoulder regions (e.g. trigger points (TrPs), zygoapophyseal
joints) may over time sensitize the central nervous system, transmit-
ting nociceptive input to the trigemino-cervical nucleus caudalis [6].
In fact, it has been found that sustained stimulation of TrPs may in-
duce central sensitization in healthy participants [7].
There is evidence supporting the role of TrPs as contributor to TTH,
and that the referred pain elicited by TrPs stimulation reproduces the
headache pattern in TTH patients [8].
The number of TrPs seems to be associated with the degree of wide-
spread pressure pain hypersensitivity in TTH patients, supporting the
role of TrPs on central sensitization: however the cross-sectional na-
ture of the study does not allow to establish a cause and effect rela-
tionship between TrPs and central sensitization, as other variables
may influence this association [9].
Physical therapy may be helpful for the management of TTH patients
[10,11], as it may decrese the peripheral nociceptive input.
However, to nowdays, studies on treatment of TrPs in TTH are still
few and more evidence is needed.
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Background
Migraine is related to the highest disability among headaches. Great
efforts are faced to improve the outcome of forthcoming treatments.
However, still now, many patients regard as unsatisfactory the low
responder rate (about the half of patients) and adverse effects that
current treatments account. Therefore, waiting for innovative, more
tolerated and effective treatments, there is a large request for non-
pharmacological approaches that in many cases have specific patho-
physiological targets. Among these treatments, nutraceuticals has a
leading role. The term “nutraceuticals” indicates any product derived
from food or herbal sources, administrated at a specific dose, ad-
equate to obtain some health benefits. Several nutraceutical prod-
ucts are proposed for migraine and sold around the world, but
researchers adequately study only few compounds
Methods
Among studied nutraceuticals compounds, only few of them have
studies of good quality in support. Moreover, also interactions
among different molecules are not studied. We have reviewed litera-
ture data in order to find researches that support the use of nutra-
ceutical molecules in migraine management.
Results
Available good quality data support the use of certain nutraceuticals,
in particular riboflavin, coenzyme Q10, magnesium, butterbur, fever-
few, and omega-3 polyunsaturated fatty acids. Even if not supported
by double blind studies, recently some prospective observational
studies about fixed combination of nutraceuticals were performed.
For instance, it is the case of a combination of coenzyme Q10, fever-
few and magnesium for migraine prophylaxis: a prospective observa-
tional study. A double blind versus placebo study about the effect of
a fixed combination of riboflavin, coenzyme Q10, feverfew, androgra-
phis and magnesium for migraine prophylaxis is currently in
progress.
Conclusions
Usually patients appreciate nutraceuticals more than traditional
drugs, since they are regarded as safe and of efficacy not inferior to
other pharmacological products. Available data seem to support this
widespread belief, but some concerns about the regulation of nutra-
ceuticals and quality of some products, still remain.
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The Journal of Headache and Pain 2017, 18(Suppl 1):S49Contrary to what is generally thought of, headaches and algology
(pain therapy) share many aspects.The first, and perhaps most im-
portant, aspect of sharing between headaches and chronic pain is
the fact that both cause a negative impact on “quoad valetudinem”
rather than “quoad vitam” [1]; in both cases it is possible to talk
about under-sized and under-diagnosed diseases as well as primary
health illnesses for the nation's health policy [2].Headaches and
chronic non-oncological pain are two paradigms of chronic illness
capable of generating enormous individual and social impact by
disabling the sick person not only in the biological, but also in the
psychological, professional, social and relational spheres. Both
cause alterations in psychological equilibrium, secondary depres-
sion, loss of social and professional roles, which, in the most serious
cases, can cause loss of work. Literature documents in both cases,
headaches and chronic pain, a rise in direct costs but above all of
the indirect ones with a huge burden of disease. Both are capable
of generating a marked drop in the quality of life associated with a
serious bio-psycho-social disability. Headaches and chronic pain, al-
though distinct according to a topographical criterion, share many
mechanisms and physiopathogenetic steps. One of the most
current fields in which neurologists and pain therapists converge is
the focus on neuroinflammation [3] and central sensitization[4],
two key mechanism for triggering, maintaining, and subsequent
perpetuation of pain: the pain as a symptom, filogenetically respon-
sible for maintaining homeostasis of the organism against actual or
potential damage, becomes unnecessary illness without any pro-
tective meaning. Another important shared pathogenetic passage
is that of neuroimmune mechanisms, which interlink the immune
system with the central nervous system[4]. Furthermore, numerous
contribution to the scientific international literature highlight the
need to modify the therapeutic approach, directing it towards a
semeiotic criterion (pain phenothype: specific sign and symptoms
of a certain type of pain in a specific moment), which is an epiphe-
nomenon of underlyng pathogenetic mechanism, instead of basing
it on a etiologic criterion[5]. This would enable a more appropriate
prescription and greater efficiency, taking into primary consider-
ation the possibility of getting back to everyday life rather than
obtaining complete analgesia. In both cases, headaches and
chronic pain, a therapeutic protocol should be effective as well as
sustainable in terms of both biologic aspect (effectiveness/safety ra-
tio) and acceptability (minimum interference with professional, rela-
tional and social life). All the above mentioned aspects are equally
important but one of them can prevail over the others depending
on patient characteristics and background. From that derives an-
other shared aspect: the concept of personalized “dynamic” ther-
apy, where the physician (neurologist or pain physician), once
identified realistic objectives that the patient wants to achieve, has
to define the best possible protocol basing on his expertise and on
the avalaible treatments, as well as periodically re-evaluate the clin-
ical trend in order to provide modifications or integrations to the
therapy, if necessary [5]. In conclusion it can be stated that the as-
pects of sharing between headaches and chronic non-oncological
pain are significantly greater than those that clearly divide them.
this must therefore be an area where researchers’ efforts must con-
verge to achieve the primary goal of recovering pain-related
disability.
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Headache is a common clinical feature in neurological patients .Usu-
ally, neuroimaging is unnecessary in patients with episodic migraine
or tension type headache with typical headache features and with a
normal neurological examination. These patients do not have a
higher probability of a relevant brain pathology compared to the
general population.
A recent study, however, reported that neuroimaging is routinely or-
dered in outpatient headache even if guidelines specifically recom-
mend against their use. In the same study, after 5 years, a patient
with a new migraine has a 40% chance of receiving a neuroimaging
examination[1].
Brain MRI with detailed study of the pituitary area and cavernous
sinus, is recommended for all trigeminal autonomic cephalalgias
TACs. Sometimes additional scanning of intracranial/cervical vascula-
ture and/or the sellar/orbital/(para)nasal region are needed to ex-
clude underlying pathological conditions [2].
Neuroimaging should be considered in patients presenting with
atypical headache features, a new onset headache, change in
previously headache pattern, headache abruptly reaching the
peak level, headache changing with posture, headache awakening
the patient, or precipitated by physical activity or Valsalva
manoeuvre and abnormal neurological examination. Other condi-
tion for which MRI is recommended are: first onset of headache
≥50 years of age, trauma, fever, seizures, history of malignancy,
history of HIV or active infections, and prior history of stroke or
intracranial bleeding [2, 3].
A recent consensus recommends brain MRI for the case of mi-
graine with aura that persists on one side or in brainstem aura.
Persistent aura without infarction and migrainous infarction also
require brain MRI, MRA and MRV. According the same consen-
sus, fFor primary cough headache, exercise headache, headache
associated with sexual activity, thunderclap headache and hyp-
nic headache apart from brain MRI additional tests may be re-
quired [3].
Particularly in emergency room it is mandatory to exclude a sec-
ondary headache that requires special attention and further
diagnostic workup. A careful patient history should be collected
and additional ‘red flags’ should be detected at the physical
examination to identify patients which can benefit of a MRI or
CT scan to detect significant brain pathology. and make a cor-
rect diagnosis and receive an adequate and prompt therapeutic
intervention.
CT scan is the first line neuroimaging examination. MRI offers a
greater resolution and discrimination and might therefore be the
preferred method of choice in non acute headache. In addition, radi-
ation due to CT scanning may be avoided
Neuroimaging non conventional techniques are of little or no value
in the clinical setting .but may contribute greatly to increasing under-
standing of the pathogenesis of primary headaches.
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Migraine frequency fluctuates over time. Chronic migraine is defined
by the occurrence of headache on more than 15 days/month for at
least 3 months. Chronic migraine affects 1–2% of the general popula-
tion, and about 8% of patients with migraine, with an annual conver-
sion rate of about 3%. In the literature, the most important
recognized factors associated to chronic migraine are overuse of
acute migraine medication, ineffective acute treatment, obesity, de-
pression, presence of allodynia and stressful life events. These latter
seem in particular relevant not only incidentally, as a precipitating/
aggravating factor in the short term, but, most importantly and inter-
estingly, as potential epigenetic modulators of disease severity over
time. Other factors reported in studies are age, female sex and low
educational status. Very recently, a large population study suggested
that the presence of additional noncephalic pain site is a risk factor
for migraine chronification.
For many of these factors the relationship with migraine chronifica-
tion may however be bi-directional. For instance, in the case of de-
pression, it is possible that depression may negatively affect the
response of migraine to acute and prophylactic treatments, but it is
also true the opposite: i.e. the recurrence of disabling headache at-
tacks may alter the psychological well-being of a normothymic sub-
ject, thus leading to mood alterations. In the case of obesity, the
association with chronic migraine may simply be ascribed to the ef-
fect of fat tissue in drug distribution.
Beside and beyond the putative biological factors that may cause a
worsening of disease, several lines of evidence suggest that the pro-
gression from episodic to chronic migraine is associated to a progres-
sive increase and stabilization of functional and anatomical changes
associated to chronic sensitization. In this frame, it appears obvious
that an additional cause for chronic migraine is quite likely repre-
sented by the low rate of prescription of preventive medications. Ac-
cording to the American Migraine Prevalence and Prevention Study,
nearly 40% of migraine sufferers should be considered for preventive
migraine therapy, while only 13% of all patients with migraine cur-
rently use preventive therapy to control their attacks. The
underutilization of preventive drugs has several explanations ranging
from drug-associated issues (limited efficacy, poor tolerability profile)
to education of practitioners, pharmacists and patients, and it also in-
volve the limited access to qualified care. Underutilization of pre-
ventative drugs also translate into a higher recourse to acute drugs,
thus feeding on a vicious cycle that leads to negative consequences.
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According to the International Classification of Headache Disorders,
3rd edition (beta version) [1], primary headaches are classified as “mi-
graine”, “tension-type headache”, “trigeminal autonomic cephalalgia”,
and “other primary headache disorders”. To date, the majority of clin-
ical studies concerning primary headaches and their comorbidities
are focused on migraine. Comorbidities of migraine may include
neurological and psychiatric conditions, as mood disorders (depres-
sion, mania, anxiety, panic attacks), epilepsy, essential tremor, stroke,
and the presence of white matter abnormalities [2]. Particularly, a
complex and bidirectional relation between migraine and stroke has
been described, including migraine as a risk factor for cerebral ische-
mia, migraine caused by cerebral ischemia, migraine mimicking cere-
bral ischemia, migraine and cerebral ischemia sharing a common
cause, and migraine associated with subclinical vascular brain lesions
[2]. A recent meta-analysis pointed out that migraine is associated
with increased ischemic stroke risk [3], and according to a systematic
review and meta-analysis [4] the risk of hemorrhagic stroke in migrai-
neurs is increased with respect to non-migraineurs. Besides, the risk
of transient ischemic attack seems to be increased in migraineurs, al-
though this issue has not been extensively investigated [5]. A recent
systematic review and meta-analysis also describes an increased risk
of myocardial infarction and angina in migraineurs compared to non-
migraineurs [6]. Concerning the association between migraine and
vascular risk factors (arterial hypertension, diabetes mellitus, dyslipid-
emia, obesity, alcohol consumption, family history of cardiovascular
disease), a recent review [7] showed no solid evidence of an in-
creased burden of conventional vascular risk factors in migraineurs,
with the only exceptions of dyslipidemia and cigarette smoking,
while a systematic review and meta-analysis regarding migraine and
body mass index categories [8] found an increased risk of having mi-
graine in underweight subjects and in obese women as compared
with normal-weight subjects. Few studies investigated the comorbidi-
ties of tension-type headache (TTH), despite the fact that tension-
type headache (TTH) is highly prevalent, and may be as debilitating
as migraine [9]. It is noteworthy that, according to a review, TTH is
associated with increased rate of affective distress [9]. Furthermore,
some medical disorders may worsen a preexisting TTH, and it has
been described the comorbidity of TTH with psychiatric disorders
and fibromyalgia [10].
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Differentiating patients with life-threatening headaches from the
overwhelming majority with primary headaches (eg migraine, tension
or cluster headache) is an important issue in emergency department
(ED). Patients with non-traumatic headaches are up to 4.5 per cent of
adults looking for emergency visits (Torelli, 2010). Of these patients,
only 20% had a secondary headache requiring diagnosis and
hospitalization (Pari, 2015). On the other hand, 80% of these patients
have a primary form, requiring evaluation and outpatient treatment.
These numbers seem to remain constant in Western countries
(Ramirez-Lassepas, 1997; Kowalski, 2004; Cvetkovic, 2007; Gaughran,
2014).
Primary headaches still pose an open challenge in the ED because
the failure to recognize a secondary headache could cause poten-
tially fatal consequences. Unfortunately, to date, there is still no a
standard diagnostic procedure for headache in emergency condi-
tions; although according to the diagnostic guidelines there are red
flags that could help in the process, the positive predictive value of
each severity indicator is not yet determined.
The problem of poor diagnostic sensitivity was attributed to IHCD-3
criteria rigidity in relation to primary headache diagnosis in emer-
gency setting (Dutto, 2009, Swadron, 2010). Attempting to overcome
the primary headache diagnostic problem in ED, the Canadian Emer-
gency Association proposed simplified IHS criteria to be easily imple-
mented in the ED environment (Ducharme, 1999). Alternatively, a
different standardized work-up has been proposed for the most fre-
quent headache scenarios in ED (Cortelli, 2004; Dutto, 2009).
A careful history and physical examination remain the most import-
ant part of the assessment of the headache patient; they enable the
clinician to determine whether the patient is at significant risk for a
dangerous cause of their symptoms and what additional workup is
necessary. This presentation will discuss how to approach adults with
headache in ED with an emphasis on those features that characterize
high-risk headaches.
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Headaches are one of the most disabling disorders [1]. That is, 50%
of general population suffer from headache (HA) during any given
year; moreover, 90% report a lifetime history of HA [1, 2].
Migraine is one of the most common type of headache with an esti-
mated prevalence of 10% [3] of the general population.
The International Headache Society (IHS) classify Migraine as a pri-
mary headache. That is, the 3rd edition of the International
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 19 of 151Classification of Headache Disorders (ICHD-III) describes also the
diagnostic criteria of each headache disorder types. Interestingly, Mi-
graine and Cervicogenic Headache (CGH) share similarities in these
criteria and clinical presentation. Moreover, Neck Pain associated dis-
orders (NAD) is a very common presentation in Migraine population
[4]. Thus, the muscolokeletal contribution in Primary Headaches is
still debate in the literature [5]. Moreover, recent knowledge suggests
that different clinical headache phenotypes arising from a common
pathophysiology rather than an independent disorder [6]. That is, in
the most prevalent headaches disorders (i.e. TTH, Migraine, CGH) the
ascending pathway of trigeminovascular system and Trigemino Cer-
vical Nucleus (TCN) play a primary role in the head | face pain etio-
pathogenesis [7, 8]. In this presentation, the role of the
musculoskeletal inputs in primary headaches it will be provided.
Moreover, evidences of the effectiveness of a manual therapy man-
agement provided by a physiotherapist and its integration in a multi-
disciplinary team it will be discussed.
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Since 2010 the armamentarium of preventative drugs for chronic mi-
graine (CM) has become wider with the introduction of Onabotuli-
numtoxinA (Botox®). The European Headache Federation recognized
the value of OnabotulinumtoxinA suggesting that, before labeling a
patient as affected by refractory CM, a proper treatment with this
drug needs to be completed [1]. In the last years several real-life pro-
spective studies provided further evidence in clinical setting of Ona-
botulinumtoxinA 155-195 U efficacy for the headache prophylaxis in
CM complicated by medication overuse headache (MOH) [2]. Re-
cently we published the results of a prospective study on the long-
term (2 years) efficacy and safety of a single dose of Onabotulinum-
toxinA (155 or 195 U) in patients with CM plus MOH had failed
previous preventative drugs and detoxification attempts [3]. Both the
doses were effective and equally safe, but 195 U was more effective
than 155 U in reducing headache days, migraine days, pain medica-
tion intake days and Headache Impact Test (HIT)-6 score. Even more,the 195 U dose superior efficacy was evident since the first injection
and maintained over all the study period of 24 months. Interestingly
we observed a progressive improvement in all the efficacy measures
during the 2 years of follow-up with both the doses and significantly
more with 195 U. Sometime a response appears only after the sec-
ond or third injections. For this reason in selected cases can be useful
to temporarily continue an oral preventative agent. CM patients close
to developing MOH, patients with high frequency episodic migraine
(HFEM), and those already abusing of drugs require special attention
and maybe an be an “early treatment”. The NICE guidelines recom-
mend OnabotulinumtoxinA only for patients who have already tried
at least three different preventative drug treatments that have not
worked. The chance to use it as first-line preventative treatment may
shorten the period of chronicity and eventually prevent the develop-
ing of MOH. Another early use of OnabotulinumtoxinA could be in
patients with HFEM. Several studies conducted before Onabotuli-
numtoxinA approval shown that it is ineffective in patients with epi-
sodic migraine [4]. Those studies had important limitations as range
doses and injection paradigm. Furthermore, the population enrolled
was represented in the majority by patients with low frequency epi-
sodic migraine (an average of 6-7 attacks per month). Interestingly
post hoc analyses including episodic migraine patients with a greater
mean frequency of headache days (≥12 and ≤15) suggested that
they have a more robust response to OnabotulinumtoxinA [4].
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Trigeminal autonomic cephalalgias (TACs) are a group of primary
headaches comprehending the following syndromes: episodic and
chronic cluster headache (CH), episodic and chronic paroxysmal
hemicrania (PH), short-lasting unilateral neuralgiform headache at-
tacks, and hemicrania continua(HC) [1]. Their phenotypes are similar
and attack duration is the main feature distinguishing the first three
TACs. An accurate diagnosis is important because of their different
response to treatments. Among TACs, CH is most common; however
TACs are approximately at least 100 times less common than mi-
graine. CH prevalence in adults is < 1% and interests specially the
male population. CH typically occurs at the same time of the day,
from once to eight times per day, and in the same period of the year.
CH is featured by severe unilateral peri-orbital and/ or temporal pain
lasting from 15 to 180 minutes if untreated, associated with at least
one autonomic symptom (conjunctival injection, lacrimation, nasal
congestion, rhinorrhea, facial sweating, miosis, ptosis and eyelid
edema). Trigger factors can include alcohol, volatile chemicals or a
warm environment (3). Acute therapy includes the use of oxygen at
a rate of 12-15L/min for at least 15 minutes and triptans. Controlled
trials have investigated the efficacy of subcutaneous sumatriptan,
nasal sumatriptan, and nasal zolmitriptan. When a preventive
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tack features are characterized by unilateral, often stabbing, head-
aches, shorter and more frequent than in cluster headaches. PH is
responsive to treatment with indomethacin. Indomethacin dosages
ranges from 25 to 75 mg, three times a day. SUNCT-SUNA attacks are
very short in duration (seconds to minutes), triggered by touching
the face or chewing, with associated autonomic features and occur
up to hundreds of times per day. SUNCT-SUNA most often responds
to lamotrigine, limited the evidences for topiramate, gabapentin,
carbamazepine, duloxetine and oxcarbazepine. In HC, clinical attack
features have been reported as unilateral, side-locked continuous
pain (although interrupted by frequent severe exacerbations), associ-
ated with autonomic symptoms and responsive to indomethacin.
Therapeutic options in TACs are limited. In many patients the pre-
ventive treatment does not help to control attack frequency, or the
acute drugs are not well tolerated or are contraindicated. For these
reasons, after the discovery of the central role of the hypothalamus
in TACs pathogenesis, neuromodulation techniques started. After the
results obtained with hypothalamic deep brain stimulation in CH,
other peripheral neuromodulation targets (occipital nerves, spinal
cord, sphenopalatine ganglion, vagus nerve) were tried in the man-
agement of refractory CH and other TACs.
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Chronic headaches are a relevant health problem characterized by
significant disability, poor quality of life and high economic burden
(1). The most common forms include chronic migraine (CM) and
medication overuse headache (MOH), which are frequently associ-
ated, given that the majority of CM sufferers do overuse acute medi-
cations (CM with MO). Chronic headaches represent a challenge for
physicians, given their frequent resistance to therapies, risk of relapse
and associated comorbidities. Their management includes several
steps aimed to: 1) make a proper diagnosis excluding secondary
forms; 2) identify exacerbating factors; 3) treat comorbidities; 4) iden-
tify and address medication overuse; 5) establish a therapeutic agree-
ment with patient; 6) define an integrated care approach. Patient-
history collection is crucial for defining headache onset and its life-
long course, chronicization factors, and outcomes of previous therap-
ies (acute and prophylactic).
Overused drug discontinuation is the first approach for MOH and it
can be achieved via multiple modalities - in-patient or out-patient
withdrawal procedures, advice alone – depending on several
headache-associated or patient-associated factors. During with-
drawal, adequate care is required to help the patient to go through
the treatment phases, given the frequent occurrence of headache
recrudescence.
Headache diaries represent useful tools in monitoring attacks fre-
quency, detecting medication overuse, checking therapies outcomes,
and assessing disability improvements. A relevant problem in MOH is
the risk of relapse into overuse after successful withdrawal. There are
only few controlled pharmacological trials on the management of
MO in CM, which does not allow to derive precise figures on the risk
of relapse into MO associated to specific therapies. Furthermore, therelapse risk is also influenced by psychological and clinical comorbid-
ities. For instance, mood and personality disorders (e.g., anxiety, de-
pression, obsessive-compulsive personality, or addictive behavior) are
very common in patients with CM with MO. Psychological factors in-
deed seem to play a crucial role in predicting the outcome (e.g., re-
duction in headache attacks and medication intake or relapse into
overuse) of detoxification and should be considered when treating
these patients (2,3). The presence of other pain-syndrome comorbidi-
ties (e.g., fibromyalgia) can further adversely affect treatment
response.
The pivotal role in the management of CM with MO is the “phys-
ician-patient alliance” deriving from the active involvement of the pa-
tient in all phases of her/his health-care management through a
comprehensive rehabilitation counseling. Such a management is not
limited to the earliest stages of treatment (diagnosis, therapies, de-
toxification), being very important also when the patients resume
their everyday life (4). It is important to prevent unrealistic expecta-
tions (e.g., complete healing) and identify intermediate steps. In con-
clusion, the complete management of CM and MOH patients derives
from an array of synergistic and multidisciplinary interventions aimed
to improve patient’s quality of life, response to treatments and clin-
ical outcome.
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Background
Headache prevalence is age-dependent and decreases progressively
over time, especially starting from the age of 55-60. The incidence of
primary headaches declines, whereas secondary headaches tend to
occur more frequently with increasing age [1]. Although the preva-
lence of headache in the elderly is relevant, few studies have been
conducted in patients over 65 so far.
Materials and Methods
The clinical records of 9075 consecutive outpatients aged over 18 re-
ferred to our Headache Centre from 2000 to 2015 were reviewed. Pa-
tients were diagnosed based on The International Classification of
Headache Disorders, 3rd edition (beta version) criteria [2].
Results
Out of 9075 patients, a total of 469 (5.2%) were over 65 at their first
observation. Primary headaches were diagnosed in 365 patients
(80.5%, mean age 70.1 ± 4.7), secondary headaches in 64 cases
(11.2%, mean age 74.1 ± 6.1), whereas painful cranial neuropathies
and other facial pains were identified in 40 subjects (8.3%, mean age
77.1 ± 5.9). In the primary headache group the most common
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headache (23.0%) and chronic migraine (20.3%). As for patients with
migraine and chronic tension-type headache, the onset of headache
occurred in most cases before 45, in particular in chronic migraine
(89.2%), while in migraine with aura patients the headache started
over 45 in 55.6% of cases. Secondary headaches were represented
above all by cervicogenic headache, frequently associated with
tension-type headache. Among cranial neuropathies, trigeminal neur-
algia was by far the most commonly diagnosed headache.
Conclusions
In our population of elderly headache patients, migraine without
aura, chronic tension-type headache and chronic migraine accounted
for 61.3% of the total cases. There was a large majority of females in
all the subgroups of headaches. In cluster headache, considered as a
typical disorder of young men, we found indeed a slight preponder-
ance of females. Migraine with aura not infrequently occurs in the
elderly; this headache, as well as cluster headache, can even start,
even rarely, over 65 and in such cases a differential diagnosis with a
possible secondary disorder is mandatory. Among patients with
chronic headaches, a medication overuse was found more frequently
in chronic migraine (71.6%), than in chronic tension-type headache
(33.3%). The choice of headache treatment is challenging, since spe-
cific guidelines are lacking and also because elderly patients com-
monly present with comorbidities. Further clinic-based studies
should be carried out, with the aim to define possible therapeutic
guidelines for these patients.
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Treatment of patients with chronic migraine remains challenging in
daily clinical practice due to several factors: variable tolerability of
the currently available medical treatments, frequent co-existence of
medication overuse and lack of disease specific treatment strategies.
At this stage, Topiramate and OnabotulinumtoxinA are the only evi-
dence based treatments for chronic migraine, of which only Onabo-
tulinumtoxinA is FDA-approved.
Therefore, anti-CGRP monoclonal antibodies are considered an at-
tractive treatment option for this patient population. Multiple studies
with anti-CGRP monoclonal antibodies for the treatment of chronic
migraine were conducted and some are still ongoing.
Here, we present an early overview on currently available efficacy re-
sults of anti-CGRP monoclonal antibodies in the treatment of chronic
migraine. Secondly, these results are compared to the results of the
currently used prophylactics for chronic migraine.
At present results from two phase 2 and two phase 3 trials are available.
In order to analyse these early results next to the efficacy results of
established prophylactics for chronic migraine the ‘change in
monthly migraine days compared to placebo’ of each agent will be
presented.Results from 1863 patients with chronic migraine, treated with anti-
CGRP monoclonal antibodies are now available, compared to 688 pa-
tients treated with OnabotulinumtoxinA and 185 patients treated
with Topiramate.
The overall mean reduction of monthly migraine days (compared to
placebo) for the anti-CGRP monoclonal antibodies is -2,05 days. For
Topiramate and OnabotulinumtoxinA these values are respectively
-1,79 and -2 days.
In conclusion, the first efficacy results of anti-CGRP monoclonal anti-
bodies in the treatment of chronic migraine are promising and at
least comparable with the effect sizes of both Topiramate and Ona-
botulinumtoxinA. Combined with the fact that the anti-CGRP mono-
clonal antibodies have, already at this stage with several trials still
ongoing, the highest number of patients studied ánd given their ex-
cellent tolerability, these new agents are emerging, from a clinical
point of view, as a promising treatment for chronic migraine.
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Background
Chronic Migraine (CM) is characterized by more than 15 days/month
for more than three months, and is frequently associated to the over-
use of acute medications. In recent years, non-pharmacological treat-
ments have been proposed and, among them, Mindfulness is one of
the most promising1 and showed to be comparable to pharmaco-
logical prophylaxis2. It was also shown that patients undergoing
pharmacological prophylaxis and Mindfulness sessions had similar
baseline levels for biomarkers and in part underwent significant im-
provement3. Here we aim to address improvement in biomarkers by
comparing results on patients with those of healthy controls.
Materials and methods
Two group of patients, one receiving pharmacological prophylaxis
alone and one treated with six group session of Mindfulness-based
training, were followed-up at 3, 6 and 12 months. We compared pa-
tients and control for white blood cell (WBC) count, neutrophils, total
lymphocytes and lymphocyte subsets CD3, CD4, CD8, CD19 at each
point with Mann-Whitney test.
Results
Data were available for 34 patients (17 per group: no differences were
found cross-sectionally, and the longitudinal course was similar) and 34
controls. Compared to controls, patients reported higher baseline levels
for WBC, neutrophils and lymphocyte subsets CD4. All levels, except
lymphocyte subsets CD4, became similar to that of controls from the third
month, and CD4 became comparable at six months from withdrawal.
Conclusions
Some biomarkers of inflammation were altered in patients with CM
associated to medication overuse: from the third month after with-
drawal patients show a reduction of inflammation that is maintained
at 12 months. Pharmacological prophylaxis and Mindfulness showed
comparable results.
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WBC Neutrophils Lymphocytes CD3 CD4 CD8 CD19
Healthy
Controls
5732
[5299-
6165]
3674
[3233-
4010]
1836 [1703-
1971]
1366
[1259-
1473]
766
[703-
829]
559
[486-
632]
196
[171-
222]
Patients-
T0
7322
[6489-
8156]
4801
[4120-
5482]
2019 [1773-
2265]
1577
[1364-
1790]
1027
[869-
1185]
568
[491-
645]
219
[186-
253]
P-value .003 .006 .611 .362 .014 .949 .627
Patients-
3M
6185
[5681-
6690]
3639
[3263-
4016]
1899 [1730-
2267]
1475
[1332-
1617]
933
[841-
1026]
550
[481-
619]
196
[166-
226]
P-value .197 .950 .677 .253 .009 .827 .663
Patients-
6M
6226
[5544-
6908]
3762
[3226-
4297]
1829 [1659-
1998]
1399
[1263-
1535]
890
[779-
1001]
525
[475-
576]
190
[156-
224]
P-value .517 .885 .820 .969 .112 .748 .264
Patients-
12M
6182
[5601-
6763]
3758
[3266-
4250]
1802 [1639-
1965]
1367
[1230-
1504]
875
[781-
969]
515
[461-
570]
186
[157-
214]
P-value .373 .890 .598 .729 .101 .480 .278
Fig. 1 (abstract P2). WBC Count (mean and 95% CI)
Fig. 2 (abstract P2). Neutrophils (mean and 95% CI)
Fig. 3 (abstract P2). CD4 Lymphocyte subset (mean and 95% CI)P3
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The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 23 of 151Objectives: Microvascular decompression (MVD) is first choice neuro-
surgical treatment option in medically refractory trigeminal neuralgia
patients with an MRI verified neurovascular contact (NVC). There is a
lack of high-quality prospective, systematic studies, using independ-
ent assessors of outcome of the procedure. Here we aimed to evalu-
ate whether sex and degree of NVC can predict outcome of MVD.
Methods: Clinical characteristics and outcome data were systematic-
ally recorded prospectively from consecutive trigeminal neuralgia pa-
tients, using standardized semi-structured interviews and schemes. A
pre-surgical 3.0 Tesla MRI was performed to evaluate the degree of
NVC blinded to symptomatic side. The patients were assessed before
and 3, 6 and 12 months after MVD by a neurologist at the Danish
Headache Center. Department of Neurosurgery had no influence on
recording or evaluation of data. Data from a self-completed 12
months post-surgical questionnaire including items on pain intensity,
complications and satisfaction, were also recorded. The primary out-
come was pain relief according to the Barrow Neurological Institute
pain score (BNI I-VB), Table 1. Secondary outcome was patient
satisfaction.
Results: From May 2012 to February 2016, 27 men and 33 women
had completed one year follow- up. Mean age at operation was 59.9
years (range 28-80 years). Mean duration of disease was 6.6 years
(range 1-40 years). Thirty-three patients (55%) had NVC with morpho-
logical changes.
Forty-three (72%) patients had an excellent outcome defined as ‘no
pain, no medication’ (BNI I). Nine (15%) patients had a good out-
come, while eight patients (13%) had poor outcome.
At multiple logistic regression the odds ratio between NVC with dis-
placement or atrophy of the trigeminal nerve and excellent outcome
was 5.2 (95% CI 1.3 – 20.1, P = 0.0183) and the odds ratio between
sex (male vs. female) and excellent outcome was 10.6 (95% CI 2.0 –
56.1, P = 0.0057). There was no significant interaction between sex
and severe NVC (p = 0.56).
Conclusion: These high-quality prospective data using independent
assessors demonstrate that patients with morphological changes of
the trigeminal nerve and male sex have a considerably better chance
of an excellent outcome of MVD. These data should guide patients
and physicians in decision-making before neurosurgery.
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In the past years a unifying definition of refractory headache (rH) has
been extensively discussed but, to date, has not been agreed upon.
It is widely agreed, that refractoriness, for whatever category and dis-
ease, implies a high burden with tremendous impact in health re-
lated quality of life (HRQoL). Despite that fact, an overall accepted
definition of rH would be more than important for managing and
triaging patients to an appropriate level of care and for determining
eligibility for epidemiological and clinical studies. What are the crit-
ical issues so far: (i) there is no standardized definition of rH; (ii) at
the time of first diagnosis headache patients do not necessarily be-
come refractory immediately, nor do they mandatorily remain refrac-
tory throughout the course of their disease; (iii) due to the necessity
that most patients should be treated rapidly after diagnosis response
to medication often is assessed without a pretreatment baseline and
it remains unclear whether or not so-called refractory patients have
had a substantial response to treatment; (iv) headache pain and as-
sociated symptoms are frequently intermittent, making this disease
different from others that have been examined for treatment resist-
ance; (v) the natural history is not known. For all these purposes the
Board of the European Headache Federation (EHF) felt the need to
develop new consensus criteria that define refractory chronic mi-
graine (rCM) and refractory chronic cluster headache (rCCH). These
new definitions of rCM and rCCH, which were agreed upon within
the EHF, allows us to separate patients into categories of refractoryand non-refractory, being important for clinicians, clinical and epi-
demiological trials.
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Background
Despite current treatments 2-4 % of migraneurs become chronic (1).
This is a very disabling condition leading to a high suffering and low
quality of life (2). Inhibiting sphenopalatine ganglion (SPG) could re-
duce the frequency of the crisis (3), but its access is quite difficult re-
quiring aggressive methods (4). Tx360 device is a nasal applicator
made of plastic material easing the access to the SPG and the applica-
tion of local anaesthetic in its vicinity with minor inconveniencies (5).
Materials and methods
Twelve blocks (three each week during four weeks), were done with
Bupivacaine 0,5% (0,3 cc each nostril), using the Tx360 device. We
evaluate at the end of the 12th block (four weeks), efficacy parame-
ters (mean reduction of headache days and pain intensity in a visual
analogue scale), impact (Headache Impact Test [HIT-6]), and quality
of life (Migraine-Specific Quality of Life Questionary [MSQ]), tools. We
also analysed 30% and 50% response rates.
Results
Nine patients refractories to habitual treatments were treated (2 M, 7 F;
mean age 48,1 ± 16). There was analgesic abuse in 8. At the 12th block
there were a significant reduction of mean headache days (17,6 vs.
25,8, p 0,034), pain intensity (5,4 vs. 8,1, p <0,001), and mean analgesic
consumption (13,6 vs. 54,6, p <0,000002). There were also a significant
reduction in mean HIT6 (57,85 vs. 66,9), and MSQ (40,14 vs. 57,22). Forty
five per cent had a reduction ≥50% of headache days. There were no
significant adverse events but minor and transient local discomfort.
Conclusions
Repetitive blocks of the SPG with the Tx360 device seem to be an ef-
fective treatment in chronic migraine, even with analgesic abuse,
with only minor adverse events. These benefits were evident both in
headache days and in quality of life measures. Although encouraging
these results must be confirmed in a greater number of patients, and
know how long they will last.
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Background
Erenumab, a fully human monoclonal antibody, selectively targets
the CGRP receptor. A phase 2, 12-week randomised, double-blind,
placebo-controlled study demonstrated efficacy of erenumab (70 mg
and 140 mg) in patients with chronic migraine (CM), with a safety
profile comparable to placebo. We report a prespecified subgroup
analysis on prior prophylactic treatment failure (≥1, ≥2 and never
failed) due to lack of efficacy and/or poor tolerability.
Methods
Patients (N=667; aged ≥18–65 years) with CM (≥15 headache days/
month; ≥8 migraine days) were randomised (2:2:3) to once-monthly
subcutaneous erenumab 70 mg, 140 mg or placebo. Efficacy end-
points were change in monthly migraine days (MMD), achievement
of ≥50% reduction in MMD, change in monthly acute migraine-
specific medication treatment days, and change in cumulative
monthly headache hours. Assessments compared weeks 9–12 to
baseline. No correction for multiple comparisons was performed.
Results
With erenumab 70 mg and 140 mg, there were greater reductions at
week 12 in MMD and more patients achieved ≥50% reduction in
MMD versus placebo in all three subgroups. Moreover, greater reduc-
tion in monthly acute migraine-specific medication treatment days
was observed with erenumab 70 mg and 140 mg in patients who
previously failed prophylactic medications versus placebo. Cumula-
tive monthly headache hours reduced with erenumab 140 mg versus
placebo in patients who failed prophylactic medications. Notably,
placebo effect was greatest in patients who had never failed a
prophylactic medication. Across endpoints, reductions were greater
with erenumab 140 mg than 70 mg.
Conclusion
Numerically, erenumab 140 mg showed better efficacy in patients
with CM who previously failed ≥1 or ≥2 current standard of care
prophylactic medication(s).
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The Journal of Headache and Pain 2017, 18(Suppl 1):P7OBJECTIVE:
The first trigeminal nerve branch is divided in three main branches:
lacrimal nerve (LN), frontal nerve, which divides into supraorbital
(SON) and supratrochlear nerves and nasociliar nerve. We describe
the case of a patient diagnosed of supraorbital nerve neuralgia who
developed an ipsilateral lacrimal neuralgia.
PATIENT AND METHODS:
47-year-old woman with prior medical history of Crohn disease treated
with Adalimumab and Azatioprine. She complained about a oppressive
continuous pain, of 5/10 intensity according to Analogic Visual Scale cir-
cumscribed to the left supraciliar region, with 2-3 seconds length super-
imposed paroxysms of 8/10 intensity. In the physical examination we
detected tenderness at the palpation of the supraorbital notch. She
was treated by anesthetic lidocaine blockade successfully and was
managed during 6 years with blockades every 3-10 months.
RESULTS:
In a regular consult she complained of a new oppressive pain of 6/10
intensity in the left superoexternal periorbital region, with 3 seconds
stabbing paroxisms of 8/10 intensity. In the exam she presented pain
at the palpation of lacrimal nerve and circumscribed hypoesthesia in
the lacrimal nerve territory. We only performed SON blockade first
but the superoexternal pain persisted, so we performed a specific
lacrimal nerve blockade with pain cessation, confirming the diagnosis
of Lacrimal Neuralgia. A facial, orbital and cranial CT did not show
any abnormality.
CONCLUSSION:
Sequential presentation of pain in contiguous nervous branches in
the absence of structural lesions supports the epicranial nature of
the trigeminal terminal branches neuralgias.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Background. Migraine and tension-type headache are highly preva-
lent brain disorders characterized by recurrent painful attacks that
lead to a highly disabling condition, particularly when chronic. Head-
ache suffers frequently reported cognitive deficits, nonetheless previ-
ously data regarding cognitive impairment are inconclusive. The aim
of this hospital-based study was to compare cognitive performance
in subjects affected by different headache types including: migraine
without aura (MWA), chronic migraine (CM), tension type headache
(TTH) and chronic tension type headache (CTTH).
Materials and methods. We studied 307 patients, 246 woman and
61 male consecutively referred to the Adult Headache Centre, Neuro-
logical Unit of the University of Palermo during a 2-year period.
Headache diagnoses were established according to the ICHD-III cri-
teria. Each patient carried out a comprehensive neuropsychological
evaluation including: MiniMental – State Examination (MMSE), Rey
Auditory Verbal Learning Test (episodic memory), Token Test (verbal
comprehension), Frontal Assessment Battery (executive functioning),
and Visual Search (selective attention). Impaired cognitive domains
were computed according to age- and education Italian normative
data (dichotomised variable of impaired versus not impaired). The
presence of co-existing anxiety and depression was evaluated with
the Hospital Anxiety and Depression Scale.
Results. In our sample mean age was 49,9±12,7 years for women
(80%) and 50,8 ±14,07 years for men (20%) (Table 1). Mean age was
higher in CTTH (55,8 ±13,7; p≤.0001). The most frequent form of head-
ache was MWA (45%) followed by TTH (27,7%), CM (14%) and CTTH
(13,7). The mean MMSE score was 28,2 ± 1,6 with no statistical differ-
ence between sex and headache types. Depression and anxiety were
more frequent in female [HAD-A: 9,9 ± 4,5 versus 7,5 ± 4,4; p≤.0001)
Table 2 (abstract P8). Prevalence of impairment in different cognitive
domains stratified by headache type
Prevalence of cognitive deficit n = 61
Prevalence
of attentive
deficit
Prevalence
of
esecutive
deficit
Prevalence
of
language
deficit
Prevalence
of memory
deficit
Prevalence
of praxis
deficit
Prevalence of
cognitive
deficit in ≥1
domain
Migraine
without
aura
11 (8%) 8 (5,8%) 2 (1.4%) 18 (13%) 0 (0,0%) 29 (21.0%)
Chronic
Migrain
4 (9,3%) 2 (4,7%) 0 (0,0%) 4 (9,3%) 1 (2,3%) 6 (14.0%)
Tension
type
headache
7 (8,3%) 4 (8%) 2 (2,4%) 7 (8,3%) 0 (0,0%) 14 (16.7%)
Chronic
tension
type
headache
5 (11,9%) 6 (14,3%) 2 (4.8%) 6 (14,3%) 0 (0,0%) 12 (28.6%)
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 25 of 151HAD-D (7,5 ± 3,9 versus 6,1 ± 3,9; p≤.0001)]. Sixty-one (19.9%) patients
reported impairment in at least one cognitive domain; CTTH suffers re-
ported the highest prevalence of cognitive deficits (28,6%), even it did
not reach statistically significance (Table 2). Just one patient reported a
praxis deficit. In our sample, after multiple logistic regression analysis,
cognitive impairment seems not to be influenced by headache type
even when data are adjusted by age and educational status.
Conclusion. Cognitive impairment is rather frequent in our hospital-
based cohort. It was reported in about 20% of the population study,
while the prevalence estimated in general population is about 5-6%.
In our sample, cognitive deficits were more frequent in CTTH. Future
research on bigger sample will evaluate cognitive performance in dif-
ferent headache types versus controls.
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Mar;262(3):654-65.Table 1 (abstract P8). Characteristics of study population
Study population n: 307
Number: Percent
Sex
Male 61 19,9%
Female 246 80,1%
Age group (year-old)
<21 5 1,6
21 – 30 20 6,5
31 – 40 38 12,4
41 – 50 94 30,6
51 – 60 86 28,0
61 – 70 48 15,6
≥71 16 5,2
Headache type
Migraine without aura 138 45
Chronic Migrain 43 14,0
Tension type headache 84 27,7
Chronic tension type headache 42 13,7
Education (years of school
0 3 1,0
1– 5 85 27,7
6– 8 104 33,9
9– 13 79 25,7
>13 36 11,7
Marital status
Unmarried 44 14,3
Married 234 76,2
Divorced 29 9,4
Mean ± DS
MMSE 28,2 ± 1,6
HAD_A 9,4 ± 4,6
HAD_D 7,2 ± 4,0P9
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Background
To compare the efficacy, safety, and tolerability of onabotulinumtox-
inA and topiramate for preventive treatment of chronic migraine
(CM) in adults.
Materials and Methods
The FORWARD Study randomized adults with CM (1:1) to receive
155 U onabotulinumtoxinA every 12 weeks (±7 days) for 3 treat-
ment cycles or topiramate 50-100 mg/day administered up to
week 36. Patients who discontinued topiramate at any time were
allowed the option of crossing-over to receive onabotulinumtox-
inA at the next scheduled office visit (week 12 up to week 36;
Fig. 1). The primary efficacy measure was a dichotomous variable
(responder/nonresponder) defined as the proportion of patients
with ≥50% reduction in headache days during the 28-day period
before week 32 (weeks 29-32). A baseline last observation carried
forward imputation method was utilized to impute missing data
replacing the missing value with the baseline value if the re-
sponder rate was missing at week 32 for any reason. Adverse
events (AEs) were monitored. Safety data include AEs from
randomization and cross-over phases.
Results
282 patients were enrolled (onabotulinumtoxinA, n=140; topiramate,
n=142) at 35 US sites. Patients were primarily female (n=239, 84.8%);
mean (SD) baseline headache days (onabotulinumtoxinA, 22.1 [4.6];
topiramate, 21.8 [4.8]) were similar across treatment groups. 148 pa-
tients completed treatment as randomized (onabotulinumtoxinA,
n=120 [85.7%]; topiramate, n=28 [19.7%]) through week 32. Primary
reasons for withdrawal were ineffective treatment (onabotulinumtox-
inA, n=7 [5.0%]; topiramate, n=28 [19.7%]) and AEs (onabotulinum-
toxinA, n=5 [3.6%]; topiramate, n=72 [50.7%]). 80 topiramate patients
crossed-over to onabotulinumtoxinA.
OnabotulinumtoxinA demonstrated significantly higher proportion of
patients with ≥50% reduction in headache frequency compared to
baseline vs topiramate (40.0% vs 12.0%, respectively; adjusted OR,
5.0 [95% CI, 2.7-9.2]; P<0.001) at the week-32 assessment.
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 26 of 151AEs were reported by 45.5% of onabotulinumtoxinA and 76.8% of
topiramate patients; serious AEs by 1.4% and 4.2%, respectively. Only si-
nusitis was reported in ≥5% of 220 patients receiving onabotulinumtox-
inA at any time; a number of individual AEs were reported in ≥5%
receiving topiramate (Table 1). Treatment-related AEs were reported by
17.3% of onabotulinumtoxinA and 69.0% of topiramate patients. One
serious AE (nephrolithiasis) was reported as related to topiramate.
Conclusions
In this open-label study, preventive treatment of adults with CM with
onabotulinumtoxinA demonstrated a more favorable tolerability pro-
file than topiramate. When using imputation methods accounting for
differences in discontinuation rates, onabotulinumtoxinA was more
effective than topiramate based on ≥50% responder rates and head-
ache day reduction.
Funding
Allergan plc
Trial Registration
ClinicalTrials.gov, NCT02191579Fig. 1 (abstract P9). FORWARD Study methodology
Table 1 (abstract P9). Adverse events in ≥5% of Patients in Any
Treatment Group
Patients
with
Adverse
Event (AE),
% (n)
OnabotulinumtoxinA
(n=220)
Topiramate
(n=142)
Total
(N=282)
Switched to
OnabotulinumtoxinA
(n=80)
Any AE 45.5 (100) 76.8 (109) 62.4
(176)
41.3 (33)
Cognitive
disorder
0.5 (1) 12.7 (18) 6.4 (18) 1.3 (1)
Disturbance
in attention
0 7.7 (11) 3.9 (11) 0
Dizziness 2.7 (6) 12.7 (18) 8.2 (23) 1.3 (1)
Migraine 2.7 (6) 2.1 (3) 2.5 (7) 5.0 (4)
Paraesthesia
0.5 (1) 31.0 (44) 16.0
(45)
0
Sinusitis 5.5 (12) 6.3 (9) 5.7 (16) 6.3 (5)
Nausea 0.5 (1) 13.4 (19) 7.1 (20) 0
Neck pain 4.5 (10) 2.1 (3) 4.3 (12) 6.3 (5)
Fatigue 0.5 (1) 13.4 (19) 7.1 (20) 0
Depression
1.8 (4) 5.6 (8) 3.5 (10) 2.5 (2)
Vision
blurred
2.7 (6) 7.0 (10) 5.0 (14) 3.8 (3)
Decreased
appetite
0 10.6 (15) 5.3 (15) 0P10
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Background
Erenumab (AMG 334) is a human anti-calcitonin gene-related peptide
(CGRP) receptor antibody being evaluated as preventive treatment for
chronic migraine (CM). When assessing efficacy of CM treatments by re-
sponder rates, there is an unmet need for more effective treatments.
Methods
In a prospective exploratory analysis of data from a phase 2 study
(NCT02066415) in patients with CM (≥15 headache days/month over
3 months with ≥8 migraine days), patients (N=667) were randomised
to erenumab (70 mg or 140 mg once monthly) or placebo. This ana-
lysis included calculation of proportions of patients with ≥50%,
≥75%, or 100% reduction in monthly migraine days (MMD) from
baseline to last 4 weeks of a 12-week double-blind phase. P-values
are based on odds ratios (ORs) from placebo and are not adjusted
for multiple comparisons.
Results
Mean (SD) baseline MMD were 18.0 (4.6). Significantly higher propor-
tions of patients treated with erenumab 70 mg or 140 mg experi-
enced a ≥50% reduction from baseline in MMD compared with
placebo at Week 12 (39.9% and 41.2%, vs 23.5%; OR: 2.2 [p<0.001]
and 2.3 [p<0.001]). The ≥75% responder rates were higher for pa-
tients treated with erenumab 70 mg or 140 mg compared with pla-
cebo (17.0% and 20.9%, vs 7.8%; OR: 2.4 [p=0.002] and 3.1
[p<0.001]). Likewise, the 100% responder rates were higher for pa-
tients treated with erenumab 70 mg or 140 mg compared with pla-
cebo (4.3% and 2.7%, vs 0.4%; OR: 12.6 [p=0.002] and 8.1 [p=0.026]).
Conclusions
Erenumab treatment resulted in higher proportions of patients with
CM experiencing ≥50%, ≥75%, and 100% reduction in MMD as com-
pared with placebo.
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Objectives
To assess the effects of botulinum toxins versus placebo, active treat-
ment or different dose for prevention of episodic or chronic migraine
in adults.
Background
Many migraine patients suffer prolonged and frequent migraine at-
tacks despite optimised acute and prophylactic treatments. Botu-
linum toxin type A has been licensed for use in chronic migraine in
some countries, based largely on two commercially sponsored trials.
Methods
Relevant trials were identified through electronic searches of
Cochrane Central Register of Controlled Trials, Medline, Embase, and
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on key publications, and correspondence with manufacturers. We in-
cluded randomised, double-blind, controlled trials. Twelve week
time-point data following final round of treatment was analysed.
Results
Twenty-eight trials (N=4192) were eligible for inclusion. No trial car-
ried out long term follow up. All larger trials (N>100) were at high
risk commercial sponsorship bias, otherwise trial quality was mixed.
Botulinum toxin was compared with placebo in 23 trials. Four trials
(N=1497) of botulinum toxin in chronic migraineurs showed a re-
duced frequency of -3.1 migraine days/month (95% confidence inter-
val (CI) -4.73 to -1.41) compared with placebo. Addition of one trial
(418 participants) in episodic migraine lowered this pooled estimate
of effect to -2.39 days/month (95% CI -4.02 to -0.76), still in favour of
botulinum toxin. Secondary efficacy measures were inconsistent.
Data for number of migraine attacks from six trials including chronic
and episodic migraineurs showed no significant between group dif-
ference (P=0.30), but severity of migraine (10 cm visual analogue
scale), was improved by -3.30 points (95% CI -4.16 to -2.45) more
with active treatment. Global assessment and quality of life measures
were poorly reported. Botulinum toxin had a relative risk of treat-
ment related adverse events of twice that seen for placebo (2.18,
95% CI 1.73 to 2.75). Insufficient data was available to establish any
dose-response relationship for any outcome measure. Three trials of
comparisons with oral prophylactic agents independently reported
no significant between group differences for a variety of diary data
outcomes but meta-analysis was not possible. Compared with oral
treatments, botulinum toxin showed a reduced relative risk of
treatment-related adverse events of 0.76 (95% CI 0.59 to 0.98).
Conclusions
In chronic migraine, botulinum toxin type A reduces frequency of mi-
graine by three days/month, reduces migraine severity by 30% and
has a favourable safety profile compared with other preventative
drugs. Evidence to support or refute the efficacy of botulinum toxin
in episodic migraine was not identified.
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Background: There is lack of evidence on how to detoxify
medication-overuse headache (MOH).
The aim was to compare the effect of complete stop of acute medi-
cation with restricted intake.
Methods: MOH-patients were included in a prospective, outpatient
study and randomized to two-month detoxification with either A) no
analgesics or acute migraine-medication, or B) acute medication re-
stricted to two days/week. Detoxification was followed by preven-
tives if indicated. Patients were followed-up at 2, 6 and 12 months.
Percentage reduction in headache-days/month after 6 months was
the primary outcome.
Results: We included 72 MOH-patients with a primary migraine and/
or tension-type headache diagnosis. Fifty-nine completed detoxifica-
tion, 58 (81%) were followed-up at month 6 and 53 (74%) at month
12. At month 6, program-A reduced headache-days/month by 46%
(95% CI 34–58) compared with 22% (95% CI 11–34) in program-B
(p=0.005), and 70% in program-A versus 42% in program-B were
reverted to episodic headache (p=0.04). Migraine-days/month were
reduced by 7.2 in program-A (p<0.001) and 3.6 in program-B
(p=0.002) after 6 months.
Conclusion: Both detoxification programs were very effective. Detoxi-
fication without analgesics or acute migraine-medication was the
most effective program.
Trial registration: Clinicaltrials.gov (NCT02903329).P13
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Background
Despite current preventive treatments almost 20% of patients with
cluster headache become chronic [1], with severe repercussion in
his/her daily activities and poor quality of life. Inhibiting sphenopala-
tine ganglion (SPG) could suppress the crisis [2], but its access is
quite difficult requiring aggressive methods [3]. Tx360 device is a
nasal applicator made of plastic material easing the access to the
SPG and the application of local anaesthetic in its vicinity with minor
inconveniencies [4].
Materials and methods
Twelve blocks (three each week during four weeks), of the SPG were
done with Bupivacaine 0,5% (0,3 cc each nostril), using the Tx360 de-
vice. We evaluate at the end of the 12th block (four weeks), efficacy
parameters (mean reduction of attack frequency and headache days),
impact (Headache Impact Test [HIT-6]), and quality of life (Migraine-
Specific Quality of Life Questionary [MSQ]), tools. We also analysed
30% and 50% response rates.
Results
Five patients refractories to standard oral therapies were treated
(4 M, 1 F; mean age 41,6 ± 11,8). At the 12th block there was a
significant reduction in mean attack frequency (6 vs. 15, p <
0,00002), and mean pain intensity (7 vs. 9,6, p< 0,005), not in
mean headache days (18,6 vs 26, p 0,15). There was a significant
reduction in mean HIT-6 (63 vs. 71), and MSQ (57 vs. 68). Four pa-
tients (80%), had a 50% or greater reduction in attack frequency,
and two (20%), in headache days. There were no significant ad-
verse events but minor and transient local discomfort; only one
patient suffer a syncope two hours after the second block, prob-
ably not related to the procedure.
Conclusions
Repetitive blocks of the SPG with the Tx360 device seem to be an ef-
fective treatment in chronic cluster headache, with minor adverse
events. These benefits were evident both in attack frequency and in
quality of life measures. Although encouraging these results must be
confirmed in a greater number of patients, and know how long they
will last. This therapy probably should be tried before invasive treat-
ments, with more serious adverse events.
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Medication Overuse Headache (MOH) impacts on patients’ daily life
and is associated to increased burden and cost1. Our aim is to ex-
plore gender differences with regard to cost and treatments.
Materials and methods
Direct (medical and non-medical) and indirect cost were directly
gathered from patients and referred to the previous three months.
Direct cost included medications for acute treatment and prophy-
laxis, diagnostic procedures, visits, complementary treatments and in-
formal care. Indirect costs were referred to missed workdays and
workdays with headache, and we relied on patients’ report on their
salaries and judgement on their overall level of performance for days
worked with headache.
Results
A total of 159 patients (25 males – 15.7%) were included.
With regard to indirect costs, males had higher salaries (202 Vs. 103
€/day; P<.001) and were less frequently unemployed (9.5% Vs. 27%).
Despite there were no differences on lost workdays and of days
worked with headache, indirect costs were higher among males
(2998 Vs. 1321 €/3-months; P=.022).
With regard to direct costs, there were no differences connected to
the overall amount and cost of drugs for prophylaxis and for acute
management, despite males consumed more triptans (89 Vs. 61 over
3 months; P=.019). Direct medical cost were comparable across gen-
der, while non-medical cost were mostly reported and were higher
for females (177 Vs. 19 €/3-months; P=.012). Taken as a whole, direct
costs were higher among females (1359 Vs. 794 €/3-months; P=.046).
Total cost were higher for males, but not to a significant extent
(3792€ Vs. 2680€ over three months).
Conclusions
Cost of MOH at the time point of withdrawal are high and wide-
spread. Males reported higher indirect cost, likely due to higher salar-
ies, while females reported higher direct cost, likely due to higher
non-medical ones. However, overall costs were similar across gender.
Taken as a whole, our data indicate that the annual cost per case of
non-treated MOH might be approximately 11400€: considering that
MOH prevalence is 2.1% among people aged 18-652 (i.e. around 39
millions), the global annual cost would be 9336.6 million €.
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Background: OnabotulinumtoxinA (OnabotA) is considered a safe
and effective preventive therapy in Chronic Migraine patients, as has
been shown in the PREEMPT clinical program and in real-life setting.
Though previously mentioned in literature, a possible excellent re-
sponse to this therapy has not been previously assessed in clinical
practice. We aimed to analyze the response to OnabotA, including
characteristics of optimal responders in a series of CM patients.
Materials and Methods: We included 124 CM patients (108 fe-
males, 16 males) treated with OnabotA according to the PRE-
EMPT paradigm in a headache unit. They had been previously
treated with topiramate and at least one other medication from
beta-blocker and flunarizine for at least three month, as recom-
mended in local guidelines. Monthly headache and migraine
days before and after OnabotA injections were recorded in a
diary. Patients were considered as responders when a reduction
of monthly headache days by at least 50% was achieved, and,
among them, as optimal responders if the reduction obtained
was over 75%.Results: Mean age at first procedure was 41.8 ± 11.4 years (18-71).
Latency between migraine onset and inclusion was 24 ± 12.9 years
(2-61), and between CM onset and inclusion 39.7 ± 44.2 months (6-
240). We classified 99 patients (79.8%) as responders and, among
them, 30 (30.3) were considered as optimal responders. Among re-
sponders group, both age at inclusion (40.5±11 vs 47±12, p:0.02) and
latency between migraine onset and OnabotA therapy (22.3±11.71
vs 20.4±15.4 years, p:0.021) were significantly decreased. Neverthe-
less, when comparing optimal responders with rest of responders we
found no differences.
Conclusion: An optimal response to the first procedures of OnabotA
is not exceptional in CM patients. It is advisable to consider this type
of response in order to look for its predictors.
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Background
To what extent do migraines differ from non-migraine headaches (per
ICHD-3beta criteria) in underlying pathophysiology? This study examined
risk factors associated with (a) occurrence and (b) severity of both mi-
graine vs non-migraine headaches. Because profiles of headache triggers
/ protectors vary greatly among patients, analyses were conducted at the
individual level and their results then used to draw sample aggregate
conclusions. For example, among participants who experienced a trigger,
the proportion for whom the trigger was associated with only migraines,
only non-migraine headaches, or both, was evaluated.
Materials and methods
Participants were 479 individuals with both migraines and non-
migraine headaches identified by clinician referral or via the internet
and registered to use a novel digital platform (Curelator HeadacheTM).
Participants completed baseline questionnaires and entered daily data
on headache occurrence, severity (level of pain), ICHD-3beta migraine
symptom criteria, and exposure to 70 migraine risk factors. Nearly 88%
of participants were female, 41% were US residents and 40% were UK
residents. Cox regression tested associations between binomial occur-
rence of a (non)migraine headache and risk factors. Hierarchical linear
modeling that was tailored for N=1 analysis (mixed model trajectory
analysis or MMTA) tested associations between risk factors and pain se-
verity of (non)migraine headaches. MMTA controlled for patient-
specific time-related trends in pain severity (mild – moderate – severe),
autocorrelation, and used conservative statistical tests for N=1 analyses.
Results
Regarding headache severity, 50% of risk factors were statistically as-
sociated with both migraine and non-migraine headaches whereas
the other half were unique to one form of headache. However,
within individuals, the particular risk factors that were associated
with either form of headache varied greatly. Moreover, regarding
specific risk factors, few individuals’ triggers / protectors were associ-
ated with both forms of headache. To illustrate, Fig. 1 presents the
proportion of participants whose protector was associated with both
forms of headache (rather than only one form).
Conclusions
Results suggest that risk factors associated with occurrence of mi-
graines both overlap and differ from the factors of migraine severity.
Moreover, these two sets of associations differ between migraine
and non-migraine headaches. These observations imply that etio-
logical factors differ between types of headaches. Results further sug-
gest that treatment of migraines could aim to not only prevent
attacks, but also reduce the pain (and thus impairment) that patients
experience during a migraine headache, a strategy that could be par-
ticularly important for patients with chronic migraines.
Fig. 1 (abstract P16). Proportion of Participants Whose Occurence
Protector Affects both Headache Types
Fig. 1 (abstract P17). See text for description
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Background
This investigation compared two within-individual analytic ap-
proaches to understand daily migraine occurrence and severity pat-
terns in relation to a spectrum of suspected risk factors. Cox
regression modelled migraine occurrence whereas headache sever-
ity was modelled using a form of hierarchical linear modeling tai-
lored for intensive within-person analyses. These two techniques
were compared in terms of which risk factors were identified as
possible “triggers” of migraine occurrence versus possibly contrib-
uting to severity of a migraine.
Materials and methods
Participants were 479 individuals with migraines identified by clin-
ician referral or via the internet and registered to use a novel digital
platform (Curelator HeadacheTM). Participants completed baseline
questionnaires and then entered daily data on headache occur-
rence and severity (level of pain), ICHD- 3beta migraine criteria, and
exposure to 70 migraine risk factors. Nearly 88% of participants
were female, 41% were US residents and 40% were UK residents.
Risk factors spanned emotions, sleep qualities, environment and
weather, lifestyle, diet, substance use, and travel. Cox regression
modelled the binomial occurrence of migraine attacks per individ-
ual participant; hazard ratios quantified their strength of association
with suspected triggers. The continuous measure of severity of mi-
graine headache was modelled using mixed model trajectory ana-
lysis (MMTA), a form of hierarchical linear modeling. MMTA
statistically controlled for patient-specific time-related trends in
pain severity, autocorrelation, and used statistical tests that gener-
ate conservative estimates for N=1 analyses.
Results
Numerous risk factors were associated with occurrence and severity
of migraine headaches. Cox regression detected potential triggers
that were associated only with occurrence (not severity) of migraine
attacks. Consistent with past evidence, the profile of risk factors
that were associated with occurrence and severity of migraines var-
ied considerably among patients, demonstrating that comprehen-
sive clinical research on migraines requires analytics at the N=1
level. Moreover, “profiles” of triggers and protectors varied consid-
erably among individuals (Fig. 1), suggesting that studies which
only consider sample-aggregate results do not generalize to many
migraine patients.
Conclusions
Cox regression and MMTA each provide unique insights regarding
within-person patterns and correlates of migraine occurrence andseverity, respectively. Cox regression’s detection of unique risk fac-
tors for occurrence of migraine headaches suggests that different
risk factors are associated with occurrence of migraine attacks ver-
sus severity of migraine pain. Moreover, treatment of migraine
headaches could aim to not only prevent occurrence of attacks, but
also reduce pain level (and thus impairment) during a migraine
headache, which could be especially important for patients with
chronic migraines.
Fig. 1 (abstract P19). Cervical MRI of the patient
Fig. 2 (abstract P19). Fluoroscopic lateral view during cervical medial
branch block
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Background
Cluster headache is a severe debilitating primary headache disorder.
Because cluster headache is very rare compared with migraine, cluster
headache is frequently misdiagnosed and neglected. We developed an
8-item self-administered questionnaire tool for detecting cluster head-
ache among patients with primary headache disorder, and test its reli-
ability and validity compared with neurologist’s diagnosis.
Materials and Methods
The candidate items were developed based on the diagnostic criteria of
cluster headache from the international classification of headache dis-
order 3rd edition beta version and expert opinions. The total score was
calculated from the sum of positive response to each items (ranging 0
to 8). The questionnaire was self-administered during the first visit to
headache clinic before neurologist’s diagnosis. The reliability and validity
were tested among patients with various primary headache disorders
Results
In total, 342 patients were enrolled: 28 with cluster headache, 254 with
migraine, 44 with tension-type headache, and 16 with primary stabbing
headache. Cronbach alpha was 0.619 and the areas under the curve were
0.922 in receiver operating characteristic curves for all 8 items. Using the
total score of 5 as cut-value, sensitivity and specificity were 83.3% and
90.9% for definite episodic cluster headache among 342 patients. The
validity was similar for differentiating cluster headache from migraine. Re-
mission or cluster period did not influence the detection rate.
Conclusions
This preliminary self-administered questionnaire for cluster headache
is reliable and useful tool. It may be suitable for detecting cluster
headache among primary headache disorders.
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Cervical medial branch block (MBB) is a frequently performed procedure
for management of neck pain that rarely has complications [1]. With
fluoroscopic guidance, the procedure is considered a relatively safer pro-
cedure than epidural block [2,3]. We report a case of a 27-year-old
woman presenting with postural headache after cervical MBB. Although
no specific evidence of dural injury was found in her cervical MRI (Fig. 1),
dural penetration by inappropriate needle placement was suspected after
reviewing fluoroscopic images of the procedure (Fig. 2). After conserva-
tive treatment, including bed rest and analgesic treatment, the patient
completely recovered without any neurological complications. Complica-
tions associated with MBB are rare and previous case reports have fo-
cused only on infection or vascular injection as etiologies. This is the first
report of complications related to dural puncture after cervical MBB. Our
findings suggest that misplacement of the block needle by inaccuratealignment of both sides of the cervical articular pillar, assessed by fluoro-
scopic view during the procedure, can result in dural injury.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Fig. 2 (abstract P20). Fluoroscopic lateral view during cervical
medial branch block at left C3, 4 and 5
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Background
Cervicogenic headache (CGH) is defined as headache originating from
various neck conditions. Transcutaneous electrical nerve stimulation,
nerve block, botulinum toxin (BoNT) injection and radiofrequency neur-
otomy have been recommended for treatment of medically intractable
CGH [1]. A few theories have been proposed to explain the analgesic
effect of BoNT. Some clinical trials of injecting BoNT near the targeted
nerves have shown its effectiveness in pain relief [2,3].
However up to this point, there is no report regarding the effective-
ness of BoNT when used in middle cervical medial branch block
(MBB) for the treatment of CGH. We hereby report a case where
BoNT was used in cervical MBB to treat cervicogenic headache.
Case Report
A 54 year-old male patient visited our pain clinic, complaining cervico-
genic headache and neck pain. The C-spine MRI revealed the osteoarth-
ritis at the facet joints of left C 3-4, 4-5 and 5-6. The MBB was
performed at left C3, 4 and 5 under fluoroscopy (Figs.1, 2 and 3). 1.2 ml
of 1% lidocaine was injected at each medial branch of C 3 to 5. The
NRS for cervicogenic headache decreased from 6 to 3 after the block
but without long lasting effect. After another trial of MBB with similar
result, we decided to use botulinum toxin under the hypothesis that it
would provide longer pain relief than diagnostic local anesthetics.
1.8ml of 1% lidocaine and BoNT (BOTOX® Type A, Allergan Inc., Irvine,
CA, USA) 50 U were mixed to 1.8ml of normal saline, and 1.2ml of the
mixture was injected at each level. The patient’s pain immediately de-
creased from NRS 6 to 3, and the effect lasted even after 3 months.
Conclusion
The use of botulinum toxin in middle cervical MBB may be effective
in treating cervicogenic headache.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Fig. 1 (abstract P22.) PRISMA diagram for the SLR of epidemiologic
studies in migraine
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Migraine is one of the most frequent neurological diseases. Specific fea-
tures of migraine are moderate to severe pain associated with photo-
phobia, phonophobia, nausea and/or vomit and it is worsened by
physical activity. It lasts 4 to 72 hours [1]. Several studies showed that
2,5% of Episodic Migraines (EM) can evolve in Chronic Migraine (CM),
characterized by high frequency of attacks (≥ 15days/month for more
than 3 months with at least 8 attacks having the features of migraine
headache) [2]. The pain intensity and the frequency may cause a
chronic excessive intake of medication for acute or symptomatic treat-
ment of migraine (triptans, AINS drugs, analgesics) leading to Medica-
tion Overuse Headache (MOH) [1].
Chronic migraine condition has a negative influence on many as-
pects of life, particularly on productivity at work. The American Mi-
graine Prevalence and Prevention Study (AMPP) showed that
migraine has a role both on absenteeism and presenteeism (reduced
performance while at work) [3].
The present study is a preliminary analysis on a sample with CM
treated with OnabotulinumtoxinA to examine work productivity in
association with sociodemographic and psychosocial variables.
Materials and methods
104 patients with a diagnosis of chronic migraine, undergoing Onabo-
tulinumtoxinA treatment (13 males; 91 females; mean age = 48,38 ±
9,85) have been enrolled in the Regional Referral Headache Centre of
Sant'Andrea Hospital in Rome. Sample healthy control has been
matched for age and sex.
All participants signed a consent form.
For this study the following tests have been used: Endicott Work Prod-
uctivity Scale (EWPS, Endicott J., 1997) is a self-report questionnaire to
evaluate work productivity through behaviours and feelings that are
likely to reduce efficiency; Quality of Life Enjoyment and Satisfaction
Questionnaire (Q-LES-Q, Endicott et al., 1993), Beck Depression Inven-
tory (BDI, Beck AT, 1961), State and Trait Anxiety Inventory (Spielberger
C, 1970); IPDQ (Innamorati et al., 2009).
Data have been analyzed using correlations and mean comparisons.
Results
There is no significant difference in work productivity between
the clinical group (M = 17,22; ± 12,31) and healthy controls (M =
17,98; ± 11,7).
In the clinical sample there is a strong negative correlation among
EWPS and Q-LES-Q scores (-,490: p<.000). Furthermore, there is a
strong correlation between less work productivity and high scores in
BDI (,445; p< .000), STAI (.499; p< .000), and IPDQ (.532; p< .000).
Conclusions
CM condition in patients undergoing treatment with Onabotuli-
numtoxinA is not associated to decreasing work productivity and
efficiency.
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Reported epidemiological estimates in migraine vary widely across
studies, mainly because of geographic variations, differences in study
characteristics and diagnostic criteria used over time. This study
aimed to identify and summarize population-based prevalence esti-
mates of migraine in the last decade, after the revised International
Classification of Headache Disorders (ICHD)-II definition.
Methods
A systematic literature review (SLR) of epidemiological studies in
migraine published from 2006 until October 2016 from MEDLINE
and EMBASE was conducted according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines. In addition, conference abstracts published in the past 3 years
(2014-2016) and references of most recent SLRs published were
also reviewed. The quality of the extracted articles was evaluated
using the modified Newcastle-Ottawa Scale for cohort studies.
Random-effect models based on the DerSimonian and Laird
method were used for meta-analysis of selected studies upon feasi-
bility and quality assessment. The results were reported as forest
plots displaying prevalence estimates and corresponding 95% con-
fidence intervals (CI).
Results
A total of 1,133 records were identified and screened, and 77 publica-
tions reporting results for 51 unique studies met study criteria for data
extraction (Fig. 1). In total 31 studies reported 1- year migraine preva-
lence, while 7 studies reported lifetime prevalence. Significant variation
was observed between studies; ICHD-II was the most commonly used
diagnostic criteria, while 25 out of 77 publications did not report the
diagnostic criteria used. The estimated migraine prevalence by any def-
inition was 14.2% (n=19, range 5.7% to 25.6%, 95% CI 13%-15.5%). The
prevalence of migraine was higher among studies based on ICHD-II or
later definitions (15.1%, 95% CI 13.6%-16.6%) than those using other
migraine definitions (11.4%, 95% CI 10.4%-12.5%). The prevalence of
episodic and chronic migraine were 13.6% (95%CI 10.4%-16.7%) and
0.9% (95%CI 0.32%-1.39%), respectively.
Conclusion
Despite marked heterogeneity of epidemiological studies across the
literature, this study provided an updated systematic summary and
evidence synthesis of the available prevalence estimates in migraine
during the last decade.
Competing interest
This study was funded by Novartis AG, Switzerland.
Table 1 (abstract P24). NNT, NNH and LHH for CM and EM
prophylactic treatments
Chronic migraine (CM) Episodic migraine (EM)
Erenumab
140 mg
Topiramate 100 mg Onabotulinum-
toxin A
Erenumab
140 mg
Topiramate
100 mg
Propranolol
160 mg
Data
source :
NCT
02066415
Silberstein
et al 2007
& 2009
Diener
et al
2007
Dodick et al
2010
NCT
02456740
Bussone et
al 2005
Diener et al
2004
NNT
≥50% RR
(95%CI)
6 (4,12) 13 (NE,
NE)
4 (3,
10)
9 (6, 15) 6 (4, 9) 5 (4, 6) 5 (4, 10)
NNH
% d/c
due to
AEs
(95%CI)
250 (NE,
NE)
21 (NE,
NE)
13 (NE,
NE)
39 (23, 100) 1000a (NE,
NE)
8 (6, 13) 11 (6, 72)
LHH
NNH/
NNT
(95%CI)
41.7 (5.3,
301.8)
1.6 (0.0,
112.8)
3.3
(0.7,
364.9)
4.3 (1.9, 11.4) 166.7 (9.0,
299.3)
1.6 (1.1, 3.1) 2.2 (0.8,
14.5)
CI confidence interval, 50% RR 50% responder rate, NE not estimable (risk difference CI overlaps zero)
aDiscontinuation rate (d/c) for erenumab was lower than placebo, yielding a negative absolute risk
reduction. Conservative imputation of 0.1% absolute difference used to calculate erenumab’s NNH
(otherwise not evaluable)
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Background: While cluster headache is one of the most disabling pain, it
has been less well studied compared with migraine. We hypothesized
that, considering its severity and chronicity, cluster headache could bring
about anxiety or depression, but the degree of psychological symptoms
might be different between active attack period and remission period.
Our aim was to investigate the association between cluster headache
and anxiety or depression during with or without headache period.
Methods: This is a preliminary analysis of ongoing prospective registry
enrolling patients with cluster headache from 17 clinics in South Korea
since June 2016. The diagnosis of cluster headache was made accord-
ing to the ICHD-III beta criteria. We assessed anxiety and depression
using the Generalized Anxiety Disorder 7 (GAD-7) and Patient Health
Questionnaire 9 (PHQ-9) scales. Control subjects without cluster head-
ache were recruited from 3 outpatient clinics. Linear regression was
performed to compare the GAD-7 and PHQ-9 scores between groups.
Results: A total of 78 patients (male 61, 78%) with cluster headache and
72 controls (male 60, 83%) were enrolled. Mean ages are 37 ± 11 years
in cases and 37 ± 9.2 years in controls. GAD-7 scores were 7.9 ± 6.0 in
cases during active attack period, 2.8 ± 3.4 in cases during remission
period, and 3.4 ± 3.8 in controls. PHQ-9 scores were 7.7 ± 6.6 in cases
during active attack period, 3.3 ± 4.4 in cases during remission period,
and 3.7 ± 4.1 in controls. On multivariable analysis, compared with con-
trol, cluster headache was significantly associated with GAD-7 (beta 4.4;
95% confidence interval 2.7 to 6.0; p value < 0.001) and PHQ-9 (3.9; 2.1
to 5.6; <0.001). Also, compared with remission, active cluster headache
was significantly associated with GAD-7 (4.7; 1.4 to 8.1), but if was mar-
ginally associated with PHQ-9 (3.2; -0.3 to 6.8; 0.07). However, compared
with control, remission status of cluster headache was not associated
with GAD-7 (-0.88; -3.1 to 1.3; 0.43) and PHQ-9 (-0.80; -3.2 to 1.7; 0.52).
Conclusion: Our study suggests that active attack of cluster head-
ache is associated with increased anxiety and depression compared
with remission status or control. However, remission period is not as-
sociated with anxiety or depression.
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Background
A key measure of successful therapy in migraine is the ability to sustain
efficacy. Numerous prophylactic medications are available for this chronic
disorder; however most of them have major shortcomings primarily due
to variable efficacy and poor tolerability due to side effects. This study
aimed to evaluate the benefit-risk of novel CGRP receptor antagonist ere-
numab, relative to other approved prophylactic migraine therapies.
Materials and Methods
Potential trials for inclusion were identified via a published systematic litera-
ture review [1] updated up to November 2016 using MEDLINE. As at thetime of evaluation erenumab’s complete pivotal trial results were unpub-
lished, clinical study reports were used (NCT02066415, NCT02456740). The
≥50% responder rates and discontinuations due to adverse
events were defined as primary efficacy and tolerability variables
to generate numbers needed to treat (NNT) and harm (NNH). The
LHH as a quantitative benefit-risk measure was computed based
on the ratio of NNH/NNT. Sensitivity analyses were conducted
using alternative efficacy and tolerability data.
Results
Of 146 articles assessed, 9 RCTs (11 articles) met inclusion/exclu-
sion criteria and were deemed of high quality per the Jadad
score. Propranolol, topiramate, and onabotulinumtoxinA (the latter
approved for CM only) were retained as comparators as they are
approved for migraine prophylaxis and available in the majority
of European countries. Table 1 shows an NNT of around 6 in
both CM and EM for erenumab. This low NNT is numerically com-
parable to topiramate and onabotulinumtoxinA and show the
strong treatment benefit of erenumab. NNH showed substantial
differences among treatments, with higher numbers indicating
better tolerability for erenumab. A favorable relative benefit-risk
was seen for erenumab with LHHs of 41.7 and 166.7 for CM and
EM respectively. In comparison, LHHs were lower in CM for topir-
amate (1.6 and 3.3) and onabotulinumtoxinA (4.3), and in EM, for
topiramate (1.6) and propranolol (2.2). Sensitivity analyses showed
results’ robustness despite residual variations and overall magni-
tude of LHH consistently favored erenumab.
Conclusions
While all prophylactic migraine treatments were more likely to
help than harm (LHH > 1), erenumab showed LHHs of high mag-
nitude, providing additional evidence to support the favorable
benefit-risk profile of erenumab to patients across the entire
spectrum of migraine compared with other migraine prophylactic
treatments available in Europe.
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Table 1 (abstract P25). Results on HRU after propensity score matched
analysis with non-migraine controls across EU5
Non-migraine
controls
(N=218)
Migraine
(N=218)
p-value
Number of HCP visits in the past 6 months (mean, SD) 5.13 (6.86) 8.48
(10.89)
<0.001a
Number of ED visits in the past 6 months (mean, SD) 0.21 (0.79) 0.46
(1.20)
0.011a
Number of hospitalizations in the past 6 months (mean, SD) 0.11 (0.53) 0.18
(0.54)
0.056a
Visited General Practitioner/Family Practitioner in the past 6
months (n, %)
147 (67.4%) 168
(77.1%)
0.025b
Visited Neurologist in past 6 months (n, %) 8 (3.7%) 30
(13.8%)
<
0.001b
Visited Psychiatrist in past 6 months (n, %) 7 (3.2%) 29
(13.3%)
<
0.001b
Visited ED in the past 6 months (n, %) 27 (12.4%) 45
(20.6%)
0.020b
Hospitalized in the past 6 months (n, %) 16 (7.3%) 28
(12.8%)
0.056b
aMann-Whitney test
bChi-square test
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Objectives
Migraine is a disabling neurological condition. The purpose of this
study was to understand the incremental burden of migraine on
healthcare resource utilization (HRU) in adults in Europe from the Na-
tional Health and Wellness Survey (NHWS), a self-administered,
internet-based questionnaire.
Methods
A retrospective, cross-sectional analysis of NHWS responses col-
lected in 2016 from the EU5 (France, Germany, Italy, Spain, and
UK) was performed. Adult (≥18 years old) respondents with a
self-reported migraine diagnosis who completed the migraine
module and with migraine experienced for ≥4 headache days in
the past month were matched by propensity scores using socio-
demographic characteristics to respondents without migraine
(controls). HRU was evaluated via the number of healthcare pro-
vider (HCP) visits, emergency department (ED) visits and hospitali-
zations in the past six months. Mann-Whitney and Chi-square
tests were used to determine significant differences between
groups.
Results
Among respondents with migraine (≥4 headache days/month;
n=218), 79.4% were female, the mean age was 43.25 years (SD =
13.48), and 60.1% were married or living with partner. Further-
more, 39.9% completed a university education and 62.4% were
employed. Analysis of the propensity score-matched sample of
218 migraineurs and 218 controls showed that in the 6 months
prior to questionnaire completion, the mean number of HCP
visits (8.48 vs. 5.13, p<0.001) and ED visits (0.46 vs. 0.21,
p=0.011) were significantly higher for migraine patients than
those without migraine. The number of hospitalizations was
higher among migraine patients (0.18 vs. 0.11, p=0.056) but mar-
ginally significant. Compared with matched controls, a signifi-
cantly higher proportion of migraine respondents had ≥1 visits to
a general/family practitioner (77.1% vs. 67.4%, p=0.025), neurolo-
gist (13.8% vs. 3.7%, p<0.001), and psychiatrist (13.3% vs. 3.2%,
p<0.001) in the prior 6 months. The proportion of individuals
with ≥1 ED visit was significantly higher for migraine patients
than those without migraine (20.6% vs. 12.4%, p=0.02) whereas
the proportion hospitalized (12.8% vs. 7.3% p=0.056) was slightly
higher, but marginally significant.
Conclusions
Results demonstrated a statistically significant increase in HRU
in terms of HCPs, neurologists, psychiatrists, and ED visits for
migraine patients compared with non-migraine controls. To help
reduce the burden of migraine on the European healthcare
system better treatment options for migraineurs should be
investigated.
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Introduction
Migraine is one of the most disabling neurological conditions world-
wide. The purpose of this study was to characterize the incremental
burden of migraine on quality of life (QoL), productivity, and health-
care resource utilization (HRU) by the frequency of migraine in adults
using European data from the National Health and Wellness Survey
(NHWS), a self-administered, internet-based questionnaire.
Methods
A retrospective, cross-sectional analysis of responses from the 2016
NHWS was performed using data from the France, Germany, Italy,
Spain, and UK (5EU). Adult NHWS respondents with a self-reported
migraine diagnosis who completed the migraine module were
matched by propensity scores to those without migraines (controls)
using sociodemographic characteristics. Outcomes of interest ana-
lyzed were from EQ-5D, SF-36v2, HRU and the Work Productivity and
Activity Impairment (WPAI) questionnaires. Migraine respondents
were stratified by frequency of migraines (headache days/month): 4-
7 episodic migraine (EM), 8-14 EM, and chronic migraine (≥15; CM).
Independent sample t-tests were used to determine significant differ-
ences between controls and the frequency of migraine groups.
Results
Results from the propensity score matched analysis demonstrated that
migraineurs reported statistically significant lower QoL and higher HRU
as compared to their matched controls. Impairment while at work and
total activity impairment was statistically significant higher among all
migraineurs compared to matched controls (Table 1).
Table 1 (abstract P27). Symptoms reported by working migraineurs at
least once in absenteeism-related migraine records. Number and propor-
tion of users reporting each of the symptoms are shown (n=3106)
Symptoms CM
(n=730)
8-14EM
(n=1237)
4-7EM
(n=1139)
Total
(n=3106)
Pain/Body 684 (94%) 1145 (93%) 1024 (90%) 2853 (92%)
Mood and cognition 661 (91%) 1114 (90%) 972 (85%) 2747 (88%)
Environmental
handicap
643 (88%) 1073 (87%) 944 (83%) 2660 (86%)
Depression 436 (60%) 590 (48%) 435 (38%) 1461 (47%)
Sleep alterations 296 (41%) 435 (35%) 256 (22%) 987 (32%)
Others 271 (37%) 296 (24%) 213 (19%) 780 (25%)
No symptoms 126 (17%) 274 (22%) 161 (14%) 561 (18%)
Note: each user could specify more than one symptom per record and
therefore numbers do not add up to 100%. Environmental handicap includes
ringing in ears (tinnitus), sensitivity to light, noise or smell; mood and
cognition symptoms include nausea, anxiety, confusion, blurred vision,
moodiness, or giddiness. Analysis of record-level data showed consistent re-
sults with the user-level data analysis.
CM chronic migraine, EM episodic migraine
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Migraine is a chronic disorder negatively affecting multiple do-
mains of individuals’ lives. This study demonstrated that there is
a statistically significant incremental burden due to migraine on
QoL, HRU and work productivity amongst the migraineurs in
comparison to matched controls.
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Introduction
The purpose of the study was to evaluate the impact of migraine on
work productivity as perceived by individuals suffering from migraine
in the real world using a self-reported smartphone application called
Migraine-Buddy©.
Methods
A retrospective, cross-sectional analysis was conducted using data
captured through Migraine-Buddy© from adult, self-diagnosed
migraineurs in 17 European countries. Data were analyzed for the
most recent 28-day period reported by migraineurs during the
study period June 2015-July 2016. Data from chronic migraine
(CM: ≥15 headache days/month, N=900), 4-7 episodic migraine
(EM) (n=1500) and 8-14 EM (n=1500) individuals were randomly se-
lected based on data completeness (fill rate >70%). Descriptive analysis
was performed.
Results
A total of 10,347, 11,301 and 6,504 migraine records were re-
trieved from CM, 8-14 EM and 4-7 EM individuals, respectively
corresponding to a total of 16,815, 14,398, and 7,693 migraine
days. Among employed migraineurs (n=3,106) who declared
‘work’ either as their migraine location or in ‘affected activities’ at
least once, an average of 57.4, 27.7 and 15.5 work days missed
per year were estimated as reported by CM (n=730), 8-14 EM
(n=1237) and 4-7 EM (n=1139) sufferers, respectively. The most
commonly reported triggers of absenteeism-related migraines
were psychological (38%), sleep (34%), nutrition (25%) and/or
menstruation (23%). Employed sufferers reporting absenteeism re-
corded symptoms relating to pain/body, mood/cognition distur-
bances, environmental handicap and depression among others
(Table 1).
Conclusion
Migraine is reported to have a considerable impact in the lives
of affected individuals with symptoms impacting the work
productivity of employed migraineurs irrespective of migraine
frequency.
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Introduction
Migraine is a neurological disorder that can cause severe disabling
pain. The purpose of the study was to describe the burden of mi-
graine on health-related quality of life (HRQOL) as perceived by indi-
viduals suffering from migraine in the real world using a self-
reported mobile application.
Methods
A retrospective, cross-sectional analysis was conducted using data cap-
tured through the Migraine-Buddy© smartphone application from adult,
self-diagnosed migraineurs in several European countries including the
UK, France, and Spain. Data were analyzed for the most recent 28-day
period reported by migraineurs during the study period (June 2015-July
2016). Migraine respondents (n=3900) were randomly selected based on
data completeness (fill rates >70%) and stratified by migraine headache
days/month: 4-7 episodic migraine (EM) (n=1500), 8-14EM (n=1500), and
chronic migraine (≥15; CM) (n=900). Descriptive analysis was performed.
Results
More than 95% of 3900 self-reported migraineurs reported that migraine
negatively impacted their daily activities in at least one migraine attack.
Attacks were estimated to affect 50.5% (184.4 days/year), 26.9% (98 days/
year) and 14.5% (53 days/year) of their calendar year among CM, 8-14EM,
and 4-7EM groups, respectively. On average, 44.8% CM, 40.9% 8-14EM
and 34.7% of 4-7EM sufferers respectively reported anxiety and/or depres-
sion symptoms during migraine attacks. Social or home activities,
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 36 of 151productivity, or sleep were highly impacted in migraineurs (Table 1). Trip-
tans (31.9%), nonsteroidal anti-inflammatory drugs (28.7%), acetamino-
phen (18.9%) and opioids (8.4%), and were self-reported as the most
common medicines used by migraineurs across migraine records
(n=28152).
Conclusion
This study highlights the high burden of migraine on HRQOL and
overall well-being of individuals suffering from migraines irrespective
of migraine frequency.
Funding: This study was funded by Novartis AG, Switzerland.
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European Academy of Neurology in Amsterdam, June 24-27, 2017.Table 1 (abstract P28). Impact of migraine on daily activities as
reported by migraineurs in at least one of their migraine records.
Number and proportion of users, by migraine frequency and overall,
reporting type of activity affected is shown
Type of activity
affected
CM
(n=900)
8-14 EM
(n=1500)
4-7 EM
(n=1500)
Total
(n=3900)
Home activities 520 (58%) 985 (66%) 933 (62%) 2438 (63%)
Productivity 590 (66%) 993 (66%) 841 (56%) 2424 (62%)
Social activities 553 (61%) 882 (59%) 736 (49%) 2171 (56%)
Sleep 470 (52%) 827 (55%) 676 (45%) 1973 (51%)
Others 268 (30%) 298 (20%) 204 (14%) 770 (20%)
Any activity 855 (95%) 1447 (96%) 1430 (95%) 3732 (96%)
Others include affected activities that do not fit in the displayed categories.
Migraine Buddy users could specify more than one activity affected in their
records; pooled results across all migraine records are presented for the most
recent 28-day period reported by migraine patients during the study (June
2015-July 2016)P29
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Background
Monthly Migraine Physical Function Impact Diary (MPFID) domain
scores (Impact on Everyday Activities [EA, 7 items] and Physical
Impairment [PI, 5 items]) range from 0–100 (higher score=greater
impact). A Global Impact on Everyday Activities score (G-EA) is
generated from a single item. We report a clinically meaningful
within-patient change (CMWPC) in migraine impact scores and
evaluation of CMWPCs in the STRIVE study (NCT02456740) in sub-
jects with episodic migraine (EM).
Methods
CMWPCs for MPFID were developed using anchor- and
distribution-based methods using data pooled across treatment
CM Chronic Migraine, EM Episodic Migrainegroups from the ARISE study (NCT02483585) and an observa-
tional study of patients who recently initiated or changed their
migraine preventive regimen. Clinically relevant anchor variables
(≥30% and ≥50% reduction in monthly migraine days [MMD]
and ≥20% and ≥50% reduction in MPFID G-EA) were used to
estimate average within-subject point change from baseline in
MPFID domain scores; distribution-based estimates based on
variability were considered supportive. These CMWPCs were
used to examine the proportion of responders to treatment in a
post-hoc analysis of the STRIVE study. Cumulative distribution
function (CDF) plots demonstrated percentage of subjects
within each treatment group achieving the range of CMWPCs
from baseline in MPFID domain scores.
Results
Estimates from the ARISE study and observational study sug-
gested that CMWPCs starting at 3-point change in MPFID EA and
PI domains represented CMWPC. In the STRIVE study, larger pro-
portions of erenumab-treated subjects than placebo achieved a
≥5-point reduction (pre-specified endpoint) from baseline to
mean of weeks 13–24 in PI (140mg: 42.5%; 70mg: 39.1% vs pla-
cebo: 30.1%, both p<0.05) and EA domain scores (140mg: 50.3%;
70mg: 49.0% vs placebo: 34.5%, both p<0.001). The CDF plots
showed that more subjects in 140mg and 70mg erenumab
groups than placebo had greater reductions in EA and PI domain
scores. The erenumab groups had consistently larger proportions
of responders than placebo starting as low as a 3-point change
from baseline score and across a range of CMWPCs.
Conclusion
Reductions starting at 3 points in MPFID domains are representa-
tive of CMWPCs. Treatment with erenumab 140mg and 70mg in
the STRIVE study was related to clinically meaningful reductions
in the impact of migraine on physical functioning versus placebo,
based on greater proportions on erenumab experiencing within-
subject change ≥5 points. This supports the utility of MPFID as a
marker for migraine clinical benefit and demonstrates the value
of erenumab as a preventive therapy to improve functioning in
subjects with EM.P30
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The Trigger Avoidance Model of Headaches
The Trigger Avoidance Model of Headaches (TAMH) has been pro-
posed to explain how triggers acquire the capacity to precipi-
tate headaches [1,2,3]. The Model is based on the theory that a
critical process in the development of a headache disorder may
be trying to avoid the triggers resulting in a sensitisation
process such that tolerance for triggers diminishes. The concep-
tual underpinning of the TAMH comes from cognate literatures
such as the anxiety literature as there is much evidence that
efforts to avoid stimuli/situations that elicit anxiety resulting in
short exposure to those stimuli, will lead to those stimuli
eliciting more anxiety in the future. Treatment of anxiety disor-
ders is based on the reverse principle of prolonged exposure to
anxiety-eliciting situations, leading to desensitisation. The TAMH
has received support in a series of laboratory investigations that
demonstrate short exposure to headache triggers results in
sensitisation, whilst prolonged exposure leads to desensitisation
[4,5,6,7].
Fig. 1 (abstract P31). Graphical representation of the mediatory
relationship between medication and sleep quality, and headache
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Advice to avoid triggers as a means of preventing headaches, has
been the standard for decades. The implication of the TAMH is that
such advice may be counterproductive for some triggers as it could
lead to reduced tolerance for those triggers. Based on the TAMH, it
has been argued that counselling avoidance should be replaced
with a philosophy of Learning to Cope with Triggers (LCT) [1,2,3].
LCT specifies use of exposure-based strategies for triggers such as
stress, negative affect, and sensory triggers (visual disturbance,
noise); and avoidance strategies for triggers that are not consistent
with a healthy lifestyle (e.g., hunger, dehydration, lack of sleep).
LCT has been evaluated in a randomised controlled trial with the
following outcomes [8]. Changes in headaches and medication con-
sumption (in parentheses) from pre- to post-treatment were (a
minus sign indicates improvement): Waiting-list, +11.0% (+15.4%);
Avoidance, -13.2% (-9.0%); and LCT, -35.9% (-27.9%). Avoidance did
not differ significantly from Waiting-list for headaches or medica-
tion use, but LCT differed significantly from Waiting-list for both
measures. Three illustrative case studies of LCT have since been
published describing the use of exposure techniques with the trig-
gers of stress/anger, tiredness and heat [9]. Coping with triggers is
now beginning to achieve recognition in the literature. For ex-
ample, the European Federation of Neurological Societies guide-
lines on treatment of tension-type headache include “Identification
of trigger factors should be performed, as coping with trigger fac-
tors may be of value (Martin & MacLeod, 2009)” [10].
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Background
Evidence that sleep dysfunction can play a role in headaches has
been well established. We have previously reported various sleep fac-
tors are correlates of headaches, particularly sleep quality [1].Medication overuse headache develops when acute or symptomatic
headache medications are used too frequently. Given commonly
used medications such as NSAIDs and opioids disrupt sleep architec-
ture [2, 3], we sought to test the hypothesis that greater use of acute
medications would be associated with more frequent headaches, as
mediated by sleep quality.
Method
Participants (n = 370, 85% female) were recruited through headache
and pain websites, and University recruitment channels. Utilising a
cross-sectional design, participants completed a battery of online
measures including headache type/frequency and use of headache
analgesic/abortive medications, and sleep variables such as sleep
quality and duration.
Results
Regression models found medication use (MU) and sleep quality (SQ)
to be significant predictors of migraine frequency, F (2, 367) = 78.21,
p < .001, R2 = .3; and non-migraine headache frequency, F (2, 367) =
98.67, p < .001, R2 = .35. Mediation analysis revealed MU had a sig-
nificant direct effect on migraine (Predictor coefficient = .417, p <
.001), which was mediated by SQ (Mediator coefficient =.048, 95%CI
.023, .083, κ2 = .061). A significant direct effect for MU was found for
non-migraine headaches (PC = .524, p < .001), and that effect was
also mediated by SQ (MC = .03, 95%CI .006, .06, κ2 = .039).
Conclusions
This paper provides a foundation for future investigations using
stronger prospective designs to examine if medication overuse head-
ache is partly mediated by the deleterious effect some medications
may have on sleep architecture and quality. Such studies may em-
ploy prospective designs and sophisticated laboratory measurements
rather than self-report. Another avenue for investigation is whether
the effect of headache relieving medications can be augmented with
adjunctive therapy for sleep (e.g., Melatonin).
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Negative affective states, like anger and fear, are deeply involved in
the emotional experience of pain [1]. It is reported that individuals
with migraine and tension type headache are more likely to hold
their anger-in than controls. One study showed that headache pa-
tients hold their anger-in more than controls, even after controlling
for depression and anxiety [2]. However, no study evaluated anger in
cluster headache (CH) and differences between migraine (M) and CH
patients. The objective is to evaluate differences between M and CH
patients in anger levels and in anger expression.
Materials and Methods:
134 M patients and 105 CH patients were administered the State
Trait Anger Expression Inventory (STAXI-2, 56 items), composed by
seven subscales. State Anger refers to the intensity of the individual’s
angry feelings at the time of testing. Trait Anger evaluates person’s
general predisposition to become angry. Anger expression is mea-
sured by: Anger Expression Out (the extent to which anger could be
expressed in an outwardly manner), Anger Expression In (the extent
to which anger is suppressed), Anger Control Out (prevent explosive
manifestations of anger), Anger Control In (try to relax and reduce
angry feelings) and Anger Expression index (an overall index of the
individual tendencies to express anger).
Results:
CH patients have higher scores than M patients (p<0.05) in State
Anger. Moreover CH patients have higher scores in Anger
Expression-Out (p<0.05). No differences were found in trait anger
subscales (tab.1). In particular, in sub-group analysis, patients with CH
during cluster period have higher state anger than chronic migraine
patients, while CH patients in headache free period did not differ
from M patients.
Conclusions:
The results indicate that M and CH patients differ in state anger, but
not in trait anger, suggesting that there are no dispositional differ-
ences in anger feeling. In CH, especially during cluster period, was
detected higher intensity of anger feeling during the time of testing.
This data support the bio-behavioral hypothesis of different behav-
ioral response to pain in M and CH patients (sickness behavior vs
defense reaction) [3], and add new information about emotional
regulation involved during headache’s attack.
References
1. Venable VL, Carlson CR, Wilson J. The role of anger and depression in
recurrent headache. Headache 2001;41:21–30.
2. Nicholson RA, Gramling SE, Ong JC, Buenevar L: Differences in anger
expression between individuals with and without headache after
controlling for depression and anxiety. Headache 2003;43:651-663.
3. Montagna P, Pierangeli G, Cortelli P.The primary headaches as a
reflection of genetic darwinian adaptive behavioral responses. Headache.
2010 Feb;50(2):273-89. Epub 2009 Dec 21.Table 1 (abstract P32). Mean scores at Staxi-2
STAXI-2 Migraine patients
(n=134)
Cluster headache patients
(n=105)
p
State Anger 17,51 20,11 P<0.05
Trait Anger 5,42 6,15 ns
Anger Expression
index
46,27 47,29 ns
Anger Expression
in
20,25 19,76 ns
Anger Expression
out
16,99 18,32 P<0.05
Anger Control in 18,48 18,79 ns
Anger Control out 20,48 20,00 nsP33
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Objectives
Fremanezumab is a fully humanized IgG2Δa monoclonal antibody that
selectively blocks CGRP isoforms (α- and β) from binding to the CGRP
receptor. Fremanezumab was effective and well-tolerated as a prevent-
ive treatment of episodic migraine and chronic migraine in phase 2 and
phase 3 trials. The present study evaluated the pharmacokinetic profile,
safety, and immunogenicity of fremanezumab doses tested in the
phase 2 and 3 trials (225mg, 675mg and 900mg) following single ad-
ministration in Japanese (n=32) and Caucasian (n=32) healthy subjects.
Methods
Japanese and Caucasian healthy subjects were enrolled into 1 of 4
cohorts: cohorts 1 and 3 were Japanese and cohorts 2 and 4 were
Caucasians. Subjects in each cohort were randomly assigned to 1 of
4 treatments: 225, 675, or 900 mg fremanezumab, or placebo. In the
first cohort only, a dose escalation scheme was applied where study
drug was not escalated to the next dose level unless the safety and
tolerability of the previous doses were acceptable by sponsor and
clinical team. Caucasian subjects were matched to Japanese subjects
based on gender, age (± 10 year) and BMI (±20%). PK and immuno-
genicity sampling and safety & tolerability assessments occurred dur-
ing 13 clinic visits including 1 inpatient visit from day -1 to day 6
and 12 ambulatory visits between post treatment days 8-225.
Results
Sixty-two subjects out of 64 completed the study; 2 Japanese subjects
(1 225mg and 1 900mg fremanezumab) withdrew consent because of
family emergencies. Overall median Tmax was similar across doses and
ranged from 5 to 7 days. Mean half-lives were similar across doses
(range 32.23 to 36.15 days). No differences due to race/ethnicity. In-
creases in Cmax and AUCs were slightly greater than dose proportional
for both Japanese and Caucasian subjects. Fremanezumab exposures
were generally higher with lower body weights. No deaths or SAEs;
most frequently occurring AEs (≥2 subjects) were injection site reac-
tions, abdominal pain, headache, upper respiratory tract infection,
constipation and nasopharyngitis. Local tolerability of the SC fremane-
zumab injection was comparable between Japanese and Caucasian
subjects. No treatment-induced anti-drug-antibodies occurred and
there were no clinically meaningful changes in laboratory findings.
Conclusion
Overall fremanezumab was safe and well tolerated following SC sin-
gle doses (225, 675, or 900mg). Pharmacokinetic exposure parame-
ters per dose were similar for Japanese and Caucasians. Half-life
following SC injections support the once monthly SC injections of
225mg and quarterly SC injections of 675mg as a treatment doses.
Trial registration
Clinicaltrials.gov NCT02673567
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Fig. 1 (abstract P35). Posterior Mean Maximum Headache Free Day
Distrivutions
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Background
Fremanezumab is a fully humanized IgG2Δa monoclonal antibody
found to be effective and well-tolerated as a preventive treatment
for migraine in phase 2 and 3 studies. Previously reported data has
shown that on headache free days, patients on fremanezumab treat-
ment had greater number of days in which they were able to work/
study normally, less time with difficulty in concentration, and more
time engaged and interested in daily activities. The present report
describes a Bayesian model performed to evaluate the number of
consecutive headache free days in the high frequency episodic mi-
graine (HFEM) study.
Methods
This was a randomized 3-month phase 2 study comparing two
doses of fremanezumab (225 mg and 675 mg) with placebo. Dur-
ing a 28 day run-in period, patients were screened and trained
to capture daily headache information using an electronic head-
ache diary. Following the run-in period, patients who were 80%
compliant in diary entry and had migraine headaches at least 8
but less than 14 days per 28 days were randomized and treated
subcutaneously once every 28 days with either 225 mg or 675
mg fremanezumab or placebo. Compared to placebo, both doses
of fremanezumab significantly reduced the primary endpoint of
the HFEM study, change in the number of migraine days at
month 3 relative to baseline; herein we assessed in a post-hoc
analysis whether there were differences in the maximum number
of consecutive headache free days among the treatment arms.
Due to the skewed nature of the distribution of maximum head-
ache free days, the data were modeled assuming a geometric
likelihood. Bayesian model using non-informative priors on the
headache rate was used.
Results
In the posterior distributions for the maximum number of consecu-
tive headache free days (Fig. 1), there is a separation between the
curves for participants taking fremanezumab 225mg (n=96) and
675mg (n=97) compared to those taking placebo (n=104). Posterior
probabilities and 90% credible intervals for the differences between
the fremanezumab 225 mg arm and placebo were 0.965
[0.316,6.709] and for fremanezumab 675 mg arm vs placebo 0.993
[1.553,8.322]. Patients in the fremanezumab 225 mg group had
mean(SD) maximum number of consecutive headache free days of
14.5(15.0), 675 mg group experienced 15.9(14.8) days and the pla-
cebo group 11.12(10.6) days.
Conclusion
The results of this post-hoc analysis suggest that HFEM patients tak-
ing fremanezumab at doses of 225mg and 675mg can expect to
have a greater maximum number of consecutive headache free days
than patients on placebo.
Trial registration
Clinicaltrials.gov NCT02025556
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Background. Fremanezumab (formerly TEV-48125) is a fully human-
ized IgG2Δa monoclonal antibody that selectively blocks both CGRP
isoforms (α- and β) from binding to the CGRP receptor. Fremanezumab
was effective and well-tolerated as a preventive treatment of episodic
migraine and chronic migraine in phase 2 and phase 3 trials. The
present study evaluated the pharmacokinetic profile, safety, and im-
munogenicity of fremanezumab doses tested in the phase 2 and 3 tri-
als (225mg, 675mg and 900mg) following single administration in
Japanese (n=32) and Caucasian (n=32) healthy subjects.
Methods. Japanese and Caucasian healthy subjects were enrolled into
1 of 4 cohorts: cohorts 1 and 3 were Japanese and cohorts 2 and 4
were Caucasians. Subjects in each cohort were randomly assigned to 1
of 4 treatments: 225, 675, or 900 mg fremanezumab, or placebo. In the
first cohort only, a dose escalation scheme was applied where study
drug was not escalated to the next dose level unless the safety and tol-
erability of the previous doses were acceptable by sponsor and clinical
team. Caucasian subjects were matched to Japanese subjects based on
gender, age (± 10 year) and BMI (±20%). PK and immunogenicity sam-
pling and safety & tolerability assessments occurred during 13 clinic
visits including 1 inpatient visit from day -1 to day 6 and 12 ambulatory
visits between post treatment days 8-225.
Results: Sixty-two subjects out of 64 completed the study; 2 Japanese
subjects (1 225mg and 1 900mg fremanezumab) withdrew consent be-
cause of family emergencies. Overall median Tmax was similar across
doses and ranged from 5 to 7 days. Mean half-lives were similar across
doses (range 32.23 to 36.15 days). No differences due to race/ethnicity.
Increases in Cmax and AUCs were slightly greater than dose propor-
tional for both Japanese and Caucasian subjects. Fremanezumab expo-
sures were generally higher with lower body weights. No deaths or
SAEs; most frequently occurring AEs (≥2 subjects) were injection site re-
actions, abdominal pain, headache, upper respiratory tract infection,
constipation and nasopharyngitis. Local tolerability of the SC fremane-
zumab injection was comparable between Japanese and Caucasian
subjects. No treatment-induced anti-drug-antibodies occurred and
there were no clinically meaningful changes in laboratory findings.
Conclusions. Overall fremanezumab was safe and well tolerated fol-
lowing SC single doses (225, 675, or 900mg). Pharmacokinetic exposure
parameters per dose were similar for Japanese and Caucasians. Half-life
following SC injections support the once monthly SC injections of
225mg and quarterly SC injections of 675mg as a treatment doses.
Table 1 (abstract P36). ISR-AEs over the 12-week DBTP, n (%)
Erenumab, mg
Placebo
(N=1043)
70
(N=893)
140
(N=507)
Any ISR-AE 33 (3.2) 50 (5.6) 23 (4.5)
ISR-AEs with >0.5% frequency in any group
Injection site pain 18 (1.7) 33 (3.7) 8 (1.6)
Injection site erythema 2 (0.2) 9 (1.0) 10 (2.0)
Injection site pruritus 3 (0.3) 4 (0.4) 4 (0.8)
Table 2 (abstract P36). ISR-AEs over the EEP
Erenumab, mg
70
(N=2128)a
140
(N=1198)a
Subjects who experienced an ISR-AE, n (%) 130 (6.1) 50 (4.2)
Total time at risk summed across subjects, years 1738 649
Exposure-adjusted subject incidence rate per 100
subject-years
7.5 7.7
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Background
Erenumab is a fully human monoclonal antibody that selectively
inhibits the calcitonin gene-related peptide (CGRP) receptor under
investigation for migraine prevention. Erenumab is administered
monthly by subcutaneous injection. Here we report the incidence
of injection site reaction-related adverse events (ISR-AEs) ob-
served in erenumab clinical trials in subjects with episodic or
chronic migraine.
Methods
Data were obtained from four placebo-controlled clinical trials
(clinicaltrials.gov NCT01952574, NCT02066415/NCT02174861,
NCT02456740, NCT02483585). Analysis was performed for two
periods: the 12-week double-blind placebo-controlled treatment
period (DBTP; erenumab and placebo) and the entire erenumab
exposure period (EEP), including the open-label extension phase
(erenumab only). AEs were graded according to Common Ter-
minology Criteria Version 4.03.
Results
Over the 12-week DBTP, incidence of ISR-AEs was 3.2%, 5.6%, and
4.5% in the placebo, erenumab 70 mg, and erenumab 140 mg
groups, respectively (Table 1).
Over the EEP, which extended erenumab exposure to median 46
weeks (mean 47, range 0–159), incidence of ISR-AEs was 6.1%
and 4.2% in the erenumab 70 mg and 140 mg groups, respect-
ively (Table 2)
Over the EEP across both doses, most ISR-AEs were mild (Grade
1). Moderate ISR-AEs (Grade 2) were injection site erythema (four
subjects, 0.2%), injection site pain (three subjects, 0.1%), and in-
jection site reaction, injection site induration, and injection site
urticaria (one subject each, <0.1%). There were no ISR-AEs of
Grade >2, and no serious ISR-AEs. Across 2519 subject years of
erenumab exposure, one subject (<0.1%) discontinued due to in-
jection site pain, one due to injection site rash, and one due to
injection site urticaria.
Conclusion
ISR-AEs occurred in a small proportion of subjects treated with
either dose of erenumab, with little change over time. Most ISR-
AEs were mild and did not require discontinuation.P37
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Chronification of migraine has many known factors and many
others under study, like psychological, psychiatric, metabolic
factors, metabolic poor management of therapy, etc.
Simple and cost-effective parameters, to identify target for new therapy
have always been the target of research. Careful observation of headache
diaries shows sometimes that some migraine attacks may be recurrent
and methodically after 2-3h after meals, especially if carbohydrates rich,
such as breakfast and lunch in the Mediterranean diet.
The fact that nutritional and metabolic factors can worse and chronify
migraine is well known, but body weight and body mass index (BMI)
are probably not the only elements to evaluate in these patients.
We therefore identify patients with chronic migraine diagnosis in which
a diary with a methodically post-prandial attack, we performed a gly-
cemic and insulin-like curve of with a load of 75g glucose and subse-
quent withdrawals at 0-60-120-180 minutes. We collected also data on
headache/day frequency per month, BMI, anamnestic presence of poly-
cystic ovary in the woman.
We currently recruited 28 subjects, 24 women, 4 men 32.6 years of
age, BMIs between 34 and 18 with an average of 26.9, mean head-
ache days per month of 18,2.
Comparing the glycemic curves of these patients it is noted that base-
line blood glucose was for everyone within the norm parameters, but
in 24 of 28 patients between 2 and 3 hours the blood glucose de-
creased below baseline and in 20 below normal values,
(hypoglycaemia), no patient has exceeded 200mg /dl.
For insulinemic values, all patients showed normal baseline values
that increase after 60 minutes reaching > 10 times of baseline, with
gradual reduction over the next 3h.
aSubjects who received >1 dose level were counted in both dose levels
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 41 of 151Based on the data obtained, we have diagnosed metabolic syndrome
in 6 patients, for the correlation between hyperinsulinaemia and high
BMI, and insulin resistance related to polycystic ovary syndrome in
22 patients with hypoglicemya and PCOS history.
Both group of patients with metabolic syndrome and insulin resist-
ance, were then subjected low charb diet. Preliminary data show that
there is a rapid reduction in body weight and the reduction/ansence
of post meal migraine attack with a mean reduction of more than
50% on headache days.
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Background
Noninvasive neuromodulation techniques promise efficacy in the
treatment of migraine [1]. Interestingly, Ayata et al. have recently re-
ported that noninvasive direct vagus nerve stimulation (nVNS) signifi-
cantly suppresses spreading depression susceptibility in the occipital
cortex in rats [2]. Here we describe a case of a female patient whose
aura was repeatedly and consistently shortened by peripheral vagal
nerve stimulation using the gammaCore device.
Case report
The subject is a 38-year-old female patient with both migraine with
(MA) and without aura (MwA), diagnosed according to the ICHD-3
beta criteria [3] The reported mean frequency of MwA days per
month was 7-8, while the frequency of MA attacks was 4-5 per year.
Usual aura consisted in monolateral negative scotoma with gradual
onset, progressively evolving in homonymous hemianopia (either left
or right) and followed by unilateral paresthesias with a progressive
involvement of the arm and hemiface. The full aura duration was 1-2
hours, being followed almost immediately by severe unilateral mi-
graine (either left or right) resistant to triptans. MRI and angio-MRI
showed a paraphysiological vascular variation of the anterior com-
municating artery which devoid of clinical relevance. The patient was
taking cinnarizine, 25 mg daily, for migraine prevention. She was also
on combined oral contraception since 2013, without any worsening
effect of hormonal treatment on either MA or MwA. Medical history
showed only an asymptomatic iron deficient anemia.
The patient first used the gammaCore device during a clinical study
for the acute treatment of migraine attacks. She was trained to de-
liver one 120” stimulation per side of the neck at the beginning of
the attack, regardless of the location of the pain.
During the open label phase of the study, the patient had the possi-
bility to treat multiple migraine attacks. During the 3 treated MA at-
tacks, the patient recorded on the electronic diary a consistent effect
of nVNS in terms of: reduction of the duration of the visual symp-
toms (from the usual 60-120 minutes to 1-2 minutes), the complete
prevention of the somatosensory aura and the prevention and/or re-
duction of the painful phase.
Conclusions
Previous data from the literature clearly show that, in animal studies,
nVNS modulates multiple pain pathways and decreases cortical spread-
ing depression. VNS activates nucleus tractus solitarius, locus ceruleus
and dorsal raphe nuclei, all of which can modulate CSD susceptibility
[2]. To the best of our knowledge this is the first documented report on
the effectiveness of nVNS using gammaCore on aura symptoms and,together with the experimental data cited above, it provides a rationale
for assessing the potential effect of nVNS in the acute treatment of MA.
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Cortical laminar necrosis (CLN) is a permanent brain injury radiologically
with gyriform distribution. CLN is caused by cerebral energy depletion
and it is characterised by high-intensity cortical lesions on T1-weighted
MRI images which follow the gyral anatomy of the cerebral cortex. In
children, cortical laminar necrosis is usually seen in the subacute or
chronic phase of brain damage in hypoxic-ischemic encephalopathy.
Other possible etiologies are metabolic disorders, hypoglycemia, renal
and hepatic dysfunction and immunosuppressive chemotherapy. CLN
may also be seen in patients with encephalitis, but it's an uncommon
finding in migraine and status migrainosus with or without aura.
We present the case of a 14-year old male patient, without known his-
tory of migraine or neurologic issues, who came to our attention for
the manifestation of an acute and long persistent (>72h) symptomatol-
ogy characterized by headache, confusional state, dysarthria, aphasia
and visual disturbances. Clinical evaluation, laboratory tests and instru-
mental examinations were performed during the hospitalization. Sub-
mitted to a first emergency RMN, a localized edema in the
supramarginal gyrus in left brain hemisfere has been identified as a
possible vascular etiology. Supramargynal gyrus (Broadmann's area 40),
a portion of the parietal lobe, is considered to be part of Wernicke's
area and it is probably involved with language perception and process-
ing. At a RMN control, it was possible to highlight a laminar necrosis of
the cortical-pial zone in that area. This case appears to be interesting
for the uncommon correlation between cortical laminar necrosis and
status migrainosus with aura as well as for the site of the hypoperfusion
revealed through RMN and for the atypical progression of the aura.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Visual snow in a patient with occipital stroke: do we have to
rethink migrainous infarction pathophysiology?
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Background
Visual snow (VS) has recently been described as a distinct event
from persistent migraine aura and classification criteria have been
proposed [1]. The latest classification of headache disorders of 2015
[2] describes migrainous infarction (MI) as a typical aura that per-
sists and neuroimaging shows an ischaemic lesion in the contralat-
eral cortex.
We describe the case of a patient who reported short-lasting daily
symptoms of VN in his entire visual field, for about 40 years, until
the day where he woke up with a continuous right sided visual
snow phenomenon and was later diagnosed a left occipital stroke.
Case report
On January 2017 a 74 years-old male was referred to our head-
ache outpatient clinic with the diagnosis of cerebral ischaemia
and migraine aura. Nine months before he was admitted to the
emergency department due to persistent visual symptoms started
8 hours before: at neurological examination he had a left visual
field impairment, therefore he was admitted to the neurological
ward with the diagnosis of possible protracted migraine aura. He
was discharged 6 days later, with the diagnosis of cerebral is-
chaemia due to occlusion of right posterior inferior cerebral ar-
tery. Few weeks after the discharge, a paroxysmal atrial
fibrillation was detected on 24-hours ECG and a treatment with
novel anticoagulants started. One month later a visual field de-
tected superior right homonymous quadrantopia.
When we first visited the patient, he referred that, prior to the
stroke, he had been suffering over the last 40 years, of sudden
impairment of vision, lasting for about 5 minutes, similar to a
badly-tuned tv channel, with little spots moving in the entire vis-
ual field, with little if no disability. He also referred no significant
headache ever. After the occurrence of the stroke the same
symptoms became persistent and localised at his left visual field.
Neurological examination disclosed, in addition to the known vis-
ual field impairment, bilateral hypoacusia with left tinnitus. There-
fore, a diagnosis of persistent partial VN phenomenon secondary
to occipital stroke was done and Magnetic Resonance Imaging
(MRI) prescribed together with a visual field: no changes were
later reported in the follow-up visit in both exams.
Conclusions
We report, for the first time, the case of a patient whose tempor-
ary daily VN phenomenon reversed to a persistent one, in the
visual field affected by ischaemic occipital stroke, as typically
happens in migraine stroke. This fact may open a new scenario
in the pathophysiogenesis of MI that is believed to be due to ei-
ther vasoconstriction or protracted oligoemia after an aura [3],while visual snow phenomenon has been associated to an in-
crease of blood flow [4]. We hypothesise that, in our patient, the
occipital lesion disrupted inhibitory circuits producing quadranto-
pic persistent VN. The same mechanism could be hypothesised
for MI, where the aura could be the result rather then the actual
cause of the stroke itself.
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Background
Migraine is a disabling neurological disease. While it is most com-
mon among working-age population, it presents significant indirect
costs to society, especially when migraine attacks are frequent. The
aim of this study was to assess the prevalence of migraine, and pro-
portion of patients needing prophylactic treatment in different age-
groups. In addition, we aimed to define the current primary care
migraine treatment patterns in Finland.
Materials and methods
We conducted a retrospective register-based study based on pre-
scription data from primary healthcare electronic medical records.
The data set covers an overall population of 2,1M inhabitants. Pa-
tients were included in the study cohort if they had ≥ 1 prescription
for an acute or prophylactic migraine medication during 1.1.2012-
30.9.2016. Patients of all ages were included in the cohort. An open
text search was combined to search based on ICD-10 and ATC-codes,
in order to confirm the accuracy of migraine-related use.
Results
Altogether 61,077 migraine patients were identified. Among these pa-
tients 94% were receiving at least one acute treatment (n=57,186), and
20% at least one prophylactic treatment (n=12,082). The prevalence of
migraine was 2,9% in the overall population, and 4,2%-5,3% among
age-groups between 15-55 years. The most commonly prescribed treat-
ments for acute events were triptans (56%) and NSAIDs (38%). Among
the prescribed prophylactic treatments, the most common were beta-
blockers (48%), tricyclic antidepressants (24%), angiotensin-receptor-
blockers (14%), and anti-epileptics (7%). The most common combin-
ation of two acute treatments (NSAID and triptan) were prescribed to
19% of the patients (n=11,625). Prophylaxis was mainly based on
monotherapy, but it was often combined with an acute treatment. The
most common combination of acute and prophylactic treatment was
triptans and beta-blockers. This combination was prescribed for 32%
(n=3,832) of patients on prophylactic treatment.
Conclusions
Medical treatment of migraine in Finnish primary care is based on
combinations of various substances. Migraine was most common
among ages between 15-55 years. Among all patients, 20% received
prophylactic treatment.
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Background
Patients with chronic migraine (CM) experience substantially im-
paired daily functioning and reduced quality of life, with daily or
near-daily headache attacks. In clinical trials, fremanezumab, a
fully humanized monoclonal antibody that selectively targets cal-
citonin gene-related peptide, reduced the frequency, severity, and
duration of headaches in patients with CM. The impact of
migraine cannot be fully understood only by assessment of head-
ache frequency; the validated 6-item Headache Impact Test (HIT-
6) was used to assess the effect of fremanezumab versus placebo
on headache-related disability.
Methods
In this multicenter, randomized, double-blind, placebo-controlled,
Phase III study, eligible patients with CM were randomized 1:1:1 to re-
ceive subcutaneous injections of fremanezumab quarterly dosing (675
mg at baseline and placebo at Weeks 4 and 8), fremanezumab monthly
dosing (675 mg at baseline and 225 mg at Weeks 4 and 8), or placebo
at each time point over a 12-week treatment period. As a secondary
endpoint, change in HIT-6 score was evaluated from baseline to 4
weeks after administration of the last dose of study drug. HIT-6 scores
range from 36 to 78, with higher scores indicating a greater impact of
headache on daily life. Efficacy analyses were performed in the full ana-
lysis set (FAS; all randomized patients who received at least one dose
of study drug and had at least 10 days of post-baseline efficacy assess-
ments on the primary endpoint) and repeated for the per-protocol ana-
lysis set (PPS). The data were analyzed using the analysis of covariance
approach, with baseline HIT-6 score and years since onset of migraine
used as covariates. P-values for treatment comparisons were based on
the Wilcoxon rank-sum test.
Results
Treatment with both fremanezumab dose regimens yielded signifi-
cant improvements in disability, as measured by the reductions in
HIT-6 scores from baseline to 4 weeks after administration of the last
study dose. In the FAS, the least-squares mean ± standard error
changes from baseline with fremanezumab quarterly dosing (–6.4
±0.45 points) and monthly dosing (–6.8±0.44 points) were greater
than with placebo (–4.5±0.45 points); resulting in significant treat-
ment differences (relative to placebo) in HIT-6 score change for
fremanezumab-treated patients (quarterly: –1.9±0.49 points,
P=0.0004; monthly: –2.4±0.49 points, P<0.0001). Similar treatment dif-
ferences were observed in the PPS (quarterly: –2.1±0.51 points,
P=0.0001; monthly: –2.3±0.51 points, P<0.0001).
Conclusions
In this Phase III study, fremanezumab treatment demonstrated a
significant improvement in headache-related disability in patients
with CM.
Trial registration
ClinicalTrials.gov NCT02621931
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Background
Chronic migraine is an underdiagnosed and undertreated condition.
Tools to improve chronic migraine detection by health care profes-
sionals may promote proper referral to dedicated care. Recently, the
self-administered tool ‘Identify Chronic Migraine (ID-CM)’ was devel-
oped and validated to help clinicians to identify patients likely to suf-
fer from CM. The aim of the present study was to develop the Italian
version of the ID-CM (IT-ID-CM).
Material and Methods
One participant in the study translated the original version of the
ID-CM into Italian. Then, a meeting was held to share the draft of
the IT-ID-CM among study participants and discuss possible issues
related to the translation and future validation. After the meeting,
each study participant was asked to compare the draft of the IT-
ID-CM with the original version and provide comments and sug-
gestions. The suggestions were reviewed by two study partici-
pants, and a revised draft was developed. The draft was back-
translated into English and compared with the original version to
develop the final IT-ID-CM.
Results
We developed a fully comprehensible and accurate Italian trans-
lation of the ID-CM consistent with the original English text
(Figure).
Conclusions
The IT-ID-CM is now available for evaluation in the clinical set-
ting. The next steps foresee the validation of the tool in special-
ized and primary care settings, and the creation of an application
for smartphones, tablets and desktop computers, which will help
to promote the diffusion of the IT-ID-CM.
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Background
The current diagnosis of primary headache has not been sufficient
for appropriate treatment. We used to make diagnosis based on the
history taking and criteria of International Headache Classification.
One of criteria is location such as unilateral or bilateral. Correct ana-
tomical diagnosis might be a clue to the problem. There are no stan-
dardized methods to decide the location (side and sites) in practice.
Traditional Acupuncture and Meridian System has been used for long
in oriental medicine. It is well described, but it is complicated to use
easily. It is difficult to resolve the underdiagnosis and undertreatment
of headache. Therefore, we propose the Acupuncture and Meridian
of Korean Hand Therapy (KHT) as a tool for diagnosis of migraine
and tension type headache.
Subjects and methods
This procedure was performed during physical examination based on
history taking including detailed palpation on the affected regions at
Department of Neurology, Pusan National University Hospital from
March, 2009 to February, 2012. The 200 primary headache patients
who had no other neurological or systemic diseases were included.
We checked pain sites or tender points on both sides of head using
Acupuncture points and Meridian of Gallbladder (CM1-12) and Urin-
ary Bladder (CI1-8) of KHT.
Results
We identified several tender points, which were connected to each
other. The points were closely related with the Acupuncture and Me-
ridian of KHT, which were different from depending on the type of
headache. The pain sites and tender points of primary headache pre-
sented as Gallbladder and Urinary Bladder Meridian of KHT. The mi-
graine belonged to Gallbladder and tension-type headache belonged
to Urinary Bladder Meridian, respectively. Also mixed type headache
belonged to various combined Gallbladder and Urinary Bladder Me-
ridian. The pure migraine groups are divided into three, pure tension
type headache groups are three and mixed form headache group
are nine, respectively.
Conclusion
The pain location of primary headache patients is closely related with
Acupuncture and Meridian System of KHT. Application of this
method might improve the diagnostic accuracy of primary headache
such as migraine and tension-type headache.
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The use of nutraceuticals in the prevention of migraine is increas-
ingly spreading, both for a more holistic approach to pathology and
for a patient’s specific request to use less “traditional drugs” and ul-
timately for their effectiveness, which it is proving to be higher than
expectations.
In this sense, Clevia combines the analgesic activity of the three
major furanodienes of Commirhora myrrha (MyrLiq), the activity of
compensating metabolic mytocondrial deficits of riboflavin, the effect
of coenzyme Q10 (CoQ10) that improves energy metabolism neur-
onal, and last vasoactive and scavenger activity of Gingko Biloba and
its derivatives.We decided to test this nutraceutical medicine in one
of the most difficult forms of migraine, that is pure menstrualmigraine, consisting of migraine attacks closely related to the men-
strual cycle.
We selected 7 women with age between 25 and 46 with migraine at-
tacks exclusively during the menstrual phase, with the possibility of
using estroprogestin therapy. Patients were given a headache diary
that monitored the last three menstrual cycles.Patients had an aver-
age of 3.8 days headache per period with an average pain intensity
evaluated with a numerical rating scale (NRS) of 8.5 and a use of
about 6.2 pain killer / menstrual cycle. Patients were then treated
with Clevia 1 cp for about 15 days a month starting 10 days before
the menstrual cycle covering the whole cycle for 3 months. There-
fore, the previously monitored parameters, headache days, mean
pain intensity, number of killer pain per menstrual cycle were com-
pared with those of patients without clevia.
The results have shown that although there was no significant reduc-
tion in the number of headache days per period, with a 3.8 to 3 day
variation, a marked reduction in pain intensity was observed, which
was more manageable with the usual pain killer and consequently
even less use of the same, thus resulting in an average pain intensity
of NRS of 8.8 to 5.5 with a reduction of Pain Killer from 7.8 to 4 per
period.Finally, NRS evaluated the degree of satisfaction of patients
with clevia therapy on various parameters (ease of use, side effects,
clinical improvement, costs, etc.) compared to non-use with a mean
satisfaction value of 7, 8 ie medium / high.This study highlights how
the use of nutraceuticals such as Clevia can be useful in the manage-
ment of migraine patients and in particular of once with pure men-
strual migraine.
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Background. A growing body of literature has showed a relationship
between insecure “attachment style” and somatic symptoms. In a re-
cent study, we found an association between ambivalent attachment
style, migraine severity and psychological symptoms in children/ado-
lescents. There is evidence that caregivers’ attachment styles and
their way of management/expression of emotions can influence chil-
dren’s psychological profile and pain expression. To date, data deal-
ing with headache are scarce. We aimed to study the role of
maternal alexithymia and attachment style on their children’s mi-
graine severity (intensity and frequency) and psychological profile
(anxiety, depression, somatization and attachment style).
Materials and methods. We enrolled 84 consecutive patients suffer-
ing from migraine without aura (female: 45, male: 39; age range 8-18
years; mean age 11.8 ± 2.4 years). Patients were divided into two
groups according to frequency of the migraine episodes (high or
low). According to headache attack intensity, patients were classified
into two groups (mild and severe pain). Children’s psychological pro-
file was assessed by SAFA Anxiety, Depression and Somatization
Table 1 (abstract P47). See text for description
Age Weight Height BMI
33.7 73.6 164.8 27.09
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SAT for patients and ASQ questionnaire for mothers. Maternal alex-
ithymia levels were evaluated by TAS-20.
Results. We found a significant higher score in maternal alexithymia
levels in children classified as “ambivalent”, compared to those classi-
fied as “avoiding” (Total scale: p= 0.011). Alexithymia levels also cor-
related with children’s psychological profile. A positive correlation
has been identified between mothers’ TAS-20 Total score and the
children's SAFA-A Total Score (p=0.026). In particular, positive correla-
tions were found between maternal alexithymia and children’s “sep-
aration anxiety” subscale (p=0.009) and “school anxiety” (p=0.015).
Maternal “externally oriented thinking” subscale correlated with
SAFA-A “school anxiety” subscale (p=0.050). Moreover, we found a
correlation between TAS-20 Total score and SAFA-D “Feeling of guilt”
subscale (p=0.014). Our data did not show any relationship between
TAS-20 and ASQ questionnaires and children’s migraine intensity and
frequency.
Conclusions. Maternal alexithymia and attachment style have no im-
pact on children's migraine frequency and intensity. However, our re-
sults suggest that, although maternal alexithymic traits don’t play a
causative role on children’s migraine severity, they show a relation-
ship with patients’ attachment style and psychological symptoms,
which in turn may impact on migraine severity.
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Background
Accidental dural puncture represents the most frequent complication
of peridural analgesic techniques.
It can cause headache variable in terms of intensity and duration,
sometimes requiring invasive treatments.
Accidental dural puncture headache treatment can be either conser-
vative or interventional.
The first one only include prophylactic measures ( bed rest, fluid
therapy, analgesia) while the second envisages the epidural blood
patch execution.
In our birth centre (2000 deliveries for year) epidural technique is
adopted for both labour analgesia and anaesthesia for cesarian section.
The aim of this observational study is to evaluate the effectiveness of
preventive/conservative treatment of women affected by post dural
puncture haedache in the obstetrics setting.
Material and Methods
We collected data from January 2014 to December 2016.
Primary end point was headache development, secondary the duration
of in hospital stay.
The diagnosis of accidental dural puncture headache was carried out
following the criteria of The International Classification of Headache
Disorders 3rd edition.
All the patients who experienced dural puncture during the procedure
received preventive/conservative treatment for headache development.
Treatment consisted in 48 hours bed rest, oral or ev fluid therapy (at
least 2000ml/day), and 1g paracetamol PRN up to a maximum of 3g.
Results
On a total of 5898 delivery we practiced epidural analgesia/anaesthe-
sia on 4128 women with an incidence of accidental dural puncture
of 0.43 % (18 patients).
Anthropometric data of the included patients are reported in Table 1.
Among the treated patients only 2 (11%) women developed head-
ache requiring analgesics administration.
These patients were discharged from the hospital in 4.18 days on
average.None experienced headache for longer than two days and in none
of the selected cases epidural blood patch was required.
Conclusion
In our experience preventive/conservative treatment has proven to
be effective on obstetrics patient with dural puncture. The complica-
tion prolonged patients hospital stay only in two cases and for three
and four days only.
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Aim: The purpose of this study is to evaluate the use and the self-
perceived efficacy and tolerability of three nutraceutical components
- Tanacetum parteninum, Griffonia simpliciofila and Magnesium - in
children and adolescents with primary headaches without other
comorbidities.
Background: Although pharmacological treatments are the first
choice for migraine, adverse effects and contraindications limit the
use of drugs in children. There is increasing evidence for the efficacy
and tolerability of some complementary approaches as nutraceuticals
in the management of headache disorders. Nutriceuticals are com-
plementary therapies that include dietary supplements in form of vi-
tamins and minerals. In the last few years, some nutraceutical
preparations as magnesium, CoQ10, vitamin D, melatonin and others
have been proposed as potential treatment for headache also in
childhood. Triptans could be used more frequently as first or almost
second choice for treating migraine attack in adolescents. [5]
Methods: 20 children (age 5 – 16 years) with ≥ three migraine at-
tacks per month are treated with Aurastop. The treatment period
was 3 months following a 4 week baseline period without prophylactic
treatment. Patients were assessed before treatment and at the end of
the 3-month-treatment-phase for days with migraine, migraine pain,
burden of disease (HIT-6) and subjective evaluation of efficacy.
Discussion: Feverfew (Tanacetum parteninum) has potential function
in reducing aura duration and complexity [1] through Parthenolide
inhibition of nitroglycerin-induced neuronal activation in specific
brain nuclei, as dorsal root ganglia. Griffonia simpliciofila has a role in
reducing NMDA-receptors aberrant activity in trigeminal-vascular sys-
tem, as well as in cortical spreading depression, (CSD) developing.
The activity of its precursor (kynurenic acid) acting as an endogenous
NMDA receptor antagonist [2]; Magnesium, is involved in numerous
enzyme reactions and important for energy metabolism. Deficiencies
in magnesium may lead to neuronal dysfunction and are found in in-
dividuals with headache attacks; it has been associated with CSD,
neurotransmitter release, platelet aggregation and vasoconstriction
all of which are important aspects of pathophysiology [3].
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tic effect of AurastopR as symptomatic treatment of migraine aura
and related symptoms in childhood and prophylaxis of headache at-
tacks too, as a already been done in adults[4]. The preliminary results
of the study, that are still ongoing, are encouraging, and Tanaceutum
partenum, Magnesium and 5HTP with their joint action would seem
to have important impact in reducing the pain intensity and the fre-
quency of headache.
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Background
Chronic migraine (CM) is characterized by frequent attacks, which ad-
versely affect health-related quality of life (HRQoL). In clinical trials,
fremanezumab, a fully humanized monoclonal antibody that select-
ively targets calcitonin gene-related peptide, reduced the frequency,
severity, and duration of headaches in patients with CM. This study
measured HRQoL using the Migraine-Specific Quality of Life (MSQoL)
questionnaire and health status using the EuroQol 5-dimension 5 re-
sponse level (EQ-5D-5L) questionnaire in patients treated with frema-
nezumab versus placebo.
Methods
In this multicenter, randomized, double-blind, placebo-controlled
study, patients with CM were randomized 1:1:1 to receive subcutane-
ous injections of fremanezumab quarterly dosing (675 mg at baseline
and placebo at Weeks 4 and 8), fremanezumab monthly dosing (675
mg at baseline and 225 mg at Weeks 4 and 8), or placebo at each
time point over a 12-week treatment period. The MSQoL question-
naire (version 2.1) assessed the role function-restrictive (RR), role
function-preventive (RP), and emotional function (EF) domains (range
0–100; higher scores indicate better HRQoL). The EQ-5D-5L question-
naire allowed patients to report their general health status on a vis-
ual analog scale (VAS, range 0–100; higher scores indicate better
health). MSQoL domains were analyzed using a mixed-effects
repeated-measures model (with years since onset of migraine and
baseline MSQoL domain score as covariates). EQ-5D-5L analyses were
conducted using an analysis of covariance approach (with years since
onset of migraine and baseline EQ-5D-5L score as covariates).Results
The study included 375 patients in each fremanezumab treatment
group and 371 patients in the placebo group. Compared with pla-
cebo, fremanezumab treatment resulted in significant improvements
in MSQoL scores from baseline to Week 12. For the RR domain of
MSQoL, there were significant treatment differences with each frema-
nezumab group relative to placebo (quarterly: 5.6±1.4, P<0.0001;
monthly: 6.3±1.4, P<0.0001). The RP and EF domains also showed sig-
nificant treatment differences (P<0.05). Significant improvements
with fremanezumab were observed as early as 4 weeks after the first
dose and were sustained at all pre-defined assessments. As mea-
sured by the EQ-5D-5L VAS, fremanezumab-treated patients reported
larger improvements in overall health status than those given pla-
cebo (4.6±1.1 [quarterly] and 4.8±1.1 [monthly] versus 2.2±1.1 [pla-
cebo]), resulting in significant treatment differences (quarterly: 2.4
±1.2, P=0.0402; monthly: 2.6±1.2, P=0.0291).
Conclusions
These results indicate that fremanezumab improves migraine-specific
QoL and overall health status of patients with CM, highlighting the
positive impact of fremanezumab on CM patients’ ability to engage
in and perform work and daily activities.
Trial registration
ClinicalTrials.gov NCT02621931
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Background
Idiopathic intracranial hypertension (IIH) or pseudotumor cerebri is a
syndrome characterized by signs and symptoms of increased intra-
cranial pressure in the absence of a secondary cause. The aim of the
study is to report the IIH clinical presentation in children and adoles-
cents presenting to our hospital during a 10-year period.
Materials and methods
Retrospective study, between January 2007 and January 2017, of IIH
patients, younger than 15 years, was conducted. Modified Dandy cri-
teria were used for IIH diagnosis. The patients were analysed accord-
ing to age (≤10 and 11-15 years).
Results
Thirty-four patients, ranging from 3.8 to 15 years, were included. Thir-
teen patients were younger than 11 years (38.2%), while twenty-one pa-
tients were 11-15 years old (61.7%). Twenty-nine patients (85.2%) were
obese (weight centile ≥ 90%). Mean cerebrospinal fluid opening pres-
sure was 422 mm H2O (260-890 mmH2O). The most common present-
ing symptoms were headache (94.1%), vomiting (29.4%), dizziness
(11.76%), blurred vision or diplopia (67.6%). Sixth nerve palsy occurred
in 11 children (32.3%). In general, headache did not respond to pain
medication. All our patients showed papilledema. Diagnostic evaluation
included neuroimaging studies and ultrasound-based optic nerve sheath
diameter (ONSD) measurement. In 6 patients (15%), MRI or CT showed
signs of empty sella syndrome, while in 9 patients (26.4%) ultrasound
ONSD measurement showed optic nerve sheath distension. There were
no significant differences between the age groups in both clinical pres-
entation and instrumental findings. Treatment included weight loss and
acetazolamide (maximum 5mg/kg/die) in 28 patients (82.3%). Furosem-
ide was added to acetazolamide in 2 patients (5.8%) and in 2 other pa-
tients was necessary added Delatcortene (5.8%). All patients fully
recovered and none of them complained visual loss in the follow-up.
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IIH should be considered in children with new-onset headache. Clinical
headache presentation can be variable, although vomiting and visual
symptoms are frequently associated. To exclude a secondary cause,
neuroimaging should be performed. ONSD measurement may be use-
ful as an additional tool to identify patients with IIH. Early diagnosis
and treatment for IIH can prevent potential visual loss that remains the
major morbidity. Acetazolamide and weight loss remain the most ef-
fective treatments in children.
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Background
Migraine is a common, chronic, incapaciting disorder, characterized by
attacks of severe headache. Episodic migraine can progress to chronic
migraine, which is defined as headache on ≥15 days/month for ≥3
months of which ≥8 days [1]. Onabotulinumtoxin A was approved in
Italy in 2013 for symptom relief in patients with chronic migraine who
have failed, or do not tolerate, oral prophylactic treatments [2].
Case Report
We describe the clinical case of a 36-year-old female patient who re-
fers to the onset of cefalalgic pain at puberty, described with
compression-type pain, diffused, with intolerance to light, hight in-
tensity that prevented her from studying and lasted about 1-3 days.
In the following years there was a further worsening of the frequency
and intensity of the crisis. During the same period she began to take
on weight, until serious obesity. She therefore carried out many hos-
pital admissions, with the assumption of various anti-inflammatory
therapies, until morphine. At 23 years she has been submitted to in-
testinal bypass surgery. Approximately 4-5 years ago, there were a
re-onset of migraine, which gradually increased in intensity, not in-
cluding anti-inflammatory therapies, with many accesses to Emer-
gency Unit and use of opioid. Becouse of the ileointestinal bypass,
shehad poor absorption with no repetition to prophylactic medical
therapy. In September 2016 she was included in botulinum toxin
treatment, meeting the criteria for chronic treatment-resistant mi-
graine. Already after the second application, there was a regression
of symptoms, a reduction of intensity and frequency of attacks and
recovery of daily life activities.
Conclusion
There is good clinical evidence that treatment with onabotulinumtox-
inA leads to a reduction of monthly headache days and improves
quality of life [3], also in this case report in which other treatment
were no possible and not efficacy due to ileointestinal bypass, with
secondary malabsorption.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Objectives: Determine the relationship between headache-related
quality of life measures and headache free days (HFDs) among pa-
tients with ≥4 headache days in the past month.
Methods: The 2016 US National Health and Wellness Survey (NHWS;
N=97,503) is a self-administered, sample of adults (≥18 years). Pa-
tients with a migraine diagnosis and reported experiencing ≥4 head-
ache days a month were considered at risk for disease progression.
Primary independent variable was the number of HFDs as both a
continuous (30-number of HFDs in the past 30 days) and categorical
(0-10;11-20;21-26 HFDs) measure. HFDs was used as a predictor in
separate generalized linear models (GLMs).
Outcomes included patient reported number of days absent from
work and days of household activities missed due to migraine, esti-
mated annual indirect costs due to work productivity loss (assessed
via Work Productivity and Activity Impairment Questionnaire).
Headache-related disability was measured via the Headache Impact
Test (HIT-6).
Results: Using HFDs as a continuous variable in the multivariable re-
gression, each HFD was found to be associated with a 0.15 (regres-
sion coefficient) point reduction in HIT-6 scores. As a categorical
variable, each 10 day increase in HFDs was associated with signifi-
cantly lower HIT-6 total scores (adjusted means=66.59 [0-10 HFDs],
65.66 [11-20], 63.91 [21-30], all p<0.02).
Each HFD associated with 0.95 (Rate Ratio [RR]) times days of work
missed due to migraines and 0.95 (RR) times days of household activ-
ities missed due to migraines. Thus, each HFD reduces both number
of work days missed and number of days of household activities
missed by 5%.
Increasing the number of HFDs from 0-10 to 21-26 (adjusted
means=4.44 vs. 1.46, p=0.002) and from 11-20 to 21-26 (3.36 vs 1.46,
p=0.009) categories was associated with significantly fewer work
days missed due to migraine. Similarly, increasing the number of
HFDs from 0-10 to 11-20 (adjusted means = 22.99 vs. 9.72, p<0.001)
and from 0-10 to 21-26 (22.99 vs. 7.34, p=0.001) categories was asso-
ciated with significantly fewer days of household activity missed due
to migraine.
Increasing the number of HFDs from 0-10 to 21-26 per month was
associated with significantly lower indirect costs.
Conclusions: Increasing the number of HFDs is associated with a de-
crease in headache-related disability among those with migraine
who are at risk for disease progression. Migraine places a substantial
indirect cost burden on this patient population and increasing total
HFDs may help to reduce this burden.
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quency, severity, and disability associated with migraine attacks, and
faster onset of action could increase benefit to patients with migraine.
Fremanezumab is a fully humanized monoclonal antibody targeting
the calcitonin gene-related peptide (CGRP) ligand, a preventive treat-
ment designed to specifically target a pathophysiologic mechanism of
migraine. This analysis assesses the early onset of action of fremanezu-
mab in the prevention of chronic migraine.
Methods: A 16-week, multicenter, randomized, double-blind, placebo-
controlled, parallel-group study comparing the efficacy, safety, and tol-
erability of 2 subcutaneous dose regimens of fremanezumab and pla-
cebo (PBO) in adults with Chronic Migraine (CM). Patients maintained a
28-day daily diary during baseline period, and throughout treatment
period. Patients were assigned randomly to 1:1:1 ratio to 1 of 3 treat-
ment groups: (1)monthly dosing: 675 mg of fremanuzemab followed
by 225 mg of fremanezumab at months 2 and 3, (2)quarterly dosing:
675 mg of fremanuzemab at month 1, followed by placebo injections
at months 2 and 3, and (3)monthly administration of matching placebo.
The secondary endpoint, the mean change from baseline (28-day run-
in period) to the 12-week randomization period in the monthly average
number of migraine days, and results at Weeks 1, 2, 3 and 4 were also
assessed using a mixed-effect model for repeated measures.
Results: Statistically significant reduction in the number of monthly
headache days of at least moderate severity was experienced during
the 12-week period after 1st dose for both fremanezumab dosing
regimens [monthly (-4.6 days);quarterly (-4.3 days); p<0.0001] vs. pla-
cebo (-2.5 days), and during the 4-week period after 1st dose, for
both dosing regimens (p<0.0001). Fremanezumab resulted in signifi-
cant reduction in the weekly number of headache days of at least
moderate severity:
 At Week 1, (-1.1 days; p<0.0001) versus placebo (-0.5 days)
 At Week 2, (-1.2 days; p<0.0001) versus placebo (-0.5 days)
 At Week 3, (-1.2 days; p<0.0001) versus placebo (-0.6 days)
 At Week 4, (-1.1 days; p=0.0006) versus placebo (-0.7 days)
Posthoc analysis indicated that more patients reported no headache
of at least moderate severity with fremanezumab (69%; p=0.0036)
versus placebo (61%) by the next day following first injection.
Conclusion: Onset of action with fremanezumab occurred rapidly for
preventive treatment of migraine. Significant improvement was
maintained for both monthly and quarterly subcutaneous injections.
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Objectives: To determine the burden of illness among patients
treated for migraine with ≥4 headache days in the past month.
Methods: The data source was the 2016 US National Health and
Wellness Survey (NHWS; N=97,503), a self-administered, nationally
representative sample of adults (≥18 years). Respondents were in-
cluded in this analysis if they self-reported a diagnosis of mi-
graine, experienced ≥ 4 headache days in the past 30 days, and
were currently using a prescription treatment for migraine. Using
propensity score matching to reduce bias, respondents meeting
the above criteria were matched with people without migraine
on age, gender, comorbidities (Charlson Comorbidity Index), an-
nual household income, education, insurance status, body mass
index (BMI), and smoking status. Outcomes included mental
health comorbidities, work productivity and activity impairment
as measured by the Work Productivity and Activity Impairment
Questionnaire (WPAI), health utilization in the past 6 months (i.e.,healthcare provider (HCP) visits, emergency room visits, and hos-
pitalizations), and estimated annual indirect and direct costs.
Post-match, groups were compared using One-Way ANOVAs and
chi-square tests on outcomes.
Results: There were 197 respondents in each cohort. A statistically
significantly greater proportion of treated migraine patients reported
being diagnosed with depression than non-migraine controls (58.4%
vs. 27.9%, p<0.001). A greater portion of treated patients also re-
ported being on long-term disability compared to non-migraine con-
trols (13.7% vs. 5.6%,p<0.003). Treated migraine patients reported
greater losses in work productivity and increases in activity impair-
ment. Compared to non-migraine controls, treated patients experi-
enced greater absenteeism (11.8% vs. 6.3%, p=0.03), presenteeism
(36.0% vs. 17.5%, p<0.001), overall work impairment (40.9% vs.
20.9%, p<0.001), and activity impairment (45.4% vs. 25.4%, p<0.001).
These patients also reported more HCP visits (7.55 vs. 4.43, p<0.001)
and ER visits (0.48 vs. 0.25, p=0.030) compared to non-migraine con-
trols in the previous 6 months. Greater work productivity loss among
treated migraine patients resulted in higher estimated annual indir-
ect costs ($14,770.57 vs. $5,764.93, p<0.001) compared to non-
migraine patient controls. Treated migraine patients utilized more
healthcare services than non-migraine patients ($24,499.90 vs.
$15,318.91, p=0.013).
Conclusions: The overall burden associated with migraine is sub-
stantial despite the availability of treatment options. Migraine pa-
tients in this survey reported a higher percentage of depression,
long-term disability, work productivity loss, absenteeism, present-
eeism, activity impairment, and use more health care services
compared to people without migraine. As a result, patients
treated for migraine incurred substantially greater direct and in-
direct costs compared to non-migraine controls.
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Background: Nausea and vomiting are a frequent accompaniment
of migraine and prokinetic medications are frequently used in its
management. Most prokinetic medications that are used in mi-
graine are dopamine antagonists and therefore have the poten-
tial to cause drug-induced extrapyramidal symptoms. We evaluate
the efficacy and safety of motilitone, a recently developed proki-
netic drug, in migraine patients with gastrointestinal symptoms.
Materials and Methods: From two outpatient neurological clinics, we
prospectively included 100 migraine patients with nausea and vomit-
ing and treated them with medications including motilitone. For the
evaluation of safety, we used drug-induced extrapyramidal symp-
toms (DIEPS) questionnaire, and the clinical improvement was
assessed with clinical global clinical impression of change (C-GIC)
and patients’ global clinical impression of change (P-GIC).
Results: Among the 100 patients, only two patients described the
presence of mild extrapyramidal symptoms (one with difficulty in
standing up from chair and the other with difficulty in find move-
ments), but it was not certain that these extrapyramidal symptoms
were associated with motiltione treatment and both patients refused
to discontinue motiltione with the clinical improvement. The mean
values of C-GIC and P-GIC were 3.26±0.8 and 3.19±1.1 respectively,
which indicate mild improvement with the treatment.
Conclusions: Our study shows that medication including motil-
tione for migraine patients with gastrointestinal symptoms is ef-
fective and there is low risk of clinically significant extrapyramidal
symptoms. Further studies are necessary to accurately evaluate
the risk of extrapyramidal symptoms with motilitone treatment in
patients with migraine.
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Background
Management of Idiopathic Intracranial Hypertension (IIH) aims to re-
duce intracranial pressure (ICP). Acetazolamide is the most commonly
used drug, with class 1 evidence demonstrating modest improvement
in patients with mild visual loss. Other drugs used include topiramate,
furosemide, amiloride and octreotide, despite there being little mech-
anistic or clinical evidence to support their use. The aim of this study
was to ascertain which of these drugs has the greatest effect on lower-
ing ICP in vivo.
Materials and methods
Using a validated epidural ICP recording method, we measured
changes in ICP in conscious female rodents after subcutaneous admin-
istration of clinical and high doses of drug over 2 hours (the time to
peak serum concentration). Drugs evaluated, with clinical and high
doses, were: acetazolamide (1g and 4g), topiramate (50mg and
200mg), furosemide (40mg and 240mg), amiloride (5mg and 20mg)
and octreotide (350μg and 2mg). In addition, we measured ICP for 12
hours after oral administration of equivalent high doses of acetazol-
amide and topiramate. Dose conversion between rodents and humans
followed the US Food and Drug Administration (FDA) guidance.
Results
At clinical doses, subcutaneous administration of topiramate lowered
ICP by 32% (p=0.0009). There was no significant reduction in ICP
noted with acetazolamide (-19%), amiloride (-11%), furosemide (-1%)
or octreotide (-1%). At high doses, subcutaneous administration of
topiramate lowered ICP by 21% (p=0.015) whilst there was no signifi-
cant reduction in ICP noted with high subcutaneous doses of acet-
azolamide (-20%), furosemide (-13%), amiloride (-27%) and octreotide
(-18%). Oral administration of equivalent high doses of topiramate
lowered ICP by 22% (p=0.018), compared to only a 5% reduction
with acetazolamide (p=>0.999).
Conclusions
Our in-vivo studies have demonstrated that, at both clinical and high
subcutaneous doses, as well as high oral doses, administration of topir-
amate significantly lowers ICP. Other drugs tested, including the acet-
azolamide the current first line oral therapy in IIH, did not significantly
reduce ICP. In the clinical setting topiramate may have additional ad-
vantages in IIH due to migraine prevention and weight loss effects,
though the potential for negative impact on mood and cognition must
also be considered. Future clinical trials evaluating efficacy and side
effects of topiramate in IIH would be of interest.
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The Journal of Headache and Pain 2017, 18(Suppl 1):P57Background: Medication-overuse headache (MOH) is prevalent but in
principle preventable. The objective is to describe the Danish national
awareness campaign for MOH.
Methods: The Danish Headache Center, the Association of Danish
Pharmacies, and headache patient organizations implemented a four-
month MOH awareness campaign in 2016. Target groups were the gen-
eral public, general practitioners, and pharmacists. Key-messages were:
overuse of pain-medication can worsen headaches; pain-medication
should be used rationally; and MOH is treatable. A range of communi-
cation technologies was used. A survey on the public’s awareness of
MOH was conducted.
Results: The Danish adult population is 4.2 million. Online videos
were viewed 297,000 times in three weeks. All 400 pharmacies re-
ceived campaign materials. Over 28,000 leaflets were distributed.
Two radio interviews were conducted. A television broadcast about
headache reached an audience of 520,000. Forty articles were pub-
lished in print media. Information was accessible at 32 reputable
websites and 5 online news-agencies. Three scientific papers were
published. Information was available at an annual conference of gen-
eral practitioners including a headache lecture. The survey showed
an increase in percentage of the public who knew about MOH (from
31% to 38%).
Conclusion: A concerted campaign to prevent MOH can be imple-
mented through involvement of key stakeholders.
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Background
Alcohol has long been suspected as a migraine trigger commonly
resulting in avoidance and possible impact on quality of life, but nu-
merous studies have been inconclusive [1]. To explore this question we
statistically compare intake of alcohol and occurrence of migraine.
Methods
Individuals with migraine registered to use Curelator Headache (1)
through a physician ‘coupon referral’ program, (2) via the Curelator
website or (3) the iOS App Store and answered questions about per-
sonal suspected triggers, including alcohol, and their importance
(0=none; 10=maximal). Curelator Headache was used daily for at
least 90 days, entering details about headaches and tracking factors
that may affect migraine occurrence. Alcohol consumption was re-
corded daily as ‘YES/NO’ and if YES by type and units. After 90 days
all factors were analyzed and for each individual the association of al-
cohol intake with attacks was determined [2].
Results
Of 531 individuals with migraine (Table 1), alcohol was suspected as
a risk factor by 304 (57%).
Consumption of alcohol was significantly different between those
who did and those who did not suspect it. A quarter of users never
consumed alcohol and 32% of those who did had inadequate data
for analysis (e.g. avoidance of alcohol or regular consumption so in-
sufficient variability). In alcohol consumers, comparisons between
those who did not vs those who did suspect alcohol as a trigger
showed no association with migraine in the majority in both groups;
alcohol as a potential trigger in 6% vs 8%; and as a potential pro-
tector in a 4% vs 7%.
No association was found between degree of suspicion of alcohol and
the percentage of individuals with a confirmed association (Table 2).
Previous day analysis (Table 3) found association in different proportions.
Conclusions
Despite the belief that alcohol is a common risk factor for migraine,
in the majority of users no association was found. Alcohol intake was
less frequent in people not suspecting alcohol, possibly because ab-
stainers would also not suspect alcohol as risk factor. Irrespective of
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 50 of 151the degree to which a user suspected alcohol as a trigger, more than
80% of users showed no association between alcohol and migraine.
Same day intake was as often found to be associated with risk reduc-
tion (potential protector) as with risk increase (potential trigger) (7%
each), but delayed association was mostly found as a potential trig-
ger (17%). Our data do not support the hypothesis that alcohol is a
common trigger for migraine.
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individual patients. Cephalalgia. 2017 Apr;37(5):452-463Table 1 (abstract P58). User characteristics and risk factor associations
in those suspecting alcohol as a risk factor, those who did not and all
users
Total Did not
consume
alcohol
Consumed
Alcohol
Adequate
data for
analysis
Potential
trigger
Potential
protector
No
Association
Suspected 304
(57.3%)
23 (8%) 281 (92%) 198 (72%) 16 (8%) 14 (7%) 168 (75%)
Not
suspected
227
(42.7%)
110 (48%) 117 (52%) 74 (64%) 4 (5.5%) 4 (5.5%) 66 (89%)
Totals 531 133 (25%) 398 (75%) 272
(68.3%)
20 (7%) 18 (7%) 234 (86%)
Table 2 (abstract P58). Association analysis by degree of suspicion
Total Potential
trigger
Potential
protector
No
Association
Mildly suspected 75 4 (8%) 11 (21%) 35 (71%)
Moderately
suspected
99 8 (11%) 10 (14%) 76 (75%)
Highly suspected 154 5 (5%) 16 (18%) 57 (77%)
Table 3 (abstract P58). Association by timing of alcohol intake
Lagged analysis (previous day) Same-day analysis
Potential
trigger
Potential
protector
No
Association
Potential
trigger
Potential
protector
No
Association
Suspected 34
(16.1%)
1 (0.5%) 176
(83.4%)
16 (8%) 14 (7%) 168 (75%)
Not
suspected
15
(20.6%)
2 (2.7%) 56 (76.7%) 4 (6%) 4 (4%) 66 (89%)
Totals 49 (17%) 3 (1%) 232 (82%) 20 (7%) 18 (7%) 234 (86%)
Table 1 (abstract P59). Medication use description
Variable / Cohort US UK
CM EM CM
+MO
CM
+nMO
EM
+MO
EM
+nMO
CM EM CM
+MO
CM
+nMO
EM
+MO
EM
+nMO
Average medication classes per
user
2.45 2.19 2.80 1.89 2.53 2.10 2.82 2.45 3.11 2.53 2.48 2.45
Average medications per user 3.55 2.81 4.13 2.63 3.33 2.67 3.58 2.91 4.26 2.89 2.95 2.90
Average medications classes
per headache
0.81 0.94 1.16 0.24 1.19 0.83 0.72 1.01 1.04 0.37 1.25 0.96
Average medications per
headache
0.86 0.97 1.23 0.24 1.22 0.84 0.74 1.02 1.07 0.38 1.28 0.97P59
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Background
Overuse of acute medications may worsen migraine and lead to medi-
cation overuse headache (MOH) [1]. Here we describe medication use
and identification of overuse (MO) in users of a digital platform for mi-
graine (Curelator HeadacheTM). The objective is to compare medication
use and possible overuse patterns in individuals’ with both chronic
(CM) and episodic (EM) migraine from the US and the UK.Methods
Individuals with migraine registered to use Curelator Headache (1)
through a physician ‘coupon referral’ program, (2) via the Curelator
website or (3) the iOS App Store and and was used daily for at least
90 days entering details about headaches and medications used
acutely and chronically. Acute medication use was analyzed at the
level of individual drug names and MO was defined according to
ICHD-3 beta criteria; other reported medication was not included in
the analysis.
Results
Individuals from the USA (n = 261) and the UK (n = 216) entered
20,353 (USA) and 17,965 (UK) headache instances. Only 6 (2.3%) US
and 4 (1.8%) UK users did not use any acute medication for their
headaches.
The average number of medications per user was significantly higher
for CM than EM but significantly higher in EM than in CM group in
both countries on a per headache basis (Table 1).
MO was significantly higher in the US EM (21%) than the UK EM
group (12%). MO groups have similar usage of medication, but CM &
no MO users typically use much less medication per headache than
their EM & no MO peers.
Triptans and NSAIDs are most frequently used by EM users in both
countries and significantly more frequently than in CM cohorts. NSAIDs
are most frequently used by CM users in both countries. While usage of
analgesic combinations by CM users is similar in both countries, UK CM
users use triptans more frequently than in the US. Opioids were used
more frequently by US CM users than UK CM users.
Conclusion
Curelator Headache identified MO in 29% of individuals in a predom-
inantly physician referred group (US) and in 19% in a predominantly
population recruited group (UK). CM and EM users showed different
frequency of medication use and overuse, similar to previously re-
ported [2]. The higher ratio of medication use in the EM MO sub-
group compared to the CM MO subgroup indicates that a MO
pattern may be identifiable in EM individuals.
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Background: As a critical component towards self-management of
their condition we examine the individual ability of patients to pre-
dict their attacks 24 hrs in advance. Prediction of attacks might be
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potential risk factors that trigger them, show significant inter-
individual variation [1] and possibly also intra-individual variation.
Accurate prediction may impact quality of life, allow optimal timing
of medication dosing and may also lead to understanding of the pro-
files and “best practice” of good predictors. Thus, the objective is to
understand and compare ability of episodic migraineurs to self-
predict attacks on an individual level.
Methods: Individuals with migraine registered to use a digital plat-
form (Curelator Headache™) via website or the App Store (iOS only)
and on a daily basis for at least 90 days entered about lifestyle
factors, possible headaches, and medications as well as migraine ex-
pectation for the next 24 hours (low/moderate/high). Patients with at
least 10 low and 10 high expectations instances of migraine were in-
cluded in the analysis. Prediction was considered successful when
24hr expectation of migraine was high and an attack occurred on
the next day; or 24 hr expectation was low and was followed by a
migraine free day.
Results: Of 497 episodic migraineurs examined in the study, 146 met
the criteria for analysis. Good predictors were defined as having an
accuracy of ≥75% at predicting an attack or a migraine-free day; bad
predictors were defined as those with ≤25% accuracy predicting a
migraine or a migraine-free day.
In this study we found 9% (n= 13) were good migraine predictors
and 27% (n=40) were defined as bad migraine predictors (Table 1),
and both groups stood up as different from the rest of the sample
with statistical significance (p<0.001). Only 5% (n=7) were good mi-
graine and migraine-free predictors.
Conclusion: A substantial proportion (64%, n= 93) of users predict
their migraine with only moderate accuracy (>25% but <75%). A
small group (27%, n=40), were considered bad predictors with ≤25%
accuracy. A smaller group (9%, n=13) were found to be good predic-
tors with ≥75% accuracy and just 5% (n=7) were able to accurately
predict migraine or migraine-free days. A next step would be to
understand the in possible differences risk factors and premonitory
symptoms that these two groups may exhibit and are possibly using
for prediction of their attacks.
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individual patients. Cephalalgia. 2017 Apr;37(5):452-463Table 1 (abstract P60). Ability to predict migraine or a migraine-free day
Good predictors
(≥75% accuracy)
Rest Bad predictors
(≤25% accuracy)
Migraine prediction 9% 64% 27%
Migraine free prediction 71% 28.3% 0.7%
Both 5% 95% 0%P61
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Background
Intracranial hemorrhage (ICH) accounts for up then 15% of strokes.
When hemorrhage is secondary to cerebral venous sinus throm-
bosis (CVST) the diagnosis is sometimes difficult to establish. The
early diagnosis of CVST is important to ensure best managementincluding best medical treatment, mechanical trombectomy or sur-
gical interventions.
Case Report
A 51 year-old woman was admitted in Emergency Room with un-
usual acute severe headache and seizure involving left-side limbs.
Recent past medical history was significant for ulcerative colitis
with ongoing steroid and anti-inflammatory therapy. Neurological
evaluation revealed facial left nerve palsy and mild left upper limb
weakness without Brudzinski and Kernig’s signs and no papille-
dema on clinical examination. A cerebral computed tomography
(CT) scan showed hyperdensity of parietal right lobe such as intra-
parenchymal hemorrhage with surrounding large hypodensity
area. The day after a cerebral magnetic resonance imaging (MRI)
revealed a large parenchymal hematoma of right parietal-occipital
lobe and surrounding hypodense ischemic injury with initial
“mass effect”; a magnetic resonance imaging with angiovenous
sequences showed a filling defect of transverse and sigmoid right
sinuses.. The patient was clinically unchanged with persistent
headache (VAS 8/10) but alert, oriented with slight life-sided defi-
cits. Suddenly she was treated with low-molecular-weight heparin
(LMWH) high dose therapy. After 48 hours of hospitalization, she
developed hyperpyrexia, hemiplegia of left limbs and became co-
matose due to a “mass effect” produced by unilateral edematous
venous infarction and parenchymal hemorrhage detected by cere-
bral CT. Decompressive surgery with hematoma evacuation was
performed with good outcome. Medical treatment after surgery
included steroid, anticonvulsants, anticoagulation. 3 months later
the patient presented a nearly complete recovery (median Rankin
Scale score 1): she was able to walk and to perfom basic daily
activities.
Conclusions
CVST is a possible cause of cerebral venous infarct or parenchymal
hematoma. Headache represents the most common symptoms of
this condition (80-90% of patients); underlyng risk factors to de-
velop CVST could be inflammatory bowel disease such as ulcerative
colitis and treatment like corticosteroids. The use of MRI is essential
for identify CVST and understand the location, volume and severity
of hemorrhage. When CVST is suspected, is important to avoid a
delay in diagnosis and treatment. Mortality in untreated cases
ranges from 13 to 48%of patients and is due to large parenchymal
lesions causing herniation. Decompressive surgery in these cases is
lifesaving and related to good functional outcome even in patients
with severe clinical conditions.
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BACKGROUND
To present the rare case of a 9-year-old girl with idiopathic intracra-
nial hypertension (IIH) secondary to hypoparathyroidism (HPTH) and
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 52 of 151our work-up, including physical examination, blood tests, diagnostic
imaging, and lumbar puncture.
CASE REPORT:
We present a 9-year old female patient who was hospitalized for head-
ache associated with nausea and vomiting for 3 weeks. She underwent
ophthalmologic examination which showed papilledema. She had
never had cramps, paraesthesias or tetany. Lumbar puncture (LP) re-
vealed an opening pressure of 65 cm H2O. CSF analysis and brain CT
scan were normal. The patient was started on acetazolamide 375 mg/
die. However, a low serum calcium level (6.3 mg/dL) was found, thus
leading us to suspect HPTH. Indeed, phosphorus was 10.2 mg/dL, para-
thormone was very low (3 pg/mL). Chvostek and Trousseau signs
scored positive. Neck ultrasonography showed normal thyroid, while
parathyroids were not viewable. Oral supplementation with calcitriol
(0.50 mcg/day) and calcium (500 mg/day) was started.
CONCLUSIONS
IIH is defined as an elevated intracranial pressure (>25 cmH2O) without
clinical, laboratory or radiological evidence of hydrocephalus, infection,
tumor or vascular abnormality. Annual incidence is 1-2 per 100,000.
Several hypotheses have been proposed for the IIH pathophysiology,
but none of them has reached a general consensus. Rare cases of IIH
secondary to HPTH have been described [1]. It is supposed that hypocal-
cemia causes a decrease in the CSF absorption at level of the arachnoi-
dal granulations [2]. Interestingly, our patient did not present with the
typical neurological HPTH symptoms, such as tetany, cramps, paraes-
thesias, seizures, behavioral disorders, and intracranial calcifications.
Only the serum calcium dosage led us to suspect this condition. There-
fore, we recommend that possible HPTH should be always checked in
children with clinical findings of benign intracranial hypertension.
Consent to publish
Written informed consent has been obtained from the parents
References
1. Aragones JM, Alonso-Valdés F. Hipertensiòn intracraneal benigna secundaria
a hipoparatiroidismo. Rev Neurology 2014; 58: 94.
2. Sambrook MA, Hill LF. Cerebrospinal fluid absorption in primary
hypoparathyroidism. J Neurol Neurosurg Psychiatry 1977; 40:1015-7.
P64
Headache following head injury: A population-based longitudinal
cohort study (HUNT)
Lena Hoem Nordhaug1; Knut Hagen1, 2; Anne Vik1, 3; Lars Jacob Stovner1, 2;
Turid Follestad4, Torunn Pedersen5; Gøril Bruvik Gravdahl2, Mattias Linde1, 2
1Department of Neuromedicine and Movement Science (INB), Faculty of
Medicine and Health Sciences, Norwegian University of Science and
Technology, Trondheim, Norway; 2Norwegian Advisory Unit on
Headaches, St. Olavs University Hospital, Trondheim, Norway;
3Department of Neurosurgery, St. Olavs University Hospital, Trondheim,
Norway; 4Department of Public Health and Nursing, Faculty of Medicine
and Health Sciences, Norwegian University of Science and Technology,
Trondheim, Norway; 5Division of Mental Health and Addiction, Oslo
University Hospital, Oslo, Norway
Correspondence: Lena Hoem Nordhaug (lena.h.nordhaug@ntnu.no)
The Journal of Headache and Pain 2017, 18(Suppl 1):P64
Objective
To explore whether subjects exposed to head injury more often de-
veloped a new headache or experienced exacerbation of previously
reported headache compared to non-exposed.
Methods
This population-based historical cohort study included headache
data from two large epidemiological surveys performed with an 11-
year interval. This was linked with data from hospital records on ex-
posure to head injury occurring between the health surveys. Partici-
pants in the surveys who had not been hospitalized because of a
head injury comprised the control group. The head injuries wereclassified according to the Head Injury Severity Scale (HISS). Multi-
nomial logistic regression was performed to investigate the associ-
ation between head injury and new headache or exacerbation of
pre-existing headache in a population with known pre-injury head-
ache status, controlling for potential confounders.
Results
The exposed group consisted of 294 individuals and the control
group of 25,662 individuals. In multivariate analyses, adjusting for
age, sex, anxiety, depression, education level, smoking and alcohol
use, mild head injury increased the risk of new onset headache suf-
fering (OR 1.74, 95% CI 1.05 – 2.87), stable headache suffering (OR
1.70, 95% CI 1.15 – 2.50) and exacerbation of previously reported
headache (OR 1.93, 95% CI 1.24 – 3.02). The reference category was
participants without headache in both surveys.
Conclusion
Individuals exposed to a head injury were more likely to have new
onset and worsening of pre-existing headache and persistent head-
ache, compared to the surrounding general population. The results
support the entity of the ICHD-3 beta diagnosis “persistent headache
attributed to traumatic injury to the head”.
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BACKGROUND: Headache is a frequent pediatric complaint in the
emergency department (ED). Although medical protocols are avail-
able at the ED, diagnosis and therapy of children with headache are
challenging, due to wide spectrum of headache aetiologies. Aim of
the study was to analyze the impact of the creation of a Headache
Clinic in our pediatric university hospital.
METHODS: Review of all medical records of children 3-18 years con-
sulting at the PED for headache as the main complaint, starting from
Jan 2011, when the Headache Clinic was created, until Dec 2016.
Statistical analysis was performed by GraphPad Instat 3.10.
RESULTS: Over the study period, 502,456 patients consulted our PED,
of whom 5,185 for headache (1%). Characteristics of these patients
and results of statistical analysis are summarized in Table 1.
CONCLUSIONS: The creation of a Headache Clinic in our hospital
allowed an improvement of the quality of care in our region, redu-
cing the delay of specialist assessment. On the other hand, although
the number of headache patients consulting at the PED did not sig-
nificantly increase, we observed a significant temporal trend in terms
of headache severity at triage, an increased length of stay, more
complementary investigations, and increased admission rate. So, the
positive effects of the creation of the Headache Clinic are actually
counterbalanced by PED overload.
To continue caring headache children with high standards, the
next step would be the implementation of the Headache Clinic in
the PED. Although this may require some structural costs to
provide a dedicated area, health benefits would be huge. The
presence of a headache team at the PED (doctors, nurses, psy-
chologists) would result in an important gain of time for emer-
gency physicians, in the reduction of the length of stay at the
PED (less waiting time for specialists, reduction of unuseful tests),
in a better multidisciplinary care, and in the reduction of parental
stress (with reduction of return visits and medical shopping). Pro-
spective analysis at both short- and long- term is required before
concluding about the usefulness of this approach and of its gen-
eralisability to other PEDs.
Table 1 (abstract P65). See text for description
2011 2012 2013 2014 2015 2016 p
PED consultants
for headache
(% on total)
647
(0.8%)
829
(1%)
824
(1%)
955
(1.1%)
933
(1.1%)
997
(1.1%)
-
Male gender 360
(55.6%)
453
(54.6%)
440
(53.4%)
490
(52.1%)
498
(53.4%)
527
(52.9%)
-
Age (mean, years) 8.9 9 9.2 9.3 9.3 9.8 <.001
Arrival during
night shift
273
(42.1%)
298
(35.9%)
266
(32.3%)
318
(33.2%)
312
(33.4%)
318
(31.8%)
-
Arrival during
weekend shift
153
(23.6%)
210
(25.3%)
219
(26.5%)
248
(25.9%)
233
(25%)
244
(24.5%)
-
Triage severity -
Low 309
(47.8%)
404
(48.8%)
394
(47.8%)
430
(45%)
404
(43.3%)
429
(43.1%)
Intermediate 272
(42 %)
326
(39.3%)
322
(39%)
385
(40.3%)
383
(41.1%)
397
(39.8%)
Urgent 66
(10.2%)
99
(11.9%)
108
(13.2%)
40
(14.7%)
146
(15.6%)
171
(17.1%)
<.05
Context of head
trauma
122
(18.9%)
198
(23.9%)
193
(23.4%)
224
(23.5%)
184
(19.7%)
193
(19.7%)
Dismissed without
investigations
392
(60.6%)
411
(49.6%)
400
(48.6%)
387
(40.5%)
417
(44.7%)
382
(38.3%)
<.05
Head CT scans
at PED (% on
all headaches)
29
(4.5%)
14
(1.7%)
25
(3%)
23
(2.4%)
16
(1.7%)
39
(3.9%)
Admission
following PED
(% on all
headaches)
40
(6.2%)
48
(5.8%)
52
(6.3%)
58
(6.1%)
91
(9.8%)
100
(10%)
<.05
Length of stay
at the PED
(mean, min)
197 193 205 203.5 211.4 230.2 <.0001
Table 1 (abstract P66). Demographics
All EM CM
Total number in population 557 473 84
Mean Age (years) (SD) 42.9 (13.4) 43.5 (13.2) 39.4
(14.2)
Age range (years) 11 - 75 11 -75 15 - 69
No. Females (%) 488
(87.6%)
409
(86.5%)
79 (94%)
Female - menstrual cycles (%) 292
(52.4%)
240
(50.7%)
52
(61.9%)
Female - menopausal (%) 90
(16.2%)
80 (16.9%) 10
(11.9%)
Female - non-menstrual or menopausal
(%)
106
(19.0%)
89 (18.8%) 17
(20.2%)
Fig. 1 (abstract P66). Shows the proportion of individuals in each
group for whom the most common ‘protectors’ were identified
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 53 of 151P66
Individual identification of factors associated with reduced risk of
migraine attacks: potential ‘protectors’
Stephen Donoghue1, Francesc Peris1, Gabriel Boucher1, Alec Mian1,
Christian Wöber2
1Curelator Inc, suite 4503, 5th floor, 195 Binney, Cambridge, MA, USA
02142; 2Headache Group, Department of Neurology, Medical University
of Vienna, Vienna Austria
Correspondence: Stephen Donoghue
The Journal of Headache and Pain 2017, 18(Suppl 1):P66
Background
Curelator Headache™ is a digital platform that collects daily data
about an individual’s migraine attacks and up to 80 factors (mood,
stress, diet, activity, weather etc.) which may affect their occurrence
and then statistically identifies factor-attack associations. Hence we
identify potential triggers (both “true” triggers and premonitory
symptoms) [1]. Our analysis also identifies factors associated with
reduced risk of attack occurrence: we call these potential ‘protec-
tors’ [2]. Here we compare potential protectors in individuals with
episodic (EM) or chronic (CM) migraine.
Methods
Individuals with migraine registered to use Curelator Headache via 1) a
physician ‘coupon referral’ program, 2) the Curelator website or 3) the
App Store (currently iOS only). They used Curelator Headache daily for
90 days, entering details about headaches and tracking factors that
may affect migraine attack occurrence, after which factor-attack associ-
ations were analyzed for each individual [1].
Results
557 individuals were included: demographic data are shown in Table 1:Overall, potential protectors were found in 471 (84.4%) individuals:
on average individuals had 3.0 (CI 0.20) such associations; range 0 -
16. The factors most commonly found (>5% individuals) were phys-
ical activity, happiness, being relaxed, sleep quality, sleep duration,
sleep quality, waking refreshed, caffeine, mean outside temperature
and humidity, time outdoors.
In general the same factors appeared as ‘protectors’ in both groups,
although for some there was a higher proportion of EM individuals,
possibly reflecting real differences or increased difficulty of identify-
ing risk factors in individuals with frequent attacks.
Conclusions:
Identifying ‘protectors’ may be clinically useful for people with mi-
graine. However it is important to guide each individual to think about
their behaviours and self-analyse the context in which ‘protectors’ ap-
pear to affect their condition. For example, apparent ‘protectors’ may
be due to avoidance immediately before/during attacks (e.g. nicotine,
physical activity) or to actions taken to mitigate a factor effect (e.g.
avoiding going out on hot days).
Our data support what many clinicians and people with migraine
believe intuitively, i.e that moderate activity, staying relaxed, and try-
ing to maintain good sleep hygiene reduce risk of attacks. In addition
warm weather may have a protective role. Caffeine appears protect-
ive for some people (but can be a trigger for others).
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Table 1 (abstract P67). Demographics
All EM CM
Total number in sample 488 391 97
Mean Age (years) (SD) 43.0 (13.4) 43.7 (13.2) 40.3
(14.0)
Age range (years) 11 - 75 11 -75 15 - 69
No. Females (%) 440
(90.2%)
348
(89.0%)
92
(94.8%)
Female - menstrual cycles (%) 275
(56.4%)
215
(55.0%)
60
(61.9%)
Female - menopausal (%) 87
(17.8%)
72 (18.4%) 15
(15.5%)
Female - non-menstrual or menopausal
(%)
78 (16.0%) 61 (15.6%) 22
(22.7%)
Table 2 (abstract P67). See text for description
All
(N = 488)
EM
(N = 391)
CM
(N = 97)
Mean no. suspected per individual
(95% CI) (range)
23.2
(1.1) (3 -
44)
22.9
(1.2) (3
- 44)
24.3
(2.4) (5
- 43)
% of total suspected triggers identified
statistically
11.5 12.2 8.9
Mean no. of previously suspected
triggers statistically identified
(95% CI) (range)
2.7
(0.21) (0
- 12)
2.8
(0.24) (0
-12)
2.2
(0.39) (0 -
8 )
Mean no. of previously suspected
triggers with no association with attacks (95%
CI) (range)
14.2
(0.74) (0
- 33)
13.8
(0.81) (0 -
33)
15.5
(0.74) (1 -
33)
Mean no. previously suspected
triggers with insufficient data to determine
statistical association
(95% CI) (range)
5.1
(0.37) (0
- 23)
5.0
(0.42) (0 -
23)
5.4
(0.74) (0 -
18)
Mean no. of unsuspected triggers statistically
identified
(95% CI) (range)
1.3
(0.15) (0
-9)
1.4
(0.17) (0
- 9)
1.1
(0.30) (0
- 9)
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Background
In this study we compare in individuals with episodic (EM) or chronic
(CM) migraine their suspected, self-reported triggers versus risk factors
identified statistically. Migraine attacks may be triggered by combina-
tions of internal and external factors which differ markedly between in-
dividuals [1]. Most migraineurs suspect a range of triggers, usually
based on a combination of popular literature and (unreliable) retro-
spective recall which is subject to misinterpretation and recall bias. Few
have been tested for causality but, when done, triggering of attacks
has usually been inconsistent and avoidance has had limited effect [2].
Previously we reported that less than 20% of suspected self-reported
triggers were shown to be statistically associated with attacks when
using individuals’ prospective data collected using a digital platform
(Curelator Headache™) [3].
Methods
Individuals with migraine registered to use Curelator Headache via 1)
a physician ‘coupon referral’ program, 2) the Curelator website or 3)
the App store (currently iOS only) and completed a questionnaire
about personal suspected triggers and their importance (1=low;
10=maximal). They used Curelator Headache daily for 90 days, enter-
ing details about headaches and tracking factors that may affect
migraine attack occurrence. After 90 days factors were analyzed for
each individual [4] and those significantly associated with attacks
were compared with self-reported triggers.
Results
488 individuals were included: demographic data are shown in Table 1:
Overall, individuals each suspected between 3 and 44 different trig-
gers; mean (SD) = 23.2 (12.4). Most frequently, and often most
strongly, suspected were: menstruation, stress, anxiety, irritability, an-
griness, sleep quality and duration, neck pain, eye strain, bright
lights, odors, loud noise, fatigue, activity, travel, weather, dehydra-
tion, missed meals, alcohol.
Table 2 shows how many suspected triggers were confirmed statisti-
cally or shown to have no association with migraine attack risk.
The CM group overall suspected more triggers per person but fewer of
these were statistically associated with migraine attacks (p = 0.008). In
the EM group stress, anxiety, sadness, tiredness/fatigue, neck pain/ten-
sion, eye strain head/neck skin sensitivity and menstruation were more
commonly confirmed as potential triggers.
Conclusions
EM and CM groups differ in the proportion of suspected risk factors
(potential triggers) confirmed statistically. This may represent real dif-
ferences between the groups, i.e ability to self-recognise triggers cor-
rectly, or difficulty in detecting some associations in the CM group.
Nevertheless, the difference contrasts with the lack of differences in
self-reported suspected triggers between EM and CM groups.
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Vestibular migraine (VM) is the most common cause of episodic ver-
tigo in adults as well as in children. (1).The exact neural mechanisms
of vestibular migraine are still unknown. Vestibular migraine often
begins several years after typical migraine and has a variable clinical
presentation. The neurological and otoneurological examination of
patients with vestibular migraine is mostly normal and diagnosis are
usually based on clinical history. Treatment trials of vestibular mi-
graine are scarce and therapeutic recommendations are based on
migraine guidelines.
Objective: The aim of study is to determine the mechanisms of ver-
tigo and dizziness in migraine patients
Methods: This study recruited 152 patients with migraine with aura
and migraine without aura as defined by ICHD-3. VM was diagnosed
by (ICHD-3) Diagnostic criteria.(2) We analyzed the medical history of
migraine patients with vertigo and dizziness, all patients had a
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 55 of 151neurological examination, and questionnaire survey by scales: Dizzi-
ness Handicap Inventory (DHI) scale (3)), HADS , HIT-6. Patients with
vertigo additionally had an otoneurological examination for exclud-
ing peripheral vestibulopathy.
Results: The main study group consisted of patients with vestibular mi-
graine (VM) – 13,8% (n=21), and controls were patients with dizziness -
42,2% (n=64) . There were no significant differences in sex, age, VAS,
HADS , HIT-6 in main and control group . Chronic migraine and mi-
graine without aura was more prevalent in patients with VM ( СМ:
88.8%, n=16 vs. 36.4%, n=12, respectively). DHI-positional scale in VM
was higher, then in dizziness patients (15,43±5,9 vs 12,28±6,9,p<0,05)
Vertigo manifest during migraine attack and dizziness was permanent.
VM patients have more often motion sickness , subjective hearing loss,
although otoneurologist found no current disease. More then 50% of
VM patients had family history of hearing loss or dizziness.
Conclusion: VM is mostly observed in patients with chronic migraine
and migraine without aura. Our study suggests the role of central
sensitization of the vestibular nuclei in the patients with preexisting
pathology of the vestibular system in VM pathogenesis. The leading
part, of central sensitization in the genesis of vertigo in migraine pa-
tients are warranted to pave the way to potential new therapies for
this condition.
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Introduction
Headache is the most prevalent symptom in idiopathic intracranial
hypertension (IIH). This study aimed to evaluate the temporal change
in headache severity in the week following lumbar puncture (LP) in
patients with active IIH.
Methods
Headache severity was prospectively recorded using the numeric rat-
ing scale (NRS) 0 (no pain) to 10 (most severe pain) immediately prior
to and following LP (1,4 and 6 hours and then daily to 7 days).
Demographic data and variables hypothesised to impact on the
post-LP headache severity were recorded.
Results
52 IIH patients were recruited with mean BMI 41 ± 10 Kgm-2, LP open-
ing pressure 33.2 ± 6.1 cmCSF and headache severity 3.6 ± 2.8. Exacer-
bation of headache was noted in 64% with 30% experiencing an
exacerbation ≥4 NRS. In the whole cohort, a small improvement in
headache severity was noted 1 hour in 58% (-1.1 ± 2.6 NRS (p<0.001))
and this was maintained at 7 days in 47% (-1.0 ± 2.7 NRS (p=0.004)). In
those with severe headaches pre-LP (NRS 7-10), 75% improve at 1 hour
(-3 ± 3.7 NRS, p=0.024) and 67% improved at 7 days (-3.0 ± 2.8 NRS,p=0.012) whilst deterioration was uncommon (8% at 1 hour and zero
at 7 days). In those with moderate headaches pre-LP (NRS 4-6), 91% im-
prove at 1 hour (-2.2 ± 1.6 NRS, p<0.001) and 61% improved at 7 days
(-1.7 ± 2.3 NRS, p=0.007) and deterioration was uncommon (4% at 1
hour and 22% at 7 days). Amongst, those with mild headaches pre-LP
(NRS 1-3), no significant improvement was noted and the likelihood of
deterioration was higher (50% at 1 hour and 19% at 7 days). In those
with no headache pre-LP, 20% will experience deterioration at 1 hour
and 27% at 7 days. There was no relationship between the response of
the headache severity post-LP and BMI, height, skin to dura depth, LP
opening or closing pressure, CSF volume withdrawn, number of LP at-
tempts, CSF red blood cell count, acute analgesics, acetazolamide use
and Frisén papilloedema grade.
Conclusion
The majority of IIH patients will experience deterioration in headache
at some point during the week post-LP. Headache severity pre-LP
significantly influenced the likelihood of improving or deteriorating
after LP. Additionally, we noted that the improvement at 1 hour
post-LP was maintained at 7 days. Characterisation of headache out-
comes post-LP in IIH has relevance when counselling patients about
the procedure.
Trial registration
ClinicalTrials.gov Unique identifying numbers: NCT02017444,
NCT02124486.
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Background. Headache represents a peculiar condition, that is often
underdiagnosed and undertreated, with remarkable dissatisfaction of
the patients. An adequate training is crucial for all the headache spe-
cialists[1,2]. Considering the unsatisfying results obtained with stand-
ard updating courses and the rising need of a continuous training, a
digital platform was developed in the last two years as a tool of
update.
Methods. A digital platform, has been activated since the 1st October
2014. The platform is easily accessible to doctors by free member-
ship, validated by the administrators of the group. Repeatedly in two
years Administrators invited to subscription members of scientific so-
cieties potentially interested to headache. The users have access to
the platform’s whole material, that includes scientific articles, e-
books, presentations and images. They can directly share their mater-
ial, discuss on clinical cases and submit new ones. The system allows
to monitor the participation of members in terms of platform access,
resource upload and / or download, introduction of cases and partici-
pation in their discussion. Finally, we sent a questionnaire to under-
stand the reasons of use or not use of platform by registered
members.
Results .The platform currently boasts 39 members. The resources in
the platform consist of many different materials concerning head-
ache ( more than 100 articles dedicated to migraine aura, several
books, many slide libraries on different headache topics, collections
of artistic or neuroimaging images related to headaches etc...). In the
last year 316 files have been downloaded, 5 discussions have been
started with 22 contributors. 15 of 37 members have never carried
out any action. The last year number of uploaded files amounts to
74, but 90% of the contributions is due to a restricted group. There
were no significant differences in use of platform between members
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The results of questionnaire show summarily that first reason of non-
use of platform is the lack of time.
Conclusions. After 2 years of activity, a the data show that about
40% of the members have never carry out any operation and the
remaining mainly used the platform in a passive way, through the re-
sources downloading. Even if the platform appears to be an easily
accessible, interactive and not expensive instrument, the passive use
suggests that a critical aspect for medical education on the diagnosis
and treatment of headaches lies more in the doctors’ ability to invest
themselves emotionally on these issues.
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Sicilia. Giornale delle Cefalee.2006; 2:10-12.Table 1 (abstract P70). Utilization of Headache digital platform by
members
Academic
groups
members Members
with no
actions
performed
Login Downloaded
files
Uploaded
files
Clinical
cases
submitted
Contribution
on clinical
cases
Sisc (Italian
society for the
study of
headache)
members
18 5 112 146 68 4 20
SINPIA (Italian
society of
neuropsychiatry
for childhood
and
adolescence)
members
11 6 28 139 3 1 2
Other specialists 8 4 7 31 3 0 0
Total 37 15 147 316 74 5 22P71
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Background: Each component of the novel phytotherapic combin-
ation of Tanacethum Parthenium (150 mg), 5-hydroxy tryptophan
(20 mg) and magnesium (185 mg) (Aurastop©) acts on a different
target among the main mechanisms involved in the pathophysi-
ology of migraine: sensitization of trigeminal vascular system, cen-
tral sensitization and activation of the “migraine generator” located
in the brainstem, through glutammate and kynurenine pathway.
Aim of this study is to test the effectiveness of Aurastop© in the
prophylaxis of migraine without aura.
Materials and methods: Sixty consecutive patients (F: n=37, M: n=23,
mean age: 37.5±17.1) presenting with an ICHD-3 beta diagnosis of
migraine without aura (MO) were enrolled in the survey and treated
with Aurastop© twice a day for a period of 3 months. Diary cards were
filled in during a 3-months period prior the beginning of the survey
and during the 3-months duration of the study. A preventative treat-
ment had been started previously and continued during the study in 5
cases (propranolol: n=2; amitriptyline: n=2; onabotulinumtoxin A:n=1).The reduction of MO attacks per month was assessed as the pri-
mary end-point; the reduction of headache days per month, the inten-
sity of the pain and the patient’s satisfaction were considered as
secondary end-points.
Results: A statistically significant reduction of both MO attacks and
number of headache days per month was observed. Moreover, a
sensible reduction of the intensity of the pain was reported. The sec-
ondary end-point regarding the satisfaction of the patients was
achieved, as participants agreed when a new cycle of Aurastop© was
proposed. No side effects were reported. The effectiveness appeared
since the first month of intake and was maintained during the three
months of therapy .
Conclusion: In this observational open study, Aurastop© appears to
be effective and safe in the preventive treatment of MO.
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INTRODUCTION: A new phytotherapic combination of Tanacethum
Parthenium (150 mg), 5 - Hydroxy tryptophan (20 mg) and Magne-
sium (185 mg) (Aurastop®) is now available for migraine patients. The
three components may tackle the main mechanisms involved in the
pathophysiology of migraine with aura: Cortical Spreading Depres-
sion, sensitization of trigeminal vascular system, central sensitization
AIM: The purpose of this open study was to evaluate the efficacy of the
combined action of Tanacethum Parthenium, 5-Hydroxy tryptophan and
magnesium in the reduction/disappearance of the aura phenomenon
and reduction of its disability when taken at the aura onset.
MATERIALS AND METHODS: Study of a population of 200 patients
aged between 18 and 65 years (mean age: 33.00 yrs ), 117 F and 83
M, suffering from migraine with aura referred to 8 Lombardia Head-
ache Centers. Patients were either without preventive therapy or
without changing the prophylaxis during the aura treatment. Inclu-
sion criteria: suffering of aura with at least 20 minutes duration. Pa-
tients retrospectively filled a aura diary for the description of the
aura features in the past 3 episodes. Then they treated 3 consecutive
aura attacks with a tablet of Aurastop® at the onset of the aura. In
case of headache they were instructed to take another 1 tablet at
the headache onset. The effect of the Aurastop® was prospectively
recorded using the aura diary in order to evaluate: duration of the
Fig. 1 (abstract P73). EM and CM respondents self-reporting (SR) an
assessed symptom or a physician diagnosis (SR-PD) of a condition
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tomatic treatment
RESULTS: We recorded a total of 600 aura episodes from a total of
200 subjects: Aurastop® produced more than 50% reduction in dur-
ation in 180 patients ( 90%of the total ) and disability in 185 patients(
92,5%). Notably 35% of the patients did not use other symptomatic
treatment due to the fact that headache intensity was less severe
after Aurastop®.
DISCUSSION AND CONCLUSIONS: The combination of tanacethum
partenum, Mg and 5-HTP, (Aurastop®), could be an effective symp-
tomatic treatment for migraine aura. Randomised controlled trials are
still required to confirm these results .
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Background
Many comorbidities associated with migraine have a higher relative
frequency in chronic migraine (CM) than episodic migraine (EM). The
objective of this study was to replicate and extend work on comor-
bid medical conditions in a systematically recruited sample of people
with migraine.
Materials and Methods
Data from the prospective web-based baseline survey of the Chronic
Migraine Epidemiology and Outcomes (CaMEO) Study were used to
identify people, recruited from an online panel using quota sampling,
with EM and CM based on criteria modified from the International
Classification of Headache Disorders, third edition, beta version. Par-
ticipants completed a Comorbidities/Endophenotypes module that
assessed 64 symptoms and conditions. Respondents were asked (1) if
they ever had a specific symptom (“Self-Reported [SR]”) and, if
present, (2) if the SR symptom or condition had been confirmed/di-
agnosed by a “doctor” (“SR-physician diagnosis [SR-PD]”). Chi-square
analysis was used to compare the proportion of people with each
symptom or condition among respondents with EM vs. CM. This re-
port presents data on the Respiratory, Sleep Disorder, Cardiovascular,
and Gastrointestinal comorbidity categories.
Results
Available CaMEO respondents with migraine (16,763) were sent the
Comorbidities/Endophenotype module and 12,810 (76.4%) provided
valid responses: 11,699 with EM; 1,111 with CM. Compared with the
EM group, the CM group had a similar mean age (EM, 41.3 years; CM,
41.9 years), was more likely to be female (EM, 74.2%; CM, 81.5%;
P<0.001) and white (EM, 84.0%; CM, 88.7%; P<0.001), and had a
mean higher body mass index (EM, 27.7 kg/m2; CM, 28.7 kg/m2;
P<0.001). The relative frequencies were significantly higher for 29
(93.5%) of the 31 SR symptoms and SR-PD conditions assessed.Conditions or groups of conditions with relative frequencies >10%
higher in CM than EM included allergies/hay fever/allergic rhinitis
(EM, 37.4%; CM, 51.0%), sinusitis/sinus infection (EM, 47.3%; CM,
58.8%), insomnia (EM, 35.6%; CM, 50.2%), vertigo/dizziness/balance
problems (EM, 17.8%; CM, 29.7%), and gastroesophageal reflux dis-
ease (EM, 14.3%; CM, 24.4%; Fig. 1).
Conclusions
Overall, significantly more respondents with CM vs. EM reported
medical comorbidities. Mechanisms explaining this association might
include manifestations of migraine, direct causality (e.g., CM causes
the comorbidity), reverse causality (e.g., the condition increases the
risk of CM), and shared genetic or environmental risk factors. Con-
founding or detection bias (i.e., “Berkson’s Bias”) could also contrib-
ute. Future analyses will address naturally occurring subgroups (taxa)
defined by migraine phenotypes and comorbidities and assess the
relationships of these groups to external validators such as treatment
response and clinical course.
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Background
Published surveys have demonstrated that 75-80% of persons meet-
ing the criteria for chronic migraine (CM) do not report having re-
ceived an accurate diagnosis [1,2]. The primary objective of this
study was to develop a claims-based algorithm for use in patients
with migraine to identify potentially undiagnosed CM patients.
Fig. 1 (abstract P75). EM and CM respondents self-reporting (SR) an
assessed symptom or a physician diagnosis (SR-PD) of a condition
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 58 of 151Materials and Methods
An observational study using claims data and survey data was con-
ducted in a large United States medical group. Eligible patients had
continuous enrollment and a migraine diagnosis (ICD-9/10 code of
346.xx/G43.xxx) in the 12-months prior to the screening date. Patients
were excluded if they had a prior CM diagnosis (346.7x/G43.7xx) or
migraine-related onabotulinumtoxinA claim. The Semi-structured Diag-
nostic Interview (SSDI) served as the gold standard for identifying CM
and was administered to a convenience sample by trained clinicians.
The SSDI included 31 questions related to headache frequency, symp-
toms, disability, medication use, and diagnosis.
A multivariate logistic regression model was used to identify potential
predictors of CM based on claims data obtained in the 12 months prior
to the screening date. Over 40 potential predictors for CM, identified
from the literature and headache expert input, were evaluated for model
inclusion. Variables that were significantly different in bi-variate analyses
(p<0.05) between SSDI+ (CM) and SSDI- (non-CM) patients were included;
each variable was categorized based on the data distribution and clinical
relevance. The c-statistic, sensitivity, and specificity were calculated.
Results
Of the 108 patients who were included, 64 were SSDI+ and 44 were SSDI-
for CM. Four statistically significant predictors of CM status were identified.
Patients with ≥15 claims for acute treatment of migraine (including opi-
oids) were nearly six times as likely to have CM as those with <15 claims
(OR=5.87, 95% CI=1.34, 25.63); patients with ≥24 visits of any type (out-
patient, inpatient, and emergency room visits) were nearly three times as
likely to have CM as those with <24 visits (OR=2.80, 95% CI=1.08-7.26); fe-
males were 9 times as likely to have CM (OR=9.17, 95% CI=1.26-66.51);
patients with claims for ≥2 unique migraine preventive classes were more
than 4 times as likely to have CM as those without claims for preventive
treatments (OR=4.40, 95% CI=1.19, 16.22). The c-statistic, sensitivity, and
specificity for the model were 0.80, 78%, and 73%, respectively.
Conclusions
The claims-based algorithm for identification of undiagnosed CM pa-
tients demonstrated acceptable sensitivity and specificity, and can be
used in health care settings to optimize the diagnosis and manage-
ment of CM patients who may not be otherwise detected.
Trial registration
Not applicable
Consent to publish
Not applicable
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Background
Migraine is comorbid with various conditions, many with a greater relative
frequency in chronic migraine (CM) versus episodic migraine (EM). The ob-
jective of this study was to replicate and extend work on the comorbidity
of pain, psychiatric, and endocrine/neurological symptoms and conditions
in a systematically recruited sample of people with EM and CM.Materials and Methods
Data from the prospective web-based baseline survey of the Chronic
Migraine Epidemiology and Outcomes (CaMEO) Study were used to
identify people, recruited from an online panel using quota sampling,
with EM and CM based on criteria modified from the International Clas-
sification of Headache Disorders, third edition, beta version. Participants
completed a Comorbidities/Endophenotypes module that assessed 64
symptoms (e.g., neck pain) and conditions (e.g., rheumatoid arthritis).
Respondents were asked (1) if they ever had a specific symptom (“Self-
Reported [SR]”) and, if present, (2) if the SR symptom or condition had
been confirmed/diagnosed by a “doctor” (“SR-physician diagnosis [SR-
PD]”). Chi-square analysis was used to compare the relative frequency
of symptoms and conditions in respondents with EM versus CM. This
report presents data on symptoms and conditions from the Pain, Psy-
chiatric, and Endocrine/Neurological comorbidity categories.
Results
Available CaMEO respondents with migraine (16,763) were sent the Co-
morbidities/Endophenotype module and 12,810 (76.4%: EM, 11,699;
CM, 1,111) provided valid responses. Compared with the EM group, the
CM group had a similar mean age (EM, 41.3 years; CM, 41.9 years), was
more likely to be female (EM, 74.2%; CM, 81.5%; P<0.001) and white
(EM, 84.0%; CM, 88.7%; P<0.001), and had a mean higher body mass
index (EM, 27.7 kg/m2; CM, 28.7 kg/m2; P<0.001). The relative frequen-
cies were significantly higher for 24 (85.7%) of the 28 SR symptoms
and SR-PD conditions assessed (Fig. 1). 5 of these conditions had
relative frequencies >10% higher in CM than EM: chronic back pain
(EM, 22.5%; CM, 37.6%), chronic pain (EM, 7.4%; CM, 22.2%), neck
pain (EM, 38.1%; CM, 55.3%), anxiety (EM, 25.7%; CM, 42.2%), and
depression (EM, 28.1%; CM, 45.6%).
Conclusions
Overall, significantly more respondents with CM versus EM reported
having specific symptoms or conditions. Mechanisms explaining this
association might include direct causality (e.g., CM causes the comor-
bidity), reverse causality (e.g., the condition increases CM risk), and
shared genetic or environmental risk factors. Confounding, or detec-
tion bias (i.e., “Berkson’s Bias”) could also contribute.
Acknowledgments
Editorial support for development of this abstract was provided by Lee B.
Hohaia, PharmD, and Dana Franznick, PharmD, at Complete Healthcare
Communications, LLC (Chadds Ford, PA), a CHC Group company, and funded
by Allergan, plc (Dublin, Ireland).
Fig. 1 (abstract P76). Prevalence of the severity classifications of
cutaneous allodynia measured by the 12 item Allodynia Symptom
Checklist (ASC-12); migraine related disability assessed using the
Migraine Disability Assessment (MIDAS) and; neck related disability
assessed by the Neck Disability Index (NDI)
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Background: Greater prevalence of migraine in women and the fact that
women seek out medical advice more often than men have lead to a
presumption that migraine is a female disorder. Possibly, this influenced
to the actual under-diagnosis of migraine and to the suboptimal head-
ache management in men. Therefore, clinicians and researchers are being
encouraged to enhance the knowledge among possible sex differences
in migraine clinical profile and comorbidities. Accordingly, the aim of the
present study is to explore the self-related pain features, regarding mi-
graine and neck pain, among patients with migraine of both sexes.
Materials and Methods: Patients with migraine, aging between 18 and
55 years old, were trialed in the university-based headache center from
November 2015 to July 2017. Migraine diagnosis was provided by an
expert neurologist according to the beta version of third edition of Inter-
national Headache Disorders Classification. Exclusion criteria were other
concomitant headache, fibromialgia, history of neck or head trauma. A
structured questionnaire was applied to verify migraine and neck pain
characteristics. The outcomes of interest were frequency of migraine,
years living with pain conditions and its intensity. Severity of the disabil-
ities related to migraine and to neck pain were respectively assessed by
the Migraine Disability Assessment and the Neck Disability Index. Add-
itionally, presence and severity of cutaneous allodynia was verified by
12 item Allodynia Symptom Checklist. Groups were compared using t
test for independent samples and distribution among questionnaires
classifications were tested by the Fisher’s exact test. All statistical analysis
was performed by SPSS 20.0 adopting a level of significance of 0.05.
Results: Groups did not differ regarding migraine features and migraine
related disability (p>0.05) (Table 1). Neck pain was reported by 83% of
women group (n=10) and by 42% of men group (n=5) (p=0.09). Women
presented more intense neck pain (p=0.045) and greater neck related dis-
ability (p=0.002) than men (Table 1). They also reported more symptoms
of allodynia (Table 1; p=0.005). The prevalence of cutaneous allodynia was
92% (n=11) in the women’s group and 77% (n=8) in the men’s group; se-
vere and mild allodynia were the most frequent classification respectively
(Fig. 1). No difference could be evidenced among severity distribution of
cutaneous allodynia, migraine- and neck-related disability (Fig. 1).
Conclusion: For instance, findings suggest that female sex may be as-
sociated with a higher frequency of cutaneous allodynia symptoms and
worse severity of neck pain and neck related disability in migraineurs.Table 1 (abstract P76). Sample characteristics considering self-report
pain features and disability related to migraine and neck pain
Men with migraine
(n=12)
Women with migraine
(n=12)
Age (years) 34.2 (8.1) 34.3 (10.6)
ASC-12 4.2 (3.3)* 9.1(4.5)
Migraine
Frequency (days/moth) 16.3 (9.8) 15.4 (8.5)
Intensity (0-10) 8.3 (1.4) 7.9 (2.3)
Onset (years) 15.2 (13.0) 19.6 (18.7)
MIDAS 19.3 (14.1) 34.1 (32.5)
Neck pain
Intensity (0-10) 2.7 (3.7)* 5.7 (3.0)
Onset (years) 2.8 (6.0) 6.6 (5.8)
NDI 6.7 (6.5)* 12.6 (5.6)
Abbreviations: ASC-12 12 item Allodynia Symptom Checklist, MIDAS Migraine Disability Assessment, NDI Neck
Disability Index
*P<0.05P77
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BACKGROUND
Patients with migraine often present neck pain. Additionally, migraine
has been associated to an altered neck muscle performance character-
ized by increased activity of the superficial cervical extensor muscles
and decreased cervical extensor strength. [1,2] Despite the evidences
of the impaired endurance capacity in neck pain sufferers [3,4], neck
muscles endurance has never been reported in subjects with migraine.
Accordingly, our aim was to evaluate the endurance capacity of neck
muscles in individuals with migraine and controls.
MATERIALS AND METHODS
Fifteen subjects with migraine were screened from a headache tertiary
clinic and fifteen headache-free controls from general population. The
participants responded to a previously structured questionnaire con-
taining general information, such as sex, age, weight, and height (Table
1). Endurance test of flexors and extensors was held by a blind evalu-
ator. The flexor endurance was performed with the patient lying in the
supine position and positioning the head and neck in slight flexion.
The examiner placed the hand under the head, and the test was termi-
nated if the head touched the hand of the examiner or if the subject
cannot sustain the position. The extensor endurance test was per-
formed with the patient lying prone. A cervical range-of-motion device
was placed on the head to maintain the head's alignment with the
horizontal plane. A Velcro band was fixed at the head of the patient
and a 2-kg weight was attached to the Velcro band, placed around the
participants’ head. The test was terminated when the subject was no
longer able to hold the position, or if the head position changed more
than 5° from the starting position[5]. Holding time (s) of both positions
were recorded with a chronometer. Approval for the study was ob-
tained from the Human Ethics Committee of the University of Sao
Paulo (6861/2016), and each subject gave informed consent before
testing. Groups were compared using Independent-samples t tests
adopting a level of significance of 0,05).
RESULTS
Migraine group presented lower holding time in the flexor endurance
test when compared to the control group. At the extensor endurance
test there was no significant difference (Table 2).
CONCLUSIONS
Preliminary findings suggest that subjects with migraine present
worse performance of neck flexor endurance characterized by a de-
creased holding time when compared to controls.
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Control (n=15) Migraine (n=15)
Age (y) 25,06(4,07) 29,93 (7,17)
Weight(kg) 64,38(11,35) 68,4 (11,28)
Height (cm) 164(8) 165 (7)
Data are expressed by mean (standard deviation)
Table 2 (abstract P77). Holding time of endurance tests
Endurance Control (n=15) Migraine (n=15)) p
Flexion (s) 81,33(51,06) 46,73(31,34) 0,03
Extension (s) 351(138,42) 242,20(169,24) 0,07
Data are expressed by mean (standard deviation)
Table 1 (abstract P78). CoP area and CoP speed at three light conditions
- mean and 95% confidence interval
Visual threshold Visual discomfort Control
CoP area (cm2) 3.54 (0.87 to 6.20)a 5.03 (1.82 to 8.25) 1.52 (0.99 to 2.06)a
CoP speed (cm/sec2) 1.74 (1.35 to 2.14) 1.78 (1.45 to 2.10) 1.49 (1.39 to 1.59)
adifferent from the visual discomfort condition (p<0.05)P78
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Background: Patients with migraine have showed balance defi-
cits with increased postural oscillation during quiet stance, alter-
ations in gait mobility, reaction time, and movement velocity in
comparison to control subjects [1,2]. Light sensibility is a mi-
graine feature that happens mostly during headache attacks,
but also can be present in lower intensity during the interictal
period, contributing to migraine disability [3]. However, it has
not been established if the exposition to different light inten-
sities modifies the semi-static posture control of migraine pa-
tients in the interictal period. Our purpose was to investigate
bipedal postural control of migraine women under different
light intensities.
Materials and Methods: Fourteen woman with migraine [4] were
selected from a headache tertiary clinic and from general popula-
tion. All participants aged between 18 and 55 years-old (mean
29.3, 95% CI 23.6 to 35.0) with body mass index lower than 30
kg/cm2 (mean 23.6, 95%CI 23.2 to 24.0). The exclusion criteria
were: volunteers affected by vascular and/or neurologicalsystemic conditions, presence of other concomitant headache,
movement coordination impairment or any musculoskeletal dis-
ability that could interfere in the test performance. Participants
were exposed to gradual light increase from 300 to a maximum
of 2000 lux, and were asked about the visual discomfort intensity
(VAS) induced by the light. For balance assessment, participants
stood upright in a bipedal position on a force platform for 30
seconds in the following light conditions: 1) visual threshold, in
which light induce the minimal visual discomfort; 2) visual dis-
comfort, in which light induce moderate-to-intense visual discom-
fort; and 3) control, with only ceiling light room (270 lux).
Participants performed three trials for each condition. Light inten-
sity was measured by a digital luximeter positioned at partici-
pant’s eye level. All participants were assessed during the
interictal period.
A repeated measures ANOVA with LSD post-hoc (p<0.05) was used
to compare the center of pressure (CoP) ellipse area and the CoP
speed among the three light conditions.
Results: We found a median visual threshold equal to 450 lux (IQR
400 to 600) and a median visual discomfort of 2000 lux (IQR 1900 to
2000). Migraineurs showed larger CoP area at the visual discomfort
condition compared to the visual threshold and control conditions
(p<0.05). CoP speed at the visual discomfort condition was higher
than the other conditions tested, but with no statistical difference
(Table 1).
Conclusion: Visual discomfort induced by light intensity manipulation
increased the CoP area of migraineurs patients in bipedal quiet stance.
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Table 1 (abstract P79). Sociodemographic characteristics of survey
participants; the total Korean population; and cases identified as
migraine, probable migraine and poor sleep quality
Survey
participants
N (%)
Total population
N (%)
p Migraine
N, % (95% CI)
PM
N, % (95% CI)
Poor sleep quality
N, % (95% CI)
(PSQI> 5)
Sex
Men 1,345 (49.3) 17,584,365 (50.6) 0.854a 36, 2.7 (1.8-3.5) 136, 10.1 (8.5-11.8) 334, 24.8 (22.5-
27.1)
Women 1,350 (50.7) 17,198,350 (49.4) 107, 7.9 (6.5-
9.4)
243, 17.9 (15.8-
19.9)
381, 28.2 (25.8-
30.6)
Age
19–29 542 (20.5) 7,717,947 (22.2) 0.917a 25, 4.5 (2.7-6.2) 69, 12.6 (9.8-15.4) 153, 28.3 (24.4-
32.0)
30–39 604 (21.9) 8,349,487 (24.0) 42, 7.0 (4.9-9.1) 102, 16.8 (13.7-
19.8)
136, 22.5 (19.2-
25.9)
40–49 611 (23.1) 8,613,110 (24.8) 39, 6.5 (4.5-8.4) 102, 16.8 (13.9-
19.8)
167, 27.3 (23.8-
30.9)
50–59 529 (18.9) 6,167,505 (17.7) 22, 4.1 (2.4-5.9) 62, 11.6 (8.8-14.4) 160, 30.2 (26.3-
34.2)
60–69 409 (15.6) 3,934,666 (11.3) 15, 3.9 (2.0-5.7) 44, 11.2 (8.1-14.2) 99, 24.2 (20.0-28.4)
Size of residential area
Large city 1,248 (46.3) 16,776,771 (48.2) 0.921a 76, 6.1 (4.8-7.5) 180, 14.4 (12.4-
16.3)
338, 27.1 (24.6-
29.6)
Medium-to-small
city
1186 (44.0) 15,164,345 (43.6) 48, 4.0 (2.9-5.2) 174, 14.7 (12.7-
16.7)
303, 25.5 (23.1-
28.0)
Rural area 261 (9.7) 2,841,599 (8.2) 19, 7.4 (4.2-
10.6)
25, 9.7 (6.1-13.3) 74, 28.4 (22.8-33.9)
Education level
Middle school or
less
393 (14.9) 6,608,716 (19.0) 0.752a 22, 5.5 (4.2-7.7) 44, 11.5 (8.4-14.7) 110, 28.0 (23.5-
32.4)
High school 1,208 (44.5) 15,234,829 (43.8) 60, 5.0 (3.8-6.3) 178, 14.7 (12.7-
16.7)
317, 26.2 (23.8-
28.7)
College or more 1,068 (39.6) 12,939,170 (37.2) 60, 5.6 (4.3-7.0) 155, 14.4 (12.3-
16.5)
281, 26.3 (23.7-
29.0)
Not responded 26 (9.6) 1, 3.8 (0.0-11.8) 2, 7.7 (0.0-18.7) 7, 26.9 (8.7-45.2)
Total 2695 (100.0) 34,782,715
(100.0)
143, 5.3 (4.5-
6.2)
379, 14.1 (12.7-
15.4)
715, 26.5 (24.9-
28.2)
N number, CI 95% confidence interval, PM probable migraine, PSQI Pittsburgh Sleep Quality Index, Variables are presented as
number (%) or number, % (95% confidence interval)
aCompared gender, age group, size of residential area, and education level between the sample of the present study and the
total population of Korea
Table 2 (abstract P79). Total and subcomponents score of PSQI of
individual with non-headache, PM and migraine
Non-headache
individuals
N = 1,422 (52.8%)
PM
N = 379
(14.1%)
Migraine
individuals
N = 143 (5.3%)
p
value
Subjective sleep
quality
2.0 (2.0-2.0) 2 (2.0-2.0) 2.0 (2.0-2.0) 0.879
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headache sufferers,[1] there is little knowledge of the associ-
ation of poor sleep quality with probable migraine (PM) in
general population. In the present study, we aimed to 1) de-
scribe the prevalence of poor sleep quality in PM in a gen-
eral population-based sample; 2) compare the prevalence of
poor sleep quality and components of Pittsburgh Sleep
Quality Index (PSQI) score among migraineurs, participants
with PM, and non-headache individuals and 3) assesse the
clinical impact of poor sleep quality among participants with
PM.
Materials and methods: We used the data of Korean
Headache-Sleep Study (KHSS) in the present study.[2] The
KHSS is nation-wide population-based survey regarding
headache and sleep for adults aged 19 – 69 years. The KHSS
used 2-stage clustered random sampling method which was
proportional to population distribution in all Korean territor-
ies. Diagnoses of migraine and PM were based on criteria A
to D for migraine without aura (code 1.1) in the Inter-
national Classification of Headache Disorders-3 beta.[3] We
investigated the components of PSQI and defined poor
sleep quality as PSQI score > 5.[4]
Results: In a representative sample of 2,695 individuals, 143
(5.3%), 379 (14.1%) and 715 (26.5 %) had migraine, PM, and
poor sleep quality, respectively (Table 1). The PM participants
with poor sleep quality were noted in 134 (35.4%). The preva-
lence of poor sleep quality was lower among individuals with
PM compared to those with migraine (35.4% vs. 47.6%, p =
0.011) but higher than those with non-headache (17.9%, p <
0.001). Among components of PSQI, sleep latency (p < 0.001),
sleep duration (p < 0.001), sleep disturbance (p < 0.001),
daytime functioning (p < 0.001), and use of sleeping medication
(p < 0.001) scores were higher in participants with PM
compared to non-headache participants (Table 2). The PM
participants with poor sleep quality had more frequent head-
ache (median [interquartile range]) (2.0 [0.3 – 4.0/month] vs. 1.0
[0.3 – 2.0]/month, p = 0.001), visual analogue scale score for
headache intensity (6.0 [4.0 – 7.0] vs. 5.0 [3.5 – 6.0], p = 0.003),
and headache impact test-6 score (50.0 [44.0 – 58.0] vs. 44.0
[40.0 – 50.0], p < 0.001) than those who without poor sleep
quality.
Conclusions: Approximately 35% of participants with PM had poor
sleep quality. Poor sleep quality was associated with increased head-
ache frequency, intensity and impact of headache among PM in gen-
eral population setting.Sleep latency 1.0 (0.0-1.0) 1.0 (0.0-2.0)a 1.0 (0.0-2.0)a <0.001
Sleep duration 0.0 (0.0-1.0) 0.0 (0.0-1.0)a 0.0 (0.0-1.0) <0.001
Habitual sleep
efficacy
0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.244
Sleep disturbance 1.0 (0.0-1.0) 1.0 (1.0-
1.0)ab
1.0 (1.0-2.0)a <0.001
Use of sleeping
medication
0.0 (0.0-0.0) 0.00 (0.0-
0.0)a
1.0 (0.0-1.0)a <0.001
Daytime functioning 0.0 (0.0-1.0) 1.0 (0.0-1.0)a 1.0 (0.0-1.0)a <0.001
Total 4.0 (3.0-5.0) 5.0 (4.0-6.0)a 5.0 (4.0-7.0)a <0.001
PSQI Pittsburgh Sleep Quality Index, PM probable migraine, Variables are
presented as median (interquartile range)
aSignificantly different compared to individuals with non-headache
bSignificantly different compared to individuals with migraineReferences
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Table 1 (abstract P80). Average and 95%CI of sample characteristics
and questionnaires scores among men and women with migraine.
Men with migraine
(n=17)
Women with migraine
(n=38)
Age (years) 33.8 (7.3) 34.2 (11.3)
BMI 27.2 (4.7) 27.2 (5.8)
Migraine
Frequency (days/month) 17.0 (9.0) 17.3 (10.7)
Intensity (0-10) 8.5 (1.4) 7.9 (2.2)
Onset (years) 14.0 (12.6) 14.1 (10.0)
Level of physical activity*
Inactive 11% 12%
Minimally active 27% 47%
Active 51% 29%
Hepa active 11% 12%
MIDAS 17.3 (13.7)* 32.0 (37.7)
FES 22.2 (11.9) 24.8 (8.7)
Tampa 39.2 (8.1) 35.3 (8.7)
Dizziness
Self-report 24%* 63%
DHI 34.5 (16.1)* 47.4 (20.5)
Abbreviations: BMI Body Mass Index, MIDAS Migraine Disability Assessment,
FES Falls Efficacy Scale, DHI Dizziness Handicap Inventory
*p<0.05
Fig. 1 (abstract P80). Pearson’s correlation between TAMPA with
FES and with MIDAS among migraineurs, p<0.05
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Background: Migraine could be associated to balance changes
and self-report of falls due malfunctioning of the cerebellum and
inner ear. Further knowledge regarding features related to bal-
ance such as kinesiophobia, fear of falling, dizziness handicap
and migraine disability are important for proper management
among migraineurs.
Objective: To investigate the presence of kinesiophobia, fear of fall-
ing, dizziness handicap and migraine disability and its correlation
among women and men with migraine.
Methods: Patients diagnosed with migraine according with the
ICHD-III were screened from a tertiary headache center and
sorted in two groups: women (n=38) and men (n=17). Subjects
with systemic diseases, vestibular disease history, presence of
other headache diagnosis or any musculoskeletal impairment
were excluded. A structured interview was conducted in order to
obtain information regarding demographics including age, BMI,
presence of dizziness, physical activity level and headache fea-
tures. Subsequently it was applied the following questionnaires:
Tampa Kinesophobia Scale, Falls Efficacy Scale (FES), Dizziness
Handicap Inventory (DHI) and Migraine Disability Assessment
(MIDAS). Demographics were contrasted using a one-tailed t-test,
questionnaires scores were compared with a Mann-Whitney for
independent samples and its classifications among groups with
Fisher’s Exact Test. Pearson’s correlation between the question-
naires was calculated based on Cohen classification (0.1-0.3:
weak, 0.3-0.5: moderate and >0.5 large correlation). The analysis
was performed in the SPSS 21.0 software with a fixed significant
level at 5%.
Results: Women and men group of migraineurs did differ in the
following outcomes: age (p=0.12), BMI (p=0.13), migraine fre-
quency, intensity and headache onset (p>0.09). However, the
level of physical activity was different between women and men
(p=0.04). No differences according with the sex was found in the
FES, TAMPA and MIDAS questionnaires, and scores for most of
them were considered moderated-to-high, even though presence
of kinesiophobia was identified just in man (DHI=0.08, FES=0.17,
MIDAS=0.06, TAMPA=0.08), Presence and handicap due dizziness
were higher in women than men (p<0.05) (Table 1). Moderate
significant correlations were found between TAMPA and FES
(r=34), and for TAMPA and MIDAS (r=41) (Fig. 1).
Conclusion: Few studies address men with migraine and these
results highlight the absence of significant differences in head-
ache disability, kinesiophobia, fear of falling, according with sex,
with found scores moderate-to-high for all migraineurs. Dizzi-
ness handicap Kinesiophobia is correlated to headache disability
and fear of falling in migraineurs. Those aspects are related to
migraineurs’ quality of life and might be addressed during clin-
ical assessment.P81
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The syndrome of transient headache and neurologic deficits with
cerebrospinal fluid lymphocytosis (HaNDL) is a rare syndrome of un-
clear pathogenesis characterized by one or more episodes of severe
headache, transient neurologic deficits and lymphocytic pleocytosis
in the cerebrospinal fluid, seldom reported in paediatric age. In most
cases it is a benign and self limited disorder, although it may mimic
various serious, including life-threatening, diseases, such as stroke
and meningoencephalitis, which is why vigorous tests should be
sought before this diagnosis of exclusion can be reached.
METHODS/RESULTS
We report three cases of HaNDL occurred in 2 boys (14 years and 10
years old) and in a 17 years old girl. Each patient presented with
headache, altered conscious state and papilledema associated with
different neurological symptoms such as dysarthria, hemiplegia, per-
nicious vomiting, ideomotor slowing and psychomotorr agitation.
None of them had fever and there was no evidence of meningeal
irritation.
They received Ceftriaxone, Aciclovir, and Dexamethasone for possible
encephalitis and/ or autoimmune disorders. Clinical manifestations
were compatible with a variety of disorders including structural brain
lesions, meningitis, seizures, autoimmune, vasculitic and paraneoplas-
tic disorders. We performed neuroimaging examinations (CT scan
and MRI of the brain), EEG and serum/CSF studies for infectious,
autoimmune and vasculitic diseases. All of these aetiologies were
ruled out. In one case, a complete tox screen was added and it re-
sulted negative. The laboratory finding common to all three cases
was a clear CSF lymphocytic pleocytosis and an elevated opening
pressure during lumbar puncture. The intracranial hypertension
treated in all three cases with acetazolamide per os with complete
remission. In one case, it was necessary the admission in the inten-
sive care unit because of the worsening of psychomotorr agitation of
the patient, requiring sedation and endotracheal intubation. All three
patients recovered without any neurological sequelae during the
follow up.
CONCLUSION
The possibility of HANDL should be considered in patients presenting
with unusual patterns of headache and transient neurological symp-
toms. It is most commonly diagnosed in the third or fourth decades
of life and is rare in the paediatric population. However, awareness
of HANDL existence also in children and adolescents can avoid un-
necessary and potentially harmful investigations and therapies.
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Background. The treatment and prevention of migraine attacks has
for long yielded insufficient results. A usual level of result achieved
(using standard treatment methods) (i.e. 50% reduction in frequency
of attacks) [1] does not produce satisfactory quality of life for the pa-
tients. Neither does it reduce the problem of resistant attacks.
We conducted the current study with the goal of increasing efficacy
of the prevention of migraine attacks using quetiapine as an add-
itional (supplementary) medicine in patients suffering from Chronic
Migraine [2] and already taking anticonvulsants.
Materials and methods. 118 male and female patients from 18 to 50
y.o., suffering from Chronic Migraine were included in this study.
Pregnant and nursing mothers and any patient suffering from som-
atic illnesses were excluded from the sample.
Patients were prescribed topiromat (up to 300 mg/per day) for a 6-
month period, but were transferred to sodium valproat (up to 30 mg/
kg of weight) in cases of non-response. In cases of response to treat-
ment quetiapine was added as a supplementary (secondary) medicine
after 6-month treatment with sodium valproat. A single dose of quetia-
pine was prescribed at night. The dosage was titrated from 25 mg to
400 mg for a period of 1-1.5 months until a therapeutic effect wasattained . The treatment using topiromat+quetiapine or sodium val-
proat+ quetiapin lasted for a period of 6 months.
Results. We observed in 68.5% of patients complete absence of at-
tacks as result of supplementing quetiapine to the achieved existing
level of their individual therapeutic dosage. In 32.5% of cases fre-
quency of attacks was no more than 2 per month. In 1%, frequency
of attacks were remained up to 4 per month. All observed attacks
were relieved rapidly by NSID or triptans.
Conclusions. Quetiapine shows a high efficacy as a supplementary
(secondary) medicine when insufficient results were achieved over a
6 months period when prescribing topiromat or sodium valproat
respectively.
The following side-effects were observed when dosage of quetiapine
was rapidly increased (up to 100mg per 1-1.5 months): daytime drowsi-
ness for the first 10 days of medication in doses up to 100 mg/per day.
This side-effect disappeared when the pain subsided. In 3 patients, con-
gestion of nasal passages was observed before sleep, which was also
reduced with increased dosage.
In addition to the pain relief achieved, the following concomitant dis-
orders were reduced: anxiety and asthenia, insomnia, hiperalgome-
norroea. The total effect was a general enhancement of the patients’
quality of life.
We suggest that increased level of transmissions of serotonin may be
underlying reason basis of high efficacy of quetiapine in resistant
and chronic forms of migraine (with and without aura).
Referenses
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Background: Headache attributed to ingestion or inhalation of a cold
stimulus is currently codified in Chapter 4 of the International Classifi-
cation of Headache Disorders 3 beta (ICHD 3 beta) [1] at the first
sub-digit of 4.5 Cold stimulus headache (CSH). Although the exact
prevalence of CSH in the general population has not been assessed,
it appears to be not so uncommon: a 15% lifetime prevalence was
found in the general population aged 25-64 [2], raising to 41% in 13-
15 years old adolescent [3].
Case report: The renowned journal Billboard published the comment
of a live performance of the American rocker Bruce Springsteen, held
at the Metlife Stadium (East Rutherford, New Jersey) on August 30,
2016. During the show, the rocker swallowed a cold beverage and,
immediately after, turned to the public, saying that he had got an ice
cream headache: “In a comical moment, Springsteen put the song on
pause for a moment when he stopped to enjoy a cold drink from the
audience. “I’ll be with you in a minute,” he said, later taking another
swig and chugging it like a teenager. “I got an ice cream headache””
[4]. From this brief comment, we can infer that criteria B and C for
4.5.1 Headache attributed to ingestion or inhalation of a cold stimulus
are satisfied, but not criterion A. Therefore, a diagnosis of 4.5.3.2
Probable headache attributed to ingestion or inhalation of a cold
stimulus could be proposed.
Discussion: CSH, as well as External pressure headache (EPH), previ-
ously considered as secondary headaches and codified in chapter 13,
have been moved in Chapter 4 of the current classification, within
Chapter 4. Other primary headaches. The reason of this modification
is justified by the fact that “they are brought on by physiological (non-
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 64 of 151damaging) stimuli” [1]. However, both of these forms of headache are
strictly related to the application of recognizable factors, fulfilling cri-
terion C of general diagnostic criteria for secondary headache.
Conclusion: This curious anecdote testifies that the intensity of
CSH may be so severe to induce a temporary interruption of a
concert held in front of a crowd of enthusiast fans. In general
terms, a causative factor, independently from its nature, is clearly
recognizable for inducing both CSH and EPH. Therefore, the pri-
mary or secondary nature of these forms of headache and their
classification will be discussed on the basis of the literature on
this subject.
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Objective: Chronic migraine is defined as headaches occurring on
15 or more days each month, at least half of which have migraine
symptoms. Botox® (onabotulinum toxin A) is used extensively in
the UK National Health Service for the treatment of chronic mi-
graine. We provide this treatment regimen to our patients in a
nurse-led clinical service. The demand for the treatment is in-
creasing and we needed to find more efficient ways of running
the service to meet the increasing demands. In 2016 we had a
waiting list for treatment with a number of patients breaching the
18 week ‘treat-by-date’. Our main objective was to eliminate the
waiting list by treating substantially more patients in each clinic
session and avoiding any further breaches of the 18 week guide-
line. To do this we needed to develop an efficient and standar-
dised process without adding additional resources into the
service.
Method: We undertook a structured work improvement program
partnering with a company called ProcEx Solutions Ltd. We utilised
the model of firstly measuring our current process (assessment)
and then secondly implementing standardised improvements (kaizen)
as identified in the measurement phase. Measurements were
made of nurse walking distances due to clinic room set-up, time
taken to reconstitute and draw up Botox and we also assessed
the amount of ‘down-time’ in the clinics. Different categories of
patients were assessed and we observed that certain patients
would require significantly more clinic time than others. We were
allocating 30 minute time slots to all patients but we realised
that we could segregate the patients into categories of 15 and
30 minute time slots. The table below illustrates the increase in
annual capacity by using this approach.Clinics Clinic Times Frequency Current Annual
CapacityNew Annual
CapacityTuesday AM 09:00-12:30 Weekly 336 546Wednesday AM 09:00-12:30 Monthly 96 156Wednesday PM 13:30-16:30 Monthly 84 132Thursday PM 13:30-16:30 Monthly 84 132Friday PM 13:30-16:30 Fortnightly 168 264768 1230% Increase 60%Results: We realised additional clinic capacity of 462 treatments per
year, an increase of 60%. We observed actual increases from 292
treatments in the second half of 2016 to 395 treatments in the first half
of 2017, an actual increase of 35%, with the same number of staff.
Conclusion: The assessment of our working practices has identified
opportunities to improve our efficiencies. The subsequent implementation
of an improved process has enabled us to treat significantly more
patients without increasing the number of clinical staff. We continue to
see further increases in the number of patients we are able to treat.
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Background
Zonisamide is an antiepileptic drug that shows broad spectrum of
anticonvulsant activity. Furthermore, recent studies have demonstrated
additional therapeutic use in migraine prophylaxis [1]. Zonisamide, a
sulfonamide analog, is a drug with mechanisms of action similar to
topiramate. Also these two drugs have similar adverse effects, such as
weight loss, ureteric stone. In contrast with topiramate, zonisamide has
no cognitive impairment or learning difficulty [2]. Therefore zonisamide
could be one of the therapies for prevention of headache in patients
with dementia.
Materials and Methods
We enrolled 10 Alzheimer’s disease patients with migraine headache,
retrospectively. For headache, we investigated headache frequency
with severity by using their headache diary and visual analog scales
(VAS). Mini-mental status examination (MMSE), clinical dementia rat-
ing (CDR) was checked on visit and 3 months later.
Results
8 patients were male. The average add-on dose of zonisamide was
230 (range: 200-300). Frequency and severity of headache was also
improved. The baseline average VAS was 6.9 (range: 6-8) and follow-
up VAS was 3.8. The headache frequency declined from 16.4 times
per month to 8.3. There is no significant change on MMSE and CDR.
Conclusions
Our findings support the use of zonisamide and an effective therapy
for headache prophylaxis in patients with dementia.
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Table 1 (abstract P86). See text for description
Case n. Sex Age Spine
NMR
Cisternography Leakage Blood
administered
(ml)
n° of Blood
Patches
1 F 35 + T2-T3 20 1
2 M 57 - + L2-L3 20 1
3 M 43 + C7-T1 20 1
4 F 45 + T12-L1 20 2
5 F 27 - / 20 1
Note: + = evidence of liquor leakage, - = not evidence of liquor leakage
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Spontaneous Intracranial Hypotension (SIH) is a rare syndrome
(incidence: 5/100.000) [1] reportedly described over the past years
[1,2]. Although SIH can produce a broad spectrum of clinical
presentations, most patients experience postural headache. A
conservative treatment is advocated as first-line therapy for pa-
tients with SIH, but in refractory cases an epidural blood patch
(EBP) may be attempted [3,4]. We aimed to assess the efficacy of
blind lumbar EBP in a case series of patients with postural head-
ache and spontaneous intracranial hypotension.
Methods. We retrospectively analysed patients with SIH treated
with EBP in our Centre. Information regarding demographics,
radiology and clinic follow up was extracted from an electronic
patient record system. The patients were asked to answer
questions regarding their daily life activities using the 12-Items
Short Form Survey (SF-12) questionnaire before and after 1 month
from the procedure (following our Pain Unit protocols). Data re-
garding their global impression of change 1-week after treatment
were collected. All patients underwent Brain MRI after 6-month
from BP to evaluate radiologic resolution and the data were com-
pared to the clinical evolution.
Results. Five patients who underwent lumbar epidural blood patching
were analysed (3 female; mean age 41 years). The site of Cerebrospinal
Fluid leak was evident in 4 patients (3 through spinal MRI, 1 through
Cisternography) (Tab. 1). Three patients reported instantaneous
headache resolution, 2 responded only partially, having symptoms
persisting for 1-2 weeks before recovering and developed a chronic
headache without postural component. All patients reported improve-
ments in Physical Component Summary and Mental Component
summary after the procedure (p<0,02), and all patients had impression
of benefit 1-week after treatment. MRI showed normal findings at 6-
month follow-up.
Conclusions. A blind blood patch procedure can provide complete
resolution in headache symptoms in selected patients. Our patients
who did not achieve instantaneous complete symptoms resolution
after the procedure, still showed improvements in their quality of life
and reported a noticeable change after the procedure, showing that
EBP might be beneficial also for those cases in which complete relief
is not instantaneous.
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Background: Retinal migraine is a rare form of migraine. According to
the ICHD-3 beta criteria the diagnosis requires an aura consisting of
fully reversible monocular positive and/or negative visual phenomena
(e.g., scintillations, scotomata or blindness) confirmed during an attack
by 1. clinical visual field examination and/or 2. the patient’s drawing of
a monocular field defect and at least two of the following three charac-
teristics: 1. the aura spreads gradually over ≥5 min, 2. aura symptoms
last 5-60 min, 3. aura is accompanied, or followed within 60 min, by
headache.
Case reports: We present three cases of patients with retinal migraine,
they all fulfill ICHD criteria but have some “case specific” interesting
features:
1. A 29-year old woman with aura always on her left eye. The pa-
tient experiences first a slight pressure beyond her eye, followed
by an aura described as slowly blackening of her visual field in all
4 quadrants, or scintillating scotoma, lasting 3-5 minutes,
followed by complete normalization of her visual field. In 50% of
attacks she has a subsequent mild headache lasting 10-30
minutes. She has 1-2 attacks per month. Case specific: headache
is present in only 50% of attacks.
2. A 40-year old woman with aura always on her left eye, beginning
with palpitation, sense of fear, followed by grey scintillating
scotoma, followed by complete blindness, with complete
resolution after 10 minutes. Aura is followed by a mild headache
lasting couple of hours to several days. She has 1 attack per
month. Case specific: has additional “autonomic aura symptoms”.
3. A 69-year old man, with migraine without aura and separately
sudden attacks of complete visual loss lasting from 10 sec-
onds to 10 minutes on right or left eye, rarely both. Simultan-
eously pressing headache behind the affected eye, duration 5
minutes to 6 hours with foto-and fonofobia, slight nausea
and aggravation by physical activity. He has 3 attacks per
month. Case specific: pt. experiences sudden visual loss, not
march, symptoms are always reversible.
Common to all cases: never typical (hemianoptic) visual aura, sensory,
speech or motor aura; accompanying headache is of mild intensity, in 2
cases not migrainous; in 2 cases aspirin had no effect on migraine.
Conclusion: Although rare, retinal migraine should not be misdiagnosed
as amaurosis fugax, papilledema or optic disc disease, transient visual
obscuration or Uhthoffs phenomenon.
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Background
Recent MRI studies have shown structural and functional abnormalities
in the brain of cluster headache (CH) and migraine (M) patients.
However, no between-group comparison of MRI measure has been
performed.
Materials and methods
Multimodal MRI was acquired on a 3T MR scanner in age-matched
patients with CH (n=12), M without aura (n=13), both during attack-
free period, and normal controls (NC, n=13). MRI processing was per-
formed with FSL. Voxelwise analyses of variance were done with
nonparametric permutation testing (p<= 0.05, corrected).
Results
Compared to NC, higher grey matter volume (GMV) occurred in CH
in the cerebellum and occipital fusiform gyrus and in M in the lateral
occipital cortex (LOC). GMV was lower than in NC in the inferior
frontal gyrus of CH and in the lingual gyrus of M. Compared to M,
GMV of CH was higher in the cerebellum and lower in the frontal
pole and LOC. Functional connectivity (FC) was, compared to NC,
higher in CH in the default mode, working memory and executive
networks (DMN, WMN, EN) and altered in DMN of M, with lateral
increase and medial decrease. FC in WMN and EN of CH was also
higher than M. FC between cerebellar and temporo-insular networks
was higher in CH than M.
Conclusions
The brain of attack-free CH seems to be characterized, compared to M,
by (i) GMV changes, with decrease in a classical pain processing region
(frontal cortex) and increase in an atypical region (cerebellum) and (ii) in-
creased FC in key cognitive networks, with a possible maladaptive role.
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Today there is the need of analysis of individual monoclonal antibody
studies for CGRP or CGRPr in migraine, and also on the future role of
these drugs in a disease with such a large impact on the general
population. Fourteen percent of the global population suffers from
migraine, and we now have to imagine how to proceed in the
dissemination of these new drugs. Excluding the prophylaxis of the
episodic form of migraine, we will have to postpone for ethical and
pharmacoeconomic reasons the choice to treat with CGRP(r) mAbs the
very low frequency migraine subpopulation (4-6 migraine days per
month). Unfortunately, the tight application of existing guideline-
recommended drugs could make this choice difficult. We must instead
focus attention towards the highly disabling and costly forms;otherwise we would hypothesize treating almost one billion people
with migraine. However, only 2% of the world's population suffers
from chronic migraine (with or without pharmacological abuse of
acute drugs – analgesics, non-steroidal anti-inflammatory drugs,
triptans, opioids, ergot derivatives, barbiturates, caffeine, etc. and
their various combinations) and this chronic form is the current true
challenge in headache management. We should attempt to prevent
the chronicization of these patients, who constitute the core group
with personal-social-working burden, and who fluctuate in a pre-
chronic phase with high-frequency migraine crisis but who are not
yet chronic. Only in this way will we reduce the huge number of
chronic migraine patients, who stray towards medication overuse
headache (MOH) and are at risk of refractoriness. And only in this
way will we reduce the cascade of multi-systemic pathologies
(gastrointestinal, renal, cardiovascular, cerebral, psychiatric, etc.) ori-
ginating from acute drug abuse, which are often not recognized or
directly correlated with it. This is a top priority, because we know
that the rehabilitation procedures for chronic migraine complicated
by MOH present with relapse in 50% of patients within the first 12
months. Another priority area of intervention is refractory migraine,
as clinically defined by the European Headache Federation. Refrac-
tory migraine is very hard to treat and has been the target for a
number of ineffective invasive techniques. These priority areas
could represent immediate targets for the application of the new
CGRP mAbs.
Reference
Martelletti P. The application of CGRP(r) monoclonal antibodies in migraine
spectrum: needs and priorities. Biodrugs 2017 in press.
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Migraine is a disabling neurological disorder and a significant
public health problem. The pathophysiology of migraine is not well
understood, but studies have shown that calcitonin gene-related
peptide (CGRP) plays a strong role. Recently there has been a sig-
nificant interest for role of pituitary adenylate cyclase-activating
polypeptide-38 (PACAP38) in migraine. We have previously shown
that administration of PACAP38 induces photophobia similar to CGRP-
induced photophobia in wild-type CD1 mice. As a surrogate to photo-
phobia, we measured light aversion behavior. The objective of this
study is to determine if pretreatment with anti-PACAP antibodies will
inhibit the PACAP-induce light aversion. We have also used anti-PACAP
and anti-CGRP antibodies to better understand the relationship be-
tween PACAP and CGRP in their involvement in migraine.
Our results show that intraperitoneal (ip) injection of anti-PACAP38
antibody was able to inhibit PACAP-induced light-aversive response
in CD1 mice compared to mice treated with control antibody. In
addition, PACAP38-induced increase in resting time in the dark,
reflecting pain as experienced during migraine, was inhibited by
anti-PACAP antibody. Our results also suggest that PACAP and CGRP
may work through different pathways as the cross antibody treat-
ment was not able to inhibit PACAP or CGRP-induce light aversion.
Future work will attempt to understand more about PACAP38 in mi-
graine and to explore PACAP as a potential novel target in migraine
therapy.
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Background
Migraine has far-reaching impacts on the family of individuals with
migraine but limited evidence is available to describe this reality. To
better understand the full burden of migraine, this study sought to
describe the impact of migraine from the caregiver’s perspective.
Materials and Methods
This cross-sectional study was conducted using Online Bulletin
Boards (OBB), an interface developed for online survey, discus-
sions and interactions led by a trained facilitator over 4 consecu-
tive days. Caregivers aged ≥25 years who were caring for an
adult migraine patient in their household were recruited to par-
ticipate in 3 OBBs in Germany, Italy and USA (1/country). Partici-
pants were blinded to each other and agreed to partake daily for
≥30 minutes in the OBBs, where they were asked to respond to
specific questions on migraine and provide their perspectives on
statements and other participants’ blinded responses. All re-
sponses were aggregated by country and qualitatively analyzed.
Results
A total of 30 caregivers participated in this pilot phase of a large
global study (10/country). All caregivers reported that they were
highly involved in the management of migraine and that they
spent an average of 15 hours/month supporting their family
member suffering from migraine. 83% of respondents (n=25/30)
reported feeling stressed, exhausted and overwhelmed with the
amount of work resulting from their caregiving activities. They
described themselves as powerless witnesses of the frequent and
intense suffering of their loved ones, wanting to be helpful while
knowing the limits of what they could do. 60% of caregivers (n=18/30)
reported a worsening of personal relationships over time due to
migraines. Regardless of whether they were employed, unemployed or
retired, 83% of caregivers (n=25/30) reported that their caregiver role
affected their lives due to the significant changes it imposed on their
own daily routines/schedules. This affected private life, social
engagements, relationships, and professional obligations, including fear
of losing employment. Most caregivers (87%, n=26/30) reported
ambivalent feelings, being torn between commitment, self-sacrifice
and resentment. All agreed that migraine patients were thankful for
their help and assistance.
Conclusions
Caregiving has a major impact on the lives of close relatives supporting
migraine patients. This study highlights how the burden of migraine
extends beyond the patients, with substantial functional and emotional
impacts of the disease on caregivers. This pilot confirmed the unique
opportunity that this type of study provides for insights into the
caregivers’ experience and unmet needs in the current treatments
available to migraine patients.
Funding
This study was funded by Novartis AG, Switzerland.
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Background
Migraine is a prevalent condition affecting about 11% of the adult
population. It has debilitating symptoms and affects patient
functioning. The present study was undertaken to understand the
full burden and impact of migraine in everyday life from the patient’s
point of view.
Materials and Methods
This cross-sectional study was conducted using Online Bulletin
Boards (OBB). This interface was developed for online survey, discus-
sions and interactions led by a trained facilitator over a period of 4
consecutive days. Adults with chronic and episodic migraine aged
between 25 and 60 years old were recruited to participate in 6 OBBs
established in Germany, Italy and USA (2 per country). Participants
were blinded to each other and agreed to partake for at least 30 mi-
nutes each day in the OBBs, where they were asked to respond to
specific questions on migraine and to provide their perspective on
statements and other participants’ blinded responses. All responses
were aggregated by country and qualitatively analyzed.
Results
A total of 60 migraine patients participated in this pilot phase of a
large global study (20 per country). About half (47%, n=28) reported
having been diagnosed with migraine, either by a general
practitioner (GP) or neurologist within the year following the date of
their 1st symptoms. Table 1 summarizes the 3 most common
migraine attack triggers, symptoms, and coping mechanisms
reported by patients. All respondents reported important limitations
resulting from migraines in private, professional and social aspects of
life, mainly the disruption of daily routines, significant strain on
personal relationships, difficulty caring for children, and missed days
of work, deadlines, or social events. Anxiety and frustration were
most frequently reported as emotional consequences of migraine in
private/social life (92% and 72%) and work (97% and 88%). 87% of
patients (n=52) had seen a physician for migraine management but
many (85%, n=51) did not consult regularly, especially if their
diagnosis had occurred long ago. Two thirds (n=38 / 63%) of
respondents reported getting functional and emotional support from
family and friends, but wished for improved understanding/
compassion from others and more efficacious medications.
Conclusions
This study highlights the substantial functional and emotional
burden migraine exerts on individuals, as well as the significant
unmet needs that remain for these patients despite currently
available care and treatment options.
Funding
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Mechanisms
3 Most Common per Category
Migraine
attack
triggers
Bright light Loud/repetitive sounds Stress
97%(n=58) 93%(n=56) 93%(n=56)
Migraine
symptoms
Pounding/throbbing Photophobia Sensitivity to s
ound and noise
97%(n=58) 97%(n=58) 93%(n=56)
Coping
mechanisms
Lying down in a
darkened room
Avoidance of
sounds/noise
Medication use
97%(n=58) 95%(n=57) 77%(n=46)P94
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Background
Physical therapy (PT) is used as single or complementary treatment
for headache. Onabotulinum toxin A (BoNT-A) has proven to be
effective in chronic migraine (CM) prophylaxis. Currently no clinical
studies about BoNT-A plus PT combined treatment (CT) are available.
Objectives
To compare the efficacy of BoNT-A plus PT combined treatment with
the single therapeutic options in CM.
Material and methods
A three-arm randomized perspective study of patients suffering
from CM admitted to the Headache Centre of the University of
Trieste was performed. All the patients underwent a clinical postural
evaluation at the beginning of the study. They had a one-month obser-
vation period (baseline), then they were treated with BoNT-A, PT or CT.
BoNT-A was administred following the “fixed site/fixed dose” and
“follow-the-pain” protocol, PT was based on combination of postural
advice, relaxation training, exercises and manual treatment on trigger
points, reinforcement and postural modification. Number of responders
(>50% reduction of headache days), headache days, headache hours,
symptomatic drug intake, disability (MIDAS) in baseline and at the
three-month follow-up visit were analyzed with SPSS 21.0.
Results
We enrolled 25 patients (22 F, 3 M; mean age 54 [34-79] years), 13
patients were treated with BoNT-A, 8 patients with CT, 4 patients
with PT. Both groups of patients treated with BoNT-A and CT had a
reduction of number of headache days (BoNT-A: Baseline=26 [16-
30] vs Three-month visit=12 [4-30] (p=0.003); CT: Baseline=21 [13-
30] vs Three-month visit=11 [3-29] (p=0.012)), symptomatic drugs
(BoNT-A: Baseline=21 [6-57] vs Three-month visit=14 [0-21]
(p=0.025); CT: Baseline=22 [11-41] vs Three-month visit=9 [1-41]
(p=0.018)), and MIDAS (BoNT-A: Baseline=93 [62-210] vs Three-
month visit=57 [10-179] (p=0.002); CT: Baseline=85 [35-124] vs
Three-month visit=34 [12-187] (p=0.03)). The reduction of headache
days, symptomatic drugs and MIDAS were comparable in both
BoNT-A and CT patients (p=NS). Only patients treated with BoNT-A
improved in total headache hours (BoNT-A: Baseline=241 [46-737]
vs Three-month visit=121 [12-214] (p=0.005)). Percentage of re-
sponders was higher in CT than in BoNT-A group (CT=62% vs
BoNT-A= 38%). Effectiveness measures did not improved in the four
patients who received only PT.Conclusions
Physical therapy is an effective add-on treatment to BoNT-A for CM
prophylaxis. Patients treated with combined therapy BoNT-A plus PT
had a higher percentage of responders than patients treated with
only BoNT-A. The other treatment efficacy measures equally reduced
in both CT and BoNT-A groups. The few patients treated with only
PT did not improved, however a higher sample is required.
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For hundreds of years, butterburs (Petasites), herbaceous perennial
plants belonging to the Asteraceae, which includes also Tanacetum
parthenium L., have been used by folk medicine of northern Eurasia
and America for therapeutic purposes, including treatment of fever,
respiratory diseases, spasms, and pain. Among the number of
compounds contained in common butterbur [Petasites hybridus (L.)
Gaertn.], the major constituents, petasin and isopetasin, are considered
responsible for the antimigraine effects of the herbal extract. The
mechanism of the antimigraine action of butterbur [Petasites hybridus
(L.) Gaertn.] is unknown. Here, we investigated the ability of isopetasin,
a major butterbur constituent, to specifically target the transient
receptor ankyrin 1 (TRPA1) channel and to affect functional responses
relevant to migraine.
Single cell calcium imaging and patch-clamp recordings in human
and rodent TRPA1-expressing cells, neurogenic motor responses in
isolated rat urinary bladder, release of calcitonin gene related pep-
tide (CGRP) from mouse spinal cord in vitro, were examined. Isope-
tasin produced (i) calcium responses and currents in rat/mouse
trigeminal ganglion (TG) neurons and in cells expressing the human
TRPA1, (ii) substance P-mediated contractions of isolated rat urinary
bladders and (iii) CGRP release from mouse dorsal spinal cord, re-
sponses that were selectively abolished by TRPA1 genetic deletion/
pharmacological antagonism. Preexposure to isopetasin produced
marked desensitization of allyl isothiocyanate (AITC, TRPA1 agon-
ist)- or capsaicin (TRPV1 agonist)-evoked currents in rat TG neurons,
contractions of rat urinary bladder and CGRP release from central
terminals of primary sensory neurons.
TRPA1 agonism by isopetasin results in excitation of neuropeptide-
containing nociceptors that is followed by remarkable neuronal
desensitization. Such attenuation in pain and neurogenic inflamma-
tion may account for the antimigraine action of butterbur.P96
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Erenumab is a fully human monoclonal antibody that selectively
inhibits the calcitonin gene-related peptide (CGRP) receptor. In the
STRIVE placebo-controlled Phase 3 trial in patients with episodic mi-
graine (EM; clinicaltrials.gov NCT02456740), erenumab 70 mg and
140 mg administered monthly by subcutaneous injection achieved
the primary endpoint of significantly reducing the number of
monthly migraine days versus placebo. Erenumab also achieved the
secondary endpoint of reducing the number of days/month versus
placebo on which patients used acute migraine-specific medications
(AMSM, triptans or ergotamines; −0.9 and −1.4 days/month averaged
over Months 4−6 for erenumab 70 mg and 140 mg, respectively
[p<0.001 for each dose]). This outcome, measured for the overall
study population, was achieved despite ~40% of patients not taking
AMSM at baseline, for whom change could only be ≥0. Here we
present two further analyses: (A) change in any acute headache
medication days/month (AHM, including AMSM as well as paraceta-
mol, NSAIDS etc,) in the overall study population as 97.7% used AHM
during baseline; (B) change in AMSM days/month in the subgroup
who used AMSM during baseline.
Methods
Patients recorded medication use with a daily eDiary throughout the
4-week baseline period and subsequent 6-month double-blind treat-
ment period. The number of days per month on which AMSM and
AHM were taken was calculated. Change from baseline was analyzed
using a linear mixed effects model including covariates of treatment,
visit, treatment by visit interaction, stratification factors (region and
migraine prophylaxis medication status), and baseline value. Nominal
p-values were provided without multiplicity adjustment.
Results
(A) During baseline, the mean number of AHM days/month in the
overall population was 6.91, 6.58, and 6.60 in the placebo, erenumab
70 mg, and erenumab 140 mg groups, respectively. Erenumab
significantly reduced AHM days/month versus placebo from Month 1
onward (Fig. 1). (B) During baseline, 561 of 955 patients (58.7%) used
AMSM. Mean number of AMSM days/month in patients who used
AMSM during baseline was 5.68, 5.67, and 5.67 in the placebo,
erenumab 70 mg, and erenumab 140 mg groups, respectively.
Erenumab significantly reduced AMSM days/month versus placebo;
treatment difference −1.57 days (−2.04, −1.10; p<0.001) for 70 mg
and −2.30 days (−2.77, −1.83; p<0.001) for 140 mg, averaged over
Months 4−6.
Conclusion
Erenumab significantly reduced both AHM and AMSM days/month
versus placebo in patients with EM.Fig. 1 (abstract P96). Change from baseline in AHM days/month†P97
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Background
The evolution of migraine (M) after the age of 50 has been insufficiently
studied; sub-population with former M was not studied at all. Aim of in-
vestigation was two-fold: 1. to present clinical portrait of patients with
former/Ex-Migraine (Ex-M) with special focus on retrospective analysis of
M in the active period of the disease (at the age of 30-40) and 2. to study
the level of cortical excitability in elderly Ex-M subjects.
Material and methods
The Ex-M group (n=18) was inhomogeneous and composed of subjects
with complete regress of M attacks (both pain and M aura; CRM, n=11,
m. age 60.0±9) and those keeping M aura only - painless M/Late-life Mi-
graine Accompaniments (LLMAs, n=7, m.age 54.0±7). All patients
underwent clinical interview focused on present and former clinical
manifestations and confirming past-diagnosis of M using Migraine His-
tory Inventory specially elaborated by us for this study. Cortex excitabil-
ity (amplitude and habituation for the N75-P100 component) was
measured using pattern-reversal visual evoked potentials (PR-VEP)
Results
Compared to subjects with LLMAs in patients with CMR migraine
terminated a decade later (39±9 vs 49.7, p<0.05), in the active period of
disease the majority of patients had MoA (72.7% vs 42.9%, p<0.05),
more long (5.0±8h vs 24.0±18h) and typical attacks with throbbing
pain and vomiting; subjects with LLMAs more often suffered from MA.
At the time of investigation CRM-Group had completely normal ampli-
tude and habituation for the N75-P100 component, while LLMAs-
Group demonstrated the signs of cortical hyperexcitability typical for
actual M, namely, significant increase in total N75-P100 (p<0.05) and
more marked dishabituation
Conclusions
1. LLMAs-Group (painless M with preserved aura) initially more
often had MA, short and less typical attacks and even after
loosing pain attacks keep the signs of cortical hyper
excitability. It could be presumed that the phenomenon of
cortical hyperexcitability in patients of any age serves the basis
for preservation of M aura/LLMAs but not M pain.
2. Ex-M elderly patients who are completely free of both pain and
M aura and have normal level of cortical excitability and
habituation initially used to have MoA with long and typical
attacks. Total normalization of brain reactivity could be
regarded as a principal neurophysiological factor for complete
regress of both pain and aura.
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The Migraine Functional Impact Questionnaire (MFIQ) is a newly
developed 31-item patient-reported outcome instrument assessing the
impact of migraine on functional outcomes over 7 days. The MFIQ in-
cludes 4 domains: impact on physical function, usual activities, social
function, and emotional function with scores ranging from 0–100 (higher
scores indicate greater impact; negative change scores represent reduc-
tion in impact [improvement]). In this phase 3 trial (NCT02456740), we
evaluated the effect of erenumab, which is being developed as a pre-
ventive treatment for migraine in adults, on functional outcomes using
the MFIQ.
Methods
In STRIVE, a total of 955 patients with episodic migraine aged 18–65
years were randomised 1:1:1 to receive monthly subcutaneous placebo,
erenumab 70 or 140 mg. The MFIQ was completed at baseline and every
4 weeks for 24 weeks. The MFIQ scores were evaluated as change from
baseline to the last three months of the double-blind treatment phase
(defined as the average of scores in Months 4–6 [Weeks 13–24]). Pairwise
comparisons of least squares mean changes from baseline in MFIQ do-
main scores were assessed for each treatment vs placebo. The p-values
were nominal and not adjusted for multiplicity.
Results
Baseline MFIQ scores were similar in the erenumab and placebo
groups in all 4 MFIQ domains (70 mg: mean±standard deviation [SD]
33.3±20.9; 140 mg: 32.0±21.2; placebo: 33.1±24.5). Greater reductions
in impact from baseline were observed for each MFIQ domain with
erenumab compared with placebo (Table 1).
Conclusions
Over 24 weeks, compared with placebo, patients treated with
erenumab experienced greater reductions in the MFIQ scores,
reflecting less impact of migraine on their physical functioning, usual
activity, and social and emotional functioning, with numerically greater
reductions for 140 mg compared with 70 mg. These improvements
complement the efficacy of erenumab demonstrated by the clinical
outcome measures in the STRIVE study.Table 1 (abstract P98). Changes from baseline in the Migraine
Functional Impact Questionnaire domain scores
Least squares mean changes
(95% confidence interval)
p-values
(Erenumab vs Placebo)
Erenumab
70 mg
Erenumab
140 mg
Placebo Erenumab
70 mg
Erenumab
140 mg
Physical
function
−13.7 (−15.5,
−11.9)
−15.1 (−17.0,
−13.3)
−9.4 (−11.3,
−7.6)
<0.001 <0.001
Usual
activities
−12.3 (−13.9,
−10.6)
−13.4 (−15.1,
−11.8)
−8.3 (−10.0,
−6.6)
<0.001 <0.001
Social
function
−13.2 (−14.9,
−11.4)
−14.5 (−16.2,
−12.8)
−9.5 (−11.3,
−7.7)
0.003 <0.001
Emotional
function
−16.4 (−18.4,
−14.5)
−18.4 (−20.3,
−16.5)
−11.2 (−13.1,
−9.2)
<0.001 <0.001P99
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Background
Migraine Physical Function Impact Diary (MPFID) is a 13-item patient-
reported outcome (PRO) measure that assesses the impact of mi-
graine on Everyday Activities (EA) and Physical Impairment (PI)domains. We report the effect of erenumab, a preventive treatment
for episodic migraine (EM) in adults, on monthly days with impair-
ment as measured by the MPFID.
Methods
The MPFID was completed using an electronic diary every evening
during a global, placebo-controlled, double-blind, 6-month, phase 3
STRIVE trial (NCT02456740) in which 955 adults with EM (18–65
years) were randomised 1:1:1 to subcutaneous, monthly placebo or
erenumab 140mg or 70mg. Reponses to items in the MPFID EA and
PI domains are on a 1–5 scale, with higher numbers indicating
greater negative impact. A day with a response ≥3 on at least one
item in a domain was defined an ‘impaired day’ (ID) for that domain,
(i.e. EA-ID and PI-ID). Mean monthly number of IDs were summarised
for the 4-week baseline period and each subsequent 4-week period.
Changes from baseline in mean monthly EA-ID and PI-ID over the
final 3 months (months 4–6) of the double-blind treatment phase
(DBTP) were assessed as pre-specified exploratory endpoints in the
STRIVE trial; primary and secondary endpoints are reported separ-
ately. All p-values are descriptive and not adjusted for multiplicity.
Results
At baseline, subjects in the erenumab and placebo groups had a
similar number of mean monthly EA-ID (140mg: mean±standard de-
viation 6.62±4.20; 70mg: 7.21±4.56; placebo: 7.12±4.85) and PI-ID
(140mg: 5.81±4.32; 70mg: 6.09±4.60; placebo: 6.20±5.05). Over the
final 3 months of the DBTP, greater reductions from baseline in EA-
IDs and PI-IDs were observed with erenumab 140mg and 70mg
groups than placebo. For EA-IDs, subjects treated with erenumab
140mg (Least Squares [LS] mean=−3.01 days (95% confidence inter-
val [CI]: −3.45,−2.57) and 70mg (−2.83 days [−3.27,−2.39]) experi-
enced larger reductions compared with placebo (−1.71 [−2.16,−1.27],
both p<0.001). Greater reductions in mean monthly PI-ID days were
also observed in the erenumab groups (140mg: LS mean=−2.51 days
(95% CI: −2.93,−2.09); 70mg: −2.25 days [−2.68,−1.83]) compared with
placebo (−1.16 [−1.59,−0.74], both p<0.001).
Conclusion
Compared with placebo, EM subjects treated with erenumab 140mg
and 70mg experienced greater reductions from baseline in mean
monthly MPFID EA-ID and PI-ID during the 6 month DBTP. Numeric-
ally greater reductions were observed with 140mg than 70mg.
Erenumab-treated patients experience reductions in functional im-
pairment due to migraine, which complements improvements ob-
served with standard efficacy measures.
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Background
Migraine is a disabling disease associated with substantial burden on
patients and society. Erenumab (AMG334) is a fully human anti-
calcitonin gene-related peptide (CGRP) receptor monoclonal anti-
body in clinical development for migraine prevention. The objective
of this study was to evaluate patient-reported outcomes in a phase 2
clinical trial of erenumab for chronic migraine (CM) (NCT02066415).
Methods
667 adults with CM were randomised (3:2:2) to monthly subcutaneous
placebo or erenumab 70 mg or 140 mg. Primary and secondary
endpoints were assessed at Week 12. Exploratory endpoints included:
Table 1 (abstract P101). Patient classification in migraine categories
during the HFEM study
Table 1A.
Overall shift in migraine categorya
Placebo
n = 104
Fremanezumab
225 mg
n = 95
Fremanezumab
675 mg
n = 96
Worsen 7 (7%) 2 (2%) 3 (3%)
Stable 42 (40%) 14 (15%) 17 (18%)
Improve 51 (49%) 69 (73%) 68 (71%)
Discontinued 4 (4%) 10 (11%) 8 (8%)
Table 1B:
Migraine Categories
Num (%) patients in 3rd month
Placebo
(n = 98)b
Fremanezumab
225 mg
(n = 88)
Fremanezumab
675 mg
(n = 91)
CM 7 (7%) 2 (2%) 2 (2%)
HFEM 41 (42%) 14 (16%) 17 (19%)
MFEM 28 (29%) 22 (25%) 21 (23%)
LFEM 20 (20%) 40 (45%) 47 (52%)
aShift in migraine category, worsen = HFEM to CM, stable = HFEM to HFEM,
improve = HFEM to MFEM or HFEM to LFEM, discontinued = left study bn
values indicate the patients per treatment group meeting HFEM classification
at baseline
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by the Migraine-Specific QoL Questionnaire (MSQ), headache impact
measured by the Headache Impact Test (HIT-6), and migraine-related
disability measured by the Migraine Disability Assessment Test (MIDAS).
No formal hypothesis was tested; p-values (placebo vs erenumab dose-
groups) are descriptive.
Results
Baseline scores were similar between groups. Improvements were
observed for all endpoints in both erenumab groups at Week 12. The
mean (95% CI) changes for placebo vs 70 mg and 140 mg groups,
respectively, were 11.8 (9.4, 14.1) vs 17.7 (14.9, 20.6), p=0.002 and
19.1 (16.3, 22.0), p<0.001 for MSQ role function-restrictive scores, 8.9
(6.8, 11.0) vs 13.0 (10.5, 15.6), p=0.013 and 13.8 (11.3, 16.4), p=0.003
for MSQ role function-preventive scores, and 9.9 (7.3, 12.5) vs 18.2
(15.0, 21.3), p<0.001 and 18.8 (15.6, 21.9), p<0.001 for MSQ
emotional-function scores. Mean changes in HIT-6 scores were −3.1
(−3.9, −2.3) for placebo vs −5.6 (−6.5, −4.6), p<0.001 for both erenu-
mab groups. Corresponding mean changes in the placebo, 70 mg,
and 140 mg dose-groups were −7.5 days (−12.4, −2.7) vs −19.4 days
(−25.2, −13.6), p=0.002 and −19.8 days (−25.6, −14.0), p=0.001 for
MIDAS days of lost productivity, −5.2 days (−8.0, −2.4) vs −10.3 days
(−13.6, −6.9), p=0.023 and −10.2 days (−13.6, −6.8), p=0.024 for
MIDAS-absenteeism, and −1.9 days (−4.7, 0.8) vs −9.3 days (−12.6,
−6.1), p<0.001 and −9.9 days (−13.2, −6.7), p<0.001 for MIDAS-
presenteeism.
Conclusions
Erenumab-treated CM patients experienced consistent and clinically
significant improvements in patient-reported outcomes including
migraine-specific QoL and reductions in headache impact and
disability.
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Objectives
Fremanezumab is a fully humanized monoclonal antibody targeting
the calcitonin-gene related peptide (CGRP) ligand, a validated target
for migraine preventive therapy. Fremanezumab was found to be ef-
fective and well-tolerated as a preventive treatment for migraine in a
high frequency episodic migraine (HFEM) phase 2 study. Study par-
ticipants included patients classified as having episodic migraine
(EM) per the ICHD III beta. Herein, we determined whether there was
a treatment-induced shift in the number of patients who met the cri-
teria for classification as having high frequency EM (HFEM) to moder-
ate frequency episodic migraine (MFEM) and low frequency episodic
migraine (LFEM) during the HFEM study.
Methods
Patients were randomized to receive either fremanezumab doses
(225mg or 675mg) or placebo every 28 days for 12 weeks. Headache
information was captured daily using an electronic headache diary.
For the post-hoc analysis, the frequency of headache days (days of
headaches lasting > 4 hours) and migraine days (days with head-
aches classified as migraine, probable migraine or treated with trip-
tan or ergot compounds) per month were categorized into four
types of migraine classification: Chronic migraine (CM) as having ≥15
headache days with 8 migraine days; HFEM 8 to 14 headache days
with 8 migraine days; MFEM 4 to 7 headache days and 4-7 migraine
days; LFEM 0 to 3 headache days and 0-3 migraine days. Analyses on
the shifts for migraine classification from baseline to month 3 were
performed to determine the percent of patients who showed im-
provement (HFEM to MFEM or LFEM), worsening (HFEM to CM) and
those who remained classified as HFEM.Results
Overall, the fremanezumab arms showed significant improvement in
migraine classification compared to the placebo arm at month 3
(Patients on 225mg 73% vs 49% for placebo, 95% CI: 0.098 to 0.358
and patients on 675mg 71% vs 49% placebo, 95% CI: 0.079 to 0.341,
Table 1A). Chi square analyses indicated that the shift of migraine
classification during the study was not independent of treatment, X2
=31.64, p=1.91E-05. As shown in Table 1B, 45% and 52% of patients
on fremanezumab 225mg and 675mg showed a shift in migraine
category from HFEM to LFEM in 3 months compared to 20% of
placebo patients.
Conclusion
As treated patients were more likely to improve and less likely to
worsen compared to those on placebo, this study suggests that
fremanezumab may potentially prevent the progression of migraine
to more chronic forms.
Trial registration
Clinicaltrials.gov NCT02025556
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Background
Erenumab is a fully human monoclonal antibody that selectively
targets and inhibits the calcitonin gene-related peptide (CGRP) receptor
and is under investigation for migraine prevention. As the ligand CGRP
is a vasodilator, inhibition of the CGRP pathway might theoretically
increase blood pressure (BP). Addressing this theoretical risk through
ancillary safety studies has been an important focus during the clinical
development of erenumab. This report summarises BP findings from
the erenumab clinical development programme.
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Systolic and diastolic BP values were obtained at baseline and every
4 weeks in four placebo-controlled erenumab clinical trials (clinical-
trials.gov NCT01952574, NCT02066415/NCT02174861, NCT02456740,
NCT02483585). Blood pressure was recorded as the average of ≥2
measurements taken ≥5 minutes apart with subjects lying supine
and rested for ≥5 minutes. Pooled placebo-controlled data from
baseline and treatment Weeks 4, 8, and 12 are presented. In categor-
ical analyses, a notable increase in BP was defined as an increase
from baseline of ≥10 mmHg in diastolic and/or ≥20 mmHg in systolic
BP. In a separate Phase 1 study (NCT01723514), 24-hour continuous
BP was assessed in healthy volunteers receiving erenumab monthly
over 12 weeks.
Results
Blood pressure was similar across treatment groups at baseline, and
remained stable throughout the 12-week period (Fig. 1), with no dif-
ference observed between erenumab and placebo. Mean (SD)
change from baseline at 12 weeks in systolic BP was −0.4 (9.6), −0.5
(10.0), and −1.0 (9.8) mmHg, and mean change in diastolic BP was
−0.6 (7.1), −0.3 (7.7), and −0.4 (7.2) mmHg, in subjects treated with
placebo, erenumab 70 mg, and erenumab 140 mg, respectively. The
proportion of subjects with a notable increase at any visit was similar
across treatment groups. In a 24-hour continuous BP assessment, ere-
numab 70 mg and 140 mg did not increase BP and had no effect on
diurnal rhythm (Fig. 2).
Conclusion
Selectively blocking the CGRP receptor with erenumab 70 and 140
mg had no relevant effect on BP in subjects with migraine over 12
weeks versus placebo, and was not associated with significant 24-
hour BP changes in healthy volunteers.
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The neuropeptide calcitonin gene-related peptide (CGRP) is a key
player in migraine. While migraine can be induced by peripherally
administered CGRP (intravenous) and can be treated using CGRP
antagonists that act peripherally, the relevant sites of CGRP action
remain unknown. To address the role of CGRP both within and out-
side the central nervous system, we used a mouse model of photo-
phobia. Photophobia is an abnormal discomfort to non-noxious
levels of light and is experienced by approximately 90% of migraine
patients. We have previously shown that peripheral (intraperitoneal,
IP) injection of CGRP resulted in light aversive behavior in wild-type
CD1 mice similar to aversion previously seen following central
(intracerebroventricular, ICV) injection. Importantly, two clinically
effective migraine drugs, the 5-HT1B/D agonist sumatriptan and a
CGRP-blocking monoclonal antibody, attenuated the peripheral
CGRP-induced light aversion and motility behaviors. To begin to
address the mechanism of peripheral CGRP action, first we used
transgenic CGRP-sensitized mice that have elevated levels of the
CGRP receptor hRAMP1 subunit in nervous tissue (nestin/hRAMP1).
Surprisingly, sensitivity to low light was not seen after IP CGRP in-
jection, but was only seen after ICV CGRP injection. Next, we used
transgenic CGRP-sensitized mice that have globally elevated levels
of hRAMP1 (global hRAMP1) in all tissues. Interestingly, sensitivity
to low light after IP CGRP in these mice was observed. These results
suggest that CGRP can act in both the periphery and the brain by dis-
tinct mechanisms. This also suggests that peripheral CGRP actions may
be transmitted to the CNS via indirect sensitization of peripheral nerves
and likely not on CGRP receptors in the nervous system to cause
migraine-like photophobia. We have now begun investigating the roleof the vasculature in peripheral CGRP-induced light aversion and allo-
dynic pain responses by using two approaches (1) injection of phenyl-
ephrine to minimize vasodilation induced by CGRP (2) genetic
overexpression of the CGRP receptor in the vasculature. We have found
that CGRP has actions on smooth muscle cells that may contribute to
the induction of migraine-like photophobia and that vasodilation may
also, in part, play a role in this migraine-like behavior.
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Objectives: Peripheral non-invasive vagal nerve stimulation (nVNS)
has become a target for the treatment of primary headaches,
though its exact mechanisms are unclear. Different studies showed
that nVNS modulates both spinal and supra-spinal nociceptive
pathways in an inhibitory direction. The nociceptive flexion reflex
paradigm is widely used to investigate modulation of nociception
and represents a reliable objective measure of the functional activa-
tion of the nociceptive network. The aim of our study is to evaluate
the effect of nVNS on the nociceptive withdrawal reflex in healthy
subjects.
Materials and Methods: We enrolled 10 healthy subjects (5 males,
age 26.5±2.2 years) in a cross-over sham-controlled study. Subjects
were randomly assigned to: 1) nVNS: one 120-s electrical stimulation
on each side of the neck using the gammaCore device and b) Sham:
one 120-s electrical stimulation of the median nerve on each wrist
using the gammaCore device. Nociceptive withdrawal reflex was
evaluated in the right lower limb according to a standardized para-
digm: electrical stimulation delivered at the sural nerve and electro-
myographic muscular response recorded from the ipsilateral biceps
femoris. The single stimulus reflex threshold (RT-SS) was the lowest
intensity (mA) needed to elicit a stable muscular response. The tem-
poral summation threshold (RT-TS) was evaluated using a train of 5
stimuli at 2 Hz.
Results: At T0 the neurophysiological parameters were comparable
between groups. In particular RT-SS was 13.86±3.67 and 16.15±3.53
in nVNS and Sham groups, respectively (p=0.086), while RT-TS was
11.0±2.79 in nVNS group and 12.64±3.67 in Sham group (p=0.107).
nVNS caused a significant increase in the RT-SS at T5 (+14.5%±4.2,
p=0.023) and T30 (+25.9%±6.6, p=0.011). Also RT-TS significantly in-
creased following nVSN at T30 (+21.7±6.7, p=0.031). Sham stimula-
tion did not induce any significant modification on the reflex
parameters. When comparing groups, we found that the increase of
RT-SS at T5 and T30 was significantly higher in nVNS vs. Sham
(p=0.008 and p=0.007 respectively). The percentage increase of RT-
TS at T30 was significantly higher in the nVNS vs. SHAM (p=0.013).
Conclusion: Using a reliable method, we demonstrated that nVNS
induces a rapid onset analgesia in healthy subjects. Because of its
neurophysiological signatures, this analgesic activity is likely related
to the inhibition of pain facilitation mechanisms occurring at the
spinal and/or supra-spinal level. The mechanistic bases of this activity
are to be elucidated, but the present observation provides additional
evidence for the role of nVNS in the acute and prophylactic treat-
ment of primary headaches.
Fig. 1 (abstract P105). Study design
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Background
Cranial autonomic symptoms such as lacrimation and conjunctival
injection are characteristic features in some primary headache
disorders [1]. Recent studies proposed non-invasive vagal nerve
stimulation (nVNS) as a novel treatment approach for migraine and
cluster-headache patients [2-4]. However, nVNS seems to be more ef-
ficient when autonomic symptoms are present and the underlying
mechanisms of action remain to be elucidated. Here, we aimed to
investigate the effect of nVNS on provoked cranial autonomic symp-
toms (lacrimation) in healthy volunteers.
Methods
Healthy volunteers were recruited and participated in a single-blind,
placebo-controlled within-subject design (Fig. 1). nVNS was per-
formed using the gammaCore device (electrocore LLC, Basking Ridge,
NJ, USA) and kinetic oscillation stimulation (KOS) (Chordate Medical
AB, Stockholm, Sweden) of the nasal mucosa was used to generate
quantifiable cranial parasympathetic output (lacrimation) [5]. Lacrima-
tion was quantified using a Schirmer’s II test. Sham controlled stimu-
lation was applied in a pseudorandomized order for 3x2 minutes
after baseline-measurement. As an indicator of autonomic activation,
the lacrimation difference between baseline and KOS after each of
the three experimental conditions was calculated.
Results
KOS-induced lacrimation was significantly reduced after nVNS
compared to sham stimulation and no stimulation. This effect was only
observed on the ipsilateral but not the contralateral eye. During nVNS-
treatment only small side effects, including facial muscle convulsion
and tingling sensations were reported by the volunteers.
Conclusion
These data show a physiologically measurable effect of nVNS on the
trigeminal autonomic reflex in humans, suggesting an interaction
between the trigeminal and the vagal system. These results support
previous findings that the vagal system modulates central structures of
the trigeminal autonomic reflex [6] that play a crucial role in various
primary headache disorders.
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BACKGROUND: Migraine and obesity are two major public health
problems in the USA and around the world. In the USA 12% of
individuals have migraine and 37% of adults are obese1. Evidence
suggests a possible link between migraine and obesity, but research
has been mixed. There are several potential mechanisms for this link,
including physiological, psychological, and behavioral.
PURPOSE OF STUDY: The purpose of our study was to determine if
obesity is more prevalent in chronic migraine than in episodic migraine.
RESULTS: We analyzed the body mass index (BMI) at presentation of
all new patients seen by the lead author in a tertiary headache center
for a period of one year. The mean BMI of chronic migraine (CM)
patients was 28.8% versus 25.3% for episodic migraine (EM) patients,
both of which are defined as “overweight.” 34.4% of CM patients and
5.4% of EM patients were obese (BMI ≥ 30).
CONCLUSIONS: Obesity was prevalent in CM patients than in EM
patients treated at a tertiary headache center. Furthermore, BMI was
significantly higher in patients with CM than in EM patients.
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Background
As the seventh most disabling condition globally, migraine adversely
affects the health-related quality of life (HRQoL) of sufferers. In clin-
ical trials, fremanezumab, a fully humanized monoclonal antibody
that selectively targets calcitonin gene-related peptide, reduced the
frequency of headaches and migraines in patients with episodic
migraine (EM). For a comprehensive understanding of the impact of
fremanezumab, this study compared HRQoL, as measured by the
Migraine-Specific Quality of Life (MSQoL) questionnaire, in patients
with EM who were treated with two dose regimens of fremanezumab
versus placebo.
Materials and Methods
In this Phase III, multicenter, randomized, double-blind, placebo-
controlled study, eligible patients with prospectively confirmed EM
(headache on 6–14 days and ≥4 days fulfilling migraine criteria per
month) were randomized 1:1:1 to receive subcutaneous injections of
fremanezumab quarterly dosing (675 mg at baseline and placebo at
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and Weeks 4 and 8), or placebo at each time point over a 12-week
treatment period. The mean change from baseline (day 0) in HRQoL,
using the MSQoL questionnaire, was evaluated as an exploratory end-
point. The MSQoL questionnaire (version 2.1) assessed three domains:
the role function-restrictive (RFR), role function-preventive (RFP), and
emotional function (EF) domains. Scores range from 0 to 100, with
higher scores indicating better HRQoL. Statistical analyses were per-
formed using an analysis of covariance approach and a mixed-effects
model for repeated-measures, both with years since onset of migraine
and baseline MSQoL domain score as covariates.
Results
A total of 865 patients were included in analyses (fremanezumab
quarterly, N=288, fremanezumab monthly, N=287; placebo, N=290).
Compared with placebo, the mean MSQoL RFR domain score for
each fremanezumab dosing regimen was significantly increased from
baseline to 4 weeks after the final dose of study drug (least-squares
mean ± standard error for quarterly: 4.1±1.4; P=0.0028; monthly: 7
±1.4, P<0.0001). The mean RFP domain scores were also significantly
improved for both fremanezumab dose regimens compared with
placebo (P≤0.001) as was the EF domain score for the fremanezumab
monthly group (P<0.0001). Significant improvements in each domain
of MSQoL were observed as early as 4 weeks after the first dose and
was sustained at all pre-defined assessments (P<0.05).
Conclusions
These results indicate that fremanezumab improves the migraine-
specific QoL and functioning of patients with EM.
Trial Registration
ClinicalTrials.gov NCT02629861
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Background
Episodic migraine (EM), characterized by attacks on ≤15 days per
month, is a risk for transition to chronic migraine and adversely
affects daily functioning. In clinical trials, fremanezumab, a fully
humanized monoclonal antibody that selectively targets calcitonin
gene-related peptide, reduced the frequency of headaches in pa-
tients with EM. The impact of migraine can be more comprehen-
sively understood through disability assessment. In this study, the
Migraine Disability Assessment (MIDAS) questionnaire was used to
assess the effect of fremanezumab versus placebo on headache-
related disability.
Materials and Methods
In this multicenter, randomized, double-blind, placebo-controlled study,
patients with EM were randomized 1:1:1 to receive subcutaneous injec-
tions of fremanezumab quarterly (675 mg at baseline and placebo at
Weeks 4 and 8), fremanezumab monthly (225 mg at baseline, Weeks 4
and 8), or placebo at each time point over a 12-week treatment period.
As a secondary endpoint, the change in MIDAS score was evaluated
from baseline to 4 weeks after administration of the last dose of study
drug. The MIDAS questionnaire assessed the lost days of activity in
three domains (work, household work, and nonwork) over the previous3 months. Scores of 0–5, 6–10, 11–20, and ≥21 were interpreted as
disability grades 1 (little or no disability), 2 (mild), 3 (moderate) and 4
(severe). Efficacy analyses were performed in the full analysis set (FAS;
all randomized patients who received at least one dose of study drug
and had at least 10 days of post-baseline efficacy assessment on the
primary endpoint) and repeated for the per-protocol analysis set (PPS).
The data were analyzed using analysis of covariance, with baseline dis-
ability score and years since migraine onset as covariates. P-values for
treatment comparisons were based on the Wilcoxon rank-sum test.
Results
A total of 875 patients were randomized to either fremanezumab
quarterly (N=291), fremanezumab monthly (N=290) or placebo
(N=294). The least-squares mean ± standard error changes from
baseline with fremanezumab quarterly dosing (–23.0±1.60 points)
and monthly dosing (–24.6±1.59 points) were larger than with
placebo (–17.5±1.57 points); this resulted in significant treatment
differences versus placebo in MIDAS score change for fremanezumab-
treated patients (quarterly: –5.4±1.78 points, P=0.0023; monthly: –7.0
±1.78 points, P<0.0001). Similar treatment differences were observed in
the PPS (quarterly: –5.5±1.85 points, P=0.0030; monthly: –7.3±1.83
points, P<0.0001).
Conclusions
In this Phase III study, fremanezumab treatment demonstrated a
significant improvement in headache-related disability in patients
with EM.
Trial Registration
ClinicalTrials.gov NCT02629861
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Background
Migraine is a debilitating disease with substantial indirect cost
burden. In the EU, the total annual cost of migraine among persons
aged 18–65 years was estimated at €111 billion. Mean per-person an-
nual costs were €1222, with 93% of these costs attributed to indirect
costs. Chronic migraine (CM) creates an especially high burden. In
clinical trials, fremanezumab, a fully humanized monoclonal antibody
that selectively targets calcitonin gene-related peptide, reduced the
frequency, severity, and duration of headaches in patients with CM.
This analysis evaluated the effect of fremanezumab on productivity
loss and activity impairment in patients with CM, as measured by the
Work Productivity and Activity Impairment (WPAI) questionnaire.
Methods
In this Phase III, multicenter, randomized, double-blind, placebo-
controlled, parallel-group study, eligible patients with CM (≥15 head-
ache days and ≥8 migraine days per month), were randomized 1:1:1 to
receive subcutaneous injections of fremanezumab quarterly dosing
(675 mg at baseline and placebo at Weeks 4 and 8), fremanezumab
monthly dosing (675 mg at baseline and 225 mg at Weeks 4 and 8), or
placebo at each time point over a 12-week treatment period. Change
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dose of study drug was an exploratory endpoint. The WPAI question-
naire assesses the impact of health on the extent of work loss and
productivity impairment during work and other activities, with higher
scores indicating greater impairment.
Results
The study included 375 patients in each fremanezumab treatment group
and 371 patients in the placebo group. Patients with CM treated with
fremanezumab reported larger reductions from baseline in overall work
productivity loss (composite of absenteeism and impairment while
working [presenteeism]) than those given placebo (–16.6%±2.09%
[quarterly] and –15.9%±2.02% [monthly] versus –9.1%±2.02% [placebo]),
resulting in significant treatment differences for each fremanezumab
group versus placebo (quarterly: –7.5%±2.24%, P=0.0009; monthly: –
6.8%±2.26%, P=0.0026). The change from baseline in presenteeism was
also greater with quarterly (–15.7%±1.89%) and monthly (–14.9%±1.82%)
fremanezumab than with placebo (–10.0%±1.82%), resulting in
significant treatment differences (quarterly: –5.7%±2.03%, P=0.0049;
monthly: –4.9%±2.05%, P=0.0169). In addition, fremanezumab quarterly
dosing significantly reduced impairment of activity outside of work
versus placebo (–15.0%±1.70% versus –11.0%±1.7%; treatment
difference: –4.0%±1.85%, P=0.0311).
Conclusion
In this Phase III study, fremanezumab treatment resulted in significant
improvements in WPAI scores, demonstrating the positive impact of
fremanezumab on the ability of patients with CM to function both at
and outside of work.
Trial registration
ClinicalTrials.gov NCT02621931.
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Background: Headeaches and temporomandibular disorders (TMD)
are highly prevalent conditions that frequently co-exist in the same
patient often associated whit myofascial pain of masticatory, pericra-
nial and neck muscles and dental occlusion alterations.In order to de-
termine the correct management and treatment, clinical examination
should be coupled whit functional assessment. Surface electromyo-
graphy(sEMG) can make an objective recording of the masticatory
and neck muscles function and disfunction induced by dental occlu-
sion as possible cause or aggravation factor of TMD associated with
headeache before and after treatment.
Case report: Woman 53 years old affected by Chronic tension-type
headeache ( according to ICHD3- beta criteria ) with pericranial ten-
derness and TMD whit myofascial long lasting pain, dental occlusion
alteration, dual bite and bruxism, was submitted to sEMG. To verify
the neuromuscolar equilibrium induced by dental contact, the stan-
dardized sEMG activities of right and left anterior temporal, masseter
and sternocleidomastoidal (SCM) muscles were recorded during max-
imum voluntary clench.Before treatment, sEMG data show an increased and more asymmetric
standardized activity of their temporalis anterior muscles and anterior
position of occlusal barycentre, presence of right mandibular torque (
precontact dental ), asymmetric activities of SCM with cervical load and
dercreased muscle work values compatible with pain and muscolar
fatigue probably as a consequence of nociceptive imputs. After one
month with treatment combining drugs, stabilization appliance and
couseling, there was the complete remission of muscle symptoms and
a news sEmg objective the normalization of all indexes to confirm
successful outcome of the therapy
Conclusion: sEMG, joins a set of clinical and morfological test, allow
to object to any relationship between clinical symptom (pain related
to muscles and palpation) and dental occlusion on masticatory and
neck muscle activity in TDM associated with headeache.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Background: The diagnosis and acute management of subarachnoid
hemorrhage (SAH) is still representing a challenge to physicians who
encounter these patients in everyday clinical practice. Headache is
recognized as a cardinal symptom, although headache does not
even occur in SAH patients. Although the severity and suddenness of
onset is the most characteristic feature of headache secondary to
SAH, little is known about other headaches attributes in reference to
SAH origin and its pathogenesis.
Methods: The medical records of 431 consecutive non traumatic
SAH patients (264 females and 167 males), ages from 19 to 91
years, presenting with headache (70.3%) and without headache
(29.7%) during period of 11 years have been reviewed. Data have
been analyzed in reference to headache attributes according to
arteriovenous malformation (AVM) persistence.
Results: The persistence of AVM was not in association with
headache occurrence (OR 0.71 [95%CI: 0.41-1.21], p=0.213), although
the persistence of AVM were significantly associated with previous
history of headache with migraine features, OR 1.74 [95%CI: 1.11-
3.03], p=0.046. Also, the findings of AVM was significantly associated
with the patients definition of headache intensity as the worst
headache of life, OR 2.24 [95%CI: 1.29-3.89], p=0.004. Headache
assigned symptoms such as vomiting/nausea and/or phono/
photophobia were significantly frequent in SAH patients with AVM,
OR 2.08 [95%CI: 1.13-3.83], p=0.018 and OR 1.75 [95%CI: 1.1-2.15],
p=0.03, respectively. The positive association was observed in
relation to AVM persistence and localized/unilateral head pain, OR
18.76 [95%CI: 9.68-36.37], p<0.0001. The association between AVM
findings and headache features such as time from onset to peak of
pain intensity, pain quality and state at time of headache onset in
SAH were not observed, p>0.05.
Conclusions: From the clinical point of view, it could be said that the
presence of AVM is not recognized as predictor for headache
occurrence in spontaneous SAH but its existence could be associated
with previous history of headache with migraine features. These facts
could provide physicians to good evidence to consider SAH in patients
with previous history of headache with migraine features newly
presented with worst headache of their life, as well as consider cerebral
angiography in all SAH suggestive headaches which are accompanied
with migraine symptoms.
Keywords: Migraine, Subarachnoid Hemorrhage
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Background
Migraine is a common and debilitating disease with a prevalence of
17.5% in women, which is more than two-fold of its prevalence in the
male population [1]. Although migraine is classically considered an epi-
sodic disorder with no long-term sequels, new evidence suggests that
at least a subset of patients may suffer progressive neuropathology
and inter-ictal changes in brain function. Similar to various neurodeve-
lopmental and neurodegenerative disorders, migraine is predisposed
by a strong genetic component (>50% [2]). Quantitative neuroimaging
of migraine has recently revealed disrupted functional brain networks
and abnormal changes in brain structure, and discovering such neuro-
imaging biomarkers of migraine may enlighten disease mechanisms
and guide future clinical trials.
Materials and methods
We enrolled 36 female migraine without-aura patients (36.6 ± 8.8 years)
and 33 age-matched healthy subjects of the same sex (36.4 ± 8.8
years). Study subjects underwent MRI using a 3T Siemens Magnetom
Trio scanner and a 12-channel head coil. Pulse sequences were as fol-
lows: 1) a 1mm isotropic T1-weighted MPRAGE anatomical scan 2) an
11-min resting-state fMRI scan with the parameters TR=2.57s and voxel
size of 3.4×3.4×3.0mm. 3) DTI with 64 diffusion gradient directions and
b-max=1000s/mm2 4) an eight-echo gradient-echo pulse sequence
with a voxel size of 0.8×0.8×1.5mm and further parameter optimization
for quantitative susceptibility mapping (QSM). Changes in resting-state
functional brain networks [3], volumetric differences in brain anatomy
[4], and white-matter microstructure [5] were explored in order to
characterize MRI correlates of migraine by using various statistical neu-
roimaging toolboxes including ANTS, FSL, MRtrix3 and in-house devel-
oped software. The HEIDI algorithm was used to quantify variations in
regional brain tissue susceptibility [6].
Results
At the time of preparation of this abstract, tensor-based morphometry
analysis has been completed and revealed significant loss of brain vol-
ume in right medial prefrontal cortex (mPFC) of migraine patients (cor-
rected p<0.05, Fig. 1) and suggestive loss of volume in bilateral inferior
frontal sulcus (uncorrected p=2.4×10-5). Resting functional networks in-
cluding the default-mode network were decomposed from 17,250 pre-
processed fMRI volumes of the study cohort in the common template
space (Fig. 2). Preprocessed diffusion images revealed white-matter
tracts and their crossing in study subjects (Fig. 3). Changes in brain tis-
sue magnetization due to regional deposition of iron and other
susceptibility-inducing materials were assessed by QSM (Fig. 4).
Conclusions
As one of the largest multispectral MRI studies of headache conducted
to date, our results demonstrate promise of quantitative neuroimaging
in exploring pathophysiology of migraine and identifying the
dysfunctional pain network in patients.P113
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Objectives. Chronic paroxysmal hemicrania (CPH) is a rare and well-
characterised headache, classified amongst the trigeminal autonomic
cephalgias (TACs). CPH has been only rarely and incompletely de-
scribed in the developmental age. The objective of the present report
was to describe the features of chronic paroxysmal migraine in four
pediatric patients.
Results. We detected 4 patients with CPH. Our children presented
with a long history of severe and unilateral pain, which occurred in
the fronto-orbital region without side shift. Attacks were accompan-
ied by at least one autonomic symptom, ipsilateral to pain. During
the attacks, besides conjunctival injection, eyelid oedema and rhinor-
rhea and all children showed a dramatic response to indomethacin.
Conclusions. Clinical symptoms and pain characteristics of our
children are similar to those found in typical adult CPH. However
our patients showed some atypical features, not fully meeting the
ICHD-III beta criteria. First, although the ICHD criteria require an at-
tack frequency higher than 5 attacks per day, in our patients, the
attack frequency was lower. Second, attack duration was variable in
all our children, but in three of four children it was sometimes lon-
ger than 30 min, which represents the maximal duration for a CPH
attack.If attack duration and frequency can make the diagnosis
more difficult, especially in paediatric age, the absolute response to
indomethacin represents the diagnostic key for CPH in both adults
and children (indotest).
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Background: Migraine prevention is intended to reduce the
frequency, severity, and disability associated with migraine attacks,
and faster onset of action could increase benefit to patients with
migraine. Fremanezumab is a fully humanized monoclonal antibody
targeting the calcitonin gene-related peptide (CGRP) ligand, a pre-
ventive treatment designed to specifically target a pathophysiologic
mechanism of migraine. This analysis assesses the early onset of ac-
tion of fremanezumab in the prevention of episodic migraine.
Methods: A 16-week, multicenter, randomized, double-blind, placebo-
controlled, parallel-group study comparing the efficacy, safety, and tol-
erability of 2 subcutaneous dose regimens of fremanezumab and pla-
cebo (PBO) in adults with episodic migraine (EM). Patients assigned
randomly to 1:1:1 ratio to 1 of 3 treatment groups: (1)monthly dosing
of fremanezumab 225 mg at months 1, 2 and 3, (2)quarterly dosing:
675 mg of fremanuzemab at month 1, followed by placebo injections
at months 2 and 3, and (3)monthly administration of matching placebo.
The mean change from baseline in the monthly average number of mi-
graine days were assessed using a mixed-effect model for repeated
measures.
Results: Statistically significant reduction in the monthly average
number of migraine days was experienced during the 12-week
period after 1st dose for both fremanezumab dosing regimens
[monthly (-3.7 days);quarterly (-3.4 days); p<0.0001] vs. placebo (-2.2
days), and during the 4 week period after 1st dose, for both dosing
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 77 of 151regimens (p<0.0001). Fremanezumab monthly dosing resulted in sig-
nificant reduction in the weekly number of migraine days:
 At Week 1, (-0.9 days; p<0.0001) versus placebo (-0.3 days)
 At Week 2, (-0.8 days; p<0.0001) versus placebo (-0.3 days)
 At Week 3, (-0.9 days; p<0.0001) versus placebo (-0.4 days)
 At Week 4, (-0.9 days; p=0.0123) versus placebo (-0.6 days)
Fremanezumab quarterly dosing resulted in significant reduction in
the weekly number of migraine days:
 At Week 1, (-0.8 days; p<0.0001) versus placebo (-0.3 days)
 At Week 2, (-0.8 days; p<0.0001) versus placebo (-0.3 days)
 At Week 3, (-0.8 days; p=0.0003) versus placebo (-0.4 days)
 At Week 4, (-0.8 days; p=0.0403) versus placebo (-0.6 days)
Posthoc analysis indicated that more patients reported no migraine
days with fremanezumab monthly dosing (79.4%; p=0.0002) and
fremanezumab quarterly dosing (79.2%; p=0.0004) versus placebo
(66.6%) by the next day following first injection.
Conclusion: Onset of action with fremanezumab occurred rapidly for
preventive treatment of episodic migraine. Significant improvement was
maintained for both monthly and quarterly subcutaneous injections.
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Background: Fremanezumab, a fully humanized monoclonal antibody
targeting the calcitonin gene-related peptide (CGRP) ligand, is a pre-
ventive treatment designed to specifically target a pathophysiologic
mechanism of migraine; has proven efficacy in the treatment of
migraine. This study evaluated the efficacy, tolerability and safety of
two subcutaneous dose regimens of fremanezumab in the preventive
treatment of episodic migraine (EM).
Methods: 16-week, multicenter, randomized, double-blind, placebo-
controlled, parallel-group study in adults with EM. Patients maintained
daily diaries during a 28-day baseline period. Patients were assigned
randomly, 1:1:1 ratio to 1 of 3 treatment groups: monthly dosing - 225
mg of fremanezumab; quarterly dosing: a single dose of 675 mg of fre-
manuzemab at month 1, followed by placebo injections at months 2
and 3; and monthly administration of matching placebo. The primary
efficacy endpoint, mean change from baseline (28-day pre-treatment
period) to 12-week randomization period in monthly average number
of migraine days was analyzed using an analysis of covariance method
or the Wilcoxon rank sum test.
Results: The mean number of migraine days was 9.1 days during the
28-day baseline period. Patients treated with fremanezumab had sig-
nificant reductions in the number of monthly migraine days during the
12-week period vs. placebo (-2.2 days from baseline=9.1 days), for both
dosing regimens [monthly -3.7 days from baseline=9.2 days) and quar-
terly (-3.4 days from baseline=8.9 days); p<0.0001], and during the 4-
week period after 1st dose, for both dosing regimens (p<0.0001).
Fremanezumab-treated patients had significant reductions in the num-
ber of monthly headache days of at least moderate severity during the
12-week period for both dosing regimens [monthly (-2.9 days); quar-
terly (-3.0 days); vs placebo (-1.5 days); p<0.0001)], and during the 4-
week period after 1st dose, for both dosing regimens (p<0.0001).Treatment with fremanezumab resulted in statistically significant
reductions in the number of monthly days of acute headache
medication use for both [monthly (-3.0 days); quarterly (-2.9 days);
p<0.0001] versus placebo (-1.6 days). A ≥50% reduction in the
monthly average number of migraine days was significantly im-
proved with both dosing regimens [monthly (47.7%); quarterly
(44.4%); p<0.0001] as compared to placebo (27.9%). The Migraine
Disability Assessment (MIDAS) Scale showed an improvement
with disability with monthly (-24.6; p=0.0021) and quarterly (-23.0;
p=0.0023) dosing regimens compared to placebo (-17.5). The
most common adverse events were injection site reactions.
Conclusion: These results confirm fremanezumab’s rapid efficacy, safety,
tolerability, and flexible dosing profile, for the preventive treatment of
episodic migraine.
Trial Registration:
ClinicalTrials.gov identifier: NCT02629861.
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Background: Fremanezumab, a fully-humanized monoclonal anti-
body targeting the calcitonin gene-related peptide (CGRP) ligand, is
a preventive treatment designed to specifically target a pathophysio-
logic mechanism of migraine; has proven efficacy in the treatment of
migraine. This study evaluated the efficacy, tolerability and safety of
two subcutaneous dose regimens of fremanezumab in the prevent-
ive treatment of chronic migraine (CM).
Methods: 16-week, multicenter, randomized double-blind, placebo-
controlled, parallel-group adult CM study. Patients were assigned ran-
domly (1:1:1 ratio to 1 of 3 treatment groups): monthly dosing=675
mg fremanuzemab followed by 225 mg of fremanezumab at months
2 and 3; quarterly dosing=fremanezumab 675 mg at month 1,
followed by placebo injections at months 2 and 3; and monthly ad-
ministration of matching placebo. The primary efficacy endpoint,
mean change from baseline (28-day pre-treatment period) to 12-
week randomization period in monthly average number of headache
days was analyzed using an analysis of covariance method or the
Wilcoxon rank sum test.
Results: The mean number of headache days of at least moderate
severity was 13.1 days during the 28-day baseline period. Fremanezu-
mab treated patients had significant reductions in the number of
monthly headache days of at least moderate severity vs. placebo
(-2.5 days) during the 12-week period after 1st dose, for both dosing
regimens [monthly (-4.6 days; p<0.0001); quarterly(-4.3 days;
p<0.0001). Patients treated with fremanezumab had statistically sig-
nificant reductions in the number of monthly migraine days during
the 12-week period after the 1st dose, for both dosing regimens
[monthly (-5.0 days from baseline=16.0 days); quarterly (-4.9 days
from baseline=16.2 days; p<0.0001)] vs. placebo (-3.2 days from base-
line=16.3 days), and during the 4-week period after 1st dose, for
both dosing regimens (p<0.0001). Fremanezumab was significantly
superior to placebo for the prespecified secondary endpoints: reduc-
tion in the number of monthly days of acute headache medication
use for both monthly (-4.2 days) and quarterly (-3.7 days) versus pla-
cebo (-1.9 days); p<0.0001). A ≥50% reduction in the monthly aver-
age number of headache days of at least moderate severity were
also statistically significantly improved with both dosing regimens
[monthly (40.8%); quarterly (37.6%); p<0.0001] as compared to
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 78 of 151placebo (18.1%); disability improved as measured by the Headache
Impact Test with both dosing regimens [monthly (-6.8; p<0.0001);
quarterly (-6.4; p=0.0001)] as compared to placebo (-4.5). The most
common adverse event in the study was injection site reaction.
Conclusion: These results confirm fremanezumab’s rapid efficacy,
safety, tolerability, and flexible dosing profile, for the preventive
treatment of chronic migraine.
Trial registration
ClinicalTrials.gov NCT02621931
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Background
Headache or other pain states are one of the most frequent
reasons to use analgesics like Aspirin for self-treatment. Pre-
treatment pain intensity may influence usage pattern, effectiveness
and tolerability. The aim was to analyze real-life data from six
pharmacy-based surveys in the self-treatment of headache or mi-
graine with Aspirin.
Materials and methods
The individual data of 11.824 patients from seven pharmacy-
based surveys performed in Germany, Switzerland and Spain were
pooled. A subgroup analysis of six studies in patients with head-
ache/migraine and information on pre-treatment pain intensity
was performed (n=6.985); this subgroup consists of 687 patients
with mild pain at baseline, 3.800 with moderate and 2.498 with
severe pain. Patients who purchased the drug in a pharmacy were
provided with a questionnaire to be filled in at home during/after
treatment.
Results
Dose at first application was dependent from pain intensity at
baseline: 77.2% with mild complaints, 72.0% with moderate and
50.8% with severe pain intensity used only one tablet at first intake.
Frequency of drug intake was influenced by baseline pain severity:
Single-dose treatment was reported by 62.9% of the patients with
mild pain but by only 38.7% with severe pain. Accordingly, total
dose, amount of tablets taken per day and treatment duration in-
creased dependent on baseline pain intensity.
Pre-treatment pain intensity influenced also the duration of
analgesia reported by the patients; an analgesic effect lasting more
than 6 hours was reported by 46.8%, 35.7% and 26.3% of the
patients with mild, moderate or severe pain. The percentage of
patients being pain free two hours after start of treatment
decreased substantially depending on pain intensity at baseline
(88.5%, 66.1% and 42.4% of patients with mild, moderate or severe
baseline pain). Already 30 minutes after first intake 63.7% of the
patients with mild baseline pain intensity (moderate 57.1%; severe
46.3%) reported ≥ 50% on visual analogue scale compared to
baseline.
The incidence of adverse events correlated with the pain intensity:
Patients with severe pain at baseline reported more than twice as
much adverse events than those with mild pain (11.7% vs. 5.5%).
Conclusions
Pre-treatment pain intensity influenced usage pattern of Aspirin in the
self-medication of headache and other pain states. Stronger baseline-pain leads to higher daily dose and a longer duration of treatment. Ef-
fectiveness of the drug was also affected by pain intensity. Adverse
event reporting was higher in patients with severe pre-treatment pain.
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Background
Cervicogenic headache originates from neck pathology, but it is yet
to discover the pathological substrate for the headache. Botulinum
toxin type A is the treatment of choice for most forms of focal
dystonia, including blepharospasm, torticollis, spasmodic dystonia
and jaw dystonia. The efficacy of Botox has been established in
adults with chronic migraine [1,2]. The injection procedure is
superficial and does not address the main target of the
botulinumtoxinA which is the muscles. Thus, it should be an efficient
treatment for cervicogenic headache.
Materials and methods
35 patients with cervicogenic headache were included in a double
blind, randomised placebo controlled study, cross over design. Each
patient filled in a questionnaire concerning symptoms, sick leave, the
social impact of symptoms, depression, post traumatic stress and
head and full body pain drawings. The clinical examination included
a relevant neurological examination, provocative tests such as
Spurling’s test, stretching of neck muscles to elicit pain, identification
of tender points of greater and minor occipital nerves with or
without radiation to forehead, and measurements of passive neck
mobility. Botox, total of 100 iu, or Placebo, was injected in defined
muscular points in the neck at 0 months, then cross over at 2
months. The frequency, duration and intensity of headache and neck
pain were registered before and after treatment.
Results
Of the 35 included patients three were excluded after entry due to
encephalitis, MS and cerebral tumour. There were three drop outs.
Seventy percent of the patients had a significantly reduced
headache intensity after Botox injections regardless of whether the
active substance was given at the first or second visit. For the
remaining, but one, the headache intensity was unchanged. This was
clinically significant as the majority of the patients labelled their
headache moderate to mild after treatment opposed to strong
before treatment. There were no serious adverse events.
Conclusions
Botulinum toxin type A (Botox) has been shown to reduce
cervicogenic headache significantly. The treatment improves the
quality of life and lifts the burden of headache in a degree that
enables the persons to engage in work and society again. It is a
simple procedure well accepted by the patients.
Trial registration
EudraCT number 2006-006700-11
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Background
Short-latency afferent inhibition (SAI) is a form of inhibition related to
the cholinergic activity in the cerebral cortex. It consists in a galvanic
stimulation of the median nerve at the wrist that can suppress motor
cortex excitability, as tested by transcranial magnetic stimulation (TMS),
when given at a short interstimulus interval (ISI) between 18 and 21
ms. SAI is considered an in-vivo way to study the sensorimotor integra-
tion mechanisms. SAI response is influenced by the excitatory effect of
acetylcholinergic thalamocortical afferents on the inhibitory GABAergic
(mostly GABAa) cortical networks.
Materials and methods
We recruited 30 migraine without aura patients (16 between [MO] and
14 during [MI] attacks), and we compared them to a group of 16
healthy volunteers (HV). We first recorded somatosensory evoked
potentials N20 latency and N20-P25 peak-to-peak amplitude at the
contralateral parietal area. Afterward, SAI was recorded in all study’s
participants as follows: after a conditioning single pulse delivered on
the median nerve at the wrist, a TMS pulse was delivered with ISIs
derived from the latency of N20 plus 2 to 8 ms in steps of 2ms and in
random order. Five stimuli were delivered at each ISI. We calculated the
SAI slope of the linear regression between the unconditioned motor
evoked potential (MEP) amplitude and the 4-conditioned MEPs as a
measure of cortical excitability.
Results
Compared with HV, SAI was significantly reduced in MO, but
enhanced in MI patients (slope HV= +11.2, MO= +242, MI= -129). In
both HV and MO groups, but not in MI, the SAI slope positively
correlated with the SSEP N20-P25.
Conclusions
The reduction of SAI in MO patients and its enhancement in MI
patients suggests a decrease and an increase respectively in facilitatory
thalamocortical cholinergic activity on GABAergic network activity in
the motor cortex. Since from the correlation analysis emerges that
slope of SAI normally correlates with the parietal response in MO, but
not in MI, we argue that more dysfunctional sensorimotor integrative
mechanisms might characterize migraineurs during an attack.
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Introduction
Brain herniations into transversal venous sinus are rare conditions.
In most of the cases are asymptomatic or they present with
headaches or seizures if the herniation occurs in some of the
epileptogenic regions in the brain.
In our case, we present a 32- years old female, with a history of
severe headaches, during the last two years. The headaches have
always been occurring on the left side, starting mainly during the
night and while sleeping, with throbbing pain.
Sometimes headeaches have been so severe, ending up with loss of
consciousness in period of 10 to 20 seconds.
MRI- examination of the brain performed prior in other diagnostic
center showed a large filling defect in the left transversal sinus. Theconclusion was clot caused by transverse sinus thrombosis.
Anticoagulation therapy was started.
One year before the symptoms occur, patient started taking
contraceptive pills. The conclusion of the radiologist was, that it is a
condition after transverse sinus thrombosis, with bilateral local
thrombotic masses in transversal sinus.
The patient came in our clinic to make new MRI- imaging of the
brain.
The MRI- imaging was made with 1. 5 T Magnetom Essenza Siemens
scanner.
During the MRI- examination, we used standard T2, T1 and FLAIR
pulse sequences with high resolution, combined with additional and
specially designed curves for reconstruction.
While processing the MRI- data, we used following pulse sequences:
T2 blade transversal ( Flair )
T2 TSE transversal
T1 SE transversal
T1MPR p2 iso 3D sagital ( gradient echo )
T2 SPC ns coronal iso ( gradient echo )
T2 3D ciss axial ( high resolution )
Ep 2D diffusion
MPR curved range
MRI- findings
Transversal T2, T1 and FLAIR pulse sequences showed presence of
clearly demarked supstrat in right transversal sinus, 8 mm in
diameter with signal characteristics similar with those of the normal
brain tissue in all pulse sequences.
Arround the supstrat, there is well demarked area with signal
characteristic similar with those of the liquor, wich in T2 pulse
sequence, showed two tubular formations with void fenomen.
Lumen of the right transversal sinus showed few smaller defects,
with signal characteristics in all pulse sequences identical with those
of the liquor.
3D scans with high resolution showed that the supstratein left
transversal sinus has the same characteristics with the normal brain
parenchyma. Grey and white matter are clearly distigushed one from
another, and near by is clearly demarked space with signal
characteristics identical with those of the liquor.
Tortuouse structures are also well shown in this scans, and there is
no doubt they are blood vessels. Those blood vessels indicate brain
herniation, but not sinus thrombosis.
Three mounts before the patient came in our clinic, postcontrast
MRI- series were made. They confirmed the findings of brain
herniation into transversal sinus. On postcontrast series, the sinus
is literally “shining” after the application of the contrast, and we
can easily see the defect, with all components of brain
herniation. Unfortunately, this finding was misdiagnosed as sinus
vein thrombosis.
Thrombs have different signal characteristics, compared to the signal
characteristics of brain herniation in vein sinus. They are solid and
hypersignal in T1, hyposignal in T2 and they can’t have identical
signal characteristics like those of the brain tissue nad cerebrospinal
fluid. They don’t damage the dura and the wall of the vein sinus.
Around the thromb there is no leptomeningeal space, nor blood
vessels or void phenomen.
Image 6 shows postcontrast series of right transversal sinus. The
image shows enlarged postcontrast signal, but little supstrates in the
lumen don,t intensify the signal, because the changes in all
postcontrast series have signal characteristics identical with the
signal characteristics of cerebrospinal fluid.
The question is: “How is that possible”?
The answer is down bellow:
Discussion
Brain herniation in dural vein sinus remains enigma.
How is it possible for defect to be made in the wall of the vein
sinus? Is it congenital or posttraumatic?
The idea of congenital etiology could be accepted. This kind of
changes could be listed in the group of meningoencephalocoeles,
congenital conditions generated as a result of bone defect of cranial
base.Through the defect, meninges and part of brain tissue exit in
the surrounding area.
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herniation occurs exactly in the dural sinus?” It is not about a bone
defect, but about the defect in the wall of the vein sinus.
Another not logical thing in our case is, if the problem is congenital,
why the first symptoms appeared two years ago, at the age of 30?
This leads us to logical explanation, that the problem is not congenital,
but it appeared several years ago.
The question is why and how, and wich condition could made defect
in the wall of the vein sinus?
Yellow arrows in Fig. 8 show polipoid anataomical structures, called
arachnoidal granulations.
They are very thiny and small, almost not visible for human eye and
they are responsible for transferring the cerebrospinal fluid from brain
convexity into dural vein sinuses.
Arachnoidal granulations act like some kind of valves, providing the
transfer of the cerebrospinal fluid.
During life, they can enlarge into gigant formations, expanding the
wall of the vein sinus, enabling the brain tissue to herniate into the
vein sinus.
Figure 11 shows the mechanism of brain herniation into the left
transversal vein sinus in our case.
The final conclusion is that brain herniation into dural vein sinus is
herniation of the brain tissue into gigant arachnoidal granulation.
Why arachnoidal granulations grow and hypertrophy?
Arachnoidal granulations grow and hypertrophy probably as a result
of increasing the pressure and the volume of the cerebrospinal fluid.
Average cerebrospinal fluid pressure is about 10 mmHg.
Pressure in dural vein sinuses is about 0 mmHg. The difference
between the pressure of cerebrospinal fluid and pressure in dural vein
sinuses enables the cerebrospinal fluid to enter into vein system.
Increased cerebrospinal fluid pressure make the arachnoidal granulations
to dilatate, grow and hypertrophy, wich enlarge the dural holes to the
degree when brain tissue can herniate through them.
Figure 12 clearly shows that arachnoidal granulations can cause bone
defects of calvary, as a result of penetration of arachnoidal granulations
in the calvary.
Conclussion
1. Brain herniation in dural vein sinus is rare condition.
2. In most of the cases is asymptomatic.
3. Sometimes ( as in our case ) herniation of brain tissue in dural vein
sinus is accompanied with headaches and seizures.
4. We have to consider theat defects in the lumen of dural vein sinus can
occur as a result of thorombosis of the vein sinus or tumor invasion.
5. Hypertrophic arachnoidal granulation can also cause defects in the
lumen of the dural vein sinuses, but their clinical significance is small.
6. Mr- imaging enables us to make precise diagnose, but it is necessary
during the procedure to apply 3D pulse sequences with high
resolutionas well as special designed curves for reconstruction.
7. Standard T1, T2 and FLAIR pulse sequences are not enogh for final
evaluation and examination of brain herniations in dural vein sinuses.
3D, T1 and T2 echo pulse sequences with high resolution are
necessary, as in our case where we gain useful informations using
making reconstructions with special curves. They enabled excellent
visualization of the herniated brain tissueand surrounding
cerebrospinal fluid spaces with concomitant vascular structures.
8. Herniated brain tissue and surrounding cerebrospinal fluid spaces
have normal signal characteristics in all pulse sequences.
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Headache is one of the most prevalence of neurological pathologies,
being tensional type headache (TTH) the most prevalent of them.
Diagnostic criteria of this primary headache were described in the
International headache classification 3ird edition [1,2].
Its etiopathology has been related, among others, to the presence of
myofascial trigger points in the craneo-cervical muscles, as well as
phenomena related to its innervation, through which harmless sig-
nals are perceived as painful at a peripheral (peripheral sensitization)
and central level, as well as an inhibition of pain control pathways
(central sensitization) [3,4].
From this perspective, there are structures such as neural tissue,
which have similar characteristics with the craneo-cervical muscles,
such as innervation based on polymodal receptors, able to send ten-
sion signals and modify this type of information in the presence of a
high tension to a nociceptive afferent, in addition to sharing a target
area of these afferents, the trigeminal-cervical nucleus. It is for this
reason that the meningeal tissue and specifically the dura mater
could have a role in this type of headache [5,6].
The objectives of this study are: to identify if there is an alteration in
neural sensitivity in subjects with tension-type headache, to identify
if there is an alteration in neural mobility in subjects with tension-
type headache, to establish a possible correlation between the range
of motion and the perception of neural pain.
Methods
The sample was 40 women (n=40; age 20.4±1.9; 22.5±5.7), divided into
two groups: tension headache (case group) and healthy group (control
group).Inclusion criteria were: presenting TTH or not. Exclusion criteria
were: to present another type of headache, to have suffered a traffic
accident or previous vertebral trauma, to suffer back or neck pain for
two or more consecutive days, to suffer pathologies or surgical
interventions that may influence mechanical neural sensitivity, hip
flexion lower than 70° degrees and psychological disorders such as
anxiety or depression.
Neural provocation tests or neurodynamic tests were used to
evaluate changes in neural tissue. Slump test: assessment of knee
extension range and pain intensity (Fig. 1); Straight leg raise test:
evaluation of the range of motion in flexion of the hip in two
different positions, using an ankle orthosis to ensure plantar flexion
of 0° and 30°. In these positions, two moments are evaluated: the
Onset 1 (O2) as minimal perceptible pain and the Onset 2 (O2) as
the maximum pain point perceptible (Fig. 2); Long seated slump
Test: evaluation of sacral flexion using an apparatus designed to
determine this position and cervical range of motion using a C-
ROM and pain intensity (Fig. 3).
Results
Statistical analysis was performed using the spss 22.0 package. T-
Student and U-Mann Withney tests were applied in order to compare
means. Pearson's correlation was applied to assess the existence of
linear correlation.
In Slump test, degrees of knee extension for cases and controls in the
dominant leg were 53.75±13.06 and 63.75±7.68, p <0.05. The intensity
of pain, through the NPRS scale was 6.2±1.7 and 5.4±2, p =0.176.In
straight leg raise test, values for case group and control in the
dominant leg were: 30° plantar flexion position 50.75±15.32 and 59.70
±13.87, p =0.06 for onset 1 (O1) and 71.40±17.54 and 86.05±17.12 for
onset 2 (O2) p<0.05.In 0° plantar flexion position, values for case and
control group were 44.75±16.71 and 53.25±14, p =0.089 for onset1
(O1); 60.30±16.96 and 74.55±19.30, p <0.05 onset 2 (O2), respectively.
The Pearson’s correlation coefficients for case group were: 30° plantar
flexion position r = 0.53, p<0.05 (Fig. 4). 0° plantar flexion position
r=0.52, p< 0.05(Fig. 5). Control group obtained values p>0.05. for both
linear correlation tests .In long setaed slump test, values of sacral
flexion degrees were 84.10±8.30 and 85,60±7.80, p> 0,05. Cervical
flexion range of motion was 76.60±16.63, and 86.85±13.65, p<0.05,
cases and control, respectively. The intensity of pain assessed by NPRS
scales was 6.7±2.2 and 5.6±2.2, p=0.065.
Conclusions
Results observed through the application of neural tension maneuvers
show changes in neural movement in the episodic tension type
Fig. 3 (abstract P121). Long seated slump test
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 81 of 151headache group versus control, being evaluated by range of motion
and pain scales. All neural maneuvers show a decrease in ranges of
motion evaluated: knee extension, hip flexion and cervical flexion;
except sacral flexion. The amplitude of hip flexion degrees at 30 and 0 °
plantar flexion and pain are correlated in moderate and positive way, in
case group. The assessment of pain intensity showed similar values in
both groups
Consent for publication: The authors declare that written informed
consent was obtained for publication.
References
1. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher AI, et al. The
global burden of headache: a documentation of headache prevalence
and disability worldwide. Cephalalgia 2007; 27: 193-210
2. ICHD-3 Headache Classification Committee of the International Headache
Society (IHS): The International Classification of Headache Disorders, 3er
ed. Cephalalgia 2013;33: 629-808.
3. Bendsten L. Central sensitization in tension type headache-possible
pathophysiological mechanisms. Cephalalgia. 2000;20(5): 486-508.Fig. 1 (abstract P121). Slump test
Fig. 2 (abstract P121). Straight leg raise test
Fig. 4 (abstract P121). Pearson’s correlation 30° plantar flexion
Fig. 5 (abstract P121). Pearson’s correlation 0° plantar flexion
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 82 of 151P122
Physiotherapy and basic headache research: Why using a pre-post
design?
Sarah Mingels1,2, Marita Granitzer1
1REVAL Rehabilitation Research Centre, Biomedical Research Institute,
Faculty of Medicine and Life Sciences, Hasselt University, 3590-Belgium;
2Musculoskeletal Research Unit, Department of Rehabilitation Sciences,
Faculty of Kinesiology and Rehabilitation Sciences, Leuven University,
3000-Belgium
Correspondence: Sarah Mingels (sarah.mingels@uhasselt.be)
The Journal of Headache and Pain 2017, 18(Suppl 1):P122
Background
In physiotherapy, headache-research is often limited to instant-
aneous cross-sectional measurements of e.g. cervical mobility.
However, a longitudinal task might affect baseline outcomes.
Understanding the influence of the latter on headache features
is relevant to develop preventive guidelines. Materials and
methods
Design. A pre-post design was set up to compare ‘Pressure Pain
Thresholds (PPT)’ and maximal active cervical range of motion
(CROM) before (pre-test) and after (post-test) a writing task be-
tween 18 females with headache (23.2±1.7 years) and 18
matched controls (23.6±2.2 years). Criteria. Headache-group
inclusion-criteria were: females between 18-30 years, meeting
the diagnostic criteria of episodic tension-type headache ac-
cording to the International Headache Society, headache pro-
voked by posture. Exclusion-criteria: pregnancy, physiotherapy
for headache 12 months before the study, serious pathology
and a history of neck or head trauma. Control-group inclusion-
criteria were: healthy age-matched females. Exclusion-criteria:
pregnancy, history of neck or head trauma. Measurements and
outcomes. Bilateral PPT, measured with the Somedic Algometer
(slope 30kPa/s/cm2) in the anterior temporal, suboccipital, upper
trapezius and anterior tibial muscles and maximal active flexion
and extension CROM, measured with the Cervical Range of Mo-
tion device (°) were primary outcomes. Headache frequency,
duration and intensity were secondary outcomes extracted from
a headache diary. Statistics. Data-analysis was done with a 95%
confidence level (p<0.05). Normality was evaluated by the
Shapiro-Wilk test, comparisons within and between groups by
the Wilcoxon Signed Rank respectively Mann-Whitney U-test.
Ethics. Approval by the Medical Ethical Committee of the
‘Ziekenhuis Oost-Limburg’ (B371201423025).
Results
At baseline only maximal active flexion CROM differed
significantly (p=0.022) between groups with lower values in the
Headache-group. From pre-to post-test the Headache-group
compared to the Control-group showed a significant: 1) PPT re-
duction vs. an increase in the Control-group in the anterior
temporal left and right (p=0.0290; p=0.0051) and the upper tra-
pezius right (p=0.0237) and 2) larger drop in maximal active
extension CROM (p=0.012) (Headache-group: post 59.65°±8.19;
pre 69.59°±6.28 vs Control-group: post 67.39°±6.96; pre 71.85°
±10.85).
Conclusion
In the Headache-group the performance of a simple writing task
decreased PPT and maximal active CROM. These results are
closely related with sensitization. Physiotherapists should be
aware that baseline characteristics of patients with headache and
healthy controls are comparable. However, the baseline headache
profile can be influenced by a task performance. Longitudinal de-
signs could therefore be relevant to evaluate factors contributing
to headache.Keywords: Headache, pre-post design, writing task.P123
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Background
The REPOSE Study, a European, multicenter, prospective, non-
interventional study, investigated the effectiveness and safety of real-
life use of onabotulinumtoxinA for chronic migraine (CM).
Materials and Methods
Adults prescribed onabotulinumtoxinA for CM were enrolled.
Patients received onabotulinumtoxinA approximately every 12
weeks according to their physician’s usual practice, guided by the
Summary of Product Characteristics. OnabotulinumtoxinA injection
practices, safety, headache-day frequency, and Migraine Specific
Quality of Life Questionnaire (MSQ) were collected at baseline
and follow-up visits.
Results
Among 644 patients enrolled, 633 patients received ≥1
onabotulinumtoxinA dose for a total of 3499 onabotulinumtoxinA
treatments. Patients had a mean (SD) age of 45.4 (12) years,
were typically women (85.3%) and had a mean of 20.6
headache days/month. The median dose and median number of
injection sites of onabotulinumtoxinA per session (baseline up
to follow-up session 8) was 155 U and 31 sites, respectively.
Through follow-up session 8, patient-reported estimates of
headache days/month (≥4 hours) were significantly reduced
from baseline (P<0.001 at each follow-up session, Fig. 1). The
MSQ domain scores (Role Restrictive, Preventive, and Emotional)
were significantly reduced from baseline at each follow-up ses-
sion. Adverse drug reactions, typically of mild to moderate se-
verity, were reported by 18.3% of patients; eyelid ptosis (5.4%),
neck pain (3.0%), and musculoskeletal stiffness (2.7%) were
most frequently reported.
Conclusion
Preventive treatment of CM with onabotulinumtoxinA in a
longer-term (24-month) real-world setting sustains a reduction
in the frequency of headache days and significantly improves
quality of life relative to baseline. No new safety concerns were
identified.
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Fig. 1 (abstract P123). Headache-day frequency calculated using
the patient-reported estimate of number of days in a month with
headache. Wilcoxon signed-rank test for change versus baseline
(level of significance: 5%). The number of patients in follow-up (FU)
sessions 9-12 were: FU9, n=67; FU10, n=38; FU11, n=21; FU12, n=16.
The mean change from baseline for FU sessions 9-12 were each
significant (*P<0.001)
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Simulated airplane headache: a proxy towards identification of
underlying mechanisms
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Background
Airplane Headache(AH) is a short lasting but intense headache which
occurs during flights, most often during take-off and landing. Litera-
ture on this condition is sparse, especially surrounding the patho-
logical mechanisms underlying the occurrence of the headache.
Diagnosis and treatment of the condition are also lacking, and would
benefit greatly if potential pathways involved in the pathogenesis of
AH were to be discovered. This study is aimed at examining a simu-
lated airplane condition as a proxy towards identification of the
underlying mechanisms of the condition.
Methods
A total of fourteen participants were included in the study. Seven of
these suffered from AH and would act as the control group, whereas
the remaining seven were healthy matched controls. A simulation of
conditions as those experienced in a real flight, were achieved by
using a pressure chamber, thereby enabling the development of AH.
A selection of potential biomarkers were to be measured, including
cortisol, blood pressure, salivary prostaglandin E2(PGE2), pulse, facial
thermos-images and saturation pulse oxygen (SPO). All biomarkers
were defined beforehand, and samples were collected before, during
and after exposure to the pressure chamber. The saliva samples were
subsequently analyzed using ELISA techniques, whereas statistical
tests and data analysis were performed using SPSS version 22.0.
Results
As expected, the non-AH-group did not develop any headache dur-
ing the session. All participants in the AH-group did experience a
headache, bearing resemblance to an AH experience during flight.
Analysis of data showed that the levels for cortisol, SPO and PGE2,
were significantly different between the two groups during the flight
simulation.
Conclusion
Not only did the pressure chamber enable us to evoke an AH-like at-
tack, it also allowed us to examine potential biomarkers for AH. We
noted a difference in values when comparing healthy controls with
the affected individuals, as cortisol levels, SPO and PGE2 were dys-
regulated during the AH-attack. These findings are promising, and
gives rise to possible use of a pressure chambers as model for indu-
cing AH, for all kinds of future AH studies.P125
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Background and aims
The Chronic Headache Education and Self-management Study
(CHESS) is a five year programme of work leading to a large multi-
centre, randomised controlled trial. As part of the programme we
have conducted a feasibility study to 1. Develop and test strategies
for recruiting participants with chronic headache from primary care
2. Validate a telephone classification interview that can be used by a
non-headache specialist to classify chronic headache disorders 3.
Pilot a group education and self- management intervention for
chronic headache.
Methods
We recruited participants from 14 general practices in the West
Midland region of the UK. The study team developed a search
strategy to identify patients with chronic headache from general
practice databases and screened potential participants for
eligibility. Participants completed questionnaires at baseline, 2
weeks and 12 weeks. Participants received a chronic headache
classification interview with a specially trained nurse and had a
second interview with a doctor specialised in headache. A sub-
sample of participants were invited to attend an education and
self-management intervention.
Results
From combined database searches 1643 (1.3% of total list size)
were invited to take part in the study. In total 393(24%) expressed
an interest in the study, 174 were eligible and 131 provided written
consent. All participants completed baseline questionnaires, 115
(88%) two week and 103 (79%) 12 week questionnaires. We
completed 100 paired telephone chronic headache classification
interviews and 18 participants attended the self-management
intervention.
Conclusion
We successfully recruited general practices and people living with
chronic headache from primary care settings. Our biggest
challenges were being able to contact participants for eligibility
and classification telephone interviews and delivering the group
intervention at times convenient for a largely working population.
We have used the findings to inform the design and delivery of
the RCT.
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Background
Acute management of headache is challenging and clinicians vary in
their approach and expertise to this problem [1,2]. We explored
practice on acute medical wards in an urban teaching hospital to
improve efficiency and quality of care.
Table 1 (abstract P127). Self-Reported Clinical History for Sleep Apnea
EM
(n=11,699)
CM
(n=1,111)
Total
(N=12,810)
Chi-square P-value
“Have you ever had sleep apnea?”a
No 10,563 (90.3) 954 (85.9) 11,517 (89.9) 21.9 <0.001
Yes 1,136 (9.7) 157 (14.1) 1,293 (10.1)
Total 11,699 (100.0) 1,111 (100.0) 12,810 (100.0)
Among those reporting ever having sleep apnea, “Has this condition been diagnosed
or confirmed by a healthcare professional?”
No 287 (25.3) 27 (17.2) 314 (24.3) 4.9 <0.05
Yes 849 (74.7) 130 (82.8) 979 (75.7)
Total 1,136 (100.0) 157 (100.0) 1,293 (100.0)
aA response of “Yes” denotes high risk; a response of “No” denotes low risk
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We conducted a retrospective analysis of clinical data in all patients
with a primary complaint of non-traumatic headache admitted to an
acute medical service in Glasgow, UK, in 2012. Hospital re-
attendances were recorded over 3 years follow-up. We excluded any
patient that did not require admission to a medical bed. From a total
population of 345 patients, 108 patients were randomly selected for
this study and data were collated from clinical records.
Results
78% (n=84) of patients were female and the mean age was 44 years
(range 15 – 91 years). Median duration of admission was 3 days. 28%
(n=30) presented with acute headache. In 44% (n=47), documented
clinical features were inadequate for classification of headache. Past
history of headache was unexplored in 57% (n=62) and in 31%
(n=34) the bedside examination was incomplete.
Brain imaging, mainly with CT, was performed in 82% (n=89). Only 3
patients with acute headache underwent initial imaging within 6
hours of symptom onset. Brain imaging identified a secondary cause
in only 5 patients. Lumbar puncture was performed in 54% (n=58)
and identified a secondary cause in only 6 patients.
In 39% (n=42) no diagnosis was made on discharge from hospital.
Final diagnosis was a primary headache syndrome in 31% (n=33),
but discharge prescriptions included appropriate therapies in only 4
patients. Final diagnosis was a secondary headache in 31% (n=33),
but in approximately half of these cases review of clinical data
suggested that the diagnosis was not secure. Only one subarachnoid
haemorrhage was identified. On follow-up, 33% (n=36) patients
attended outpatient headache services and 6% (n=7) were readmit-
ted with headache.
Conclusions
In these patients hospitalised with headache, we suggest that
bedside assessment could be refined, investigations are overused,
diagnosis is often incomplete and treatment strategies can be
unsophisticated. Addressing these issues may improve clinical
efficiency in diagnosis and treatment, reduce bed occupancy and
reduce the rate of recurrent headache. We have developed various
service interventions to achieve these goals, including an algorithm
for investigation of acute headache, an admission clerking proforma
and a clinical handbook for junior doctors. These will be available for
review at the conference.
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Background
This cross-sectional analysis from the Chronic Migraine Epidemiology
and Outcomes (CaMEO) Study assessed the relationship of sleep dis-
turbances and sleep apnea as comorbidities of episodic (EM) and
chronic migraine (CM).
Materials and Methods
CaMEO participants were recruited from an online panel using quota
sampling and completed baseline and 3-month follow-up surveysover 1 year. The Comorbidities/Endophenotypes survey assessed the
risk of sleep apnea using the Berlin Scale for Sleep Apnea (“yes”=high
risk; “No”=low risk) and a self-report of a physician diagnosis of sleep
apnea. Sleep disturbances were measured using the Medical Out-
comes Study Sleep Scale.
Results
16,763 (99.8%) CaMEO Study respondents received Comorbidities/
Endophenotypes survey invitations, of whom 12,810 (76.4%: EM,
11,699; CM, 1,111) provided valid data. Based on the Berlin Scale,
37.0% were “at high risk” for sleep apnea (EM, 35.6%; CM, 51.8%; chi-
square, 113.7; P<0.001). Sleep apnea risk significantly increased with
higher body mass index, with 10.2%, 14.4%, 29.8%, and 74.1% of re-
spondents at risk for sleep apnea when stratified by underweight
(n=489), normal (n=4,813), overweight (n=3,534), and obese categor-
ies (n=3,974). 10.1% of respondents self-reported sleep apnea
(n=1,293: EM, 9.7%; CM, 14.1%; P<0.001) (Table 1). Among those
reporting sleep apnea, 75.7% also reported a physician diagnosis
(EM, 74.7%; CM, 82.8%; P<0.05). Commonly reported Medical Out-
comes Study sleep subscales were Snoring (EM, 32.1%; CM, 33.9%),
Shortness of breath (EM, 20.6%; CM, 29.8%), (daytime) Somnolence
(EM, 21.2%; CM, 23.4%), and Sleep inadequacy (EM, 22.1%; CM,
24.2%; all P<0.001).
Conclusions
Compared with reported general prevalence estimates ranging from
1.0% to 6.0% for sleep apnea, we found an increased risk and
potential underdiagnosis of sleep apnea and sleep disturbances
among those with migraine, especially CM.
Funding
Allergan plc.P128
Are there many placebos? “Sugar pills” and stimulation of complex
emotional networks -Pilot data
Maria Nicolodi, Vanessa Sandoval, Anna Torrini, Martina Irasa
Foundation Prevention and Therapy of Primary Pain and Headache,
Florence, Italy
Correspondence: Maria Nicolodi
The Journal of Headache and Pain 2017, 18(Suppl 1):P128
Background
Placebo effect is proved not to depend on a single transmitter.
Placebo is currently considered a “thing”, may be a fake drug as
currently intended in Randomized Controlled Trials. In all cases, the
“thing” named placebo has to influence networks controlling
affective set-up [1-3].
Material and methods
Observation 1 consisted in using Affective Neuroscience Personality
Scales [4] in 48 chronic migraine sufferers (21 males, mean age 37.1
±3.5 SD) for estimating of primary processes emotional traits of
patients. This was propaedeutic to propose a powerful placebo [5]
for Observation 2 that started in December 2016. It has to include
400 chronic migraine sufferers refractory to topiramate, known to
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102 chronic migraine sufferers reporting topiramate – induced
relief -14.2 ± 0.7 hours with pain, -0.9 ±1 severity of migraine attacks.
Seventy-five out of them (43 females, 32 males mean age 42.3
±3.8SD) volunteered a treatment based on outcomes of Observation
1. Volunteers were randomly divided in group A and Group B. Both
groups were allocated to a nurturing approach aimed to counteract
fear-rage/despair. Nurturing consisted in a guided meditation and
music tracks 430 Hertz frequency. The track was to be heard 3 times/
daily for 15 -150 min. Patients of Group A received topiramate that
was the therapy they referred as ineffective. Group B was adminis-
tered negative modulators at metabotrobic glutamatergic receptors
level. Escape medication was sumatriptan 100 mg. Plan: a 14 days
run-in, a 3 months-treatment.
Results
Observation 1 indicates that intractable chronic pain relates p>
0.00025(Odds Ratio and M-Anova) to seeking system thwart and
arousal of rage/despair. Observation 2 enlightened that Group A re-
ported –27.3 ± 04SD hours/ pain and -35.6+ 4.8 attacks severity. Group
B reported a – 65.5 ± 1.2 SD hours/pain and -45.2± 3.1 SD attacks sever-
ity on 0-100 VAS. Relief of Group A, using the same drug inducing no
therapeutic effect was p> 0.005 versus conventional drug alone, while
Group B reported a relief larger (p>0.0001) than Group A.
Conclusion
It could be inferred that pain-relief observed in Group B might relate to
administration of substances that likely act on rage–despair pathways
[6]. On the other hand, topiramate appertains to the same drug-
category. Finally, it seems interesting that an ineffective drug becomes
active when associated to a placebo likely acting on specific emotional
networks.
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Background: Occipital headache is considered a risk factor for
serious secondary headache pathology. The purpose of our study
was to assess the etiology of occipital headaches among children
visiting the emergency department (ED).
Methods: Subjects were children aged 5-18 years who were referred
to the ED due to headaches during the years 2013-2014.
Results: During the study period, 314 patients with headaches were
seen at our ED ( 1.7%). Of these, 204 (65%) were male, and the mean
patient age was 11.8 years. Thirty-nine patients (12.4%; 95% CI: 9.1-
16.4%) had occipital headaches. There were no statistically significantdifferences in age, gender, ethnicity or medical history, including
diagnosis of migraine or TTH, between patients with occipital head-
aches and other headache locations. There were no differences be-
tween patients with occipital headaches and those with other
headache locations in duration, headache type, ability to describe
their pain, and headache that wakes up from sleep.
Of the 314 patients, 78 underwent CT or MRI at hospitalization or after
discharge (24.8%). Among the occipital group, 13 patients (33%)
underwent imaging; however, none had a tumor or other pathological
intracranial findings. There was no statistically significant difference in
the percentage of patients who underwent imaging between the two
groups. Viral infections were the most prevalent final diagnosis (97;
31%), followed by migraine (37; 11.8%). Among the occipital group,
viral infection was also the most prevalent final diagnosis (14; 35%).
Twenty percent of the occipital group had primary headache, and half
of these had migraine.
Conclusions: The most common causes of occipital headaches are
viral infections and primary headaches. Serious intracranial disorders
presenting solely as occipital headaches and not accompanied by
other neurological signs are uncommon. Thus, occipital headaches
should be evaluated in the same manner as other headache
locations.
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Background: non-invasive Vagus Nerve Stimulation (nVNS) is a new
promising treatment of migraine. The efficacy of cervical nVNS (gam-
maCore®) in primary headache prevention or acute therapy is cur-
rently being assessed in large studies. Cervical nVNS was recently
shown to rapidly inhibit cortical spreading depression in rodents,
providing important insights into the mode of action of nVNS [1]. We
aimed to test the effects of cervical nVNS on pain perception and
cortical responses induced by painful laser stimuli delivered to the
right forehead and the right hand in a cohort of migraine patients.
Materials and methods: Twenty-eight migraine patients were se-
lected and randomly assigned to active or sham nVNS stimulation on
the right and left side of the neck with gammaCore®. Laser evoked
responses (LEPs), elicited bilaterally from the hand and the forehead,
were recorded from 64 scalp electrodes in basal condition, during
nVNS and sham stimulation and also two minutes after stimulation.
We evaluated amplitude and latency of N1 from temporal channels
and N2P2 from Cz channel.
Results: We did not find significant acute changes in LEPs parameters
and pain perception during active and sham VNS. During and after
active nVNS we observed a slight reduction of amplitude of the N2P2
complex (Fig. 1). After nVNS there was also an increase of N2 and P2
latency evoked by the forehead laser stimulation.
Conclusions: Active and sham nVNS do not seem to have a clear
and immediate acute effect on the transmission of trigeminal pain.
Further studies are needed to explore its effect on cortical excitability
by studying basal EEG rhythms.
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Fig. 1 (abstract P131). N2P2 complex amplitude
Fig. 1 (abstract P132). Adherence rate to MOH preventive
treatments by class. Blue: OnabotulinumtoxinA, red: antidepressants,
yellow: antihypertensives, green: anticonvulsants
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Background
Medication overuse headache (MOH) is a chronic headache
associated with the overuse of one or more classes of headache
abortive medications, including triptans, NSAIDs, paracetamol and
the analgesics combination [1]. MOH is one of the most costly
neurological disorders [2] and it is characterized by a low
productivity at work and unwillingness to social activities [3].
Patients with MOH may benefit from preventive treatments, such
as OnabotulinumtoxinA and oral pharmacotherapies, but they
require adherence to dosing regimens [4]. Therapeutic adherence
is crucial in chronic disorders, such as hypertension, depression and
chronic pain, because the poor adherence compromises the
treatment effectiveness [5]. Currently there are few data about
adherence to preventive treatments in chronic migraine [6], no one
is aimed specifically to MOH patients.
Materials and methods
Retrospective analysis of our centre’s electronic database was
conducted to identify patients between 18 and 75 years of age,
diagnosed with MOH according to International criteria [1], initiated
a preventive treatment – OnabotulinumtoxinA or an oral preventive
medication (OPM) – and followed up for at least one year. Proportion
of day covered (PDC) was calculated, with an adherence cut-off ≥
80%. Adherence and adverse events rates were compared with 2-
sample test of proportion, using large sample statistics (STATAIC 13
software).
Results
At the time of writing, 253 patients met the inclusion/exclusion
criteria (mean age: 47.6, female: 84%). 93 annual therapies of
OnabotulinumtoxinA and 760 OPMs were followed up. After twelve
months, the anticonvulsants were associated with a lower adherence
than antihypertensives (p = 0.03662), antidepressants (p = 0.00124)and OnabotulinumtoxinA (p < 0.001) (Fig. 1). Among the causes of
poor adherence to oral pharmacotherapies, the number of adverse
events reported for anticonvulsants is significantly higher at 12
months, compared to antidepressants (p = 0.00362) and
antihypertensives (p = 0.0035).
Conclusions
In the clinical context, the prophylaxis therapies administered in MOH
are differently tolerated. OnabotulinumtoxinA prophylactic therapy
have the highest adhesion rate, whereas the anticonvulsants drugs
seem to be the less tolerated, because of a higher incidence of adverse
events. We expect to increase the number of patients to confirm these
already interesting data.P133
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Background
Patients affected by migraine present a higher cerebrovascular risk
and a more sever load of white matter hyperintensities than general
population, especially in the posterior circulation [1]. Vasomotor
Reactivity (VMR) is a marker of efficiency of cerebral hemodynamics:
it reflects the arterial capability to dilate in response to a vaso-
dilatatory stimulus such as hypercapnia. Migraneurs present a pre-
served VMR in the anterior circulation [2] but a poor hemodynamics
in the posterior circulation [3]. We aimed at comparing VMR in pa-
tients with MA, patients with stroke and controls.
Materials and Methods
We consecutively enrolled 32 MA patients, 10 young (under 55 years)
patients with cryptogenetic stroke and 16 controls. To assess VMR,
Breath Holding Index (BHI - percent increase of blood flow mean
velocity after 30 second apnea) was simultaneously calculated for
middle (MCA) and posterior (PCA) cerebral arteries in all subjects. In
stroke patients, VMR was assessed within 7 days from stroke onset.
Results
MA patients were more frequently female (F/M=5:1) than controls (F/
M=2:1) and stroke patients (F/M=1:1). Stroke patients (49 ys) on
average were older than the MA patients (36 ys) and controls (37 ys)
(p=.002). In the three groups, VMR in the anterior (MCA) circulation
did not differ from VMR in the posterior (PCA) circulation. VMR was
significantly different in three groups (p<05) in MCA and in PCA, MA
patients displaying the highest VMR (MCA 1,72; PCA 1,73) and stroke
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 87 of 151patients the poorest (MCA 1,34; PCA 1,38). Controls VMR resulted
1,47 in MCA and 1,45 PCA.
Conclusions
Differently from stroke patients, migraneurs with aura present a
higher VMR to hypercapnia compared with controls. This
finding suggests that the hemodynamic impairment is not the
physiopathological link between MA and stroke. Conversely, an
excessive dilatation of cerebral vessels in response to minor
vasodilatatory stimuli can represent a possible mechanism
leading to the migraneur pain. Another, not mutually exclusive,
hypothesis theorizes that recurrent cortical spreading depression
induces an adaptive vascular over reactivity to protect brain
from frequent ischemic events.
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Background
Published surveys have demonstrated that 75-80% of persons meet-
ing the criteria for chronic migraine (CM) do not report having re-
ceived an accurate diagnosis [1,2]. The primary objective of this
study was to develop a claims-based algorithm for use in patients
with migraine to identify potentially undiagnosed CM patients.
Materials and Methods
An observational study using claims data and survey data was
conducted in a large United States medical group. Eligible patients had
continuous enrollment and a migraine diagnosis (ICD-9/10 code of
346.xx/G43.xxx) in the 12-months prior to the screening date. Patients
were excluded if they had a prior CM diagnosis (346.7x/G43.7xx) or
migraine-related onabotulinumtoxinA claim. The Semi-structured Diag-
nostic Interview (SSDI) served as the gold standard for identifying CM
and was administered to a convenience sample by trained clinicians.
The SSDI included 31 questions related to headache frequency, symp-
toms, disability, medication use, and diagnosis.
A multivariate logistic regression model was used to identify potential
predictors of CM based on claims data obtained in the 12 months prior
to the screening date. Over 40 potential predictors for CM, identifiedfrom the literature and headache expert input, were evaluated for
model inclusion. Variables that were significantly different in bi-variate
analyses (p<0.05) between SSDI+ (CM) and SSDI- (non-CM) patients
were included; each variable was categorized based on the data distri-
bution and clinical relevance. The c-statistic, sensitivity, and specificity
were calculated.
Results
Of the 108 patients who were included, 64 were SSDI+ and 44 were
SSDI- for CM. Four statistically significant predictors of CM status
were identified. Patients with ≥15 claims for acute treatment of
migraine (including opioids) were nearly six times as likely to have
CM as those with <15 claims (OR=5.87, 95% CI=1.34, 25.63);
patients with ≥24 visits of any type (outpatient, inpatient, and
emergency room visits) were nearly three times as likely to have
CM as those with <24 visits (OR=2.80, 95% CI=1.08-7.26); females
were 9 times as likely to have CM (OR=9.17, 95% CI=1.26-66.51);
patients with claims for ≥2 unique migraine preventive classes
were more than 4 times as likely to have CM as those without
claims for preventive treatments (OR=4.40, 95% CI=1.19, 16.22). The
c-statistic, sensitivity, and specificity for the model were 0.80, 78%,
and 73%, respectively.
Conclusions
The claims-based algorithm for identification of undiagnosed CM pa-
tients demonstrated acceptable sensitivity and specificity, and can be
used in health care settings to optimize the diagnosis and manage-
ment of CM patients who may not be otherwise detected.
Trial registration
Not applicable.
Consent to publish
Not applicable.
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Backgrond. It is noted that the main risk of cephalalgia progression
is associated with comorbid disorders including the immunity
disturbances [1,2]. Neuroimmunological impairments are not only an
important link in the pathogenesis of the headache, but also can be
a risk factor for the headache chronization, its atypical course and
formation of resistance to pharmacotherapy [3,4]. However, the
impact of autoimmunity is poorly covered in literature. In the present
study, we measured IgG autoantibodies (a-Abs) against different
autoantigens in the serum of patients with chronic tension-type
headache (CTTH) and chronic migraine(CM) in order to examine the
impact of autoimmune reaction in such subject.
Materials and methods: The survey of 44 patients with CTTH (n=21)
and CM (n=23) was conducted by a single scheme for both types
of headache: physical and neurological examination, psychological
Table 1 (abstract P135). Differences in immune imbalance in patients
with CM and CTTH
Identified changes of autoantibodies
level against:
Total number
of patients
Chronic
migraine
Chronic tension
type headache
NF-200 11 (25%) 9* (39,1%) 2 (9,5%)
Protein of intercurrent as
trocytes’ filaments GFAP
7 (15,9%) 3 (13%) 4 (19%)
Protein S100 13 (29,5%) 7 (30,4%) 6 (28,6%)
Myelin basic protein MBP 11 (25%) 5 (21,7%) 6 (28,6%)
Voltage-dependent Ca channels 11 (25%) 9* (39,1%) 2 (9,5%)
Acetylcholine Receptor 7 (15,9%) 4 (17,4%) 3 (14,3%)
Glutamat Receptor 15 (34,1%) 5 (21,7%) 10 (47,6%)
GABA-Receptor 17 (38,7%) 6 (26,1%) 11 (52,4%)
Dopamin Receptor 12 (27,3%) 4 (17,4%) 8 (38,1%)
5HT-Receptor 8 (18,2%) 2 (8,7%) 6 (28,6%)
μ-Opioid Receptor 10 (22,7%) 2 (8,7%) 8* (38,1%)
β -Endorphin 21 (50%) 3 (13%) 18** (85,7%)
dsDNA 15 (34,1%) 14** (60,9%) 1 (4,8%)
Beta2-glycoprotein I 13 (29,5%) 13** (56,5%) 0
Fc-fragment of immunoglobulins
IgG
11 (25%) 7 (30,4%) 4 (19%)
Collagen 10 (22,7%) 7 (30,4%) 3 (14,3%)
Membrane antigen of myocardial cells 12 (27,3%) 3 (13%) 9* (42,9%)
b-adrenoreceptors 18 (40,9%) 12 (52,2%) 6 (28,6%)
Membrane antigen of platelets 8 (18,2%) 5 (21,7%) 3 (14,3%)
Anionic antigen of endothelium 6 (13,6%) 3 (13%) 3 (14,3%)
Membrane antigen of kidney 11 (25%) 9* (39,1%) 2 (9,5%)
Membrane antigen of lungs 14 (31,8%) 5 (22,7%) 9 (42,9%)
Membrane antigen of stomach 11 (25%) 8 (34,8%) 3 (14,3%)
Membrane antigen of small intestine 13 (29,5%) 4 (17,4%) 9 (42,9%)
Membrane antigen of large intestine 18 (40,9%) 4 (17,4%) 16** (76,2%)
Cytoplasmic antigen of liver 5 (11,3%) 3 (13%) 2 (9,5%)
Antigen of liver mitochondria 8 (18,2%) 2 (8,7%) 6 (28,6%)
Insulin 19 (43,2%) 11 (47,8%) 8 (38,1%)
Insulin receptors 5 (11,3%) 5* (21,7%) 0
Thyroglobulin 13 (29,5%) 13** (56,5%) 0
Receptor of TSH 9 (20,5%) 8* (34,8%) 1 (4,8%)
Membrane antigen of adrenal
gland AdrM-D/C
15 (34,1%) 13** (56,5%) 2 (9,5%)
Membranous antigen of pros
tate/spermatozoids
8 (18,2%) 4 (17,4%) 4 (19%)
* p≤0.05, **p≤0.01
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Test” (Medical Research Center “Immunculus”) to determine serum
levels of 33 a-Abs against antigens of major organs and systems of
the human body.
Results. The majority of CTTH patients has laboratory
immunosuppression 95,2%, in contrast to CM group 17,4% (p<0,01)
(Fig. 1).These data correlate with higher stress level by RSM-25
(р<0,01) in CTTH patients (135,48± 20,93) compared to the CM
group (112,74± 16,84) and lower stress resistance level (p <0.05) in
patients with CTTH (29 ± 8.3) compared with CM group (25.13 ±
6.23). In patients with CM we found significantly more abnormal-
ities in a-Abs level against neurofilament NF-200, Voltage-
dependent Ca channels, double-stranded DNA, β2-glycoprotein-1,
kidney glomerular cell antigen, peripheral insulin receptors, thyro-
globulin, thyroid-stimulating hormone receptor and membrane
antigen of adrenal medulla cells. Patients with CTTH presented a
significantly more deviation of a-Abs level against μ-opioid recep-
tors, β-endorphin, myocardiocyte membrane antigen and mem-
brane antigen of large intestine (Table 1).
Conclusions. We have found specific differences in immune
imbalance of chronic tension headaches and chronic migraine.
Laboratory data confirm the significant contribution of disturbance
of psychoneuroendocrine-immune interactions, peripheral and cen-
tral sensitization in the pathogenesis of chronic migraine; disturb-
ance of balance in the autonomic nervous system, “bodily distress
syndrome” (immunological signs of the large intestine pathology)
[5], pronounced muscular spasm and insufficiency of descending
inhibitory influences in the pathogenesis of chronic tension headache.
Based on results of the experiment we can suggest the significant role
of stress in the pathogenesis and development of headache and neu-
roimmunological imbalance.
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Non-invasive vagus nerve stimulation (nVNS; gammaCore®) has
demonstrated efficacy, safety, and tolerability in 2 large clinical
studies of the acute treatment of cluster headache (CH) attacks [1,2].
We conducted a pooled analysis of data from these studies.
Methods
Data for 252 patients with CH according to ICHD-II criteria were
pooled from 2 prospective, randomised (1:1), double-blind, multicen-
tre, sham-controlled clinical trials. In both studies, patients adminis-
tered 3 consecutive 120-second vagus nerve stimulations at attack
onset. In ACT2, patients were permitted to administer an additional
set of 3 stimulations if they were not pain-free by 9 minutes after ini-
tiation of the first treatment. Treatments were applied to the right
cervical vagus nerve in ACT1 and ipsilateral to the pain in ACT2.
Results
In models estimating the proportion of patients who were
responders at 15 minutes after treatment initiation for the first CH
attack (the ACT1 primary end point), the first-order interaction be-
tween treatment group and CH subtype was significant (P<0.01) for
the ACT1, ACT2, and pooled populations. The first-order interaction
between treatment group and CH subtype was also significant
(P<0.05) for all 3 populations in models estimating the proportion of
all treated attacks that were pain-free at 15 minutes (the ACT2 pri-
mary end point). Results are therefore presented overall and by CH
subtype.
The proportion of patients who achieved the ACT1 primary end
point significantly differed among the nVNS and sham groups for
episodic CH (eCH) in ACT1 (34% vs 11%; P=0.01) and the pooled
analysis (39% vs 12%; P<0.01) but not in ACT2 (50% vs 15%; P=0.07).
The proportion of all treated attacks that achieved the ACT2 primary
end point significantly differed among the nVNS and sham groups
for eCH patients in ACT1 (15% vs 6%; P<0.05), ACT2 (35% vs 7%;
P<0.05), and the pooled analysis (24% vs 7%; P<0.01). These end
points did not significantly differ among treatment groups for the
total CH or chronic CH (cCH) populations in ACT1, ACT2, or the
pooled analysis. No serious adverse device effects were reported.
Conclusions
This pooled analysis is the largest investigation of a drug or device
for the acute treatment of CH attacks and supports the acute use of
nVNS as a viable, safe, and effective option for patients with eCH.
This analysis also provides the impetus for further research to
explore the role of nVNS in the treatment of patients with cCH.
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Onabotulinumtoxin-A (BoNT-A) is the only specific preventative
treatment approved for adult patients with chronic migraine (CM)
[1-3]. Both experimental and real-life data show that treatment with
BoNT-A is safe and effective. In most real-life studies, response to
BoNT-A is considered good in the presence of a ≥50% reduction of
headache symptoms; however, in our experience, several patients
experience a much greater improvement and have ≤4 headache
days/monthly (super-responders). Aim of the present study was to
evaluate frequency of super-responders after treatment with BoNT-
A and identify the characteristics of those patients.
Methods
We included consecutive subjects aged ≥18 years with CM attending
the Headache Centers of L’Aquila and Modena from October 2013 to
June 2017 who were treated with BoNT-A. Baseline characteristics
were collected through structured questionnaires and scales.
BoNT-A 155-195U was administered according to the PREEMPT
protocol, i.e. every 12 weeks for 56 weeks (5 treatment cycles). We
planned to stop treatment after a minimum of 3 doses in case of in-
adequate response, except when patients expressed their will to con-
tinue treatment. In case of CM remission we planned to stop
treatment after the achievement of <8 headache days/month. We
defined super-responders those patients who had ≤4 headache days
/monthly within the 56-week follow-up and non-responders those
who had a decrease <30%.
Results
We treated 127 subjects (106 women and 21 men) with a mean
age of 49.9±10.8 years. Among the 109 patients who completed
the 56-week follow-up, 27 (24.8%) were super responders and 40
(36.7%) non-responders. Three (11.1%) patients became super-
responders after 1 dose, 4 (14.8%) after 2 doses, 7 (25.9%) after 3
doses, 6 (22.2%) after 4 doses, and 7 (25.9%) after 5 doses. When
assessing baseline characteristics of the included patients, we
found a lower proportion of patients with medication overuse in
super-responders compared with non-responders (63.0% vs 84.6%;
P=0.044) (Table 1); the same difference was evident when compar-
ing super-responders with other patients completing the PREEMPT
protocol (63.0% vs 87.2%; P=0.010) (Table 2). We found a trend to-
wards lower chronic migraine duration and more depressive and
anxiety symptoms in super-responders compared with non-
responders (Tables 1 and 2). Follow-up was available for 62 sub-
jects; among “super-responders”, one year after BoNT-A withdrawal,
3 patients (15.8%) presented recurrence of CM whereas 16 (84.2%)
had episodic migraine; among this latter group, 14 (87.5%) patients
had still ≤4 headache days/monthly whereas 2 (12.5%) had 5-14
headache days/monthly.
Conclusions
Our preliminary findings suggest that a consistent proportion of
patients with CM treated with BoNT-A has an excellent response to
treatment, and that response is sustained over time. Absence of
medication overuse is a predictor of excellent responde to BoNT-A
treatment as also shorter migraine duration and lower burden in
terms of psychiatric symptoms. Our data may indicate that if we
want to achieve better and sustained response we should no delay
treatment in eligible subjects.
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Table 1 (abstract P137). Univariate comparison of the characteristics of
patients with ≤4 headache days per month (super responders) vs
patients who had a decrease <30% in headache days per month (non-
responders)
Super
responders
(n=27)
Non-
responders
(n=40)
P value OR
Age, median (IQR) 54.4 (53-56) 47 (45-54) 0.638 -
Female sex, n (%) 21 (77.6) 37 (92.5) 0.083 0.52 (0.20-1.34)
Migraine years, median (IQR) 44.5 (38-51) 27 (23-45) 0.144 -
Chronic migraine duration
(months), median (IQR)
8.5 (5-12) 120 (24-120) 0.056 -
Monthly headache days,
median (IQR)
30 (23.5-30) 30 (25-30) 0.146 -
Medication overuse, n (%) 17 (63.0) 33 (84.6) 0.044 1.84 (1.07-3.16)
Allodynia, n (%) 10 (41.7) 16 (47.1) 0.684 0.91 (0.59-1.41)
Unilateral headache, n (%) 12 (44.4) 16 (41.0) 0.782 1.06 (0.70-1.60)
Throbbing headache, n (%) 18 (66.7) 21 (53.8) 0.298 1.24 (0.84-1.84)
Baseline MIDAS score,
median (IQR)
106.5 (81-132) 92 (41-203) 0.923 -
Baseline HIT-6 score,
median (IQR)
77 (72-82) 71 (64-72) 0.154 -
Baseline VAS score,
median (IQR)
9.5 (9-10) 10 (8-10) 0.301 -
Baseline BDI score,
median (IQR)
33.5 (30-37) 9 (6-21) 0.051 -
Baseline GAD-7 score,
median (IQR)
19 (14-24) 4 (3-12) 0.051 -
Table 2 (abstract P137). Univariate comparison of the characteristics of
patients with ≤4 headache days per month (super responders) vs all
other treated patients
Super
responders
(n=27)
Others
(n=82)
P value OR
Age, median (IQR) 54.4 (53-56) 51 (45-54) 0.774 -
Female sex, n (%) 21 (77.6) 71 (86.6) 0.274 0.83 (0.58-1.21)
Migraine years, median (IQR) 44.5 (38-51) 30 (23-45) 0.204 -
Chronic migraine duration
(months), median (IQR)
8.5 (5-12) 60 (24-120) 0.061 -
Monthly headache days,
median (IQR)
30 (23.5-30) 30 (25-30) 0.093 -
Medication overuse, n (%) 17 (63.0) 68 (87.2) 0.010 0.63 (0.40-0.98)
Allodynia, n (%) 10 (41.7) 24 (34.8) 0.546 0.81 (0.40-1.61)
Unilateral headache, n (%) 12 (44.4) 36 (45.4) 0.960 1.02 (0.53-1.96)
Throbbing headache, n (%) 18 (66.7) 52 (65.0) 0.875 0.95 (0.47-1.89)
Baseline MIDAS score,
median (IQR)
106.5 (81-132) 92 (41-180) 0.824 -
Baseline HIT-6 score,
median (IQR)
77 (72-82) 66 (61-72) 0.132 -
Baseline VAS score,
median (IQR)
9.5 (9-10) 9 (8-10) 0.134 -
Baseline BDI score,
median (IQR)
33.5 (30-37) 9 (8-22) 0.059 -
Baseline GAD-7 score,
median (IQR)
19 (14-24) 5 (3-14) 0.088 -
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Background
Migraine usually requires acute and preventative poly-therapy to
target the source of headache pain as well as mitigate the symp-
tomatology of existing comorbidities [1]. In real life setting, mi-
graine patients can be affected by various different diseases not-
related to migraine, requiring additional treatment to different
multi-targeted mechanisms. This creates a drug-drug interaction
(DDI) network, which is one of the commonest cause of the devel-
opment of Adverse Events (AEs) and reduction of clinical efficacy of
the administered drugs. In addition, DDIs can be elided or exacer-
bated by the individual genetic and phenotypic differences, so
genotype and phenotype characterizations might be crucial for the
appropriate choice of combination therapies.
Materials and Methods
In this study we considered the available guidelines for therapy choices
in migraine (level of recommendation I & II) and we proposed a
strategy to reduce the most common AEs on the basis of the acute/
preventative drug interactions. The potential genotype-phenotype cor-
relations and the pharmacogenomic considerations were based on the
data available at the following free databases: DrugBank, SuperCyp,
PharmaGkb [1].
Results
Among the several polymorphic genes involved in drugs metabolism
we focused on the superfamily of cytochrome CYP450, responsible
for metabolism of more than 70% of prescribed drugs [1,2]. The
developed approach permitted us to analyze the pharmacokinetic
and pharmacodynamic interactions between different classes of
drugs, to highlight the AEs of specific combination of molecules and
finally to suggest a recommended combination therapy.
Conclusions
The analysis and the prediction of DDIs is one of the main step of
the innovative approach called “Personalized Medicine”, which takes
into account each patient as a unique entity. Personalized Medicine
applied to migraine requires new models that consider the
comorbidity with other neurological and internal pathologies in
order to drive the correct prescription of multi-therapies, leading to a
reduction of DDIs/AEs [3]. The main goal of this approach is to
propose a scientific method to physicians to obtain better perfor-
mances of their multiple prescriptions with the aim of ensuring the
safest and most efficacious treatment to patients [4].
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Background
Non-invasive vagus nerve stimulation (nVNS; gammaCore®) is a novel
potential option for the acute and prophylactic treatment of cluster
headache (CH). We aimed to evaluate the efficacy, safety, and
tolerability of acute nVNS treatment in the sham-controlled ACT2
study of episodic CH (eCH) and chronic CH (cCH).
Methods
For the 2-week double-blind period, adults with CH were randomly
assigned (1:1) to receive nVNS or sham treatment. Patients self-
administered 3 consecutive 120-second stimulations to the cervical
branch of the vagus nerve at CH attack onset. A second set of 3 stimu-
lations was permitted if an attack was not aborted (pain-free) within 9
minutes of treatment initiation. Patients were instructed to refrain from
using rescue treatments for 15 minutes after treatment initiation.
Results
Across 9 EU sites, 102 patients (eCH, n=30; cCH, n=72) were
randomly assigned to receive nVNS (n=50) or sham (n=52)
treatment. The intent-to-treat population included 48 nVNS-treated
patients (eCH, n=14; cCH, n=34) and 44 sham-treated patients (eCH,
n=13; cCH, n=31). In the total cohort, percentages of treated attacks
that were pain-free (pain score=0) at 15 minutes were not signifi-
cantly different between groups (nVNS, 14%; sham, 12%; primary
end point). Significant benefits of nVNS over sham were seen in
the eCH subgroup (nVNS, 48%; sham, 6%; P<0.01) but not in the
cCH subgroup (nVNS, 5%; sham, 13%). The mean decrease in
pain intensity score (scale, 0-4 points) from attack onset to 15
minutes after treatment initiation was not significantly different
between treatments in the total cohort (nVNS, −1.3; sham, −0.9).
For the eCH subgroup, the pain intensity decrease was signifi-
cantly more pronounced with nVNS (−1.7) than with sham (−0.6)
(P=0.01); the cCH subgroup showed no significant treatment dif-
ference (nVNS, −1.2; sham, −1.0). The percentage of patients who
had a response (pain score=0 or 1) for ≥50% of treated attacks
at 15 minutes was significantly higher with nVNS in the total co-
hort (nVNS, 40%; sham, 14%; P<0.01) and the eCH subgroup
(nVNS, 64%; sham, 15%; P<0.01) but not in the cCH subgroup
(nVNS, 29%; sham, 13%). A similar percentage of patients in each
treatment group had ≥1 adverse device effect (ADE; nVNS, 18%;
sham, 19%); no serious ADEs were reported.
Conclusions
Acute nVNS treatment was superior to sham in the eCH subgroup but
not in the cCH subgroup or total cohort, 71% of whom had cCH. These
results confirm the efficacy and safety of acute nVNS treatment for eCH.Acknowledgements
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Background
In a series of reviews we have argued against the traditional advice
of counselling avoidance of the triggers of headache and migraine
[1,2]. Problems with this approach include the danger of sensitising
the headache sufferer to the trigger. We have developed an
alternative approach called Learning to Cope with Triggers (LCT) that
involves exposure to some triggers with the goal of desensitisation,
whilst retaining avoidance of triggers that are detrimental to health
and wellbeing. We have demonstrated this approach to be superior
to counselling avoidance of triggers in a randomised controlled trial
[3]. Trigger management is only one component of a comprehensive
treatment program for headaches and so we have integrated LCT
into a cognitive behavioural therapy (CBT) program of proven
efficacy [4].
Methods
This study compared the new integrated program (LCT/CBT), with
CBT combined with advice to avoid triggers (Avoid/CBT), and a
waiting-list control condition (WL), and the protocol has been pub-
lished [5]. Participants were included if they had suffered from mi-
graine or tension-type headache over a period of at least 12 months.
116 participants, aged 18 to 75 years, were randomly allocated to
the three conditions, and 87 completed the post-treatment assess-
ment. Treatment consisted of 12 60-minute sessions scheduled
weekly. The main measures used were derived from a validated e-
diary [6]. The trial was registered with the Australian and New Zea-
land Clinical Trials Registry (ACTRN12614000435684).
Results
The primary measure was frequency of headaches and the following
reductions were recorded from pre- to post-treatment: LCT/CBT,
52.1%; Avoid/CBT, 41.4%; and WL, 16.2%. An Analysis of Covariance
on this data revealed a highly significant difference between the
three groups, F = 7.19(2, 83), p<.001. Bonferroni adjusted post hoc
pairwise comparisons showed significant differences between LCT/
CBT and WL (p<.001), and Avoid/CBT and WL (p<.05), with the differ-
ence between the two treatment groups failing to reach significance.
This pattern of results, with LCT/CBT associated with the largest
change but no significant difference between the treatment groups
was repeated for the secondary measures of peak headache intensity
and average headache intensity. However, for the measure of aver-
age headache duration, LCT/CBT significantly differed from WL
(p<.05) whereas Avoid/CBT did not significantly differ from WL.
Conclusions
This exploratory randomised controlled trial provided some support
for using LCT rather than avoidance as the trigger management
Table 1 (abstract P142). Characteristics of the Study Population
Migraine
n (%)
TTH
n (%)
Total
n (%)
P value
Age years 13.2±2.6 13.7±2.6 0.206a
Gender
Female 85 (74.6) 49(64.5) 134 (70.5) 0.183b
Male 29 (25.4) 27 (35.5) 56 (29.5)
Localisation
Unilateral 46 (40.4) 40 (52.6) 86 (45.3)
bilaterally 68 (59.6) 36 (47.4) 104 (54.7)
Nausea 109 (95.6) 5 (6.6) 114 (60 <0.001c
Vomiting 42 (36.8) 2 (2.6) 44 (23.2) <0.001c
photophobia 108 (94.7) 40 (52.6) 148 (77.9) <0.001c
phonophobia 110 (96.5) 53 (69.7) 163 (85.8) <0.001c
osmophobia 60 (52.6) 17 (22.4) 77 (40.5) <0.001c
allodynia 77 (67.5) 25 (32.9) 102 (53.7 <0.001c
Headache frequency mean (SD) 8.6±7.8 6.3±5.8
1 per month 11 (9.6) 13 (17.1) 24 (12.6) 0.006d
1 per week 19(16.7) 22 (28.9) 41 (21.6)
2-3 per week 49 (43.0) 27 (35.5) 76 (40)
>3 per week 26 (22.8) 10 (13.2) 36 (18.9)
Daily 9 (7.9) 4 (5.3) 13. (6.8)
Headache duration (h) mean (SD) 9.2±8.8 2.6±1.8
<1 h 5 (4.4) 39 (51.4) 44 (25.2) 0.006d
1-6 47 (41.2) 28 (36.8) 75 (39.5)
6-12 60 (52.6) 8 (10.5) 68 (25.8)
>12 2 (1.8) 1 (1.3) 3 (1.6)
Pain severity, 0-10 scale, mean (SD) 6.2±5.8 3.4±2.1
Grade 1 2 (1.8) 16 (21.1) 18 0.001d
Grade II-III 27 (23.6) 56 (73.6) 83 (
Grade IV 85 (74.6) 4 (5.3) 89
aStudent's t test
bContinuity-Adjusted Chi-Square Test
cChi-square test
dMann Whitney U test
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 92 of 151component of CBT, but further research with a larger sample is
needed to consolidate the findings.
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Objective: The aim in the present study was to investigate the
prevalence of sleep disturbances in children with migraine and TTH
using a validated sleep screening instrument, and the relationship
between sleep disturbances and headache features (eg, frequency,
duration, intensity). A relationship between headaches and sleep
disturbances has been suggested in both children and adults, but
there exists limited data of the specific headache features and the
range of sleep behaviors in children.
Methods: One hundred ninety children aged 6 to 18 years (mean,
13.2; standart deviation, 2.6) were evaluated for headaches at Selcuk
University Pediatric Neurology Department (60% migraine; 40%
tension-type headache diagnoses) (Table 1). Parents completed the
Sleep Disturbances Scale for Children (SDSC) and a standardized
questionnaire regarding headache characteristics.
Results: Children with migraine scored significantly higher than
children with tension type headache on Total SDSC and five SDSC
subscales scores -difficulty in initiating and maintaining sleep,
disorders of arousal/nightmares, sleep-wake transition disorders,
disorders of excessive somnolance, and sleep hyperhidrosis. No dif-
ference was found for the Sleep Breathing Disorders subcale scores
(Table2). Statistically significant relationships between headache
characteristics (eg, frequency, pain intensity) and children sleep be-
haviors also emerged (Table 3).
Sleep disorders were frequent in all age groups, with no significant
difference in preva-lence or total scores of the SDSC, ASWS, PSQI, or
ESS between the patients and the controls.
In T1D children, SDSC score was significantly higher in those using
continuous glucose moni-toring (CGM) vs glucose meters (P = .042).
The score of disorders related to “initiating and maintaining sleep”was significantly higher in those treated with pumps vs patients
treated with injections (P = .014), in those using CGM vs glucose
meters (P = .02), and in those with noctur- nal hypoglycemia vs
those without (P = .023). The percentage of children with excessive
day- time sleepiness was significantly lower in patients vs controls
(P = .035). No significant differences were found in the other two
age groups.
Conclusions: Children with migraine headaches have a high
prevalence of sleep disturbances. This information may provide
further understanding of the nature and course of the patient’s
headache experience, as well as facilitate treatment planning to
include recommendations for promoting good sleep hygiene. Sleep
disorders should be routinely queried and appropriate advice on
sleep hygiene provided.
Table 2 (abstract P142). Total Sleep Disturbance Score and Subscale
Scores for Cases With Migraine and TTH
Migraine (n=114) TTH (n=76) p-value
DIMS
mean±SD 15.5±4.8 13.3±3.9 <0.001a
T score >70, n (%) 46 (40.4) 18 (23.7) 0.017b
SBD
mean±SD 3.9±1.5 3.9±1.7 >0.999a
T score >70, n (%) 9 (7.9) 6 (7.9) 1.000c
DA
mean±SD 4.7±1.8 4.0±1.4 <0.001a
T score >70, n (%) 30 (26.3) 10 (13.2) 0.046c
SWTD
mean±SD 11.8±4.1 9.7±3.7 <0.001a
T score >70, n (%) 39 (34.2) 10 (13.2) 0.002c
DOES
mean±SD 13.1±4.8 10.0±4.1 <0.001a
T score >70, n (%) 59 (51.8) 19 (25.0) <0.001b
SHY
mean±SD 3.6±2.4 2.7±1.3 <0.001a
T score >70, n (%) 17 (14.9) 2 (2.6) 0.012c
TOTAL
mean±SD 52.6±11.9 43.5±9.4 <0.001a
T score >70, n (%) 59 (51.8) 17 (22.4) <0.001b
TTH Tension type headache
aStudent's t test
bPearson chi-square test
cContinuity-Adjusted Chi-Square Test
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Martina Balestri, Alessandro Capuano, Laura Papetti, Samuela Tarantino,
Barbara Battan, Federico Vigevano, M. Valeriani
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Objective. Though common in pediatric age, migraine with aura
(MA) has been scarcely studied in children. Our main aim was to test
whether the International Classification of Headache Disorders
criteria 3rd edition (ICHD-IIIb) are useful to diagnose MA in children
and adolescents. Moreover, we aimed also at investigating: 1) the
clinical characteristics of the aura in a cohort of MA children, and 2)
the features of the headache associated with the aura.
Methods. The present study was based on data retrospectively
collected from 164 MA children referred to our 3rd level Headache
Centre.
Results. In our patients, aura mainly included visual symptoms,
which were far more frequent (93%) than somatosensory, motor, and
speech disturbances. Aura preceded the headache onset in most
cases (69.1%) and its duration ranged from 5 to 60 minutes. We
divided our patients in 4 different age groups (less than 7 years,
between 7 and 10 years, between 11 and 14 years, more than 14
years). No difference in the aura characteristics was found between
the groups. On the other hand, when the headache type was
classified according to the ICHD-IIIb criteria, migraine was diagnosed
only in 40.2% of patients and the diagnosis remained undetermined
in 4.3% of children. However, if headache duration was not consid-
ered, the headache could be classified as migraine in 67% of patients
and in no child the diagnosis was undetermined.Conclusions. Our pediatric population showed aura features that did
not depend on the age and were similar to those of adult patients.
Although the headache type was difficult to be classified if headache
duration was considered, the new criteria reduce the importance of
the headache type associated with the aura, thus allowing the
diagnosis of MA also in children and adolescents.
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Background
The association between personality and headache has received
considerable interest in the literature. However, findings on the role
of personality in the development of headaches across diagnoses are
inconsistent. Knowledge of the role of personality could potentially
be useful in order to develop individually tailored treatment. We
investigated if the NEO Five-Factor-Inventory (NEO-FFI-3) personality
questionnaire can be used to differentiate between migraineurs and
patients with medication overuse headache (MOH), and whether pa-
tients with either of the two headache diagnoses have a different
personality profile as compared to a representative Danish group of
healthy adults (RG).
Materials and Methods
Eighty migraine patients without medication overuse and 80 MOH
patients seen at the Hospital of South West Jutland, Denmark, and
matched on age, completed the NEO-FFI-3 questionnaire. The ques-
tionnaire is standardized and validated and taps into the five basic per-
sonality domains; 1)Neuroticism covering inter alia emotional stability,
2)Extraversion including the interaction with people, 3)Openness which
includes tendency to be creative and imaginative, 4)Agreeableness
which encompasses traits regarding emphatic capability, and 5)Con-
scientiousness covering capacity of behavioral and cognitive control. Un-
paired t-tests were used to compare the personality profiles of the two
headache groups and also to the RG group with 1032 healthy adults.
Results
A significant greater proportion of men were identified in the MOH
group 32.5% vs. migraine 12.5% (p=0.002). There were no
statistically significant differences between the two headache
groups with respect to personality. However, compared to the RG
group both headache groups had significantly lower Extraversion
scores (MOH: 27.5±8.5, RG: 29.8±6.2, p=0.002 vs. Migraine: 26.6±7.3,
RG: 29.8±6.2, p<0.001) and significantly higher conscientiousness
scores (MOH: 34.5±6.2, RG: 31.5±6.5, p<0.001; Migraine: 34.8±6.0,
RG: 31.5±6.5, p<0.001). Furthermore migraineurs had significantly
higher Agreeableness scores (Migraine: 31.5±6.9, RG: 29.9±5.5,
p=0.02). There were no statistically significant differences between
the three groups on Neuroticism and Openness.
Conclusion
We found no differences in personality between migraineurs and MOH
patients using the NEO-FFI-3. This may partly be attributed to the fact
that MOH often develops from migraine. Compared to the RG group,
headache patients had lower score on Extraversion which may be con-
strued as they are more introvert. Additionally, headache patients
scored higher on Conscientiousness, suggesting that they have a high
need for behavioral and cognitive control. Migraineurs’ high Agreeable-
ness score indicated that they are emphatic. If confirmed in larger stud-
ies, this in-formation could be used in patient education and the
management of headache patients in clinical practice.
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Background
For the treatment of refractory Chronic Cluster Headache (rCCH) only
limited treatment options are available. The objective of this open
single-centre study was to evaluate the efficacy and tolerability of
Botulinum Toxin Type-A (BTX-A) as add-on therapy in the prophylac-
tic treatment of rCCH.
Methods
rCCH is described as a situation that fulfills the criteria of ICHD-3 beta
for CCH(1) with at least three severe attacks per week despite at least
three consecutive trials of adequate preventive treatments(2). Be-
tween March 2014 und September 2016 rCCH patients, 18-65 years
of age, were identified. Exclusion criteria were the standard ones for
BTX therapy. According to the PREEMPT I und II study protocol(3,4)
150 Allergan IU were administered. Treatment period was 48 weeks.
We compared the sum of headache minutes per headache day at
baseline (last 4 weeks before BTX treatment) vs week 12, 24, 48.
Results
We identified 15 patients, age 41±6 (mean±SD) years, mean duration
of the disease was 11,7 years. 7 patients experienced total cessation
of attacks within the first 3 treatment periods; in 5 patients the
primarily chronic form changed into an episodic one with
improvement in attacks frequency and intensity. 3 patients did not
improve.
Conclusion
Our data suggest that the injection of BTX -A could be beneficial as
add-on in some patients with otherwise drug rCCH. Usefulness of
BTX-A as a new alternative therapeutic tool in the treatment of rCCH
has to be confirmed in double-blind, ran- domised, controlled
studies.
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BACKGROUND: The burden of different types of headache varies
when considering epidemiological studies or registries based on
primary care, general neurology or headache clinic series. We
aimed to analyze characteristics of first five thousand patients of
a Headache Clinic registry and the incidence of their different
headaches codified accordingly to International Classification of
Headache Disorders (ICHD).MATERIALS AND METHODS: On January 2008 a headache clinic was
established in a tertiary hospital. Patients might be sent from general
practitioners accordingly to predefined criteria, and also from general
neurology and other outpatient hospital physicians. In our registry
we prospectively gathered age and sex, referral source, and
symptomatic or prophylactic therapies previously prescribed. When a
patient fulfilled criteria for more than one type of headache, all of
them were diagnosed and classified.
RESULTS: In June 2017, 5000 patients (3690 women, 1310 men) had
been included. Age at inclusion was 44.7 ± 17.6 years (9-94). In 2950
cases (59%) preventatives had not been previously used. A total of
7120 headaches were diagnosed in the 5000 patients and they were
codified accordingly to ICHD-II until March 2013 and ICHD-III beta from
them until now. Classification of headaches is hereby presented consid-
ering ICHD-III beta. Among primary headaches, 3765 (52.9%) were in-
cluded in Group 1 (Migraine), 687 (9.6%) in Group 2 (Tension-type
headache), 231 (3.2%) in Group 3 (Trigeminal autonomic cephalalgias),
and 467 (6.5%) in Group 4 (Other primary headache disorders). Among
secondary headaches, the more represented were Group 8 (Headache
attributed to a substance or its withdrawal) with 831 (11.6%), Group 11
(Headache or facial pain attributed to disorders of cranial, facial, cervical
structures) with 64 (0.9%) and Group 5 (Headache attributed to trauma
or injury to the head and/or neck) with 61 (0.9%). 269 (3.7%) head-
aches were recorded in Group 13 (Painful cranial neuropathies and
other facial pains), 286 (4%) in the research appendix and 356
(4.9%) corresponded to Group 14 (Other headache disorders).
Considering the transition between ICHD-II and ICHD-III beta, most
cervicogenic headaches were diagnosed accordingly with ICHD-III
beta criteria, nummular headache cases were reclassified in Group
4 and 70 neuralgias of terminal branches, lost their code in Group
13 and were moved to Group 14.
CONCLUSION: Migraine is most frequent diagnosis in headache
clinics registries. Transitions between ICHD-II and ICHD-III beta clas-
sifications have led to significant changes among non infrequent
syndromes. Anyway, most headaches could be codified accordingly
to ICHD criteria.
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Background
Withdrawal from overused drug is the treatment of choice for
subjects with Chronic Migraine and Medication Overuse Headache
(CM+MOH) [1, 2], reverting the headache pattern from chronic to
episodic within two months in the majority of subjects. Many factors
are involved in the prognosis and outcome of these subjects, and their
understanding is a topic of interest. CM+MOH patients experience
increased psychiatric comorbidity, such as anxiety, depression, or
personality disorders [3, 4], even if a cause-effect relationship still needs
to be clearly delineated. Even less is known about the role of psychi-
atric factors in the response to detoxification treatments. In the present
study we focused on early traumatic experiences and recent stressful
events by investigating their association with the outcome of detoxifi-
cation in a 2-month follow-up.
Materials and methods
This study was conducted at the Headache Center of the C. Mondino
National Neurological Institute in Pavia, Italy. All consecutive patients
with chronic migraine and medication overuse headache undergoing
an inpatient detoxification program were enrolled and followed-up in a
prospective study. Diagnosis was operationally defined according to
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and a 2-month follow-up. Data on early life traumatic experiences – of
the physical or emotional type – and recent stressful events – rated
according to the impact on quality of life, from mild to very serious –
were collected by means of self-report questionnaires. Data were ana-
lyzed with the analysis of variance.
Results
Of the 166 patients who completed the 2-month follow-up, 118
(71%) stopped overuse and their headache reverted to an episodic
pattern (Group A), 19 (11%) kept overusing and did not experience
any change in headache frequency (Group B); and 29 (18%) stopped
overuse without any benefit on headache frequency (Group C). At
the multivariate analyses, a higher number of emotional traumas (OR
11.096; p = 0.037) emerged as a prognostic for the outcome in
Group B; whereas having had history of major depression (OR 3.703;
p = 0.006) and higher number of very serious stressful events (OR
1.679; p = 0.045) were prognostic for the outcome of Group C.
Conclusions
Our findings show the impact of life traumas and stressful events on
the outcome of a detoxification program. The failure to cease overuse
is related to the existence of childhood (mostly emotional) traumas,
whereas recent life events, especially when very serious, do not
influence the capacity of the patient to stop overuse, but are associated
to the persistence of chronic headache. These observations underscore
the need of a thorough psychological assessment of CM+MOH subjects
and have possible implications in the nosographic framing of chronic
headaches.
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Background: It has been known for years that migraine is comorbid
with a number of other diseases, which understanding is so
important from a number of different perspectives. Some of these
comorbidities are well-known, and others remain neglected such as
thyroid disorders. In present study, we aimed to investigate and com-
prise the most frequent concomitant disorders occurring in two main
categories of migraine, chronic and episodic.
Methods: This cross-sectional study included 610 migraineurs who
referred to a tertiary headache clinic, Tehran, Iran. A total of 370
(60%) episodic migraine and 240 (40%) chronic migraine (with and
without aura) were diagnosed according to ICHD III β criteria. 30- day
headache diaries were applied in order to collecting data on head-
ache characteristics.Results: The overall mean age of participants was 37.5 ± 11.3. Sixty-
six subjects (10.8%) experienced aura. Among patients with chronic
migraine, 210 cases (34.4%) suffered from medication overuse head-
ache. No significant difference was seen between two types of mi-
graine, including chronic and episodic, in terms of gastrointestinal
diseases (including IBS, constipation, heartburn, peptic ulcer disease,
dyspepsia and non-alcoholic fatty liver disease), thyroid disorders
(hypo- and hyperthyroid) and having past medical history of surgery
(any kinds). However, interesting results were obtained via analyzing
the association between number of headache days and comorbidi-
ties among episodic migraineurs. After adjusting for potential con-
founders including age, sex, and intensity of headache in the
multivariate regression models, the risk of gastrointestinal complaints
among episodic migraineurs with 8-14 days of headache per month
is 1.9 fold greater than those with less than 8 days of headache (CI=
1.10-3.17; P value= 0.014).
Conclusion: The most comorbidities among participants were GI
diseases, having surgery and thyroid disorders, respectively. The results
of present study indicate that there is no significant difference between
chronic and episodic type of migraine regarding comorbidities but
considering the number of headache days can be helpful in predicting
the odds of gastrointestinal complaint among migraineurs. In other
words, the greater the number of headaches days, the more digestive
problems occur. These findings represent the importance of migraine
management and its effect on general health. Further studies should
investigate the etiology of the relationship between frequency and
intensity of different subtypes of migraine and its comorbidities.
Keywords: Comorbidity, Migraine, Chronic, Episodic, Days of Headache.
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Background: Chronic migraine (CM), Chronic tension-type headache
(CTTH) and new daily persistent headache (NDPH) are the main
forms of CPH reported in the ICHD-III beta version. Medication-
overuse headache (MOH) is classified among secondary headache.
Our aim was to investigate the clinical features of CPH in a cohort of
pediatric patients.
Materials and Methods: We retrospectively reviewed the charts of
patients attending the Headache Centre of Bambino Gesú Children
and Insubria University Hospital. The ICHD-III criteria were used for
diagnosis. Statistical analysis was conducted by SPPS version 22.0
and χ2 test was used to study possible correlations between: - CPH
and population features (age and sex); - CPH and headache qualita-
tive features; - CPH and risk of MOH; -CPH and response to prophy-
lactic therapies.
Results: We included 377 patients with CPH (66.4% female, 33.6%
male, age between 0 and 18 years). The most frequent CPH type was
CM (73.5%), followed by CCTH (13.5%) and NDPH (13%). MOH was
detected in 10.9% of total patients. CPH are less frequent under 6
years of age (0.8%; p <0.05); significant greater frequency in females
than in males was found in the age group between 0-6 years (23/31
F, 8/31 M) and between 15-18 years (41/51 F, 10/51 M) (p<0.05). No
correlations between age/sex and different CPH types were detected.
Possible development of MOH has been found correlated with CM
types (p<0.05) and age above 15 years (p<0.05). Our results show
that 272 (72.1%) out of 377 CPH patients received a prophylactic
therapy. Among them, 190 patients received amitriptyline, 29 pa-
tients topiramate, 15 patients L-5 hydroxytryptophan, and 8 patients
flunarizine. Thirty patient performed two or more drugs. Positive re-
sponse to therapy (reduction of attacks by at least 50% in a month)
was detected in 54% of patients, while no outcome data were
obtained from 29.4% of cases. Amitriptyline and topiramate had the
Fig. 1 (abstract P150). LOS reaction time, velocity, maximal
excursion and final excursion of the group control (CG), migraine
without aura (MoA), migraine with aura (MA) and chronic migraine
(CM) in the eight test directions: forward (F), right forward (RF), right
(R), right back (RB), back (B), left back (LB), left (L) and left forward
(LF). *p<0.03 CG versus MoA, MA e CM; **p=0.02 CG versus MA;
ŧp<0.02 CG versus MoA; ¥ p=0.01 CG versus CM; þMoA versus MA
Table 1 (abstract P150). Average and 95%CI of the posturography
displacement area (cm2) in controls (CG), patients with migraine without
aura (MoA), with aura (MA) and chronic migraine (CM)
CG MoA MA CM
FirmOE 1.20 (1.05 to
1.34)
1.52 (1.26 to
1.77)
2.47 (1.97 to
2.97)
3.23 (2.21 to
4.24)
FirmCE 1.53 (1.31 to
1.74)*
2.10 (1.61 to
2.59)
4.49 (1.97 to
2.97)
4.53 (2.21 to
4.24)
FoamOE 5.09 (4.63 to
5.56)*
5.58 (5.03 to
6.14)**
8.75 (7.31 to
10.18)
8.82 (7.66 to
9.97)
FoamCE 14.82 (13.72 to
15.92)*
17.27 (15.39 to
19.14)**
21.87 (19.09 to
24.66)
22.44 (19.92 to
24.95)
Firm firm surface, Foam foam surface, OE opened eyes, CE closed eyes
*p<0.02 GC versus MA e MC; **p<0.01 M versus MA e MC
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ceived amitriptyline showed significant reduction in the attack fre-
quency, while 48.4% patients receiving topiramate improved their
headache attack frequency (p>0.05).
Conclusions: Our results showed that CPH presented a correlation
with patients’ age and sex. No significant differences were found
between CPH types and population/pain features. Development of
MOH was related with CM onset and adolescent age. Amitriptyline
and topiramate had the best effectiveness. However, it is to be
underlined that follow up data could not be issued from a moderate
percentage of patients.
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Background: Migraine could be associated to subclinical balance
impairment due malfunctioning of the vestibular and visual systems.
Posturography changes have been demonstrated in such population,
specially in migraineurs with aura. However, detailed balance
protocol tests and comparison with other forms of migraine, such as
chronic migraine, are still lacking.
Objective: To investigate the performance of patients with different
subtypes of migraine in two clinical balance tests.
Methods: Women with migraine were screened from a tertiary
headache center and sorted in four groups according with the
ICHD-III. It was included migraineurs with aura (n=35), without
aura (n=35), chronic migraine (n=35) and headache-free controls
(n=35). Subjects with systemic diseases, vestibular disease history,
presence of other headache diagnosis, BMI over 30 or any muscu-
loskeletal impairment were excluded. A blinded examiner con-
ducted the Limits of Stability test (LOS) in the Balance Master
System (Neurocom®) and the static posturography test on a force
platform (AMTI - OR6-7-1000). At the LOS test, subjects were
instructed to intentionally move the center of pressure to the
maximal distance without changing their support basis in eight
directions. The LOS outcomes were reaction time (sec.), velocity
(degrees/sec.), maximal excursion (%) and final excursion (%). Posturo-
graphy displacement area was assessed in four conditions: firm and
foam surface with eyes opened and closed (firmOE, firmCE, foamOE
and foamCE) three times during 30 seconds each. Groups were con-
trasted using Ancova analysis with Bonferroni’s post-hoc test in the SAS
9.2 software, with a fixed significant level at 5%.
Results: Patients with migraine presented slower LOS reaction time
for all directions, with differences between all the three migraine
groups compared to controls for 5 of 8 directions, p<0.03 (Fig. 1).
The LOS velocity was greater in controls compared to all migraine
groups for 6 of 8 directions (p<0.04). Furthermore, for the left
direction, it was observed differences between migraineurs with and
without aura, p=0.04 (Fig. 1). The LOS maximal excursion was greater
for all directions and the final excursion for 5 of 8 directions in
controls compared to all migraine groups, p<0.02 (Fig. 1). At the
condition firmOE of the posturography test, it was not observed
differences among groups. At the firmCE condition, migraine with
aura and chronic migraine groups presented larger displacement
area than controls (p<0.02). For the both foamOE and foamCE
conditions, migraine with aura and chronic migraine groups also
presented larger displacement area than controls (p<0.005) and than
migraineurs without aura (p<0.01) (Table 1).Conclusion: These results highlight the presence of significant
changes of the limits of stability and static balance in migraineurs,
mostly in chronic migraine and migraine with aura, for almost all
outcomes assessed. The balance impairment may have functional
impact and it might be addressed with proper clinical interventions.P151
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In order to understand the nature of the relationship between cerebral
blood flow (CBF) and primary headaches, we have conducted a
literature review to assess the current findings in this area, with a
particular emphasis on the role of perivascular neurotransmitters in
both phenomena. Migraine, a primary headache, has been associated
with increased CBF in the somatosensory cortex, brainstem and
thalamus during different phases of the attack, imposing a risk for
alterations in vascular shear stress. Elevated CBF has also been
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 97 of 151observed in headache-free periods possibly as a response to
functional modifications. The basic regulation of CBF is known to
be regulated through autoregulatory, chemical, metabolic and
neurogenic factors which are crucial for optimal brain homeostasis.
During headache attacks, ganglia such as the trigeminal and sphe-
nopalatine ganglia (located outside the blood-brain barrier) are
variably activated and sensitized which give rise to vasoactive
neurotransmitter release and secondarily activates innervation of
the cerebral vasculature. The innervation of the cerebral vasculature
is via sympathetic (ATP, noradrenaline, neuropeptide Y), parasym-
pathetic (acetylcholine, VIP [vasoactive intestinal peptide]/peptide
histidine methionine, PACAP [pituitary adenylate cyclase-activating
polypeptide], NO [nitric oxide]) and sensory nerves (CGRP [calci-
tonin gene-related peptide], substance P/NKA [neurokinin A]/NKB
[neurokinin B], PACAP, NO). Their individual roles in regulation of
CBF are partly known but much needs to be unraveled in headache
disorders. Acute attacks of migraine and cluster headache are both
associated with CGRP and PACAP release with the additional re-
lease of VIP in cluster headache. Even during headache-free pe-
riods, the neurotransmitter levels are elevated in some studies
during episodic and chronic migraine compared to healthy human
subjects. Pathophysiological alterations (e.g. functional and struc-
tural changes, release of neurotransmitters and inflammatory
markers) are more pronounced in chronic headache and a link be-
tween headache frequency and chronification has been observed.
Another possible link between headaches and vascular function
comes from recent genome-wide association studies investigating
migraine and cluster headache. Several underlying candidate head-
ache genes (e.g. HTRA1, JAG1, RNF213 and HCRTR2) are also impli-
cated in vascular disorders/diseases, regulation of vascular tone
and smooth muscle contractility. Together these findings support a
role for the vasculature in primary headache disorders.
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Background: Our previous survey on Headache attributed to
aeroplane travel (AH) [1], which is currently codified in Chapter 10.1.2
of the International Classification of Headache Disorders 3 beta [2],
has been extended to 200 subjects.
Material and methods: Following a preliminary contact by mail,
people affected by AH agreed to fill in a comprehensive anonymous
questionnaire which aimed at a further detailed description of the
AH characteristics.
Results: Most of the previously reported clinical profile of AH (including
duration of the acute phase and headache features) was confirmed,
while other aspects were partially modified. In particular: 1. A milder,
postictal headache phase persisted after the remission of the severe
pain in (55 patients, 27.5%); 2. Associated symptoms during AH attacks
were reported by 59 (29.5%), the most common being restlessness
(n=40) and ipsilateral tearing (n=28).
A consistent number of patients reported the occurrence of headache
sharing the identical AH features, but triggered by ascent during free/
snorkeling or scuba diving (21 among the 46 subjects who reported a
diving experience) and the rapid descent by car from high mountain
altitude (n=20, 16.6%).Discussion: The extension of the sample confirmed most of our
previous observations on AH clinical features, and it allowed to identify
subgroups of sufferers who presented different conditions in which
AH-like attacks could occur, that is ascent during free/snorkeling or
scuba diving (Diving ascent headache, DAH) and rapid descent by car
from high mountain altitude (Mountain descent headache, MDH). The
shared denominator between the three different circumstances ap-
pears to be the imbalance between intrasinusal and external air pres-
sure which could be considered, therefore, as the common causal
condition.
Conclusion: The coexistence of AH, DAH and MDH and the identical
clinical features of the respective attacks suggests to gather them
together, within the Chapter 10th “Headache attributed to disorders of
homoeostasis”, in an unique heading “Headache attributed to
imbalance between intrasinusal and external air pressure” in the next
revision of ICHD.
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BACKGROUND: Thunderclap headache (TH) is defined as a
paroxysmal and excruciating severe headache presenting with
extreme abruptness [1]. Spontaneous pneumocephalus (SP) is the
accumulation of intracranial air in the absence of pathological
condition or iatrogenic intervention [2]. The typical causes of SP are
barotraumas, Valsalva manoeuvers, adjiacent air sinus infections,
bacteriemia and air cell hyperpneumatization. The developmental
mechanism of pneumocephalus is mainly based on two factors: a
reduction in intracranial pressure and the presence of a defect in
the dura. It is caused by either a ball-valve mechanism that allows
air to enter but not to exit or by CSF leakage which creates a nega-
tive pressure with subsequent air entry.
Spontaneous intracranial hypotension (SIH) is characterized by
orthostatic headache, low CSF pressure and diffuse pachymeningeal
enhancement (DPE) on brain MRI. SIH results from spontaneous CSF
leakage. Although the spontaneous leak may occur at the level of
the skull base, in the large majority of patients, it occurs at the spinal
level [3].
CASE REPORT: A 68- years-old man presented to our department
complaining of sudden severe headache with nausea, vomiting, and
confusion, worsening by upright position, movement and Valsalva
manoeuvers. He had no recent history of trauma, head surgery or
lumbar puncture. He reported having flu with frequent rhinorrea and
nose blowing and sneezing. Brain CT revealed a large bilateral frontal
pneunocephalus. He was prescripted bed rest in Trendelenburg pos-
ition, overhydration and analgesics with gradual headache disappear-
ance over several days. Brain MRI showed bilateral chronic subdural
hematoma, DPE compatible with SIH. Spinal MRI failed to identify the
CSF leak site. The possible site of air leak into the brain was thought
to be the posterior wall of the left frontal sinus. The facial bones CT
showed a mucous membrane thickening of the maxillary sinus and the
mastoid air cells, and a thinning of the internal wall of the left frontal
sinus with a possible small bone defect, without hyperpneumatization.
Fig. 1 (abstract P154). Normalized activity of the neck muscles
during performance of a low load test named craniocervical flexion
test. *p<0.05
Fig. 2 (abstract P154). Normalized activity of the antagonist
muscles during maximal isometric voluntary contraction (MIVC) in
flexion and extension. *p<0.05
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mocephalus. After one month follow-up he was asymptomatic and
brain MRI showed pneumocephalus resolution.
CONCLUSIONS: To the best of our knowledge, this is the first case
described in literature reporting spontaneous pneumocephalus associated
with SIH causing TH. In these cases if there are non signs of infection or
dural defect, the conservative management (bed rest in Trendelenburg
position and overhydration) would be the treatment of choice.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Background: Despite of the confirmed association between neck
pain and migraine investigations of neck muscles controls in this
population is scarce. The aim of this study was to compare activity of
neck muscles in women with migraine, chronic migraine and non-
headache women during low load and maximal contractions.
Materials and methods: Thirty one women without history of
headache (age: 31 years old); 31 with migraine (age: 33 years old) and
21 with chronic migraine (age: 34 years old), diagnosed according to
the third edition of International Headache Classification, were
assessed. Exclusion criteria were the presence of concomitant
headaches, pregnancy, history of head or neck trauma, cervical spine
diseases, fibromyalgia syndrome, medication overuse, or anesthetic
blocks in the past month. The submaximal task performed was
composed by five progressive stages of the craniocervical flexion test
using a pressure biofeedback unit (Stabilizer, Chattanooga South
Pacific). After a 15 min of rest, they performed three repetitions,
sustained for 3s, of maximal isometric voluntary contraction (MIVC) of
the neck in flexion and extension. Surface electromyography of
sternocleidomastoid, anterior scalene, splenius capitis and upper
trapezius muscles were acquired using a Trigno TM Wireless System
(Delsys Inc). Sensors were positioned by a blind examiner after proper
skin cleaning according to standard recommendations. Raw signal was
filtered (4dB; band pass 20-500Hz) and Root Mean Square (RMS) was
calculated by a customized MATLAB code. Muscles activity during sub-
maximal task was normalized by the RMS of MIVC and; antagonist ac-
tivity was normalized by its own activity while acting as agonist during
MIVC. Groups were compared using ANOVA with Bonferroni’s test as
post hoc by the SPPS version 20.0 adopting a significance level of 0.05.
Results: In the low load task, chronic migraine group demonstrated
greater activity of upper trapezius in all stages of the craniocervical
flexion test and greater activity of splenius capitis in the last two
stages compared to control (p<0.001) (Fig. 1). No differences couldbe observed between migraine and control groups not even among
three groups regarding superficial flexors activity (Fig. 1). Extensors
activities of both migraine groups were significant higher than
controls during MIVC in flexion (p=0.03), but no differences were
observed among groups during MIVC in extension (Fig. 2).
Conclusion: Migraine is associated with higher activity of neck
extensor muscles during maximal tasks. However, for low load tasks,
this pattern of hyperactivity of neck extensor can be observed only
in chronic migraine group.P155
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Background: Migraine is a disabling condition affecting quality of life
and social relations worldwide. To date few studies have focused on
the occurrence and possible role of sexual dysfunction in migraine
patients quality of life [1,2]. Attachment behaviour is supposed to
influence psychological and physical well-being, coping, illness be-
haviour and social functioning [2].
Objectives: This study was conducted to investigate the association
among sexual dysfunction, psychological factors, attachment style
and quality of life, in a sample of migraine patients.
Patients and Methods: 70 adult migraine outpatients (14 males; 56
females, mean age 39,56±12,55) consecutively referred to Headache
Centre, were recruited and submitted to: a) the International Index of
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Index (FSFI) for female patients, c) 36-Item Short Form Health Survey
(SF-36), d) Symptom Check List 90 Response (SCL-90R), e) Attachment
Style Questionnaire (ASQ).
Results: FSFI- IIEF Sexual dysfunction was found in 54,30% of the whole
sample (males: 42,85% vs females: 57,14%, p=0,38), without difference
according to age, marital status, job and migraine type (with or without
aura). Sexual Dysfunction was observed more frequently in chronic
migraine patients than in episodic ones (73,07% vs 40,62%, p=0.02).
Migraine patients with sexual dysfunction showed significantly
lower scores in SF-36 Mental Component Summary (41,52+10,88
vs47,12+9,41, p=0,02) and in ASQ Confidence subscale (31,39+8,15
vs 35,87±5,55, p=0,01). No difference was found between patients
with and without Sexual dysfunction both in SCL-90R Anxiety
(57,93±12,26 vs 51,69+14,37, p=0,07) and Depression (53,93±15,80
vs 46,79+12,71, p=0,08) subscales scores.
A positive bivariate correlation was observed in the whole sample
between SF-36 Mental Component Summary and ASQ Confidence
subscale(r=0,37, p=0,001) whereas a negative correlation was found
between SF-36 Mental Component Summary and both ASQ sub-
scales: Discomfort with Closeness (r=-0,23, p=0,04), and Preoccupa-
tion with relationships (r=-0,37,p=0.001).
Conclusions: This study supports the role of Sexual dysfunction as an
independent factor than anxiety and depression in migraine related
quality of life. Migraine patients with insecure attachment both with
and without sexual dysfunction showed worse quality of life. Future
longitudinal studies including larger populations are requested to
confirm these results.
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Background Migraine and hypothyroidism (HT) are frequent disorders.
Migraine occurs in about 15% of the general population, while the
prevalence of HT varies between 0.2 and 2.0% [1]. Both conditions are
more common in women and are associated with significant
comorbidities.
Materials and methods We retrospectively evaluated the clinical
records of 4,583 patients with primary headaches referred to our
Headache Centre from 2006 to 2016. We studied the prevalence of
HT in the different groups of headache sufferers.
Results The population consisted of 2,640 patients with migraine
without aura (MO), 303 with migraine with aura (MA), 235 with MO +
MA, 207 with chronic migraine, 566 with tension-type headache (TTH),
388 with MO + TTH, 155 with cluster headache, and 89 with other pri-
mary headaches. Overall, 192 cases (185 females and 7 males) with HT
requiring hormone therapy were observed. Of these cases, 166 (5
males) were migraineurs and 25 suffered from TTH (2 males). The
prevalence of HT was 5.4% in migraine women, while it was 0.6% in
men. The onset of migraine occurred prior to HT in 97.5% of women,
whereas in TTH group HT preceded the headache in 78.2% of female
patients. The mean age of migraine onset was 23.9 ± 8.5 in womenand 25.6 ± 10.8 in men, whereas the mean age of HT onset was 36.2 ±
10.1 in women and 36.2 ± 9.7 in men.
Conclusions In this study HT was found in a significant proportion of
migraineurs, particularly in women. Our results are consistent with
past clinic-based studies demonstrating migraine and HT to be co-
morbid conditions [2]. In migraineurs the headache onset occurred
before the appearance of HT in almost all cases (97.5%), whereas in
patients with TTH an opposite trend was noted, HT occurring prior to
headache in 78.2% of cases. In a recent cohort study, patients with
pre-existing migraine showed a 41% increased risk of developing
new onset HT, thus suggesting migraine to be a possible risk factor
for this endocrinopathy [3]. A plausible proposed mechanism to ex-
plain the association between migraine and HT include alterations in
the immune system, predisposing to thyroid autoimmunity. Auto-
immune diseases are well known to be more common in women.
The two disorders may share genetic, environmental and hormonal
factors, which can explain why this association occurs almost exclu-
sively in women. These represent interesting results that will require
to be confirmed in future epidemiologic studies.
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Fig. 1 (abstract P157). Forest plots of the meta-analyses
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According to current literature, both migraine and hormonal
contraceptive (HC) use are risk factors for ischemic stroke (IS). HC use and
migraine likely interact in increasing the risk of IS in young women;
however, studies assessing that interaction have heterogeneous designs.
We aimed to perform a pooled analysis of the available data regarding
the association among migraine, IS, and HC use.
Materials and methods
A systematic literature search was conducted to identify key papers
addressing the association between migraine and IS in women using
HC. The reference lists and Google Scholar citations of the selected
articles were also screened. Unadjusted data were pooled by means
of a meta-analysis of binary outcome data with a random effects
model.
Results
The systematic review of the literature identified 12 studies, among
which 6 were excluded ( not reporting the number of subjects in the
subgroups), while 6 (4 case-control and 2 cohort studies) were in-
cluded in the analysis of binary outcome data [1-6]. When consider-
ing female patients with IS, migraine and HC use were not
associated in cohort or in case-control studies (overall odds ratio [OR]
1.25; 95% confidence interval [CI], 0.74-2.10; P=0.40 (Fig. 1). When
considering women using HC, migraine and IS were not associated in
case-control studies (OR 1.65; 95% CI, 0.94-2.90; P=0.08), while when
considering women with migraine, HC use and IS were associated
(OR 1.82; 95% CI, 1.34-2.47; P<0.001) (Fig. 1). The combination of mi-
graine and HC use was strongly associated with IS in case-control
studies (OR 3.02; 95% CI, 2.01-4.54; P<0.001).
Conclusions
Our findings suggest that the combination between HC use and
migraine contributes to increase the risk of IS in women. Notably, our
results are from unadjusted analyses and do not take into account
potential confounders, including cardiovascular risk factors. Further
studies are needed; 1) to formally assess the interaction between HC
use and migraine in the risk of IS in women; 2) to ascertain the role of
cardiovascular risk factors in the IS risk of women with migraine using
HC; 3) to clarify whether migraine with aura and migraine without aura
carry the same risk of IS in women using HC; 4) to determine whether
some formulation of HC are safer than others in women with migraine.
More robust data will help better to improve decision making in HC
use among women with migraine.
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Background
Many comorbidities associated with migraine have a higher relative
frequency in chronic migraine (CM) than episodic migraine (EM). The
objective of this study was to replicate and extend work on
comorbid medical conditions in a systematically recruited sample of
people with migraine.
Materials and Methods
Data from the prospective web-based baseline survey of the Chronic
Migraine Epidemiology and Outcomes (CaMEO) Study were used to
identify people, recruited from an online panel using quota sampling,
with EM and CM based on criteria modified from the International
Classification of Headache Disorders, third edition, beta version. Par-
ticipants completed a Comorbidities/Endophenotypes module that
assessed 64 symptoms and conditions. Respondents were asked (1) if
they ever had a specific symptom (“Self-Reported [SR]”) and, if
present, (2) if the SR symptom or condition had been confirmed/di-
agnosed by a “doctor” (“SR-physician diagnosis [SR-PD]”). Chi-square
analysis was used to compare the proportion of people with each
symptom or condition among respondents with EM vs. CM. This re-
port presents data on the Respiratory, Sleep Disorder, Cardiovascular,
and Gastrointestinal comorbidity categories.
Results
Available CaMEO respondents with migraine (16,763) were sent the
Comorbidities/Endophenotype module and 12,810 (76.4%) provided
valid responses: 11,699 with EM; 1,111 with CM. Compared with the EM
group, the CM group had a similar mean age (EM, 41.3 years; CM, 41.9
years), was more likely to be female (EM, 74.2%; CM, 81.5%; P<0.001)
and white (EM, 84.0%; CM, 88.7%; P<0.001), and had a mean higher
body mass index (EM, 27.7 kg/m2; CM, 28.7 kg/m2; P<0.001). The
relative frequencies were significantly higher for 29 (93.5%) of the 31
SR symptoms and SR-PD conditions assessed. Conditions or groups of
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 101 of 151conditions with relative frequencies >10% higher in CM than EM in-
cluded allergies/hay fever/allergic rhinitis (EM, 37.4%; CM, 51.0%), sinus-
itis/sinus infection (EM, 47.3%; CM, 58.8%), insomnia (EM, 35.6%; CM,
50.2%), vertigo/dizziness/balance problems (EM, 17.8%; CM, 29.7%),
and gastroesophageal reflux disease (EM, 14.3%; CM, 24.4%; Fig. 1).
Conclusions
Overall, significantly more respondents with CM vs. EM reported
medical comorbidities. Mechanisms explaining this association might
include manifestations of migraine, direct causality (e.g., CM causes
the comorbidity), reverse causality (e.g., the condition increases the
risk of CM), and shared genetic or environmental risk factors.
Confounding or detection bias (i.e., “Berkson’s Bias”) could also
contribute. Future analyses will address naturally occurring
subgroups (taxa) defined by migraine phenotypes and comorbidities
and assess the relationships of these groups to external validators
such as treatment response and clinical course.
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Background: Migraine is a neurobiological disabling disorder with an
estimated prevalence of 11% to 16% worldwide.
Methods: 50 CM patients, diagnosed according to the International
Headache Society criteria (ICHD-IIIβ), were recruited. Subjects in
intervention group (n=21) received 2 capsules of multispecies probiotic
product Bio-kult-protexin daily, while patients in control group (n=18)
took 2 placebo capsules daily for 8 weeks. Due to ethical considerations,
participants were advised to continue their previous medications withoutchanges during the study. Also they were asked not to change their diet-
ary and exercise habitats during the intervention. A 30-day headache
diary was given to patients to report the migraine characteristics includ-
ing the intensity of headaches, the number of headache days, duration
of each headache episodes and the number of abortive drugs that they
have taken. In order to assess the disability, the Migraine Disability As-
sessment Scale (MIDAS) questionnaire was applied. Serum levels of CRP
and TNF-alfa of patients were also measured. Data analysis performed
using SPSS 19.
Results: After the intervention, the number of abortive drugs
significantly reduced in probiotic group compared with baseline (-1.029
±0.93, P value ≤0.000). Probiotic supplementation also significantly
decreased the frequency of headache days per month (- 9.67±6.69, P
value ≤0.000). The migraine severity (VAS) and attacks duration also
significantly reduced with mean ±SD of changes of -2.69± 2.19 and
-0.59± 1.19; for each variable respectively; P value ≤0.034). In addition,
the MIDAS score showed a significant reduction in probiotic
supplemented subject’ disability compared to baseline (-1±1.1; P value
≤0.000). However, no significant differences were found between the
groups in CRP and TNF-alfa serum concentrations. Although there was
a slight increase in serum CRP levels in probiotic group compare with
baseline.
Conclusion: The results indicate that multispecies probiotic
supplementation lead to decrease the number of abortive drugs,
headache days and severity of headaches and it may also improve
MIDAS score. However, more clinical trials with longer durations are
needed to confirm these results and to show the effects of
probiotic on inflammatory markers in patients with CM.
Keywords: chronic migraine headache, probiotic, MIDAS, abortive
drugs, frequency of headache days.
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Background
A capsaicin treatment is known to reduce by 60%-70% CGRP-LI in
nerve endings included in rodents [1-2] and to block transient vanil-
loid receptors (TVR)-1 (capsaicin) receptor [3]. We previously evi-
denced a tachykinins increased release at trigeminal nerve endings
during both cluster and migraine attacks [4]. Nonetheless, tachyki-
nins’ release seems not pivotal in promoting vegetative or painful
symptoms of cluster headache attack [5]. Zingember, active at vanil-
loid receptors [6], was matched versus capsaicin, since the zingember
is suggested, but not proved to be a pain medication [7]. Compari-
son was aimed to debate whether capsicum-induced headache relief
was completely related to capsaicin-induced tachykinins exhaustion
and TVR-1 block.
Material and methods
Since capsaicin low concentration has been indicated as not useful
when treating pain [8], we used an emulsion with a 7% capsaicin
content or zingember essential oil (Ternelli Laboratory). Observation
-April 2016- March 2017. Entry criteria: Diagnosis of chronic migraine
(IHCD III b), exemption from other diseases. Drugs:100 μl pure
zingember or 100 μl emulsion 7% capsaicin were administered into the
right nostril by using 1 ml graduated pipette. Observation 1 consisted
in test-retest acutely performed during headache attacks of chronic mi-
graine sufferers (n= 48, 20 males, mean age 31.8 ± 2.9SD). Observation
2: Enrolled subjects (n=168) were randomly allocated to zingember –
Group A (n= 99, 38males, mean age 31.9 ± 3.6SD) or capsaicin -Group
B (n=89, 49 males, mean age 32.2 S ± 7.9SD.
Results
In Observation 1, capsaicin induced a pain decrease mean -72,3 ± 4.8
SD versus -28.4 ± 3.1SD zingember (p>0.005). Observation 2: A 30-
days capsaicin treatment resulted in a pain relief –67.1 ± 6.3SD hours
with pain. Zingember treatment did not decrease hours with pain.
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treated mucosa, transient local pain. Three patients dropped out be-
cause of these side-effects. Zingember had similar adverse-effects
but milder (p>0.05) than capsaicin.
Conclusions
A 30 days capsaicin treatment as well as a capsaicin acute treatment
induced a pain relief significantly higher (p >0.0001) than zingember.
Zingember also induced lower side effects regarding itching and
redness- i.e. it seemingly exerts a lower (p>0.05) thermal stimulus. All
together, these results seemingly indicate that, at the given doses,
capsaicin, but not zingember may acutely induce counter-irritation
and TVR-1 refractoriness in the time.
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Background: Headache is a common complaint among children. The
most common primary headache syndromes in childhood are
migraine and TTH. However many times they seem to overlap. The
purpose of our study was to assess the relationship between
pediatric migraine, tension-type headache (TTH) and learning
disabilities
Methods: Children presenting with headache to three pediatric
neurology clinics in the last 5 years were assessed. 262 children, 5-18
years of age, who met the criteria for migraine were included.
Results: Of 262 children (54% female) who had migraine, 26.2%
had migraine with aura. 59 children (22.5% of the full sample)
reported also having headaches that met the criteria for episodic
TTH /mixed headaches. Females were more than 2.8 times more
likely to experience mixed headaches than males (OR: 2.81, 95% CI:
1.43-5.54; p<.003). Multiple logistic regression analysis revealed
that older age (p<0.02), family history of aura (p<.02), and (lack of)
TTH (p<.003) were significant predictors of aura, whereas genderwas not significant (p>0.20). Children who had migraine with aura
were less likely to have mixed headaches than children who did
not have aura (OR: 0.26, 95% CI: 0.11-0.63; p<.003). Children with
mixed headaches were 2.7 times more likely to have a learning
disability than children with migraine alone.
Conclusions: Episodic TTH and migraine without aura (mixed
headaches) in children might be part of a continuum, which can
explain the high incidence of their co-occurrence as opposed to mi-
graine with aura. Children with mixed headaches have a higher inci-
dence of learning disability compare to those with migraine alone.
SISC POSTER PRESENTATIONS
P162
Clinical features of headache attributed to Idiopathic intracranial
hypertension: results from a prospective study
Domenico Cassano1, Vincenzo Pizza2, Vincenzo Busillo3
1Headache Centre, Distretto N. 60, Via S. Giordano, 7 – 84014 Nocera Inf.
(SA); 2Headache Centre, S. Luca Hospital, Vallo della Lucania, ASL Salerno;
3Headache Centre, Maria SS. Addolorata Hospital, Eboli, ASL Salerno
Correspondence: Domenico Cassano (081-5157425,
info@domenicocassano.it)
The Journal of Headache and Pain 2017, 18(Suppl 1):P162
Introduction
Headache is the most common presenting symptom (over 90% of cases)
reported in Idiopathic intracranial hypertension (IIH), a challenging
disorder characterized by increased intracranial pressure (ICP) in the
absence of identifiable cause. Recent advances in neuroimaging are
providing valuable insights into its etio-pathogenesis.
Material and Methods
Aim of this study is to describe the clinical features of headache related
to IIH in a sample of 16 patients (13 women and 3 men) aged from 22
to 48 years with a mean of 31 years at diagnosis.
The management included general physical examination (with
evaluation of body mass index), neurologic examination (with
assessment of cognitive functions), study of the visual field,
endocrinology visit and techniques of neuroimaging - CT scan of
the brain, combined MR imaging with angiography (MRA) and
magnetic resonance venography (MRV).
Clinical features of headache are referred to the starting period of
observation (lasting 1-2 months). Data were recorded on headache
diary. Follow-up was performed every month for a long-lasting period
(at least 1 year).
Results
In more than 60% of cases, the headache is described as unilateral
with focal pain, rather than generalized; 50% reported as retrobulbar
and 22% referred worsening pain with extraocular movements.
In 85% the quality of pain is throbbing, exacerbated by coughing,
straining and physical activity. Typical and very common is pulsing
tinnitus, a symptom not often reported by the patients but to be
specifically investigated. 78 % evaluated their headache as the most
preeminent symptom. 75% reported headache as the initial symptom
related to their diagnosis.
70% reported daily or nearly daily symptoms usually costant; 85%
reported the pain gradually increasing in intensity.
In 80% headache lasted tipically > 1 hour. In 50% headache features
are similar to migraine con nausea-vomiting, photophobia and pho-
nophobia. In addition, patients may report associated neck stiffness
and shoulder or arm pain (due to the dilatation of spinal nerve root
sleeves).
Conclusions
This study about modalities of presentation of headache secondary
to IIH, even if referred to a small sample of patients, consents to
underline the lack of specific features, with the most common
phenotypes represented by chronic tension type headache, chronic
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 103 of 151migraine and chronic daily headache. A phenotypic classification is
useful in the management especially to comparing pre- to post-
treatment headache.
Keywords: Idiopathic intracranial hypertension (IIH), headache related
to IIH
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Safranal is an aromatic compound contained in high quantities in the
Crocus sativus (saffron). Safranal exhibits a series of biological responses
including, antioxidant, antinociceptive, and antiinflammatory properties
that possibly are responsible for its therapeutic effects reported by
traditional medicine. Here, we investigated the hypothesis that safranal
could act, at least in part, by targeting transient receptor potential
channels expressed by primary sensory neurons, thus limiting pain and
neurogenic inflammation. Calcium imaging, electrophysiology (both in
HEK293 cells and trigeminal neurons), organ bath studies/rat urinary
bladder and CGRP release experiments were performed in vitro.
Behavioral tests, acute nociception, and mechanical (von Frey) and cold
(acetone test) allodynia were performed in mice.
Calcium imaging and electrophysiology experiments showed that,
among the different TRPs expressed in peptidergic nociceptors,
safranal stimulated the ankyrin 1 subtype (TRPA1), but not the
vanilloid 1 and 4 (TRPV1 and TRPV4, respectively) subtypes. In the rat
urinary bladder strips safranal evoked a TRPA1- and neurogenic
inflammation-dependent moderate contraction that indicated partial
agonism. Safranal evoked release of CGRP from rat dorsal spinal cord
slices. However, after exposure to safranal the ability of TRPA1 ago-
nists to evoke CGRP release underwent desensitization. Safranl
evoked acute nociception and mechanical and cold allodynia, all ef-
fects that were attenuated in TRPA1 deleted mice or after TRPA1 an-
tagonism. After exposure to safranal TRPA1 pain-like responses were
attenuated, indicating desensitization.
Although safranal is a TRPA1 agonist, its action is weak and its
behavior resembles that of a partial agonist that, depending from
the specific circumstances, reduces channel activity by an antagonist
or desensitizing action. Recently we have reported that two anti-
migraine compounds, parthenolide [1] and isopetasin [2], are TRPA1
partial agonists and desensitizing agents. Here, we propose that the
alimentary use of saffron, because of the antagonistic and desensitiz-
ing actions on TRPA1 of safranal may be of help in migraine.
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Background and aims
Our aim was to investigate the differences in clinical features and
widespread pressure pain sensitivity according to the use of
symptomatic medication in tension type headache (TTH).
Methods
Individuals with TTH diagnosed according to the International
Classification of Headache Disorders (ICHD-III) criteria participated.
Exclusion criteria included other primary headaches, medication
overuse headache, whiplash, fibromyalgia or any neurological disorder.
A 1-month headache diary was used to collect clinical data and symp-
tomatic medication. Pressure pain thresholds (PPT) were assessed over
the temporalis muscle, C5-C6 zygapophyseal joint, second metacarpal,
and tibialis anterior muscle.
Results
One hundred and sixty eight patients (72% women, age: 45±14
years; headache frequency: 14±8 days/month; headache intensity:
5.7±1.3; headache duration: 6.1±3.2 hours) participated. One
hundred and thirty-six (80%) reported use of symptomatic medica-
tion for headache (73% NSAIDs); 58 (43%) took the medication at
the beginning of headache whereas 78 (57%) took the medication
when the headache intensity was intense. No differences in clinical
features and widespread pressure pain sensitivity was observed de-
pending on the use of medication intake (all, P>0.157). However,
patients taking the symptomatic medication when the headache
was intense exhibited lower PPTs than those taking the medication
at the beginning of the attack (all, P<0.05).
Conclusions
This study found that the use of symptomatic medication intake was
not related to clinical and widespread pressure pain sensitivity in
TTH, but it seems that consuming symptomatic medication at the
beginning of the headache could be related to lower widespread
pressure pain sensitivity.
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Background
Recurrent painful ophthalmoplegic neuropathy (RPON) represents a
condition, characterized by recurring headaches and palsy of the
third, fourth or sixth cranial nerves [1].
The etiopathogenesis of this disease is still unrevealed and some
authors propose a migraine-based mechanism while others support
its neuropathic nature [2,3]. Here we report a case of RPON without
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 104 of 151migraine-like features, with negative neuroimaging and inflammatory
characteristics evidenced with cerebrospinal fluid (CSF).
Case report
A 55-year-old man came to our department with headache and dip-
lopia. Pain started two days earlier and was initially referred to the
left fronto-orbital region, described as stabbing with severe intensity.
In two days, pain became moderate, pressure-like and holocranial
with diplopia in all gaze directions and ptosis of the left eye. The pa-
tient described a similar episode 4 months before on the right side
with complete remission in 3 weeks, without therapy. He had no his-
tory of migraine and never suffered of headache with similar charac-
teristics. He also had no history of diabetes. On examination we
found a left third nerve palsy without pupil asymmetry, an incom-
plete ptosis and inability to adduct or lower his left eye. Diplopia was
found in all gaze directions. The rest of the neurologic exam was
normal.
Two brain magnetic resonance imaging (MRI) with contrast, few
days after the episodes of ophthalmoplegia, were normal, even
focusing specifically on the orbital region and studying both
arterial and venous circulation. Cerebrospinal fluid (CSF) analysis
performed after the second episode showed slight damage of the
blood brain barrier (BBB) with elevated albumin ratio (total proteins
59 mg/dl, albumin 30.9 mg/dl). Blood routine tests and other
investigations including autoimmune, sarcoidosis, tuberculosis and
venereal disease screens, viral genome on CSF, antiganglioside and
paraneoplastic antineuronal antibodies, HbA1c dosage and exams
for tumor screening were normal.
The International Classification of Headache Disorders 3 Beta (ICHD-
3Beta) criteria for the diagnosis of RPON were met [1]. He started
corticosteroid therapy with progressive remission of the symptoms.
Conclusion
Neuro-inflammatory pathogenesis of RPON is usually supported by
MRI finding of third cranial nerve post-contrast enhancement and/or
nerve thickening [4,5]. In our case, two MRI were negative so we sug-
gest CSF evidence of BBB damage as a supportive element of diag-
nosis that reinforces the hypothesis of RPON inflammatory nature,
even when unverified with advanced neuroimaging. Moreover, the
effective treatment with corticosteroids, together with the previously
enlisted exams, further validates the diagnosis of RPON.
Consent for publication
Consent was obtained from the patient for this abstract publication.
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Migrainous aura (MA) occurs with acute-onset of neurological symp-
toms ant it can be erroneously mistaken for an acute stroke (AS) [1].
A complete diagnostic workup in Emergency Department (ED) is im-
portant for differential diagnosis between MA and AS [2]. Perfusion
computed tomography (PCT) is a readily available tool and it may as-
sist the clinician in a prompt differential diagnosis of AS, considering
its high sensitivity and specificity and the low probability of false-
negatives [3,4]. Only four patients performed PCT during MA. In these
cases patients underwent PTC after 70-120 minutes from symptoms
onset. Two patients presented with aphasia [5, 6], one patient with
aphasia and right hemiparesis [7] and the last one with left hemipar-
esis [7], always followed by headache. Three patients suffered from
headache in the past. In all cases reduced CBF, normal CBV and in-
creased MTT were recorded in the left hemisphere and in the right
frontal lobe respectively. These findings were consistent with hypo-
perfusion. Focal neurological symptoms gradually resolved within 30
minutes-24 hours. No thrombolysis was given. Patient were dis-
charged with final diagnosis of migraine with aura.
Cases report
We report six cases accessed to ED for acute-onset of focal neuro-
logical symptoms, two patients had mild headache (Table 1). All pa-
tients had history of migraine in the past. Unenhanced CT, Angio-CT
of intra and extracranial vessels and PCT were performed 30-90 mi-
nutes after neurological symptoms onset. No acute lesions were
found and PCT showed normal perfusion pattern (Fig. 1). Neurologic
symptoms fully recovered within 2-10 hours. Only one patient met
criteria for thrombolysis. A control brain-CT scan, brain MRI, diagnos-
tic tests for cerebrovascular diseases were normal in all cases. Pa-
tients were discharged with diagnosis of migraine with aura,
probable sporadic hemiplegic migraine and probable first attack of
migraine with visual aura, according with ICHD-3 beta criteria.
Conclusions
Perfusion findings during MA are still controversial in literature. Four
cases of PCT performed during MA have been described and all
findings showed cerebral hypoperfusion. Otherwise we recorded six
patients in which PCT showed normal perfusion maps during MA.
These contrasting findings should be considered in the decision-
making process. We suggest that clinical history of migraine, rapid
improvement of symptoms and normal imaging results, in particular
PCT, may indicate a MA status. Our data suggest that PCT could be
useful in discriminating between MA and AS, avoiding unnecessary
reperfusion therapies.
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Table 1 (abstract P166). Patient Characteristics
Age Sex History
of
Migraine
Presenting
symptoms in
ED
Headache
at the
onset of
symptoms
NIHSS Time to
PCT after
symptoms
onset
Thrombolysis Symptoms
duration
1 22 M yes
(without
aura)
right
hemiparesis
and blurred
vision in the
right hemifield
yes 8 60
minutes
no 2 hours
2 26 F yes
(without
aura)
blurred vision
in the right
hemifield
no 2 60
minutes
no 2 hours
3 43 M yes
(with
aura)
left emipharesis yes 6 90
minutes
yes 10 hours
4 50 F yes
(without
aura)
left
hemiparesis,
dyrarthria and
left facial palsy
no 2 60
minutes
no 2 hours
5 81 F yes
(with
aura)
aphasia no 4 60
minutes
no 2 hours
6 91 F yes
(with
aura)
aphasia no 3 90
minutes
no 10 hours
Fig. 1 (abstract P166). Tomography computed perfusion during
migrainous aura
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Background
The coexistence of headache and neuropsychiatric disorders affects
not only health and quality of life, but also the behaviour and the
acquisition of knowledge. So far, only a few studies evaluated the
association between headache and neuropsychiatric disorders,
especially as regards specific learning disorders and cognitive
performance. On the contrary, the association between headaches
and sleep disorders, which have a high prevalence in the pediatric
population, has been deeply investigated.
Materials and methods
We analysed retrospectively 242 children (age range: 2 – 18 years)
with primary headache, seen between November 1st, 2015 and
November 30th, 2016 at the Regina Margherita Children’s Hospital
Headache Center of Turin, Italy. We collected personal and family
history, type and characteristics of headache and neuropsychiatricdisorders, the results of neuroimaging and blood tests. Statistical
significance was set at p<0.05.
Results
On the total of 242 children (mean age: 10.6 ± 2.71 years; 116 males
and 126 females), 152 (62.81%) had migraine (23 with aura), 24
(9.92%) had tension-type headache, 32 (13.22%) mixed headache
and 34 (14.05%) unclassified headache. The prevalence of children
with at least one neuropsychiatric disorder was 61.16%. Among 148
patients with neuropsychiatric disorders, 120 (81.08%) had at least
one sleep disorder, 14 (9.46%) a neuropsychiatric disorder without
any sleep disturbance and 14 (9.46%) reported both. The prevalence
of specific learning disorders was 6.61%, while the prevalence of
sleep disturbances was 55.37%. The percentage of patients with at
least one neuropsychiatric disorder was significantly higher in the
group of patients with migraine with aura: this applies to both
neuropsychiatric disorders considered as a whole (p 0.026) – in par-
ticular sleepwalking (p 0.0072) – and neuropsychiatric disorders,
sleep disturbances excluded (p 0.0029). In addition, a borderline as-
sociation (p 0.0678) between tension-type/mixed headache and spe-
cific learning disorders was found.
Conclusions
In this study we demonstrated that children with migraine with
aura significantly more probably have neuropsychiatric disorders in
general and sleepwalking in particular, while the association
between tension-type headache and specific learning disorders
needs to be confirmed on a wider population. A careful assessment
of neuropsychiatric disorders in children with headache is essential
for optimal control of headache itself. On the other hand, identify-
ing the association with specific neuropsychiatric disorders may be
useful for their earlier diagnosis and better control, both pharmaco-
logical and non-pharmacological.
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Background
The synergistic effects of TanacetumParthenium, GriffoniaSimpliciofila
and Magnesium (Aurastop ®) have been retrospectively analyzed. Until
now, the nutraceutical preparation have been given to adults with
migraine with aura as symptomatic treatment and as prophylactic
treatment in those with episodic migraine without aura, with several
benefits. In this study we prospectively evaluate the efficacy of
prophilactic administration of Aurastop ® in terms of reduction of
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 106 of 151intensity, duration, frequency and analgesics use in children with
episodic migraine without aura.
Materials and methods
In this open prospective study, we selected 21 children (age range: 6-
16 years) suffering from episodic migraine without aura for at least 6
months followed at the Headache Centre of the Regina Margherita
Children’s Hospital of Turin, Italy.The diagnosis of migraine without aura
was done on HIS criteria (ICH-III b) and the recruitment was voluntary.
Informed consent was obtained by the parents of the patients before
their inclusion. The study protocol has been approved by our Ethical
Committee. Clinical information about duration, intensity, frequency of
the episodes and need of analgesics (number of medication) has been
recorded for each patient on personal headache diary before the treat-
ment and three months later. In 6 cases the follow-up was stopped
after one month and in 3 cases after two months because of insuffi-
cient compliance.
Results
We report the descriptive analysis of our study. On the total of 21
patients (mean age: 12.38 ± 2.11 years; 4 males and 17 females), 7
(33.33%) showed a reduction in frequency and 4 (19.05%) in duration
of migraine episodes. A decrease in intensity was detected in 16
patients (76.19%). In 13 (61.90%) cases, lower use of analgesics was
reported. Only 3 patients (14.29%) didn’t obtain any benefit and in
reverse 2 children (9.52%) showed improvements in all the variables;
both of them had been under Aurastop® for at least three months.
Conclusions
Our observational study suggested that the treatment with
TanacethumPartenium, 5-Hydrossitriptophan (5-Http) and Magnesium
(Aurastop®) could represent an efficient prophylactic therapy also for chil-
dren with episodic migraine without aura. However, a large randomised
control trial should be designed to confirm the efficacy of this treatment.
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Background: Trigeminal autonomic Cephalalgias (TACs), including
SUNCT (short –lasting neuralgiform headache), SUNA(short-lasting
neuralgiform headache attacks with cranial autonomic symptoms), HC
(Hemicrania Continua), PH (Paroxysmal Hemicrania) and CH (Cluster
Headache); according to the International Classification of Headache
Disorders (third edition, beta version, ICHD-3 beta) are considered dif-
ferent disorders other than trigeminal neuralgia (TN) 1. However clinical
and terapheutic similarites let us suppose a possible physiopatology
overlap among TACs and NT.
Case Report: A 62 years-old male, with no familial history of headache,
came to our Headache Centre, describing daily episods of severe stab-
bing sharp pains, centred to retro-orbital and temporal right region
which had begun 2 months previously. Headache attacks were accom-
panied by ipsilateral lacrimation, ptosis, eyelid edema and conjunctival
injection, lasted between 15 seconds and one minute and occurred on
average 20-30 times daily. The pain could be triggered by touching theperiorbital or temple area and the others trigger points. The attacks oc-
curred mainly during the daytime, and were sometimes followed by an
achy feeling along the right side of the face. He performed a TC scan
and a MRI of the brain, which resulted normal and was treated with
corticosteroids without any benefit on the symptoms. His medical his-
tory was remarkable for shoulders periarthritis and renal colics. After
the assessment in our Centre, a diagnosis of SUNCT was performed;
however because of some atipical clinical features (for example trigger
points presence) Carbamazepina 400 mg/day was prescrived, with ex-
cellent response to therapy.
Conclusion: Interestingly, whereas Carbamazepina is the drug of
choice in TN therapy, it has been successfully used to treat this
SUNCT. Open label evidence, updated now, suggests only a partial
effect of Carbamazepina in patient with SUNCT, as the first
therapeutic choice is Lamotrigina or intravenous lidocaine 2,3. The
therapeutic and clinical similarities in SUNCT and NT suggest a
possible similar physiopatological mechanism. Some Authors have
described that lesions located in the medullary can cause
simultaneous SUNCT and TN in the same patient4,5. The proposed
physiopatological mechanism for SUNCT/SUNA is the activation of
the trigemino-autonomic reflex due to activation of posterior hypo-
thalamus which results in autonomic features, possibly produced
by the connection of posterior hypothalamus to trigeminal nucleus
caudalis. The exact mechanism and causes of this reflex arc are yet
not understood; but the available information at present time sug-
gests a close connection between SUNC/SUNA and TN, which could
be considered different manifestations of a single pathology6.
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Fig. 1 (abstract P170). See text for description.
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Ehlers–Danlos syndromes (EDS) are a heterogeneous group of heritable
connective tissue disorders mainly characterized by joint hypermobility,
skin hyperextensibility and tissue fragility. We observed that EDS
patients have a substantially stronger headache syndrome with respect
to normal migraineurs, regarding both headache frequency and its
characteristics [1].
Altered autoregulation in migraine with aura patients, possibly
secondary to impaired cerebrovascular autonomic control has been
demonstrated [2]. Because EDS patients may have a different
vascular connective tissue elasticity, we investigate by Transcranial
Doppler if EDS patients with migraine had the same vasoreactivity
than controls.
Materials and methods
We recruited EDS patients with migraine and sex and age matched
healthy controls.
Patients had to be in the interictal period and free from
vasoactive drugs. Cerebral vasoreactivity was evaluated with the
Breath-holding Index (BHI). Haemodynamic parameters have
been recorded in basal conditions and after hypercapnic stimu-
lus with a 2 MHz probe through acoustic temporal bones
windows.
Results
Twenty-one patients (mean age 32±12 years, F/M:17/4) affected
by EDS and migraine (9 without and 12 with aura) and twenty
healthy controls (mean age 37±6 years, F/M:15/5) have been
enrolled.
At rest, EDS migraine patients presented a significant higher mean
flow velocities (p<0.01) and a reduced pulsatility index (p<0.01) than
controls (Table 1).
After hypercapnia, vasomotor response (BHI) of EDS migraine
patients differ with respect to controls according to the presence or
not of aura and the presence of lateralized pain: BHI was lower in
those without aura (p<0.001) whereas it was higher in EDS with
migraine with aura and lateralized pain (p<0.001) (Fig. 1).
Conclusions
At rest, changes of TCD parameters are probably related to the
different vascular connective tissue elasticity, owed to connective
tissue disorder.
After hypercapnia, TCD variations are more suggestive for the
migraine features. Increased BHI in patients affected by aura and
pain with side predominance reflects alterations of intracranial vessel
tone already observed in migraine with aura [2].
In conclusion, in EDS migraine patients TCD study showed two
different responses, mainly reflecting the EDS disease at rest and the
migraine component during hypercapnia.
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and controls
EDS
(mean ±SD)
Controlli
(mean ±SD)
p-value
MFV at rest 73,42 ±16,21 60,54 ±11,73 < 0,01
Pi 0,76 ±0,15 0,9 ±0,15 < 0,01
Ri 0,54 ± 0,09 0,6 ±0,05 0,02
Bh MFV 94,76 ±21,1 79,36 ±13,56 < 0,01
BHI 1,22 ±0,44 1,19 ±0,17 0,707P171
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Background: BoNT-A effectiveness in chronic migraine (CM) with or
without medication overuse (MO) has been confirmed since 2010 [1].
Further observation have better defined the role of this prophylactic
agent [2] as well as the optimal doses and paradigms of injection [3].
Material and Methods: In the present study we analyzed data from
patients selected within a wider group of CM patients admitted to
BoNT-A treatment at the Headache Center-Varese University Hos-
pital–Italy, between Jan 2014 and Sept 2016. Besides diagnosis of
CM-MO, admission criteria included a follow-up of at least 12
months, reliable monthly records on headache diaries, adherence
to the follow-up schedule, disability and psychological assessment
(MIDAS, HIT-6, SDS) [3].
N. 60 CM-MO patients (F: 51/ M:9, mean age 42.5 ± 9.9) were consid-
ered for a preliminary descriptive analysis of the parameters related
to effectiveness: ≥ 30 % reduction of Headache days/Month (Hd)
and/or Medication intake/Month (Mi). Our case series was then di-
vided into two groups (G1 and G2) according to the different para-
digms of treatment administered: wide range of doses and number
of sites injected in the early series of patients (G1: 2014-15/N.30
cases) vs. standard dose and “follow- the- pain” paradigm of injection
in the most recently treated group (G2: 2016-17/N. 30 cases).
Statistical descriptive and analytical methods were used: T- test for
paired data, Chi–Square test and one-way ANOVA.
Results: Different percentages of response to BoNT-A treatment are
shown according to the items considered as measures of efficacy: Hd/
Mi /Hd +Mi (Fig. 1). The comparison between groups shows a signifi-
cant decrease of Hd and Mi in favour of the most recently treated
group (G2): p< 0.029 for Hd and Mi p< 0.053 for Mi (Fig. 2). In the G1
group the number of patients with lower compliance during follow-up
was significantly higher than in G2 group (p< 0.001). No significant dif-
ference in term of side effects was found. Patients showing a significant
decrease in Hd and Mi scored higher baseline values at HIT-6 scale ( p<
0.026); SDS score was also significantly more elevated ( p< 0.03) among
cases with lower adherence to the treatment protocol. Group compari-
son for SDS and HIT-6 was also significant (Fig. 3)
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 108 of 151Conclusions: BoNT-A for CM-MO shows sustained responses in 53 %
of patients: 10 % for Hd, 8% for Mi, 35% for Mi + Hd. The percentage
of responders increases trough the time with the growing accuracy
of patient’s management and optimal set-up of protocols.
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Background
Aim of the study was to assess the efficacy of Onabotulinumtoxin
Type-A (BoNT-A) in the long-term treatment of Chronic Migraine
(CM) with Medication Overuse (MO), and to verify if a preliminary
pharmacological program for controlled withdrawal program may in-
fluence the therapeutic response to this prophylactic agent (1-2).
Material and Methods
We analyzed N. 49 CM-MO patients (ICHD-III beta criteria), with chronic
headache and substained abuse from at least 3 yrs. Main efficacy vari-
ables included: headache days/month, medication intake/month,
MIDAS, HIT-6, SDS, FSS, HADS-A/D scores. All variables were assessed at
baseline and at 12 months, and analyzed by statistical descriptive and
analytical methods: Wilcoxon and T- test for paired data, Chi–square
test and one-way ANOVA. We divided our case series into two groups:
group A - N. 29/49 pts (59%) underwent a preliminary detoxification
(infusion of vitamin complex, glutatione and clordemetildiazepam: 0,25
mg for the first 3days, then gradually reduced until withdrawal in 5
days) before being treated with “follow the pain paradigma” (BoNT-A:
195 UI) every 12 weeks for up to12 months, based on PREEMPT trial ex-
perience; group B - N.20/49 pts (41%) were treated only with BoNT-A,
without any preliminary pharmacological wash-out.
CM-MO treatment was considered successful when the improvement,
obtained after BoNT-A - preceded or not by detoxification - resulted in
more than 30% decrease from baseline in the frequency of headache
days at the 12 month control.
Results
The two groups didn’t shown any significant difference in terms of
overuse patterns, baseline psychological, disability assessment and in
the frequency of side effects to injections. BoNT-A was effective in
improving clinical outcome in both groups without evidence of sig-
nificant differences in the clinical response between patients submit-
ted to detoxification followed by BoNT-A treatment (group A) and
subjects treated only with BoNT-A (group B).
In general, more than 55% of patients had a good clinical outcome:
HIT-6 and MIDAS score showed a statistically significant improve-
ment at 12 months, mean medications intake/month decreased sig-
nificantly (mean at T0:30±23 to n 18,9±21,5 at T1; p≤0,0001) and
frequency of headache days decreased from baseline (mean at
T0:22,5±5,9 at T0 to 13,8±8,5 at T1; p≤ 0,0001). About 28% of pts
were non responder.
The group comparison between responder and non responder to
BoNT-A showed significantly elevated SDS score (p≤ 0,05), more ele-
vated scores for anxiety (p≤0,1) and more stress factors (p≤0,01)
among non-responders.
Conclusion
Our data confirm that CM-MO pts are responsive BoNT-A showing an
early discontinuation of the overused medications without significant
differences between those submitted to a preliminary pharmaco-
logical detoxification program vs those simply advised about overuse
mechanisms and risks(3). These results support the role of a struc-
tured approach to CM-MO able to integrate the start of BoNT-A
prophylaxis with non-pharmacological interventions aimed to coun-
teract and prevent symptomatic drug overuse.
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Clinical evidence of beneficial action of petasin/isopetasin, major
constituents of butterbur [Petasites hybridus (L.) Gaertn.], in migraine
prevention has been obtained with a preparation that contains
standardised amounts (minimum 15%, corresponding to 7.5 mg) of the
compounds. Several hypotheses have been advanced to explain the
antimigraine action of petasin/isopetasin, However, none of these
actions seems to be relevant for migraine pathophysiology. Petasin and
its cross-conjugated isomer, isopetasin, contain electrophilic double
bonds and can potentially interact with bionucleophiles. TRPA1 belongs
to the larger family of the TRP channels and, together with the TRP
vanilloid 1 (TRPV1) and vanilloid 4 (TRPV4), is expressed by a subpopu-
lation of primary sensory neurons also characterised by their dual
function of signaling pain and releasing the neuropeptides substance P
(SP) and calcitonin gene-related peptide (CGRP), which mediate neuro-
genic inflammation.
The possible role of TRPA1 in migraine is supported by its co-
expression in the same nociceptor subpopulation with CGRP, the
neuropeptide that markedly contributes to migraine pain. Given
the role of electrophilic compounds for the paradoxical induction/
prevention of headache via modulation of the activity of the TRPA1
channel, we wondered if the butterbur sesquiterpenoids could tar-
get the channel.
Isopetasin produced facial rubbing that recapitulated the features of
the TRPA1 selective agonist, AITC, being abrogated by HC-030031,
and unaffected by TRPV1 and V4 selective antagonists. In addition,
systemic isopetasin administrations for 3 consecutive days reduced
rubbing responses to AITC, demonstrating desensitization of pepti-
dergic TRPA1 expressing neurons.. With more direct relevance for
headaches and migraine, we tested whether this would also affect
CGRP-mediated dilation of meningeal arteries, which we subse-
quently assessed in rats. After isopetasin administrations for 5 con-
secutive days, increases in blood flow produced by the TRPA1
agonist, acrolein, and the TRPV1 agonist, ethanol were reduced.
Present findings add the butterbur constituent, isopetasin, to the list
of TRPA1-tropic agents, which, like parthenolide, stimulate the chan-
nel, thereby causing defunctionalisation of peptidergic trigeminal
nerve terminals, and attenuating their ability to release CGRP and
signal pain. Successful treatment and prevention of migraine by tar-
geting of TRPA1 ion channels and the ensuing peptidergic sensory
neuron defunctionalisation by parthenolide and isopetasin, provides
a solid basis for future basic and translational-medical investigations
of TRPA1-tropic approaches for migraine.P174
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Backgroud
Nervus intermedius neuralgia (NIN), also called geniculate neuralgia, is
a rare cause of otalgia, more common in people over 65, characterized
by paroxysmal pain, lasting from seconds to minutes, localized to the
auditory canal and retro auricular area, that may radiate to temporal or
parieto-occipital regions during severe episodes [1].
Despite its unclear aetiology, a neurovascular compression (NVC) is one
of the most advocated causes of secondary NIN, leading to a
hypothetical demyelination at the root entry zone. There are anecdotal
reports of herpes zoster, schwannoma or Lyme disease involving
nervus intermedius [2].
Nervus intermedius is usually undetectable on MRI because of its
small diameter and course along with the vestibular and facial
nerves, but a NVC can be revealed as a vascular structure in contact
with brainstem and the aforementioned cranial nerves.
Case Report
A 77-year-old caucasian male was referred to our Neurology Clinic
because of episodes of deep left-ear pain, lasting from 4 months.
This paroxysm occurred several times a day, especially by night, fre-
quently triggered by cold air and chewing. The patient suffered also
from episodic migraine without aura, gastritis and he recently under-
went dental implantation. Different clinical and radiological evalua-
tions were performed, including an otolaryngologist and a
maxillofacial surgeon visit and an orthopantomography, all negative.
Our neurologic examination, performed in an asymptomatic period,
was normal, except for left-sided mild hearing loss. A 1.5 T MRI with
gadolinium, focused on posterior fossa and temporal bone, was nor-
mal, except for a nodular area of contrast enhancement at left gen-
iculate ganglion level, possible expression of blood-brain barrier
damage or demyelination.
The patient started gabapentin until a dose of 300 mg/bid, with a
complete resolution of symptoms in 1 month. A further MRI is planned
at 6 months in order to assess the neuroradiological evolution.
Conclusions
This case report suggests that NIN, although rare, should be considered
in the differential diagnosis of atypical facial pain disorders. To the best
of our knowledge this is the first case report that postulate a possible
demyelinating lesion of geniculate ganglion as causative of NIN.
The first-line therapy of NIN is pharmacological, as in more common
craniofacial neuralgias, including anticonvulsivants, such as carba-
mazepine, lamotrigine or gabapentin. A surgical approach is reserved
for refractory cases and consists in microvascular decompression or
neural and geniculate ganglion transaction (3).
Consent for publication: The authors declare that written informed
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Background
Migraine (M), particularly with a high frequency of attacks or chronic,
very often coexists with visceral pain of various origin, e.g., irritable
bowel syndrome (IBS), primary dysmenorrhea (Dys) or pelvic pain
from endometriosis (Endo) [1,2]. The clinical observation suggests
that visceral pain episodes in comorbid patients trigger/exacerbate
migraine symptoms but systematic studies are still lacking with this
respect. This study assessed the impact of visceral pain comorbidities
and their treatment on migraine symptoms and pain sensitivity in
somatic tissues of extracranial sites in patients with M+IBS, M+Dys
and M+Endo as compared to M-only patients, before and after spe-
cific therapy of the visceral comorbidity.
Materials and methods
Female patients [18-43 years] with high frequency episodic migraine
were examined, who presented concurrent: IBS [n.37], Dys [n.35] or
Endo [n.26] in comparison with Migraine-only patients [n.30]. They
underwent pain threshold measurement to pressure and electrical
stimulation of skin, subcutis and muscle in nonpainful extracranial areas
(trapezius, deltoid, quadriceps) in basal conditions. In comorbid patients
the sensory evaluation was repeated after treatment [6-month diet for
IBS (n.22), 6-month hormonal therapy for Dys (n.23), laser for Endo (n.
12)] or no treatment (n.15,12,14)] of the visceral pain syndromes; values
before and after treatment or no treatment were compared [3]. Mi-
graine symptoms [n. of monthly attacks, symptomatic drug consump-
tion] after visceral pain treatment, or no treatment, were compared
with those preceding treatment.
Results
In basal conditions all comorbid patients vs M-only patients presented
significantly higher migraine pain and somatic tissue hypersensitivity
(0.05<P<0.01). After visceral therapy there was a significant reduction
of number of monthly migraine attacks and relative symptomatic drug
consumption [0.05<P<0.01] and pain hypersensitivity [increased pain
thresholds in all tissues and body sites (P<0.03)]. No improvement oc-
curred in comorbid patients not undergoing visceral treatment.
Conclusions
Visceral pain significantly contributes to migraine pain, probably
through enhancement of the level of central hyperexcitability by the
visceral nociceptive input. Its specific and systematic treatment is
thus recommended in comorbid patients as a complementary step
towards optimal management of migraine.
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Four our Country Thermalism is an essential resource, available to
National Health System. The idea to use thermal facilities
indetoxification of chronic headache patients, who need to clean out
complex pharmacological interaction, by combined treatments leads
to the Projet “Tabula Rasa” launch. These patients need complex
therapeutic strategies directed to enzymatic normalization. The
Project consider an enzymatic nutritional supplements and drugs
withdrawal, under direct medical monitoring, during a period of two
weeks in thermal setting. The patients will continue at home the
treatment with biodynamic agents and will be addressed to follow-
up. The daily monitoring by Headache Specialist during the stay in
thermal setting will allow to establish tailored therapeutic stretegies.
The “Tabula Rasa” Project
After the initial visit to the patient, a 3-day period of 10 to 10 ml of
Citozym will be recommended for a total of 20 ml daily, which will
be taken from the fourth to the fourteenth day at a total dosage of
0.5 ml / kg of body weight to be taken in small sips of 500 ml of
water over the course of the day. On the basis of our pilot experi-
ences already at this stage, the gradual reduction of previously taken
medications will be possible, based on an evaluation (by Ad-hoc
Diary) of the Psychological-Behavioral Profile, with a general evalu-
ation by the Specialist and, necessary, with massotherapy sessions.
At the end of the “thermal” stay, patients will be asked to continue for
two months a protocol based on the use of 0.5 ml / kg / day of
Citozym, to which another biodynamic agent (Propulzym) will be
added to the dosage of 10 ml / day, mixed with Citozym aqueous
solution, and 10 ml in the morning of a third biodynamic agent
(Ergozym Plus) aimed at energy balance and necessary vitamin
supplementation. According to the basic design of CARE I protocol.
After the first months of home treatment, scheduled periodic checks
are planned, monitoring by the clinician / ambulatory / Reference
Center; oriented towards the progressive elimination of previous drugs
and the possible introduction of new ones.
The problem of the wash out of previous therapies represents a
potential obstacle to the establishment of rational therapeutic
strategies in chronic headache patients: with the help of new
biodynamic preparations, which can favorably alter the “enzyme
soil”, it is considered possible to exit the empirical operation and
set up rational therapeutic strategies.
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Background. Painful trigeminal neuropathy and “orofacial pain” due to
brain stem stroke have already been described[1,2,3]. We report a case
of pontine stroke presented as a migrainous attack with subsequent
onset of trigeminal sensory deficit.
Case report. A 74-year-old, migrainous woman (ICHD-III) [4] presented
with sudden onset of a severe right migraine attack with nausea,
phono and photophobia stopped after NSAIDs treatment. The attack
was followed by persistent hypoesthesia in the distribution of mascellar
and mandibular branch of ipsilateral trigeminal nerve. No cardiovascu-
lar risk factors were known in her medical history. Brain CT was normal.
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right blink reflex and mild right hypoacusia. Brain MRI highlighted a re-
cent ischemic lesion in right pons, corresponding to the trigeminal
entry root zone. We therefore started antiplatelet and statin treatment.
Routine blood tests, echocardiogram, Holter ECG monitoring were nor-
mal. Neck and transcranial doppler ultrasound detected mild bilateral
carotid stenosis and intracranial Angio-CT was normal. During the re-
covery the patient reported another right migrainous episode, resolved
with acetaminophen treatment, while right face hypoestesia showed
some initial improvement in following weeks.
Conclusions. Pons infarction is known to cause pseudo-peripheral tri-
geminal symptoms and to determine a post-stroke painful trigeminal
neuropathy[3]. Here we described a trigeminal sensory deficit due to
selective trigeminal root entry zone ischemic lesion onset after a mi-
graine attack.
Consent for publication: The authors declare that written informed
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Fig. 1 (abstract P177). Ischemic stroke of the right brachium pontis,
corresponding to the trigeminal root entry zone. a-b show high
signal on DWI sequence which is confirmed by ADC maps to
represent abnormal restricted diffusion. FLAIR sequence (c to f)
display marked hyperintensity at the right trigeminal nucleus and
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Migraine is very common in childhood, and it has been reported in
about 10% of school-age children. Unfortunately, there aren't inter-
national guidelines yet and pharmacological therapies differ in Europe
and USA. Therefore, a proper management relies on a multidisciplinary
approach, which could improve outcomes and patients quality of life,
especially in pediatric age. [1] We strongly believe that in every visit all
aspects of management should be addressed and reviewed.First of all, physicians must educate the patient and the family
regarding the physiology of headache and migraine, how to fulfill
the migraine's diary and what are the goals of chosen therapies. The
“red flags” for migraine must be particularly highlighted and
indications, on when and how a clinical evaluation is needed, must
be given.
Is very important to underline some aspects of lifestyle, such as the
importance of a balanced diet, a good sleep hygiene, the maintenance
of an ideal body weight, regular sports and no smoking and no
drinking alcohol (especially in adolescence).
Then physician must focus on the symptomatic therapies and the
correct use of analgesics, in particular the timely administration of age
and weight appropriate dose. Overuse and abuse of analgesics should
be avoided to prevent chronic headache. In childhood, paracetamol
and ibuprofen are drugs of choice. Triptans are approved over twelve
years of age and different triptans are available in different countries:
e.g. sumatriptan and zolmutriptan in Italy and almotriptan and
rizatriptan in USA.
Finally, preventive therapy should be discussed with all patients, even
though only patient with chronic headache could benefit from it. A real
challenge in pediatric age is when and how to start a preventive therapy
in children with frequent and debilitating episodes, since there isn't a
international consensus on the drug of choice (even on the superiority of
drug compared to placebo). Non pharmacological therapy, such as
integrators and vitamins (magnesium and tryptophan), is usually
recommended as first choise. Behavior therapy and biofeedback could
also be suggested, although there aren't complete data to support their
use, yet.
In our opinion the multidisciplinary approach plays an irreplaceable
role in the management of headache and migraine in childhood on
which physician should be properly educated.
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Background:
Medication-overuse headache (MOH) is one of the most common
chronic disorders characterized by headache occurring more than
15 days per month and by regular overuse of symptomatic
medications. Several studies suggested a causative role of the
mesocorticolimbic dopaminergic system in the development of
MOH [1]. Several areas of this network, as the ventral striatal medial
prefrontal circuit, are primarily associated with metacognitive
executive functions described as both the self-evaluation of cogni-
tive abilities and the subsequent achivement of self-directed behav-
iors. The aim of our study was to analyze the role of metacognitive
executive dysfunctions in the pathogenic mechanism that underlies
substance abuse in MOH.
Material & Methods:
Fifty-two patients were selected for the study: 30 patients [M/F=5/
25; age (mean±SD)=46.6±10.9 yrs] fulfilled the criteria for MOH and
22 [M/F=7/15; age=42.6±12.2 yrs] for episodic migraineurs (EM) [2].
Twenty-five healthy control (HC) were also included in the study.
All the subjects were recruited at the Headache Center of the De-
partment of Neuroscience in Turin (Italy). Metacognitive executive
functions were assessed using the metacognitive version of the
Wisconsin Card Sorting Test (M-WCST) [3] which differs from the
standard version for the presence of two requests: (I) the level of
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to gamble. Different metacognitive indexes were achieved: accur-
acy score (AS); free-choice improvement (FCI); global monitoring
(GM); monitoring resolution (MR); control sensitivity (CS) and mon-
etary gains (MG). Metacognitive aspects were compared between
groups using ANOVA test. All statistical analyses were performed
with SPSS (version 21.0).
Results:
Metacognitive examination of M-WCST showed that patients with
MOH present worse performances than HC in FCI (p=.033), GM
(p=.006), MG (p=.039) and CS (p<.001). Intriguingly we also found
statistically significant differences between MOH and EM in the same
metacognitive indices, as FCI (p=.024), GM (p=.003), MG (p=.025),
and CS (p<.001). No differences were found among groups either in
the AS or in the MR.
Conclusions:
Our data show that patients with MOH present the same self-
monitoring ability as HC and EM but worse performances in indices
that assess the patients’ ability to use a proper monitoring process
to guide an adequate behavior. In particular, our MOH patients
show low scores in CS, given by the correlation calculated across
all sorts between the level of confidence and the decision to bet. In
conclusion we speculate that a disadaptive coping behavior predis-
poses MOH patients to a relapse of chronic substance abuse. Add-
itional studies are needed to confirm our data.
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Prevalence of migraine in women is almost three times greater
than in men. This is true particularly in the childbearing age,
whereas the migraine prevalence tends to be similar in both
genders during the childhood and in the elderly patients. Although
the migraine disease is known to run in families, and it is thus
suggested to have a strong genetic predisposition, migraine attacks
are usually started by external/internal triggers, among which the
hormonal cycle plays a major role. Menstrual-related migraine
attacks are known to be longer and more severe than the ones oc-
curring during other phases of the hormonal cycle, and most
women report a worsening of their disease in the premenopausal
phase, when hormonal levels tend to be less stable, or during oral
contraceptive treatments, and a significant amelioration of their mi-
graine frequency and severity during pregnancy and in menopause.
This strict correlation between migraine and the hormonal cycle
represents usually a therapeutic challenge to the headache special-
ists, as most of the common pharmacological preventative and
symptomatic strategies are unsuccessful when applied to control
hormonal-related migraine attacks.P181
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Introduction - To date, the pharmacological treatment of migraine
remains somewhat unsatisfactory, partly because the pathophysiology
of this disabling disease is still poorly understood. Clinical and
experimental studies have pointed to the possible involvement of the
transient receptor potential ankyrin type-1 (TRPA1) channels in mi-
graine pain. To further investigate the role of TRPA1 in the mechanisms
of migraine pain in an animal model of migraine using a novel TRPA1
antagonist (ADM_12) as a probe.
Methods - The effects of ADM_12 on nitroglycerin-induced hyper-
algesia at the trigeminal level were investigated in male rats using
the quantification of nocifensive behavior in the orofacial formalin
test. The expression levels of the genes coding for c-Fos, TRPA1, cal-
citonin gene-related peptide (CGRP) and substance P (SP) in periph-
eral and central areas relevant for migraine pain were analyzed.
CGRP and SP protein immunoreactivity was also evaluated in nucleus
trigeminalis caudalis (NTC).
Results - The findings show that in the nitroglycerin-induced hyper-
algesic rats, ADM_12 has an anti-hyperalgesic effect in the second
phase of orofacial formalin test. This effect is associated to a significant
inhibition of nitroglycerin-induced increase in c-Fos, TRPA1 and neuro-
petides mRNA levels in medulla-pons, cervical spinal cord and in tri-
geminal ganglion. Whereas, no differences between groups were seen
as regards CGRP and SP protein expression at NTC level.
Conclusion – The present findings support a critical involvement of
TRPA1 channels in the pathophysiology of migraine, and show their
active role in counteracting hyperalgesia at the trigeminal level.
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Background: Calcitonin gene related peptide (CGRP) is a key
neuropeptide involved in the activation of the trigeminovascular
nociceptive system and it is likely implicated in migraine chronicization.
In the present study we investigated the role of CGRP in migraine
chronicization in an animal model that mimics the condition of chronic
migraine.
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administration of nitroglycerin (NTG). Male Sprague-Dawley rats were
injected with NTG (5mg/kg, i.p.) or vehicle, every two days over a 10-
day period (5 injections total). A group of animals was injected with
Topiramate (30mg/kg, i.p.) or vehicle every day for 9 days. Twenty-
four hours after the last administration of NTG or vehicle, animals
underwent a tail flick test for the evaluation of nociceptive threshold
and a Von Frey test, for the evaluation of orofacial mechanical allody-
nia. Rats were subsequently sacrificed and their medulla-pons region,
cervical spinal cord (C1-C2) and trigeminal ganglia were immediately
chopped into parts for the evaluation of c-Fos and CGRP gene ex-
pression by real-time polymerase chain reaction (RT-PCR).
Results: Chronic and intermittent NTG administration caused a
condition of hyperalgesia and orofacial allodynia, detected respectively
as a reduction in the latency of the tail flick test and as a reduction in
the threshold of mechanical sensitivity when compared either to
baseline values. NTG administration also induced a significant increase
in c-Fos and CGRP gene expression in the medulla-pons region, cervical
spinal cord and trigeminal ganglia. Topiramate treatment prevented
the development of NTG-induced pain hypersensitivity, allodynia and
alteration of gene expression in the above areas.
Conclusion: These findings describe the occurrence of neuronal
activation and CGRP synthesis in the trigeminal ganglia and in specific
areas of the CNS that are relevant for trigeminal pain processing in an
animal model of chronic migraine. The inhibitory effect of topiramate,
whose mechanisms of action involve blockade of voltage-dependent
sodium channels, potentiation of GABAergic transmission and inhib-
ition of glutamatergic transmission, points to an important role for
these mechanisms in CGRP mediated processes underlying pain chroni-
fication. From a translational clinic of view, these findings underline the
possibility and opportunity to pharmacologically intercept and prevent
migraine chronification.
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Patients with Medication Overuse Headache (MOH) show a complex
psychopathological profile characterized by high rate of mood and
anxiety disorders, obsessive–compulsive disorder and dependence [1, 2];
this profile assessment should be included in patients’ evaluation [3].
We arranged a set of questionnaires to assess psychological profile of
MOH patients followed by our Headache Centre. This set is composed
by Beck Depression Inventory II Edition (BDI-2), trait subtest of State-
Trait Anxiety Inventory (STAI-Y), Difficulties in Emotion Regulation Scale
(DERS), Barratt Impulsiveness Scale (BIS-11), Toronto Alexithymia Scale
(TAS-20).
Our aim was to correlate patients’ psychological profile both with
number of medications taken per month and degree of disability
measured by Headache Impact Test (HIT-6).
From November 2015 to July 2016 we recruited 22 patients (F=73%;
M=27%), mean age 46,5 +/- 12,5.
Patients showed a median of 24,5 days of headache per month (IQR
10) and a median of 30 medications taken per month (IQR 28,5),
without significant difference between men and women. Median
total HIT-6 score was 69 (IQR 9), higher in female (median 70, IQR 7;
males showed a median of 63,5, IQR 8; p=,040). The percentage of
MOH patients showing normal score on questionnaires was 38% for
BDI-2 (83% for males and only 20% for female, p=,005), 68% for
STAI-Y trait, 50% for TAS-20 and only 32% for DERS.We found a significant correlation between total HIT-6 score and de-
pression (BDI, p=,012) regulation of emotion (DERS, p=,014), trait anx-
iety (STAI-Y trait p=,012). We failed to find a correlation with
alexithymia (TAS-20, p=,22) and with impulsivity (BIS-11, p=,15). No cor-
relation was found between psychological questionnaires and medica-
tions taken per month.
Our results showed a high rate of depression and anxiety in MOH
patients; moreover, they seem unable to recognize/regulate their own
emotions: the analysis of subcomponents of DERS scale demonstrated
that, in response to a negative emotion, MOH patients have difficulties
in acceptance, concentration and maintaining control of their own
behavior. Patients with DERS pathological score present higher score of
impulsivity (BIS-11, p=0,08).
Conclusions: Assessing psychopathological profile in MOH patients is
mandatory. We confirmed the comorbidity with mood and anxiety
disorders in our group of patients suffering MOH. We showed that
DERS scale correlates with the degree of disability and is useful for
highlight specific maladaptive behaviors in MOH patients. We need a
larger number of patients to be assessed by our set of questionnaires
to confirm those preliminary results.
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Migraine is associated with a decrease in quality of life and a heavy
socioeconomic burden. In patients with migraine, education is essential
to improve the clinical conditions, to reduce the use/overuse of
analgesics and to increase adherence to both acute and preventive
medications .
Aims of effective patient education should be: strengthen the doctor-
patient relationship; improve medication adherence and reduce drop-
outs; encourage patient participation to decision making favouring a
joint responsibility approach; tailor personalized therapies.
We propose the following educational programme.
Pre-visit: ask to the patient to recall and note down relevant facts of
his/her medical history, the main features of headache, possible
triggering factors, treatments previously used and their efficacy.
During the visit: discuss the impact of headache on quality of life;
communicate adequately and thoroughly the diagnosis; investigate
patient expectations and needs; examine the possibilities and goals
of treatment; reach an agreement on therapeutic strategy; hand over
the headache diary and instruct the patient to fill it in; provide
educational brochures as educational tools, if available; schedule
follow-up visits.
Post-visit: recommend filling in the headache diary to monitor the
effectiveness or failure of prescribed treatment, the clinical course,
possible adverse effects, medication adherence, and use/overuse of
rescue drugs; supervise positive changes of lifestyle; encourage contact
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 114 of 151with the specialist at any change of clinical conditions; ensure
complete and prompt availability to any request of information; in case
of drug abuse, provide explanations on specific treatment and possible
hospitalization.
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Background: The trend in the prevalence of headaches shows an
increase over the past 10 years, with a gap between the primary
headaches underlying a significant increase chronic headaches. The
quality of life is compromised and 1% of school absences are due to
headache.[Tozzi et al, 2012]. The present study proposed to verify in
the childhood that is more present in adulthood literature
Materials and methods: The sample of 121 children was divided on
the basis of diagnosis of headache made according to ICHD-II and III
criteria. Patients were selected in to Abruzzo Regional Headache Cen-
ter,during 2015 and 2016 years. Investigated the following diseases:
Sleep Disorders such as Parasomnie and Insomnie, Learning and/or
School, Emotional and Neuropsychological Disorders. Used Tests:
Cornoldi AC-MT Test, SAFA Test, Leiter, Corsi, CBCL.
Results: In the sample, 91 patients(pt) are suffering from Chronic
Migraine(CM) (80%), 30 M and 61 F; 30 pt from Chronic Tension Type
Headache(CTT) (20% ), 17 M and 13 f. In all the sample the percentage
of sleep disorders is high : 57% of M and 63% of F with Migraine (CM),
56% of M and 71% of F with CTT. In M is greater the Bruxism as in M as
in F, but in CTT, as in M as in F, the insomnia prevails ( 30% of F with M
and 29% of F). The insomnia and the bruxism are factors of
chronification and aggravation of headache.We found the significant
correlation between headache and emotional disorders.In the M with
CM there are externalizing disorders (10%), 6% of CTT show both
internalizing and externalizing disorders, and 18% have externalizing
disorders. Through the SAFA scales relative to the psychic state
emerged that only groups with M have a psychopathological
disorder.Only 3% are positive in the Depression assessment (D) scale
and Psychogenic Disorder (P) scale, while 10% have only the risk of
these pathologies in the same scale (DP) and the scale for symptoms
obsessive compulsive (O). 5% of females has a risk in the scale of
psychogenic eating disorders and 3% is positive on the same scale. In
CCT 28% of children has a specific learning disorder; in Migraine
learning disorders are present in 6% of M and 8% of F.
Conclusions: The sample studied shows significantly comorbility with
Sleep Disorders. This relationship is controversial since Headache and
Sleep Disorders can be a single disease.
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Background: The majority of headache episodes of childhood are
benign and self-limiting, anyway they frequently cause multiple accesses
to the Pediatric Emergency Department (ED) [1-4]. The collaborationbetween the Pediatric Headache Centre (PHC) and the ED of our
hospital aims to limit such visits: according to the decision of the
ED pediatricians, the patients with primary headache and those
with repeated episodes of headache can be referred to the PHC
within few days. Therefore, we have analyzed the data about the
follow-up at our PHC and in particular the possible effect on re-
peated visits at the ED for headache, as there are very few studies
investigating such relation [3].
Methods: All the patients ≤18 years referred to the ED of the
Regina Margherita Children’s Hospital of Turin, Italy between
January 2011 and December 2015, reporting headache as main
symptom, were retrospectively reviewed. We screened the medical
record databases of our ED and also the one of our PHC for
information relative to those children who had been referred there
after discharge from the ED.
Results: During the study period, 1833 patients accessed ED 2086
times: 1659 had one single access, 139 had 2 visits, and 25 had
>2 visits; the median time between consecutive ED visits was 42
days (range 0-1433). On discharge, 646 patients (30.9%) received
the indication to refer to the PHC, and 259 of them (40.0%) actu-
ally did.
A total of 115 patients had repeated visits within 3 months since
the previous access, corresponding to 272 accesses (59.3% of
repeated visits); 90 of such visits occurred within 10 days with a
peak within 3 days. As regards the follow-up of the children who
had multiple ED accesses for headache, 32 patients who had re-
peated visits within 3 months received the indication to refer to
the PHC; 24 of them were actually followed-up, and only 1 of them
accessed the ED again because of headache after starting the
follow-up.
Discussion: Almost all the repeated visits within 3 months occurred
in patients who had not been referred to the PHC after the first
visit at our ED or in patients who received specific indication to
follow-up, but did not attend it. Such observation suggests that the
collaboration between the ED and the PHC is very important and
might play a role reducing the so-called “revolving doors”.
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Background
A migraine without aura is the most common type of migraine
headache ( about 60% to 80% of all migraines). In recent years there is
growing interest in the use of nutraceuticals for the prevention of
migraine, as there are no specific drugs for this indication. A new kudzu
based food supplement (Kuzik), thanks to its innovative mechanism of
action, has attracted our interest in this use.
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Between January and April 2017, 30 patients with migraine without
aura were treated with Kuzik, once a day for 2 months, recruited in
various neurological structures including university centers, general
hospitals, territorial structures and private outpatient clinic; for all
patients, the diary was completed and full fill the headache card (
IHS criteria). Patients were evaluated at baseline and after 2 months
regarding number of crisis, headache days and VAS (Visual Analogue
Scale ): data relative to efficacy and tolerability were collected.
Patient's characteristics: 25 female and 5 male; median age 34 (range
22-56 ); median years of disease 9,4 ( range 2-30 ) and previous treat-
ments 1,2 ( range 1-2). At the baseline average number of crisis was
4 (range 2-10), headache days 7,4 ( range 3-14) and medium VAS 7,1
(range 5-10) .
Results
Kuzik was well tolerated: in a numerical scale from 1 to 10 the average
score was 8 ( range 6 -10); the compliance of patients was optimal, no
side effect related to product were reported and no weight gain in
patients occurred. Regarding efficacy, at the end of treatment, all
parameters analyzed were significantly improved : average number of
crisis was 1,2 ( range 0-3 ), headache days 2 ( range 0-5 ) and medium
VAS 1,9 ( range 0-4 ) .
Conclusions
Our study has clearly demonstrated the benefits, safety, and good
tolerability of Kuzik in the prophylaxis of migraine without aura and the
use of this medication should be taken in consideration as a good
practice in this setting of patients. Data from our study are encouraging
to be confirmed by further investigations.
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Background and aim of the study
Dural arteriovenous fistulas (DAVFs) are intracranial vascular
malformations. Their low presentation rate[1] justifies the limited
availability of data about clinical features of these lesions.Aim of
the study is to show a 10-year single institution experience with di-
agnosed and/or treated DAVFs, analyzing their clinical presentation
and angiographic features, as well as their long-term outcome.
Materials and Methods
Looking for patients discharged from our Hospital in a 10-year period
with the diagnosis of a “cerebral-vascular system abnormality”, we
found 964 cases: 922 was excluded because they were vascular malfor-
mations of other subtype than DAVFs.Finally, we analyzed 42 intracra-
nial DAVFs.For each one, we collected data about demographic
characteristics, anamnesis and risk factors, clinical presentation, location
and other neuroimaging features, as well as treatment and outcome.
Results
We found 42 DAVFs in 40 patients aged between 25-89 years at the
time of the diagnosis. Twenty-one (52.5%) patients were women.
Dividing all 42 DAVFs according to the angiographic features [2], we
found 14 (33.3%) Carotid-Cavernous Fistulas (CCFs), 6 (14.3%) anter-
ior cranial fossa (ethmoidal) DAVFs, 1 (2.4%) superior petrosal sinus
DAVF, 18 (42.9%) transverse sigmoid junction DAVFs and 3 (7.1%) ten-
torial DAVFs.The most common complained symptom was headache(45.2%).Besides, a cerebellar/hearing/vestibular dysfunction was present
in 28.6% of cases, especially in other DAVFs different from CCFs, al-
though without a statistically significant difference between the two
subgroups.
Discussion and Conclusions
Headache is a common onset symptom of DAVF, usually described
as localized to the same site of the lesion, becoming generalized as
a result of the dural stretching [2].Therefore, IHS has drawn up the
classification criteria for the headache associated with DAVF [3].
Nevertheless, none of the previous studies on DAVFs have classified
headaches according to the IHS classification criteria [3]. In our
series of DAVFs, 45.2% of patients complained headache as a
presentation symptoms, without a significant difference among the
DAVFs subtype. Analyzing clinical features of headache, we found
that 12/19 (63.2%) of patients had migraine-like headache, looking
like a typical characteristic of other DAVFs different from CCFs
(p=0.036). On the other hand, 7/19 (36.8%) patients complained not
migraine-like headache, characteristics typical of CCFs (p=0.003).These
findings suggest a link between the neuroradiological site of the lesion
and the clinical features of the headache, symptom that led to
hospitalization. Our study confirmed the majority of literature data
about DAVFs, but it also provided significant insight about presentation
symptoms, in particular regarding the characteristics of headache,
which are suggestive of further dedicated studies.
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Object: we have analyzed headache during pregnancy, especially in
puerperium.
Content: In pregnant patient, headache is a symptom caused
frequently by primary forms but also by secondary forms [1]. During
puerperium, about 30-40% of women experience headache in the
first week after delivery; and the 5% of women feel headache for the
first time in the first month after delivery [2,3,]. We have found in lit-
erature many studies about the physiopathology and clinical effects
involved ,related and typical in the pregnant patient [4,5,6.7,8]. More
it would be studied and understood yet.
Methods: we examined international literature from 1997 since the
beginning of 2017, using Pubmed, Cochrane Library, EMBASE; we
found meta-analysis, case reports, prospective and retrospective
studies.
Conclusions: evaluation, knowledge and treatment of headache in
obstetrical population are very important in the course of care: it
would be multidisciplinary for the occurrence of comorbilities and to
avoid near miss, it would be useful having a protocol, in rare but
serious clinical situation.
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Background: migraine is a severely debilitating desease, causing
significant morbidity and negative impact on sufferers’ quality of life
(Bigal 2008). Botulinum toxin was shown to be effective in treatment
of chronic migraine (Kollowe, 2016)
Materials and methods: 24 patients, suffering from chronic
migraine as defined by ICHD-3 ß criteria, subjected to at least 3
botulinum toxin treatments, were enrolled in the period between
June 2015 and June 2017. All subjects were examinated at T0 and
every six months with the following scales: SF-36, for assessing the
perceived state of health, DISS, for the degree of disability and a
diary, where patients recorded the intensity and frequency of pain
and the number of days / month of migraine.
Results: the sample was mostly female (79.16%), had an average
age of 42.3 years (ds ± 5.86) and mean time since diagnosis with
CM was 10.5 years (ds ± 2,88). At T0 the sample had 13,6 days/
month with migraine and hight vaue of disability expecially in
work and family activities. SF-36 showed at T0 showed low value
in physical role, general health and vitality, with a higher level of
disability at DISS and average frequency of migraine episodes of
15.87 (ds ± 4.2) days per month. After 6 month we observed a re-
duction in the frequency and intensity of migraine, as well as an
improvement in the quality of life. Such improvement becomes
statistically significant to the 12-month evaluation in all the sub-
dimensions of SF-36 (p < 0,05). After the fourth treatment,
monthly headache days were reduced from 15.87 (ds ± 3.9) to
4.92 (ds ± 3.24) (p < 0.05), with statistically significant improve-
ment in DISS values (p < 0,05).
Conclusions: The results showed the efficacy of botulinum toxins for
the prevention of cronich migraine, with a improvement in quality of
life. Significant improvement in the scales was obtained after 12
months of treatment.
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Background. A growing body of literature has showed a relationship
between insecure “attachment style” and somatic symptoms. In a
recent study, we found an association between ambivalent
attachment style, migraine severity and psychological symptoms in
children/adolescents. There is evidence that caregivers’ attachment
styles and their way of management/expression of emotions can
influence children’s psychological profile and pain expression. To
date, data dealing with headache are scarce. We aimed to study the
role of maternal alexithymia and attachment style on their children’s
migraine severity (intensity and frequency) and psychological profile
(anxiety, depression, somatization and attachment style).
Materials and methods. We enrolled 84 consecutive patients suffering
from migraine without aura (female: 45, male: 39; age range 8-18
years; mean age 11.8 ± 2.4 years). Patients were divided into two
groups according to frequency of the migraine episodes (high or
low). According to headache attack intensity, patients were classi-
fied into two groups (mild and severe pain). Children’s psycho-
logical profile was assessed by SAFA Anxiety, Depression and
Somatization scales. Attachment style was measured by the semi-
projective test SAT for patients and ASQ questionnaire for mothers.
Maternal alexithymia levels were evaluated by TAS-20.
Results. We found a significant higher score in maternal alexithymia
levels in children classified as “ambivalent”, compared to those
classified as “avoiding” (Total scale: p= 0.011). Alexithymia levels
also correlated with children’s psychological profile. A positive
correlation has been identified between mothers’ TAS-20 Total
score and the children's SAFA-A Total Score (p=0.026). In particular,
positive correlations were found between maternal alexithymia and
children's “separation anxiety” subscale (p=0.009) and “school anx-
iety” (p=0.015). Maternal “externally oriented thinking” subscale
correlated with SAFA-A “school anxiety” subscale (p=0.050). More-
over, we found a correlation between TAS-20 Total score and SAFA-
D “Feeling of guilt” subscale (p=0.014). Our data did not show any
relationship between TAS-20 and ASQ questionnaires and children’s
migraine intensity and frequency.
Conclusions. Maternal alexithymia and attachment style have no
impact on children's migraine frequency and intensity. However, our
results suggest that, although maternal alexithymic traits don’t play a
causative role on children’s migraine severity, they show a relationship
with patients’ attachment style and psychological symptoms, which in
turn may impact on migraine severity.P192
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A number of studies recently reported an association between lower
vitamin D levels and the worsening of the symptoms of migraine.
This association has been explained with the reduced neurotrophicity
and the altered levels of CGRP, dopamine, noradrenaline and
adrenaline observed with lower vitamin D levels.
Moreover, the presence of vitamin D receptors (VDR) and of 1-
αhydroxylase (1a-OHase), the enzyme responsible for the formation of
the active vitamin, has been recently demonstrated in many areas of
the central nervous system[1].
As overviewed by Humble[2] et al., the vitamin D-endocrine system
acts within the central nervous system as a neurosteroid, mediating
multiple actions.
Study aim:
To evaluate the efficacy of vitamin D administration in mild migraine.
To evaluate the efficacy of a combined treatment with vitamin D
administration plus traditional therapy in moderate and severe migraine.
To evaluate the effect of vitamin D administration on the mood tone
in the study group.
Material and Methods:
45 patients aged 18-50 years and suffering from primary migraine
were enrolled in the study.
Patients were divided into three main subgroup:
Group 1: patients suffering from mild migraine (no more than 4 days
of disability per month and less than 5 attacks monthly). This group
was treated with vitamin D administration only.
Group 2: patients with moderate-severe migraine (more than 4 days
of disability per month or more than 5 attacks monthly). This group
was treated with traditional therapy only.
Group 3: patients with moderate-severe migraine, treated with the
combination of traditional therapy plus vitamin D administration.
Patients were followed for a period of nine months.
MIgraine symptomatology was monitored throughout the compilation
of a diary in which patients reported the number and the intensity
(using a Numeric Pain Rating scale ranging from 0 to 10) of the
migraine attacks during the month. These two values were then
combined in unified score, called intensity–weighted frequency
score (IwF).
Results:
In the group 1, treated with vitamin D administration only, a reduction
in migraine severity of 67% was observed at the end of the study.
The combined treatment (group 3) resulted 1,24 more effective in
reducing migraine severity than traditional therapy alone (group 2)
(Fig. 1).
The effect on the mood tone observed during the study was not
statistically significative.
Conclusion:
Currently, mild migraine is normally treated with once-a-need anti-
inflammatory drugs. In our study Vitamin D administration for the
treatment of mild migraine resulted effective, with a decrease in the
number of the attacks of 67%.
Study results did not support the hypothesis that vitamin D
supplementation has an effect on the mood tone.
Combined treatment with vitamin D plus traditional therapy
improved migraine symptoms of 69%, and this result suggests that
vitamin D administration may improve the efficacy of traditional
therapy alone for severe migraine (Fig. 2).
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Background
Idiopathic intracranial hypertension (IIH) or pseudotumor cerebri is a
syndrome characterized by signs and symptoms of increased
intracranial pressure in the absence of a secondary cause. The aim of
the study is to report the IIH clinical presentation in children and
adolescents presenting to our hospital during a 10-year period.
Materials and methods
Retrospective study, between January 2007 and January 2017, of IIH
patients, younger than 15 years, was conducted. Modified Dandy
criteria were used for IIH diagnosis. The patients were analysed
according to age (≤10 and 11-15 years).
Results
Thirty-four patients, ranging from 3.8 to 15 years, were included.
Thirteen patients were younger than 11 years (38.2%), while
twenty-one patients were 11-15 years old (61.7%). Twenty-nine pa-
tients (85.2%) were obese (weight centile ≥ 90%). Mean cerebro-
spinal fluid opening pressure was 422 mm H2O (260-890 mmH2O).
The most common presenting symptoms were headache (94.1%),
vomiting (29.4%), dizziness (11.76%), blurred vision or diplopia
(67.6%). Sixth nerve palsy occurred in 11 children (32.3%). In gen-
eral, headache did not respond to pain medication. All our patients
showed papilledema. Diagnostic evaluation included neuroimaging
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measurement. In 6 patients (15%), MRI or CT showed signs of
empty sella syndrome, while in 9 patients (26.4%) ultrasound ONSD
measurement showed optic nerve sheath distension. There were no
significant differences between the age groups in both clinical pres-
entation and instrumental findings. Treatment included weight loss
and acetazolamide (maximum 5mg/kg/die) in 28 patients (82.3%).
Furosemide was added to acetazolamide in 2 patients (5.8%) and in
2 other patients was necessary added Delatcortene (5.8%). All pa-
tients fully recovered and none of them complained visual loss in
the follow-up.
Conclusion
IIH should be considered in children with new-onset headache. Clin-
ical headache presentation can be variable, although vomiting and
visual symptoms are frequently associated. To exclude a secondary
cause, neuroimaging should be performed. ONSD measurement may
be useful as an additional tool to identify patients with IIH. Early
diagnosis and treatment for IIH can prevent potential visual loss that
remains the major morbidity. Acetazolamide and weight loss remain
the most effective treatments in children.
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Objectives. Chronic paroxysmal hemicrania (CPH) is a rare and
well-characterised headache, classified amongst the trigeminal
autonomic cephalgias (TACs). CPH has been only rarely and in-
completely described in the developmental age. The objective of
the present report was to describe the features of chronic parox-
ysmal migraine in four pediatric patients.
Objectives. Chronic paroxysmal hemicrania (CPH) is a rare and
well-characterised headache, classified amongst the trigeminal
autonomic cephalgias (TACs). CPH has been only rarely and in-
completely described in the developmental age. The objective of
the present report was to describe the features of chronic parox-
ysmal migraine in four pediatric patients.
Results. We detected 4 patients with CPH. Our children presented
with a long history of severe and unilateral pain, which occurred
in the fronto-orbital region without side shift. Attacks were ac-
companied by at least one autonomic symptom, ipsilateral to
pain. During the attacks, besides conjunctival injection, eyelid
oedema and rhinorrhea and all children showed a dramatic re-
sponse to indomethacin.
Conclusions. Clinical symptoms and pain characteristics of our
children are similar to those found in typical adult CPH. However
our patients showed some atypical features, not fully meeting the
ICHD-III beta criteria. First, although the ICHD criteria require an at-
tack frequency higher than 5 attacks per day, in our patients, the
attack frequency was lower. Second, attack duration was variable in
all our children, but in three of four children it was sometimes lon-
ger than 30 min, which represents the maximal duration for a CPH
attack.If attack duration and frequency can make the diagnosis
more difficult, especially in paediatric age, the absolute response to
indomethacin represents the diagnostic key for CPH in both adults
and children (indotest).P195
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Background
Headache is one of the most frequent neurological disorders; 90% of
general population have at least one episode per year which is
disabling in the 40% of cases. Most prevalent primary forms are
tension type headache and migraine without aura and there are
specific criteria and guidelines for their diagnosis and treatment [1].
When several days of pain occur, initiation of a prophylactic therapy
is necessary. SISC Italian guidelines [2] suggest to use amitriptyline as
one of first choices, which is a tricyclic antidepressant with well
known possible disabling cognitive and effects and for this reason it
is included in a specific list of drugs forbidden to drive car. The aim
of this study is to validate a multimodal approach to assess the
possible cognitive and driving effects of prophylactic therapy with
amitriptyline in relation to its plasma level.
Material and Methods
We administered neuropsychological tests such as Minimental Status
Examination, Continuous Performance Task and Berg version of
Wisconsin Card Sorting Test to analyse cognitive profile. Driving skills
were evaluated with a simulation in virtual-reality setting assessing
the passive fatigue’s degree (Karolinska Sleepiness Scale, Standard
Deviation of Lateral Position) and the reaction-time to visual and
acoustic stimuli. Plasma assay were set to determine level of amitrip-
tyline and its active metabolites in patients’ blood.
Results
Sample population (n=10) is mainly composed by females (80%) with
mean age of 26 years; average body mass index and surface area are
respectively 20,31 and 1,65 m2. Patients are all treated with
amitriptyline 16 mg per os (most employed dosage in our Headache
Centre) for at least three months. Preliminary results of all variables of
the tests have been compared with normative values and with a
control population (n=30) showing no significant changes on cognitive
profile (p> 0,05). Plasma levels are at the lower limits of the means of
detection sensitivity. Driving variables were compared with two control
populations (n1=61, n2=24) and preliminary results seem to be not
significantly influenced by daily administration of therapeutic dose of
amitriptyline.
Conclusions
These results need to be confirmed studying a larger number of
patients in order to give them a more specific and adequate
information about effects of therapies in their daily-life activities, espe-
cially on driving. Moreover, our results will increase and will improve
the community's toxicological and scientific knowledge offering a bet-
ter service to the population.
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Deep brain stimulation (DBS) is an invasive therapeutic option for
many neurologic disorders: epilepsy, Parkinson disease, obsessive-
compulsive disorders, chronic cluster headache, neuropathic pain,
depression resistant to pharmacological treatments (1).
The site of the implantation is the key for the therapeutic response:
in each disorder, it is carefully selected after advanced neuroimaging
evaluations (fMRI and PET studies) that highlight precisely the parts
of the brain involved in the pathologic process (1). In Parkinson
disease, as in many others conditions, these areas have been widely
analyzed and the DBS has given remarkable results (1).
Among painful head diseases, DBS of the posterior hypothalamus
has been investigated for the treatment of chronic cluster headache
in medication-refractory patients (2). The posterior hypothalamus is
thought to play an essential role in the pathophysiology of cluster
headache, and likely accounts for the circadian and diurnal rhythmi-
city of both cluster periods (i.e. the months during which patients
with episodic cluster have cluster attacks) and individual cluster at-
tacks. Probably, the posterior hypothalamus covers an important role
in the pathophysiology of the other trigeminal autonomic cephalal-
gias, as well (2).
As far as migraine pathophysiology is studied, it remains poorly
defined and partially understood: although the areas involved in the
development of migraine attacks are mainly localized in the
brainstem (3), other structures, included the basal ganglia, seem to
play a role during migraine attacks (4).
Because of this pathogenetic complexity, there are not well-defined
targets to hit with DBS in migrainous patients. Therefore the few ob-
servations we have about DBS in migraine derived from case reports
conducted on patients with different underlying conditions requiring
treatment with DBS. For example, a recent case reported a significant
improvement of chronic migraine after anterior thalamic DBS, per-
formed for drug-resistant idiopathic generalized seizure (5).
We report the case of a 55 year-old-woman, who underwent DBS for
Parkinson disease. The implantation interested both the subthalamic
nuclei and produced an important improvement in her parkinsonian
symptomatology, in particular in the movement impairment. The pa-
tient suffered from chronic migraine too: prophylactic treatments
with topiramate 50 mg x 2 die and botulin injection were on course.
Painful pattern did not present any positive or negative modification
after DBS, as confirmed by a one-year clinical follow-up.
We believe useful to report this observation even if negative, since it
allows collecting relevant and uncommon data: as this case suggests,
subthalamic system stimulation seems not to determine significant
changes on chronic migraine.
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The authors after history reference at communication in medicine do
dwell among patient (and interacting people) with health figure (Not
only medical) in the temporal dimensions of the past, present and
future.
Detect than a correct interpretation is indispensable today, work’s
tool fot the doctor.
Do dwell in “medicine narrative” for take the “experienced” framework
painfull and it projection in the prospects of the future of the patient
and the figures at it next.
Shall analyse on the specific the directives to respecton the patient
with disorders pain that tend make chronic and the consequent
aspects psychic they put on guard against risks of communication
contemporary easily forgery-resistan and manipulable.P198
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Background
Chronic migraine (CM) is a highly disabling headache disorder (1).
Onabotulinum toxin A (OnabotA) is approved for the prophylactic
treatment of CM, and consists of cyclic treatment every 12 weeks.
Although response to OnabotA treatment varies among patients,
current guidelines suggest to stop treatment after cycle 2 if no
response has been experienced (2). This prospective study aimed to
define, in real-life setting, the evolution of the response to OnabotA
over 5 cycles of treatment among patients non-responders to cycle
1. The results of this study might help in decision making, in par-
ticular whether prosecuting OnabotA further or not, when facing a
patient not responding to the first cycle of OnabotA.
Materials and methods
Continued OnabotA treatment among patients non-responders to
cycle 1. Key outcomes: (i) a ≥50% reduction in moderate/severe
headache days, (ii) a ≥50% reduction in total cumulative hours of
headache on headache days and (iii) a ≥5-point improvement in
HIT-6 scores.
Results
Overall, 56 patients were included, all non-responders to cycle 1.
Mean age was 45.7 years (female 79.7%). Severe (≥60) HIT-6 score
was reported at baseline by 95.8% of patients, with 75% of them in-
curring in symptomatic medications overuse. The headache days per
month decreased significantly during the one year treatment period
from cycle 1 to cycle 5 (overall from 23.3 ± 5.7 to 9.2 ± 3.6; p<0.001).
During 12 months (5 cycles), migraine days per month progressively
abated (from 18.5 to 8.7; p<0.001), symptomatic medications intake
per day consistently decreased (from 17.4 to 8.1; p<0.001), and mean
HIT-6 score lowered progressively (from 72.4 ± 5.7 to 50.2 ± 4.3;
p<0.001) (Fig. 1).
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27% to 48%) (Fig. 2).
Over 5 cycles, patients regressing from CM to episodic migraine
doubled (from 32% to 66%), with 78% of them reaching less than 9
migraine days/month.
Conclusions
The positive effect of OnabotA treatment seems to spread over the
course of the treatment, and might also manifest late in treatment
course among patients with no benefit after the first 2 cycles. The
results of this real-life study suggest to consider extending OnabotA
treatment further, beyond cycle 2, to avoid premature withdrawal in
patients who would have become responders at cycle 3, 4 or 5.
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Background
Tanacethum parthenium, 5 - hydroxy tryptophan and magnesium
have an effect on various pathological mechanisms of migraine.
5 - hydroxy tryptophan (by his metabolite, kynurenic acid) and
magnesium inhibit the activity of glutamate receptor NMDA, reducingcortical hyperexcitability; NMDA is also involved in peripheral and
central sensitisation. Partenolide, the active component of Tanacethum
parthenium, is an antagonist of TRP, the receptor that contributes to
neurogenic inflammation by releasing CGRP. Moreover, it blocks 5HT2A
and 5HT2B serotonin receptor and inhibits serotonin release by
platelets, biosynthesis of prostaglandins and NOS expression.
Aim of this study is to prove the effectiveness of a novel combination
between Tanacethum parthenium 150 mg, 5 - hydroxy tryptophan 20
mg and magnesium 185 mg (TP-5HT-M) Aurastop ® in the prophylaxis
of migraine without aura with an episodic pattern.
Materials and methods
Twenty consecutive patients (F: n=12, M: n=8) of an age between 19-
and 55 years (mean age 32.9) presenting with a ICHD 3 βeta diagno-
sis of migraine without aura with a frequency of less than 10 head-
ache days a month were enrolled in the survey. Patients were
suffering from episodic migraine for at least 6 months and they were
not assuming any migraine preventive therapy. Patients were asked
to report in the headache diary card frequency, intensity, and dur-
ation of attacks for 3 months after taking Aurastop ® tablet bid for
the following 3 months. The reduction of migraine attacks per month
was assessed as the primary end-point, while the secondary end-
points considered were the reduction of headache days per month,
the intensity of the headache (VAS scale) and the patient’s satisfac-
tion using a scale of 0-5 where 5 was the maximum satisfaction.
Results
A significant reduction of migraine attacks per month (mean 2.8 vs
6.6) and number of headache days per month (mean 5.2 vs 8.5)
was observed; positive the results regarding the intensity (VAS
value 3,5 vs 8,5) and the satisfaction of the patients (4.5). No side
effects were reported.
Conclusion
In this observational open study, the combining action of Tanacethum
partenum, Mg and 5-HTP show to have a good therapeutic profile in
headache control without any major side effects. Further studies are
needed to confirm these preliminary results.
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Background
A new phytotherapic combination of Tanacethum Parthenium (150 mg),
5-Hydroxy tryptophan (20 mg) and Magnesium (185 mg) (Aurastop®) is
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 121 of 151now available for migraine patients. The three components may tackle
the main mechanisms involved in the pathophysiology of migraine with
aura: Cortical Spreading Depression, sensitization of trigeminal vascular
system, central sensitization.
The purpose of this open study was to evaluate the efficacy of the
combined action of Tanacethum Parthenium, 5-Hydroxy tryptophan
and magnesium in the reduction/disappearance of the aura
phenomenon and reduction of its disability when taken at the aura
onset.
Materials and Methods
Study of a population of 200 patients aged between 18 and 65 years
(mean age:33.00 yrs), 117 F and 83 M, suffering from migraine with
aura referred to 8 Lombardia Headache Centers. Patients were either
without preventive therapy or without changing the prophylaxis
during the aura treatment. Inclusion criteria: suffering of aura with at
least 20 minutes duration. Patients retrospectively filled a aura diary
for the description of the aura features in the past 3 episodes. Then
they treated 3 consecutive aura attacks with a tablet of Aurastop® at
the onset of the aura. In case of headache they were instructed to
take another 1 tablet at the headache onset. The effect of the
Aurastop® was prospectively recorded using the aura diary in order
to evaluate: duration of the aura, disability caused by the aura,
number/efficacy of habitual symptomatic treatment.
Results
We recorded a total of 600 aura episodes from a total of 200
subjects: Aurastop® produced more than 50% reduction in duration
in 180 patients (90% of the total) and disability in 185 patients
(92,5%). Notably 35% of the patients did not use other symptomatic
treatment due to the fact that headache intensity was less severe
after Aurastop®.
Conclusion
The combination of tanacethum partenum, Mg and 5-HTP (Aura-
stop®) could be an effective symptomatic treatment for migraine
aura. Randomised controlled trials are still required to confirm these
results.
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BACKGROUND
To present the rare case of a 9-year-old girl with idiopathic intracra-
nial hypertension (IIH) secondary to hypoparathyroidism (HPTH) and
our work-up, including physical examination, blood tests, diagnostic
imaging, and lumbar puncture.
CASE REPORT:
We present a 9-year old female patient who was hospitalized for
headache associated with nausea and vomiting for 3 weeks. She
underwent ophthalmologic examination which showed papilledema.
She had never had cramps, paraesthesias or tetany. Lumbar puncture
(LP) revealed an opening pressure of 65 cm H2O. CSF analysis andbrain CT scan were normal. The patient was started on acetazolamide
375 mg/die. However, a low serum calcium level (6.3 mg/dL) was
found, thus leading us to suspect HPTH. Indeed, phosphorus was
10.2 mg/dL, parathormone was very low (3 pg/mL). Chvostek and
Trousseau signs scored positive. Neck ultrasonography showed nor-
mal thyroid, while parathyroids were not viewable. Oral supplemen-
tation with calcitriol (0.50 mcg/day) and calcium (500 mg/day) was
started.
CONCLUSIONS
IIH is defined as an elevated intracranial pressure (>25 cmH2O)
without clinical, laboratory or radiological evidence of hydrocephalus,
infection, tumor or vascular abnormality. Annual incidence is 1-2 per
100,000. Several hypotheses have been proposed for the IIH patho-
physiology, but none of them has reached a general consensus. Rare
cases of IIH secondary to HPTH have been described [1]. It is sup-
posed that hypocalcemia causes a decrease in the CSF absorption
at level of the arachnoidal granulations [2]. Interestingly, our patient
did not present with the typical neurological HPTH symptoms, such
as tetany, cramps, paraesthesias, seizures, behavioral disorders, and
intracranial calcifications. Only the serum calcium dosage led us to
suspect this condition. Therefore, we recommend that possible
HPTH should be always checked in children with clinical findings of
benign intracranial hypertension.
Consent to publish
Written informed consent has been obtained from the parents.
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Background: Each component of the novel phytotherapic combination
of Tanacethum Parthenium (150 mg), 5-hydroxy tryptophan (20 mg)
and magnesium (185 mg) (Aurastop©) acts on a different target among
the main mechanisms involved in the pathophysiology of migraine:
sensitization of trigeminal vascular system, central sensitization and ac-
tivation of the “migraine generator” located in the brainstem, through
glutammate and kynurenine pathway. Aim of this study is to test the
effectiveness of Aurastop© in the prophylaxis of migraine without aura.
Materials and methods: Sixty consecutive patients (F: n=37, M: n=23,
mean age: 37.5±17.1) presenting with an ICHD-3 beta diagnosis of
migraine without aura (MO) were enrolled in the survey and treated
with Aurastop© twice a day for a period of 3 months. Diary cards
were filled in during a 3-months period prior the beginning of the
survey and during the 3-months duration of the study. A preventa-
tive treatment had been started previously and continued during the
study in 5 cases (propranolol: n=2; amitriptyline: n=2; onabotulinum-
toxin A: n=1).The reduction of MO attacks per month was assessed
as the primary end-point; the reduction of headache days per month,
the intensity of the pain and the patient’s satisfaction were consid-
ered as secondary end-points.
Results: A statistically significant reduction of both MO attacks and
number of headache days per month was observed. Moreover, a
sensible reduction of the intensity of the pain was reported. The
secondary end-point regarding the satisfaction of the patients was
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 122 of 151achieved, as participants agreed when a new cycle of Aurastop© was
proposed. No side effects were reported. The effectiveness appeared
since the first month of intake and was maintained during the three
months of therapy .
Conclusion: In this observational open study, Aurastop© appears to
be effective and safe in the preventive treatment of MO.
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Background The aim of prophylactic treatment of cluster headache
(CH) is to produce a suppression of attacks and to maintain a remission
until the cluster bout is over, or for a longer period in patients with
chronic CH. Verapamil is the drug of choice in both episodic and
chronic CH. For short-term transitional therapy, corticosteroids are the
most commonly prescribed medications [1]. Unfortunately, attacks al-
most invariably relapse when steroids are tapered.
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, which
has been tested as an analgesic compound in a variety of patients with
several pain conditions [2].
Materials and methods We evaluated 18 patients, previously treated
with verapamil and note responding to transitional steroids. The
study group included 10 males and 8 females, 13 suffering from
episodic CH (7 M and 6 F) and 5 from chronic CH. The patients mean
age at first observation was 49,3 ± 13,9, while the mean age at onset
was 29,7 ± 15,5. The subjects with episodic CH had frequent bouts,
at least one per year; the patients kept a diary card to record the
number of attacks during the last two active periods in episodic CH
and for the last three months in chronic CH. In episodic CH, patients
refractory to steroids in previous clusters were treated at the onset
of a new active period with a daily dose of 240-480 mg verapamil,
associated with PEA in a single dose of 600 mg/day. In chronic CH
the same regimen was commenced after the inefficacy of steroids
for the previous three months was clinically demonstrated.
Results A reduction of attacks by at least 30%, as compared to
baseline, was observed in 12 cases (66%). In two patients (one with
chronic CH) the response was dramatic, with an almost complete
headache remission. On average the cluster attacks decreased by
36%; no adverse events were reported.
Conclusions Patients with CH sometimes fail to respond to
conventional treatments; therefore, due to this severely disabling
condition, new emerging therapies for medically refractory CH
patients are under active investigation [3]. PEA may be a promising
option for CH refractory to steroids. The anti-inflammatory and anal-
gesic effects of PEA have been confirmed in models of inflammation
and neuropathic pain. Limitations of this study are the open-label de-
sign and the small patient population. Despite these caveats, our re-
sults warrant further investigations to test the possible efficacy of
PEA for CH prevention.References
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Background
A new phytotherapic combination of Tanacethum Parthenium ( 150
mg ), 5 - hydroxy tryptophan ( 20 mg ) and magnesium ( 185 mg )
(Aurastop @) is now available for migraneous patients. The three
components act on the four main mechanisms involved in the
pathophysiology of migraine with aura: Cortical Spreading Depression,
sensitization of trigeminal vascular system, central sensitization and
activation of “migraine generator” at the brainstem’s level. Since many
years Magnesium is well known to interact with the aura phenomena
and migraine itself.With this study we want to compare the efficacy on
the aura phenomenon and its disability of the combination of
Tanacethum Parthenium, 5 - hydroxy tryptophan and magnesium
versus magnesium alone, when taken at the beginning of the aura.
MATERIALS AND METHODS: We selected from the Headache Center
of Istituto Clinico Citta’ di Brescia a population of 50 patients aged
from 18 to 55 years (mean 31 years ), 27 women and 23 men,
suffering from migraine with aura, not assuming migraine preventive
therapy. They have to refer of an aura with a duration of at least 20
minutes to be included. We gave to the patients a form where they
have to describe the aura features of the 4 aura episodes following
the administration of 1 tablet of Aurastop at the beginning of the
aura and 1 tablet at the beginning of the headache ( if present ) in
the first 2 aura and 1 tablet of magnsium 2,25 gr in the same
modality at the 3° and 4° episodes of aura. Patients were evaluated
for duration and disability of the aura, need and response to their
habitual analgesic drug
RESULTS: A reduction in duration greater than 50% in 48 patient
versus 7 and of disability >50% in 48 patients against 5 were
observed respectively after taking Aurastop o Magnesium alone
.Furthermore 35% of the aurastop group did not have to take pain
reliever after the aura as the headache intensity was more
tolerable, only 5% of the magnesium group. We also noted a
marked improvement in the benefit of the usual pain killer quite
similar in both groups.
CONCLUSIONS: by the fact that these combination pass very quickly
the ematoencephalic barrier Aurastop has been shown to have a
quick impact on the evolution of aura reducing the duration and
disability of symptoms than the magnesium alone.
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Background
The prevalence of recurrent headache in children and adolescents, as
reported in the literature, ranges from 4-20% in pre-schoolers to 57-
82% in adolescents aged 15 years. This variability is related to differ-
ences in bothassessment methods (diagnostic criteria, data collection
tools)and samples[1]. We set out to assess the level of agreement be-
tween mothers’ and children’s reports of headache (characteristics
and frequency) in a non-clinical sample of children, through compil-
ation of a medical questionnaire.
Materials and methods
We recruited a sample of 374 schoolchildren (mean age 9.58±0.2).
All children were administered a standardised battery ofmedical
questionnaires individually by a clinical expert, while their mothers
filled in the questionnaires independently.
Results
Reports of at least one previous episode of headache were
considerably more frequent in children’s than mothers’ questionnaires
(68.7% vs 52.4%, k=0.01). For all the items considered in this group of
subjects, the level of agreement was “poor” (k<0.20) or “fair” (k<0.40).
Conclusions
The low correlations found between the mothers’ and children’s
reports on the frequency and characteristics of childhood headache
suggest that questionnaire compilation by a single subject does not
allow accurate estimation of the prevalence of headache, or a precise
description of its features. The high variability in published prevalence
estimates of childhood headache from non-clinical samples could be
explained, at least in part, by these findings. Combined information
from children/adolescents and their mothers could allow better estima-
tion of the prevalence of headache in this age group.
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Background: Tanacethum parthenium, 5-hydroxy tryptophan and
magnesium have an extensive literature supporting their role in the
prophylaxis of migraine without aura. Aim of this study is to prove
the effectiveness of a novel combination between tanacethum
parthenium 150 mg, 5 - hydroxy tryptophan 20 mg and magnesium
185 mg (TP-5HT-M) in the prophylaxis of migraine without aura.Materials and methods: Twenty consecutive patients (F: n=17, M:
n=3) presenting with a ICHD 3 beta diagnosis of migraine without
aura (MO) were enrolled in the survey. Age at onset of MO and
mean age at the observation were respectively 18.7±9.4 and 45.8
±13.1. Patients were asked to report in the headache diary card the
frequency, intensity, and duration of MO attacks for 3 months;
thereafter, such information was recorded and TP-5HT-M bid was ad-
ministrated for the following 3 months. A preventative treatment
had been started previously and continued during the study in 5
cases (propranolol: n=2; amitriptyline: n=2; onabotulinumtoxin A:
n=1). The reduction of MO attacks per month was assessed as the
primary end-point, while the secondary end-points considered were:
i. reduction of headache days per month; ii. tolerability; iii. patient’s
satisfaction.
Results: A significant reduction of MO attacks per month (mean 5.0 vs
7.9) and the number of headache days per month (mean 6.5 vs 9.8)
were observed. No side effects were reported. All the subjects were
satisfied and answered positively when a new cycle of TP-5HT-M ther-
apy was proposed.
Conclusion: In this observational open study, TP-5HT-M combination
appears to be safe and effective in the prophylaxis of MO. Further
studies are needed to confirm these preliminary results.
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Background
Reversible splenial lesions of the corpus callosum (CC) have been
reported in different central nervous system (CNS) disorders [1]. The
prevalence of acquired CC lesions on brain MRI is estimated to be
about 3% [2]. Migraine with aura and status migrainosus rarely
correlate with this type or neuroradiological findings [3-5].
Case report
A 52-year-old woman was admitted for a status migrainosus. She was
previously followed for episodic migraine without aura (ICHD-3). During
the month preceding hospital-admission, the patient suffered from a
gradual and significant worsening of her migrainous headache: it be-
came daily and non-responsive to usual non-steroid-antinflammatory
drugs. Subjective-objective dizziness appeared, followed by an episode
of visual aura (never experienced before): she went to the Emergency
Room (ER), where a brain and a cervical CT scan were performed, with
no pathological findings. The hematological profile as the neurological
examination were unremarkable. In the following days, further episodes
of visual auras brought her back to the ER and to the admission to our
ward. Her past medical history was unremarkable. She took no continu-
ative therapy at home. A therapy with Ketoprofene, Diazepam and
Indomethacin was started, with resolution of headache. Before dismis-
sion, a gadolinium-enhanced brain magnetic resonance imaging (MRI)
showed an alteration of the signal of the splenium of the CC: a high-
signal lesion on T2-weighted and fluid-attenuated inversion recovery
images, with hyperintensity on diffusion-weighted images and minimal
contrast-enhancement was present (Fig. 1a-d). CSF analysis was unre-
markable except for an IgG mirror pattern at immunoelectrofocusing. A
detailed immunological blood screening test was unremarkable. A PET-
MRI brain imaging showed no hypermetabolism of the splenial lesion.
After an efficacious composite prophylactic therapy with Candesartan,
amitriptyline and Baclophene, and no other visual auras, a six-month
control brain MRI scan showed an almost complete resolution of the
splenial lesion (Fig. 1e-h).
Conclusions
For the first time we describe a reversible splenial lesion in an adult
patient with status migrainosus, characterized by substantial reversibility
only at a long-term MRI follow-up: a slow temporal evolution that has
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 124 of 151never been reported before. The pathophysiology of this type of lesion
remains quite obscure: reversible demyeliation, extrapontine osmotic
myelinolysis, intramyelinic edema, relative lack of adrenergic tone (with
consequent susceptibility to hypoxic vasodilation), breakdown of the
blood-brain barrier and high vulnerability to extracellular glutamate are
some of the postulated hypotheses.
Consent to publish
The patient gave her written informed consent for the publication of
this case report.
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Background
During pregnancy, headache is mostly due to primary disorders,
including migraine and tension-type headache. Pregnancy tends to
ameliorate migraine that however may also begin or worsen in this
condition [1]. Headache medications, because of the potential risks
to the foetus, should be avoided during pregnancy. However, severe
migraine is often not controlled by nonpharmacologic strategies, and
many women, in the end, treat it with drugs, including paracetamol,
nonsteroidal anti-inflammatory drugs (NSAIDs), and triptans [2]. Not-
withstanding the large portion of women affected by headache
hence candidate to drug consumption in pregnancy, only scarce evi-
dence is available. Our study aims to investigate headache and its
treatment during pregnancy.
Materials and methods
From July 12, 2017 to September 2, 2017, women either in
pregnancy or who have delivered in the previous 7 days were
prospectively screened at the Maternal and Child Department,
Careggi University Hospital for enrolment in a retrospective cohort
study, still ongoing. Patients who reported having experienced
headache before and/or during pregnancy were asked for filling a
self- administered questionnaire, adapted from Amundsen et al [3].
The study was approved by the competent Ethics Committee, and all
patients gave their informed consent before enrolment.
Results
One-hundred (37%, median age 35) out of 271 screened patients
reported a history of headache, prior to and/or during pregnancy,
and filled the questionnaire. Headache onset was reported to be, on
average, at the age of 17.3±6.3. Few women before pregnancy
received a diagnosis by a physician of migraine (n=15) or tension-
type headache (n=3). The mean frequency of headache attacks per
month before pregnancy was 3.5, and in the first, second, and third
trimesters of gestation, the mean frequencies were 2.3, 1.2, and 1.4,
respectively. Eighty-six (86%) women reported pre-pregnancy use of
drugs for headache, including NSAIDs (69 out of 86, 80%), paraceta-
mol (26 out of 86, 30%), analgesic combinations (2 out of 86, 2%),
and triptans (2 out of 86, 2%). In pregnancy, the percentage of
women using pharmacotherapy decreased to 38% (38 out of 100),
with a shift in the pattern of medication use in favour of paracetamol
(35 out of 86, 41%).
Conclusions
Headache is common in pregnant women, especially in the first
trimester. Although in pregnancy there was a reduction in the
consumption of medicines with a change in the pattern of use, more
efforts to improve diagnosis and pharmacologic treatment of
pregnant women with headache should be undertaken.
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Background
Little is known about most rare primary headaches. Their diagnostic
criteria are summarized in Chapter 3 and Chapter 4 of part one of
the International Classification of Headache Disorders [1]. Due to
the paucity of research on these disorders, which mainly comes
from case reports or small cohort studies, and except for cluster
headache, recommendations on diagnostic and therapeutic
management are lacking [2]. In order to favour research, thus
improving the knowledge, on these disorders and to promote a
consensus about their management, we started up a registry aimed
to collect nationwide data about patients that from May 1, 2014
have been diagnosed with a rare primary headache in Italian
tertiary Headache Centres.
Materials and methods
We planned to collect data from May 1, 2014 and afterwards, by
means of both retrospective and prospective approaches. All
patients who have received or will receive a diagnosis of rare
primary headache will be asked to participate and, to this aim, to
give their informed consent. Each participating Centre should have
received the approval of the competent Ethics Committee before
commencing any study procedures. The registry will contain
anagraphic information and data about diagnosis, treatment,
comorbidity, and clinical features of the headache. Patients’ data
will be coded through the Italian Health System unique identifier,
in order to avoid duplications of patients referring to more than
one Centre and also to monitor multiple referrals. A web-based
open source platform (SurveyMonkey.org) will be used to collect
data.
Results
Eleven Headache Centres were asked to participate and 10 have
agreed to contribute to the retrospective portion of data collection
as requested information can be easily retrieved from electronic
sources used for clinical practice. Eight participating centres have
obtained ethical approval and started study procedures, however
up to date only 6 centres have already collected data with the
retrospective approach. According to this latter dataset, in the
period going from May 1, 2014 to April 30, 2017 a total of 15847
patients referred to the Centres, and 724 (4.5%) of them were
affected by rare headaches.Conclusions
Data collected in a portion of participating Centres make us
confident that in a short period a quite large amount of data may be
collected and analysed. The availability of a nation-based registry will
importantly contribute to our knowledge of rare headaches and their
management in the setting of Headache Centres.
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Background. Since the 1928, ketogenic diet (KD) was proposed as
possible preventive treatment for migraineurs.[1] Unfortunately, no
data are still now available about the effect of KD in patients with
tension-type headache (TTH), both episodic and chronic (CTTH). TTH
is the most diffused form of primary headache. Usually CTTH disabil-
ity is not severe; however, it is an open challenge in the field of
headache management: other than amitriptyline, there are very few
effective prophylactic treatments. Likewise, effective symptomatic op-
tions are very limited, and restricted to the non-steroidal anti-
inflammatory drugs (NSAIDs), pending a class of drugs ad hoc devel-
oped, like triptans for migraine. In order to evaluate if, similarly to mi-
graine, CTTH responds to KD, we observed a group of overweighed
CTTH patients that underwent to a weight-loss KD.
Methods. Among overweighed patients self-referred to a dietician,
with a positive anamnesis for headache ≥ 15 days/month, a neur-
ologist specializing in headache recruited 29 CTTH patients. After
one month of headache diary recording, they started a 1-month
weight-loss program named very low-calorie ketogenic diet (VLCKD),
characterized by a dramatic caloric restriction (<800 Kcal/day) and a
very low-carbohydrate intake, able to lead to ketone bodies (KBs) pro-
duction. At the end of the VLCKD, they started a weaning phase, to go
out from ketogenesis. To verify variations in headache frequency dur-
ing the month of VLCKD, we used as baseline the month before the
diet.
Results. Out 29 enrolled patients, no one was regarded as
responder (at least, 50% of headache reduction). At the baseline,
headache frequency was 21.5 ± 4.4 days/month, while at the end
of the VLCKD month it was 19.3 ± 5.6 (p=0.07). About the
consumption of symptomatic drug doses, at the baseline, it was
11.9 ± 6.2 doses/month, while at the end of the VLCKD month it
was 8.2 ± 5.6 (p=0.002).
Conclusions. Our results are suggestive for the absence of efficacy
of KD in CTTH patients, unlike in episodic migraineurs. In fact, no
one patient has halved the monthly headache frequency during
Table 1 (abstract P211). See text for description
Questions Answer
Nausea or Vomiting - Yes
- Not
Photophobia - Yes
- Not
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 126 of 151the diet, nor did revert its chronic form of headache in episodic
one. In terms of days/month with headache, there was a trend of
reduction, unable to achieve the statistical significance. It is in
line with a previous report on chronic daily headache.[2] On the
contrary, the drug consumption improved, but it is unclear if it
could depends by the medical advice to avoid ineffective drug
treatments.
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2010;30(8):1014-6.Degree of disability - Mild
- Moderate
- Severe
Gets worse with physical activity - Yes
- Not
Aura - Always
- Sometimes
- Never
Duration - <4h
- 4-72h
- >72h
Localization - Unilateral, always on the same side
- Unilateral, alternating
- Other (median, bilateral, variable…)
Chronic
(>15 days/month)
- Yes
- Not
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Background. The high prevalence of headache disorders is a
challenge for the National Health System: not all the sufferers should
be addressed to specialist consultation but general practitioners
(GPs) are often not well trained to discriminate among their patients
who needs neurological evaluation. To support the GPS in the
headache patients’ management, we have created a clinical decision
support software (CDSS). Aim of this study is perform the validation
of this tool.
Methods. The CDSS consists of an 8 answers questionnaire (Table 1).
According to the reply, patients were divided in 2 categories (Fig. 1):
complex (who needs specialist consultation) and simplex (who can
be managed by GPs). In the first group, we have comprised patients
with chronic (>15 day/month), atypical, and trigeminal-autonomic
headaches. In the second, episodic forms of tension type headache
or migraine (with or without aura).
We have tested the CDSS by the direct interview to 201
headache patients referred to the Headache Clinic of Polo
Pontino. An independent operator interviewed patients prior to
the clinical evaluation, blind to the further diagnosis performed
by the specialist. After the clinical evaluation, according to the
diagnosis, also the specialist allocated patients in one of the two
groups. The results of the CDSS were matched with the ones of
the specialist.
Results. Out 201 patients, 115 received by specialist a diagnosis of
episodic forms of tension type headache or migraine with or
without aura (Simplex category); 86 patients have other forms of
headache (Complex category). The results of CDSS were 98 Simplex
forms, 103 Complex forms. The sensibility of the test was 96%,
specificity 82%
Conclusions. The CDSS is an easy questionnaire that can be self-
administrated by an informatic device, or by the GPs. Our results
show that CDSS is a sensible test, able to detect patients needing
to be addressed to a specialist consultation. In fact, only the 4%
of patients with a Complex form of headache did not receive the
indication to be addressed to the specialist visit. On the contrary,
the 18% of patients with a Simplex form were anyway addressed
by CDSS to the specialist. The underestimation of Simple formsreduces the specificity of the test; however, it makes possible to
have a high sensibility, reducing the number of false positive
cases. If implemented in the GPs clinical practice, this question-
naire could be a useful tool in support of clinical decisions about
headache patients.P212
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Background
Chronic migraine (CM) represents one of the leading causes of
disability. It occurs in 2-5% of general population, often associated
with medication overuse (MOH) [1,2]. Pharmacological preventive
therapies in CM patients are often unsatisfactory for both efficacy
and tolerance. The short-term psychodynamic psychotherapy
(STPP), inspired by freudian psychoanalysis, associated with drug
therapy, was more effective in patients with MOH to reduce head-
ache symptoms and relapse rate than only pharmacological
prophylaxis [3]. Moreover, in a pilot study on CM preventive ther-
apy, STPP alone seems not to be inferior to sodium valproate [4].
We investigated a large cohort of CM patients treated with STPP
to confirm the feasibility and clinical usefulness of this non-
pharmacological approach.
Materials and methods
We recruited CM patients, with or without MOH, according to the
ICHD-III beta criteria, attending to our Headache Clinic. Patients
underwent a Brief Psychodynamic Investigation (BPI) formed by 4
meetings. BPI provides a diagnosis of psychodynamic profiles accord-
ing to different mentalizing levels, i.e. ability to process the emo-
tional content. In the following 2 months, 8 psychotherapy meetings
were conducted. Follow-up controls were planned at 30 and 60 days.
At this time, if patient still present a high headache burden, the most
appropriate additional treatment was started. A final follow-up evalu-
ation was planned after 6 months.
Results
We recruited 117 patients with CM (66,6% with MOH). Mean age
was 40.3±14 years, headache/month number was 24±6.4, with a
HIT-6 score of 63.7±9.8. By BPI, patients resulted having low menta-
lization. The STPP treatment was completed by 64 (55%) cases.
After 2 months, they showed a significant improvement of head-
ache: -33% headache days (14.7±8.7), -19% pain intensity, -39%
MIDAS score, -7% HIT-6 score, -21% HAM-A and -21% HAM-D
scores, and 91% of cases had no more medication overuse. Forty-
two (65%) still had a high headache frequency (17±8.8 headache
days/month; HIT-6 score:62±9.1) requiring additional preventive
therapy.
At the 6-month control, patients showed a significant global clinical
improvement with respect to baseline (-12.1 headache days/month).
Patients treated with STPP alone had a reduction of -14.6 headache
days/month with respect to -10.6 of those treated with STPP plus
additional therapy at 6 months.
Conclusions
Our results suggest that STPP is an effective preventive treatment of
CM, with or without MOH, either alone or in combination with other
prophylaxis therapies. This therapeutic approach seems particularly
effective in resolving drug abuse and its effect seems to remain
constant over time.
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Background
Chronic Migraine (CM), with or without medication overuse headache
(MOH), represents a therapeutic challenge in migraine management.
These patients have frequently psychiatric comorbidities that may
influence clinical outcome [1]. We investigated the correlation between
psychiatric comorbidities and the effect of a non-invasive neurostimula-
tion treatment, by transcranial direct current stimulation (TDCS), in pa-
tients with CM with or without MOH.
Materials and Methods
We recruited consecutive CM patients, who had had an unsatisfactory
responses to at least 3 pharmacological preventive therapies, including
OnabotulinumtoxinA. All patients underwent a psychopathological
assessment (including Structured Clinical Interview, Akiskal’s Temps-
A for bipolar spectrum, Young Mania Rating Scale [YMRS]). They
were treated with anodal right prefrontal and cathodal occipital
TDCS (intensity: 2mA, time: 20 min, three times a week for four
weeks). Clinical migraine data were recorded at baseline (t-0), at
the end of the treatment (t+30 days) and during follow-up (t+60
days). Post treatment psychiatric evaluation was planned within 2
weeks after the end of the TDCS.
Results
Sixteen patients (F=12, mean age=54 y.o.) with CM, with or without
MOH were studied. We found 6 patients affected by bipolar disorder
(BD), and 5 other patients with bipolar spectrum. In our series, the
prevalence of BD and bipolar spectrum in resistant CM patients was
approximately 70% compared to 11% reported in the literature for
migraineurs. At t+60 days, patients showed a significant decrease of
both severe headache days/month (6.13 to 4.56, -25%, p=0.005) and
headache days/month (18.25 to 14.31, -22%, p=0.04). By considering
the days of severe headache per month, patients with CM and BD
had a baseline worse condition (11±5.05 vs. 3.91±5.10, p=0.02). At t
+60 days, however, patients with CM and BD showed a greater
response to TDCS for severe headache days (-3.4 vs. -0.73; -30% vs.
-19%, p=0,009). Post stimulation psychiatric evaluation showed an
improvement in YMRS score with a significant halving of baseline
scores (p=0.03).
Conclusions:
TDCS seems to be effective in the treatment of CM patients, with or
without MOH, which have a poor response to different classes of
prophylactic pharmacological therapies. The prevalence of BD and
Table 1 (abstract P215). Summary of the significant results obtained
with the three treatments
Acupuncture
(N=27)
Supplements
(N=23)
Pizotifen
(N=23)
Frequency of the headache
(gg/30 gg) pre e post-T (median)
From 9 to 3,5
(p=0.0002)*
From 12 to 1
(p<0.0001)*
From 4 to 3
(p=0.02)*
Duration of the headache (h)
pre e post-T(median)
From 8 to 5,4
(p=0.0002)*
From 3,4 to 3
(p=0.58)
From 3,5 to 3
(p=0.18)
Nausea pre e post-T(median) From 78,9% to
0% (p=0.0005)*
From 0% to
0%
(p=0.49)
From 26,7% to
6,7% (p=0.22)
Photophobiapre e post-
T(median)
From 32,5% to
26,5% (p=0.08)
From 28,6% to
0% (p=0.07)
From 75% to
0%
(p=0.03)*
Phonophobia pre e post-T
(median)
From 40% to 0%
(p=0.005)*
From 37,5% to
0% (p=0.85)
From 100% to
25% (p=0.003)*
Symptomatic drug
consumption pre e post-T
(median)
From 4 to 1
(p=0.003)*
From 8 to 1
(p=0.0002)*
From 4,5 to 4
(p=0.15)
Items PedMidas° *4 *2 *1
Items CBCL 6-18° *1 *1 *1
Adverse and unpleasant
effects (p=0.05)
6 (24%) 7 (70%) 4 (31%)
Satisfaction (*) 8,75 6 7
Positive secondary effects 7 (28%) 0 (0%) 0 (0%)
Legend: *=p<0.05; T=treatment. Pre-T=2 months before, post-T=1 month after the
end of T. Duration of T =3 months. °Number of items PedMidas e CBCL which im-
proved after treatment. Satisfaction: reported on scale from 0 (unsatisfied) to 10 (ex-
tremely satisfied); (*) the differences between the 3 groups were statistically
significant
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 128 of 151bipolar spectrum in patients CM is higher than expected in both
general population and migraine patients. BD patients showed a
worse baseline headache burden as well as a better response to
TDCS, both for headache and psychiatric parameters. In conclusion,
BD psychiatric status might influence the response to TDCS, a non-
pharmacological neuromodulation therapy.
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Background
Prophylaxis of primary pediatric headaches has some limitations:
poor efficacy, adverse effects, contraindications for comorbidity, off-
label use of drugs in pediatric age, limited knowledge and few con-
trolled studies.
The aim of the study is to describe the effect and tolerability of three
types of treatments (acupuncture, supplements or drug) for prophylaxis
of primary headaches in children and adolescents.
Materials and methods
Observational and prospective clinical study conducted at the Juvenile
Headache Centre of Paduabetween October 2016 and August 2017.
Inclusion criteria: age 6-17 years; headache for at least 6 months; diag-
nosis according to the diagnostic criteria of the current International
Classification of Headaches Disorders (ICHD-3 beta, 2013) of migraine
without or with aura (> 4 attacks/month), chronic migraine, frequent
episodic tension-type headache (> 6 attacks/month), chronic tension-
type headache; prophylactic therapy with acupuncture or supplements
(magnesium with multivitamins) or pizotifen. The last is the only drug
licensed in Italy for migraine prophylaxis in children.
Outcomes: headache diary; PedMidas and CBCL 6-18 questionnaires;
adverse events and unpleasant aspects; level of total self perceived
satisfaction of the patient and the parents. Statistical analysis con-
ducted with software SAS 9.3.
Results
73 patients were enrolled: 27 (acupuncture), 23 (supplements) and
23 (pizotifen). Significant results were summarized in Table 1.
Conclusions
Acupuncture improved both episodic and chronic headaches,
associated symptoms, overall functioning and quality of life, and it
was very well tolerated. Supplements had a good effect in reducing
headache's frequency and drugs’ consumption, in both episodic and
chronic headaches; however, this treatment was perceived as
unpleasant by some subjects. Pizotifen showed limited positive
effects on headache and on overall functioning and it did not reduce
the analgesics’ consumption. Patients complained more side effects
with pizotifen than the other two treatments.
In conclusion our data showed that acupuncture is a good
prophylactic treatment of primary headaches in the developing age.
Further studies are needed on larger series and with longer follow-
up to assess the effect of these treatments on natural history of pri-
mary headaches.P216
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Background
Withdrawal from overused drug is the treatment of choice for
subjects with Chronic Migraine and Medication Overuse Headache
(CM+MOH) [1, 2], reverting the headache pattern from chronic to
episodic within two months in the majority of subjects. Many factors
are involved in the prognosis and outcome of these subjects, and
their understanding is a topic of interest. CM+MOH patients
experience increased psychiatric comorbidity, such as anxiety,
depression, or personality disorders [3, 4], even if a cause-effect rela-
tionship still needs to be clearly delineated. Even less is known about
the role of psychiatric factors in the response to detoxification treat-
ments. In the present study we focused on early traumatic experi-
ences and recent stressful events by investigating their association
with the outcome of detoxification in a 2-month follow-up.
Materials and methods
This study was conducted at the Headache Center of the C. Mondino
National Neurological Institute in Pavia, Italy. All consecutive patients
with chronic migraine and medication overuse headache undergoing
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 129 of 151an inpatient detoxification program were enrolled and followed-up
in a prospective study. Diagnosis was operationally defined accord-
ing to ICHD-IIIβ. The protocol consisted in inpatient detoxification
treatment and a 2-month follow-up. Data on early life traumatic ex-
periences – of the physical or emotional type – and recent stressful
events – rated according to the impact on quality of life, from mild
to very serious – were collected by means of self-report question-
naires. Data were analyzed with the analysis of variance.
Results
Of the 166 patients who completed the 2-month follow-up, 118
(71%) stopped overuse and their headache reverted to an episodic
pattern (Group A), 19 (11%) kept overusing and did not experience
any change in headache frequency (Group B); and 29 (18%) stopped
overuse without any benefit on headache frequency (Group C). At
the multivariate analyses, a higher number of emotional traumas (OR
11.096; p = 0.037) emerged as a prognostic for the outcome in
Group B; whereas having had history of major depression (OR 3.703;
p = 0.006) and higher number of very serious stressful events (OR
1.679; p = 0.045) were prognostic for the outcome of Group C.
Conclusions
Our findings show the impact of life traumas and stressful events on
the outcome of a detoxification program. The failure to cease overuse
is related to the existence of childhood (mostly emotional) traumas,
whereas recent life events, especially when very serious, do not
influence the capacity of the patient to stop overuse, but are
associated to the persistence of chronic headache. These observations
underscore the need of a thorough psychological assessment of CM
+MOH subjects and have possible implications in the nosographic
framing of chronic headaches.
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Background
Migraine is often comorbid with several conditions including
cardiovascular diseases [1,2]. The association between migraine and
several thrombophilic alterations has been studied in migraineurs,
giving variable results [3-5]. Aim of the present study was to assess
the association between migraine and some thrombophilic disorders.Methods
We included consecutive migraine patients referring to a tertiary
headache center between September 1st 2008 and March 31st 2010.
For each migraine patient a control subject without migraine, matched
by age (±2 years) and gender, was selected among hospital employees.
We excluded those people who were using anticoagulants. Selected
thrombophilic disorders included deficiency in protein C (activity
<60%), deficiency in protein S (activity <62%), activated protein C
resistance (APCR; if APC ratio below 2.0), antiphospholipid antibodies
(aPL) positivity (lupus anticoagulant in plasma and/or anticardiolipin
antibodies titre > 99% and/or Ab-antiβ2GP1 titre > 99%, on two or
more occasions at least 12 weeks apart and within 6 months), and hy-
perhomocysteinemia (above 15 μmol/L).
Results
We included in the study 329 subjects with migraine (37.7% with aura)
and 329 controls. Mean age±SD was 40.9±12.0 for migraineurs and
41.1±10.4 for controls. In both groups 254 subjects (77.2%) were
women. Characteristics of included subjects are shown in Table 1.
Deficiency in protein S (5.5% vs 1.2%; OR 4.7, 95% CI 1.6-14.0; P= 0.002)
and aPL positivity (12.5% vs 5.2%; OR 2.6; 95% CI 1.5-4.7; P=0.001) were
more common in migraine patients than in control subjects whereas we
found no differences in deficiency in protein C (0.3% vs 0.6%; OR 0.5,
95% CI 0.1-5.5; P= 0.556), APCR (3.3% vs 3.4%; OR 1.0, 95% CI 0.4-2.3;
P=0.977), and hyperhomocisteinemia (15.9% vs 15.1%; OR 1.1, 95% CI
0.7-1.6; P=0.784) between the two groups. Migraine patients having
deficiency in protein S were younger than those without the deficiency
and had more often history of cerebrovascular diseases (OR 7.1, 95% CI
2.0-24.9; P=0.002) whereas other comorbid conditions and headache
characteristics (age at onset, frequency or severity) were not different.
Migraine patients having aPL positivity had more often history of
cerebrovascular diseases (OR 4.8, 95% CI 1.6-16.9; P=0.004) and ischemic
heart disease (OR 22.7, 95% CI 2.3-223.4; P=0.008) than those not having
the condition. In an exploratory analysis we did not find any difference in
the thrombophilic disorders between subjects with migraine with and
without aura.
Discussion
Migraine is comorbid with some thrombophilic disorders and
particularly with deficiency in protein S and aPL positivity. Migraine
patients with those thrombophilic comorbidities reported more often
history of vascular disorders in the cerebral or cardiac districts. Our data
may indicate that some thrombophilic disorders may be associated
with occurrence of vascular events in a subset of migraineurs patients.
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Table 1 (abstract P218). Descriptive summary of cannabinoid
pharmacokinetic parameters
Parameters
(mean ± SD)
Cannabis decoction
(200 ml)
Cannabis oil
(1 ml)
p-value
Δ9-THC
Tlag, hours 0.57 ± 0.19 0.71 ± 0.27 0.356
Tmax, hours 1.07 ± 0.35 1.29 ± 0.39 0.200
Cmax, ng/ml 1.58 ± 0.72 3.76 ± 1.15 < 0.01
AUC0-24, ng/ml · min 3.63 ± 1.84 8.39 ± 2.83 0.011
t1/2, hours 1.68 ± 1.55 1.65 ± 0.75 0.964
11-OH-THC
Tlag, hours 0.86 ± 0.63 1.21 ± 0.49 0.283
Tmax, hours 1.00 ± 0.71 1.43 ± 0.45 0.143
Cmax, ng/ml 0.49 ± 0.41 1.19 ± 0.85 0.054
AUC0-24, ng/ml · min 0.85 ± 0.84 1.98 ± 1.41 0.044
t1/2, hours 0.70 ± 0.51 1.90 ± 2.70 0.33
THC-COOH
Tlag, hours 1.07 ± 0.35 1.21 ± 0.27 0.356
Tmax, hours 2.00 ± 0.76 2.14 ± 1.03 0.752
Cmax, ng/ml 4.74 ± 1.70 8.13 ± 4.74 0.037
AUC0-24, ng/ml · min 22.61 ± 15.05 44.25 ± 42.26 0.203
t1/2, hours 3.80 ± 3.99 6.29 ± 6.38 0.452
THC-glucuronate
Tlag, hours 1.36 ± 0.24 1.21 ± 0.27 0.356
Tmax, hours 4.43 ± 1.13 3.14 ± 0.69 0.035
Cmax, ng/ml 30.47 ± 8.23 31.92 ± 9.34 0.471
AUC0-24, ng/ml · min 453.69 ± 86.48 556.66 ± 258.97 0.208
t1/2, hours 20.75 ± 5.69 20.05 ± 7.23 0.843
CBD
Tlag, hours 0.50 ± 0.00 0.79 ± 0.39 0.103
Tmax, hours 0.57 ± 0.19 0.93 ± 0.35 0.047
Cmax, ng/ml 5.32 ± 2.80 3.49 ± 2.81 0.256
AUC0-24, ng/ml · min 5.16 ± 2.46 3.35 ± 2.09 0.157
t1/2, hours 0.53 ± 0.19 0.52 ± 0.31 0.923
Data were analysed with paired T-test (2 dependent means)
SD standard deviation
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The plant Cannabis sativa has a long history as an analgesic
medication in chronic pain, neuralgia and migraine [1]. It contains
more than 60 phytocannabinoids, all ligands of the endogenous
cannabinoid receptors. The active substance decisive for the
psychoactive and analgesic effects is delta-9-tetrahydrocannabinol
(Δ9-THC, or THC). At the same time, other cannabinoids, such as
cannabidiol (CBD), have shown promising anti-nociceptive proper-
ties [2]. Currently, the interest in cannabinoids for the treatment
of neuropathic pain is increasing, because they have improved
post-surgical pain, as well as migraine symptoms, with a safety
profile comparable to the most widely used pharmacological ther-
apies [3]. However, the fear of dependence and psychiatric disor-
ders limits their use and investigating. Given the recent possibility
to prescribe an Italian cannabis strain (FM2, 5-8% THC and 7-12%
CBD), we plan to study the pharmacokinetics and clinical effects
of a single oral dose of Cannabis FM2 taken as a decoction or in
olive oil.
Material and Methods
In an open-label two-period crossover study, 7 patients with
MOH diagnosed according to International Criteria [4] received a
single oral dose of cannabis decoction and, two weeks later, a
single oral dose of cannabis oil. Blood samples for THC, CBD and
their metabolites in whole blood were collected up to 24 hours
after the intake of each preparation. THC, CBD and their metabo-
lites were determined using chromatography coupled to mass
spectrometry (LC-MS/MS). Tolerability and adverse events were
assessed by numerical rating scale (NRS) about defined sensa-
tions. Pharmacokinetic parameters were determined by non-
compartmental methods, using PK solver [5]. Statistical analysis
was performed using STATAIC-13.
Results
The pharmacokinetics properties of the Cannabis edible products were
significantly different (Table 1). Specifically, the active ingredients THC
and CBD have shown different kinetic properties depending on the
oral solution in which they are taken. The cannabis oil showed lower
THC whole blood AUC24 h and Cmax than the cannabis decoction
(respectively, p=0.01128 and p<0.01). On the other hand, the median
CBD whole blood Tmax was higher for the cannabis decoction,
compared to cannabis oil (p=0.04653). No side effects were observed,
except for a high drowsiness one hour after the administration of
cannabis oil (p<0.01).
Conclusions
A single oral dose of Cannabis FM2 demonstrated different
pharmacological properties depending on whether it is taken as a
decoction or in olive oil. Further studies are needed to assess the
real usefulness of these therapies in clinical practice.
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The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 131 of 151Background Onabotulintoxin A (BONTA) is a treatment recommended
for chronic migraine CM). Its efficacy in reducing migraine frequency and
disability was fully demonstrated (1), though its effect on other
invalidating features as allodynia, vegetative symptoms and pain
topographical distribution is still unclear. Recent preliminary studies
suggested the utility of an easy-to-use smartphone-based electronic pain
diary (IHCS AID Diary) which enables assessment of clinical features of
pain over time. (2) This study aimed to monitor the effect of single doses
of BONTA in CM patients, by the used of the electronic diary ( )-
Materials and methods: Twelve CM patients were selected at
three different Apulian Headache Centers. Each patient was
submitted to 2 consecutive BONTA treatment sessions, according
to the PREEMPT study, over a a total time of six months. The
subject's task, during migraine, was to indicate the location and
topographical extension of pain (on a bodymap), the intensity of
pain (on a visual analogue scale - VAS), the state of discomfort
(on the Wong-Baker FACES pain rating scale), vegetative symp-
toms and therapeutic response by using the AID Diary. All sub-
jects also completed paper pain diaries.
Results. A significant and progressive reduction of migraine episodes
was observed from the paper and the electronic diary, in respect to
the average frequency computed in the three months preceding
BONTA intake. The time- regression analysis showed no relevant
change of number of allodynia symptoms and vegetative symptoms.
The topographical extension of headache and the state of
discomfort, went into progressive reduction during the six months of
observation, being mutually correlated (Fig. 1).
Conclusions
The use of an innovative electronic diary, suggested a positive action
of BONTA on the topographical extension of headache, with a
consequent subjective clinical improvement. This peculiar effect
could confirm that the clinical efficacy of BONTA is mediated by its
action on the mechanism of central sensitization at trigeminal level.
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Background
Cluster Headache (CH) is a severe primary headache that affect around
0.1% of general population. Twin and family studies provided the
importance of genetic factors in CH [1]; recently, our study suggested
an association between CH with both a common variant of the PACAP
(pituitary adenyl-cyclase activated peptide) receptor gene (ADCYAP1R1)
and a rare potentially damaging missense variant in the MME gene,
encoding for the membrane metallo-endopeptidase neprilysin [2]. The
aim of this study is to evaluate the clinical characteristic of those pa-
tients with mutations and to compare them to unmutated CH suffers.
Materials and methods
One hundred patients with CH were enrolled at the Headache
and Drug Abuse Centre, University of Modena and Reggio Emilia
(Italy). CH diagnosis was made following the ICHD-III beta criteria.
All participants provided a written informed consent to parteci-
pate; the study was approved by the local Ethical Committee. For
each patient a blood sample was collected and analyzed through
a genome-wide association study (GWAS) using the Infinium Psy-
chArray (Illumina) which combines common highly-informative
genome-wide tag SNPs and exonic SNPs [3]. Furthermore, pa-
tients reported in a specific format, the clinical characteristics of
headache, the vital parameters, the results of psychological tests
and their smoke habits.
Results
The data collected suggest a higher age for the NEP unmutated
group compared with the mutated one [58.64±17.34 vs 46.96±12.56;
p<0.001]. Moreover, the statistical analysis point out that there is a
tendency to have a higher age of CH onset in the NEP-mutated pa-
tients (n=7) than in the unmutated one (n=93) [36±14.1 vs 30±12.53;
p=0.053]; this trend is also evident in PACAP-R mutated group (n=36)
than in unmutated ones (n=64) [33.31±13.61 vs 28.56±11.63; p:
0.049]. Furthermore, a higher number of smoked cigarettes was reg-
istered for the PACAP-R unmutated group, both at the beginning of
the habit [19±10.56 vs 14.22±10.59; p=0.016] and during CH active
phases [10.11±10.9 vs 14 ± 9.44; p=0.047].
Conclusions:
ADCYAP1R1 and MME genes are involved in pain processing;
and, their gene variants seems to have a role in CH susceptibility
[4,5]. Also our data suggest an involvement and a potential
protective effect of these gene variants, in fact, the patients with
PACAP-R unmutated smoke a higher number of cigarettes (it is
well known that smoke and CH are closely related); both PACAP
and NEP mutated group show a higher age of CH onset. How-
ever, further and larger investigation are needed to confirm these
hypothesis.
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Background and aim of the study
Medication Overuse Headache (MOH) is a chronic disorder with a
prevalence of 1-2%, and a peak of 5% in women aged 40-50 years
[1].There is no established consensus concerning MOH standard of
care, but advice and educational intervention has proved to be ef-
fective likewise structured inpatient/outpatient detoxification pro-
grammes in reducing medication overuse in uncomplicated MOH
[2].This multicentre study aimed to assess any differences in pheno-
typical characteristics, type and amount of drugs overused and co-
morbidities between MOH patients who respond to an advice and
educational intervention and who did not.
Materials and Methods
Our group previously demonstrated the efficacy and tolerability of
sodium valproate (VPA) in a 12-week treatment period of MOH pa-
tients after detoxification, within the multicenter placebo-controlled
SAMOHA study [3].At V1 demographic and clinical data of the pa-
tients were collected.Then, they filled out a daily headache diary for
an observational period of 4 weeks.At V2, therefore, all patients were
divided in two subgroups:the one who could continue the study
(randomized group-R group) and the drop-out one (non-randomized
group-NR group).
Results
One-hundred and thirty patients were screened nine participating
centers [104 (80%) women;mean age was 42 years old].At V2, 88
(67.7%) patients continued meeting the inclusion/exclusion criteria
and were, then, randomized to placebo/VPA (R group), while 42
patients drop-out the study(NR-group).Analyzing in detail the drop-
out reasons,we find that 34 of the 42 NR patients left the study at V2
because they were no more satisfying the inclusion/exclusion criter-
ia(screening failure group-SF group). The remaining 8 patients left
the study before reaching V2 for other reasons.Comparing the clinical
and demographic differences between the R and SF groups,R group
was significantly older and with more years of migraine in history
than SF group.Moreover, in R group, the headache has become
chronic for more than twice of years, compared to SF group.
Conclusions and Discussion
The first conclusion is that in every MOH trial, after an educational
session (simple advice) on this disease, an observational period must
precede the assignment to any type of treatment, in order to confirm
the diagnosis of MOH.Obtaining a sample representative of “pure”
MOH will certainly improve the reliability of the results.On the other
hand, in the clinical field, our findings demonstrate that early diagnosis
(young age and/or few years of episodic and chronic migraine in
history) of MOH is needed to ensure a high remission rate. Necessarily,
early diagnosis must start from the general practitioner and before that
by the pharmacist.References
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Background
Non traumatic convexity SAH may rarely complicate SIH and can be
attributed to stretching/rupture of a cortical bridging vein. We
describe one patient with lung cancer who had orthostatic headache
secondary to SIH complicated with convexity SAH
Case report
A 64 years old male undergone to left pneumectomy for lung cancer
one year before, presented with one month history of severe
orthostatic headache following a strong coughing. Headache kept on
worsening in following days changing from orthostatic to non
positional and persistent one. Brain CT showed left frontal anterior
SAH and bilateral fronto-parietal hygromas. Brain MRI revealed dif-
fuse pachymeningeal enhancement typical sign of SIH and confirmed
the SAH. One month after symptoms beginning cerebral angiog-
raphy revealed no aneurisms or arterio-venous malformations and
normal visualization of cortical veins. Spinal MRI showed no CSF leak
site. We treated this patient with conservative measures: Trendelen-
burg bed rest for 3 weeks, overhydration and analgesic therapy.
Within 3 weeks his headache progressively disappeared and brain CT
was normal
Conclusions
Non traumatic convexity SAH is uncommon and may be associated
with isolated cortical veins thrombosis, which in turn, may rarely
complicate SIH [1]. Reduced intracranial pressure and brain descent
can result in dilatation and distortion of cerebral veins and finally
rupture of cortical veins leading to convexity SAH in SIH, as in our
case. Our case underlines the importance of differential diagnosis
between SIH pachymeningitis and meningeal carcinomatosis. Brain
MRI showed thickening of dura mater with diffuse symmetric and
linear pachymeningeal enhancement, typical and specific sign of
SIH [2], which is different from meningeal carcinomatosis
conversely characterized by focal and or nodular pachymeningeal
enhancement but also by leptomeningeal enhancement, which is
absent in SIH
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Table 1 (abstract P223). Association between sociodemographical and
clinical factors and awarness of migraine
Sign OR (95% CI)
High educational level <0.001 1.97 (1.43-2.78)
Number of family members with migraine 0.005 1.17 (1.04-1.31)
Duration of attacks (hours) 0.001 0.98 (0.97-0.99)
Throbbing pain 0.005 2.02 (1.23-3.31)
Localization of pain: lateral 0.043 1.36 (1.01-1.83)
Vomiting 0.018 1.43 (1.06-1.93)
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Objectives
To assess the awareness of migraine (M) and previous diagnostic and
therapeutic paths in naïf migraineurs visited by headache specialists
in several neo-Latin countries.
Methods
This is a multicentre study was conducted in parallel in 12 headache
centers located over 7 neo-Latin speaking countries and coordinated
by Mondino Institute, Pavia, Italy. Each center recruited up to 100
consecutive M patients aged 18 to 75 years who had been referred
for a first visit. Patients answered questions about the type of head-
ache they thought to suffer from, previous diagnosis received and
previous visits/investigations/treatments for M.
Results
1161 patients were enrolled. 326 patients (28%) knew that they
suffered from M, while 72% patients did not. 64% of patients simply
called their M “headache”. Other common names were cervical pain
(4%, mostly in Italy), tension-type headache (3%, mostly in Mexico,
Chile and Uruguay), sinusitis (1%). After multivariate analysis factors
associated with the awareness of M were 6 (Table 1).
Only variables which reached a statistical significance (p<0.05) after
multivariate analysis were reported.
Mexico had the highest rate of M awareness (51%) followed by Chile
(39%), Argentina (34%), Brazil (30%), Italy (25%), Moldova (17%) and
Uruguay (12%). All our patients had previously visited by a GP for M,
but only 8% of them diagnosed it as M. The majority of patients
(80%) has been visited by at least one specialist for their M, but only
35% of them formulated the correct diagnosis.
High rates of M diagnosis were observed in Moldova (53%),
Argentina (68%) and Uruguay (52%), but a minority of patients in
these countries was aware to suffer from M: 17%, 34% and 11%
respectively. 50% of patients were prescribed a X-ray and/or CT and/
or MRI of the cervical spine. 76% of patients underwent to imaging
of brain and/or cervical spine that exposed them to radiation. 28% of
patients had previously received a symptomatic migraine specific
medication and 29% had received at least one M preventative
medication.
Conclusion
Although M is the 3rd most common pathology worldwide and the
7th for disability, there is poor awareness of it among patients even
after consultation with physician(s). These findings speak in favour of
the importance of educating doctors and patients in the field of M in
order to reduce its burden worldwide.
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Background
Headache neuroimaging (NI) is commonly ordered even in absence
of red flags and despite guideline recommendations. Enhancing the
continuity of care was suggested as one potential way to reduce
unnecessary NI [1]. The aim of the study was to evaluate if a
different headache care organization and strict observation of
guidelines may optimize headache NI practices.
Materials and methods
Integration between a general practitioner (GP), specialized in
internal medicine, particularly expert in the headache management
due to previous long lasting experience in a Headache Center (HC),
and neurologists in the conduction of a HC was experimented for
the first time in Italy in the Health Authority 11 of Empoli,
covering about 240000 residents. The aim was to optimize the
headache care through a strict collaboration between GPs and HC for
better continuity of care. Only non-acute referrals are seen by HC special-
ists and the waiting time for appointment was less than 3 months. Head-
ache specialists had access to health information of previous specialist
visits, hospital recovery or emergency department access, contained in
the electronic records of Health Authority. The aim of this study was to
evaluate the NI investigation rate in patients referred for the first time in
2011-2013 years to HC. To reduce the unnecessary and overused NI, the
GP, basing on clinical history and first level neurological examination,
could only order magnetic resonance imaging (MRI) or computed tomog-
raphy (CT) in presence of red flags considered in the principal guidelines,
which were specified in the consultation record. NI for reassurance or pa-
tient request was not ordered. The rate of NI request was compared to
that of the two consultant neurologists of HC (χ2 test).
Results
There were large differences in the proportion of headache patients
imaged by the consultants. Neurologist visits were associated with
increased NI (26.3% vs. 10.9%, p <0.001) (Table 1). In patients visited
by GP, considering only the 676 (62%) subjects whom had never
undergone NI, the percentage was 14.6.
Conclusions
This study highlights that, following guideline recommendations, the
rate of NI utilization was largely inferior to that of neurologist
consultation in HC, and also to that previously reported in various
clinical settings [2]. In this study the correlation of reasons for
investigation with neuroradiological findings shows significant
abnormalities possibly related to headache in only 2.2% [2], in
agreement with the literature data. Therefore, optimizing headache
NI practices should be a major priority. It would be necessary a more
exact definition of which changes in headache pattern, and their
onset interval, require investigation.
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Patients
(n)
Mean age ± SD
(range)
♀ ♂ RMI/CT
(n)
Imaged
(%)
Neurologists 520 41.6 ± 18 (4-91) 75.2% 24.8% 127/10 26.3
GP 1078 41.0 ± 15 (4-90) 74.4% 25.6% 107/11 10.9
Fig. 1 (abstract P225). Availability of CH symptomatic effective
treatments in the EU countriesP225
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Background: Treating cluster headache can be tricky because the
pain becomes extremely severe very quickly and only few evidence
based treatments can work. Recent data from IHS suggest that
oxygen is not universally reimbursed or available for CH patients. The
aim of this study was to assess the reimbursement option and
accessibility of 3 effective medicines for CH (sumatriptan s.c, oxygen
zolmitriptan spray) across EU
Materials and Methods: A brief survey investigating the availability
of symptomatic treatments for CH was send on e-mail on January
2017 to at least one headache specialist for every single country of
the EU. For a complimentary point of view. In the countries where
active CH patients’ associations exist the survey was completed by
CH expert patients.
Results: The questionnaire was completed by 26 headache specialists
(93% of the EU countries representing 99.75% of the European
population) and 10 CH expert patients (representing 72% of the
European population). The answers provided by the headache
specialists and expert patients were coherent in every country.
Availability of ETs was defined as: a) complete: both oxygen and
sumatriptan s.c fully reimbursable and accessible; b) restricted: partial
reimbursment or inaccessibility of one between Oxy and Suma s.c; c)
lacking: both oxygen and sumatriptan s.c not reimbursable and not
accessible Oxygen was reimbursable for 62.68% of the CH population.
Oxygen device was reimbursable for 49% of the CH population.
Sumatriptan s.c. was reimbursable for 66% and accessible without
restrictions for 45% of the CH population. Zolmitriptan spray was
reimbursable for 23.7% and accessible without restrictions for 30.9% of
the CH population. Availability of CH effective treatments resulted
complete, restricted or lacking for 47%, 35.2% and 18% respectively of
the CH European patients (Fig. 1)
Conclusion: Based on this survey only 47% of the EU population had
an unrestricted access to CH effective treatments with unacceptable
inequalities between eastern countries and the rest of Europe.
Headache societies and patients’associations should pressure European
and national health authorities to improve the availability of effective
symptomatic treatments for CH
Consent for publication: The authors declare that written informed
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Background
Short-latency afferent inhibition (SAI) is a form of inhibition related
to the cholinergic activity in the cerebral cortex. It consists in a
galvanic stimulation of the median nerve at the wrist that can
suppress motor cortex excitability, as tested by transcranial
magnetic stimulation (TMS), when given at a short interstimulus
interval (ISI) between 18 and 21 ms. SAI is considered an in-vivo
way to study the sensorimotor integration mechanisms. SAI re-
sponse is influenced by the excitatory effect of acetylcholinergic
thalamocortical afferents on the inhibitory GABAergic (mostly
GABAa) cortical networks.
Materials and methods
We recruited 30 migraine without aura patients (16 between [MO] and
14 during [MI] attacks), and we compared them to a group of 16
healthy volunteers (HV). We first recorded somatosensory evoked
potentials N20 latency and N20-P25 peak-to-peak amplitude at the
contralateral parietal area. Afterward, SAI was recorded in all study’s
participants as follows: after a conditioning single pulse delivered on
the median nerve at the wrist, a TMS pulse was delivered with ISIs de-
rived from the latency of N20 plus 2 to 8 ms in steps of 2ms and in ran-
dom order. Five stimuli were delivered at each ISI. We calculated the
SAI slope of the linear regression between the unconditioned motor
evoked potential (MEP) amplitude and the 4-conditioned MEPs as a
measure of cortical excitability.
Results
Compared with HV, SAI was significantly reduced in MO, but enhanced
in MI patients (slope HV= +11.2, MO= +242, MI= -129). In both HV and
MO groups, but not in MI, the SAI slope positively correlated with the
SSEP N20-P25.
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The reduction of SAI in MO patients and its enhancement in MI
patients suggests a decrease and an increase respectively in facilitatory
thalamocortical cholinergic activity on GABAergic network activity in
the motor cortex. Since from the correlation analysis emerges that
slope of SAI normally correlates with the parietal response in MO, but
not in MI, we argue that more dysfunctional sensorimotor integrative
mechanisms might characterize migraineurs during an attack.
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Background - We previously reported that a short-lasting period of
ketogenic diet (KD) regimen can help to prevent migraine and can
normalize its interictal abnormal cortical hyperresponsivity. Here, we
aimed to verify whether cerebral cortex is the primary site of KD-
related changes or if the latter are the expression of ketones ability
to modulate brainstem subcortical structures.
Methods - We simultaneously recorded the nociceptive specific blink
reflex (nBR, a marker of the brainstem trigeminal activity) and cortical
pain-related evoked potentials (PREP) elicited by the stimulation of the
right supraorbital division of the trigeminal nerve in 18 migraine with-
out aura patients before and after 1-month of KD, during ketogenesis.
We measured nBR R2 component area-under-the-curve as well as PREP
amplitude habituations as the slope of the linear regression between
the 1st and the 2nd block of 5 averaged responses.
Results - We confirmed the ability of 1-month KD of significantly de-
creasing mean attack frequency and duration. KD significantly induced
normalization of the interictally reduced PREP habituation (pre: +1.8,
post: -9.1), while nBR habituation remained unchanged.
Conclusion - The results of the present study suggest that the clinical
efficacy of a short-lasting KD regimen in migraine can be primarily due
to a general normalization of the interictal cortical dysfunction, and not
to a direct modulation of the subcortical brainstem activation.
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Background
Few neuroimaging studies have explored brain morphometry in
patients affected by chronic migraine (CM). Most of these studies were
performed in patients with medication overuse. Here, we performed
voxel-based morphometry (VBM) analysis to investigate the grey matter
(GM) density of the whole brain in patients affected by CM without
medication overuse. Our aim was to investigate whether there are fluc-
tuations in the GM densities in relation to the patients’ clinical features.Materials and methods
Twenty untreated CM patients without a past medical history of
medication overuse underwent 3T MRI scans and were compared to a
group of 20 healthy volunteers (HV). SPM12 and CAT12 toolbox were
used to process MRI data and to perform VBM analysis of structural T1-
weighted MRI scans. The patients’ versus HV relative GM density was
assessed with an uncorrected threshold of p < 0.005. To check for pos-
sible correlations, patients’ clinical features and GM maps were regressed.
Results
Compared to HV, CM patients presented 4 clusters of significantly
lower GM densities: I) right cerebellar lobules (VIIIa, CrusII), II) the left
occipital areas (BA17/BA18), III) the left middle temporal gyrus, and
IV) the left temporal pole /amygdala /pallidum /orbitofrontal cortex.
The GM density of cerebellar hemispheres correlated negatively with
the years of headache disease, and positively with the number of
tablets intake per month.
Conclusions
To summarize, CM is associated with lower GM density in several brain
areas known to be involved in antinociception, multisensory
integration, and analgesic dependence. The GM density within the
cerebellum was significantly related to longer duration of headache
disease and to higher consumption of acute headache medications.
We hypothesize that this morphological pattern we identified may be
considered as a predisposing ground on which to develop medication
overuse headache.EHF ORAL PRESENTATIONS
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Background
There is a high unmet need for new preventive migraine treatments,
especially for patients who have failed existing migraine therapies.
Erenumab is a fully human monoclonal antibody that blocks the
calcitonin gene-related peptide receptor. In a large, multicenter,
double-blind, placebo controlled, phase 3 study (STRIVE), erenumab
70 mg and 140 mg demonstrated efficacy in subjects with episodic
migraine and showed a safety profile similar to placebo. Here we re-
port efficacy results in a subgroup of trial subjects with prior prevent-
ive treatment failure(s).
Methods
Subgroup analyses were conducted in subjects from the STRIVE trial
who had failed ≥1 (n=369) or ≥2 (n=161) prior preventive treatments
due to lack of efficacy and/or intolerability. Analyses included change
from baseline in mean monthly migraine days (MMDs) and
achievement of ≥50% reduction from baseline in MMDs, assessed over
weeks 13–24 (months 4, 5, and 6). In the full trial, subjects (N=955)
were randomized 1:1:1 to subcutaneous monthly placebo or erenumab
70 mg or 140 mg for 24 weeks (6 months). P values for subgroup
analyses are descriptive and not adjusted for multiple comparisons.
Results
Greater reductions from baseline in MMDs were observed for the
erenumab 70 mg and 140 mg groups compared with placebo in both
treatment failure subgroups (Table 1). More subjects who received
erenumab achieved ≥50% reduction in MMD in both subgroups
compared with placebo. For the 70 mg group, the odds (95%
confidence interval) of achieving ≥50% reduction in MMD were 2.9
times higher than that of placebo for both treatment failure subgroups.
For the 140 mg group, the odds were 3.1 and 4.5 times higher than
placebo, respectively.
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Robust treatment effects were observed for both 70 mg and 140 mg
erenumab in subjects who had previously failed preventive migraine
treatments. For 140 mg, effects were numerically greater in this
subpopulation than in the overall trial population, and as in the overall
population, erenumab 140 mg showed numerically greater efficacy
than erenumab 70 mg. These results suggest that erenumab may have
particular utility in this subgroup of patients.
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Background
Current therapies for reducing raised intracranial pressure (ICP) in
conditions such as idiopathic intracranial hypertension have limited
efficacy and tolerability. As such, there is a pressing need to identify
novel drugs. Glucagon-like peptide-1 receptor (GLP-1R) agonists are
used to treat diabetes and promote weight loss but have also been
shown to affect fluid homeostasis in the kidney. Here, we investigate
whether exendin-4, a GLP-1R agonist, is able to modulate cerebro-
spinal fluid (CSF) secretion at the choroid plexus and subsequently
reduce ICP.
Methods
GLP-1R mRNA and protein was assessed by quantitative PCR,
immunohistochemistry and fluorescently tagged exendin-4 in human
and rat choroid plexus. The effect of exendin-4 on GLP-1R activation
and CSF secretion was evaluated in cultured rat choroid plexus epithe-
lial cells using cAMP assays and a Na+ K+ ATPase activity assay. The ef-
fect of Exendin-4 on ICP was assessed in adult female rats with normal
and raised ICP.
Results
We demonstrated that the GLP-1R is present in human and rat
choroid plexus. Exendin-4 significantly increased cAMP levels (2.14
± 0.61 fold, P<0.01) part of the GLP-1R signalling pathway, in a
concentration-dependant manner and this response could be inhib-
ited by the addition of the GLP-1R antagonist exendin 9-39.
Exendin-4 also significantly reduced Na+ K+ ATPase activity, a
marker of CSF secretion (39.3±9.4% of control; P<0.05). Finally,
in vivo ICP recording in female adult rats demonstrated that sub-
cutaneous administration of 20μg/kg exendin-4 significantly re-
duced ICP in normal (65.2 ± 6.6% of baseline; P<0.01) and raised
ICP rats (56.6 ± 5.7% of baseline; P<0.0001).
Conclusion
We demonstrate that exendin-4 reduces CSF secretion by the choroid
plexus, and ICP in normal rats and rats with raised ICP. Repurposing
existing GLP-1 drugs may represent a novel therapeutic strategy for
conditions of raised ICP such as idiopathic intracranial hypertension.
Additionally, GLP-1R agonist therapy promotes weight loss, which
would be advantageous in idiopathic intracranial hypertension.O3
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Background
Efficacy and safety/tolerability of erenumab, a human anti-CGRP re-
ceptor monoclonal antibody, were evaluated in episodic migraine
(EM) subjects in a multinational, phase 3 trial (NCT02456740).
Methods
Adults with EM (n=955) were randomised 1:1:1 to subcutaneous
monthly placebo or erenumab 70 mg or 140 mg for 24 weeks. The
primary endpoint was change from baseline in mean monthly
migraine days (MMDs) over weeks 13-24. Secondary endpoints were
≥50% reduction in MMDs; change in acute migraine-specific medica-
tion days; change in Physical Impairment (PI) and Impact on Every-
day Activities (EA) (as measured by the Migraine Physical Function
Impact Diary [MPFID]). P-values are for pairwise comparisons of each
erenumab dose with placebo, statistical significance determined after
multiplicity adjustment.
Results
Subjects reported 8.3 MMDs at baseline and experienced -3.2, -3.7,
and -1.8-day reductions in the 70 mg, 140 mg, and placebo groups,
respectively (p<0.001). A ≥50% reduction in MMDs was achieved by
43%, 50%, and 27% in the 70 mg, 140 mg, and placebo groups
(p<0.001), and monthly acute migraine- specific medication was
reduced by -1.1, -1.6, and -0.2 days (p<0.001). Subjects had
improved PI scores (-4.2, -4.8, -2.4 points in the 70 mg, 140 mg, and
placebo groups; p<0.001) and EA scores (-5.5, -5.9, and -3.3 points;
p<0.001). The safety/tolerability profile of erenumab was similar to
placebo; subjects most frequently reported nasopharyngitis, upper-
respiratory-tract infection, and sinusitis.
Conclusion
Erenumab 70 mg and 140 mg significantly reduced migraine frequency
and use of migraine-specific medications, reducing migraine’s impact
on physical impairment and everyday activities in this EM trial. Numer-
ically greater efficacy was observed for the 140 mg dose consistently
across endpoints.
Trial registration
Clinical trials.gov NCT02456740.
O4
Modelling cortical spreading depression by a computational
algorithm of distributed neural excitability: correlation with clinical
features in single migraine with aura patients
Marina de Tommaso1,2, Julia Maria Kroos3, Eleonora Vecchio1,
Nicola Burdi4, Sebastiano Stramaglia2,5, Luca Gerardo Giorda3
1Applied Neurophysiology and Pain Unit, SMBNOS Department, Bari
Aldo Moro University (Italy); 2TIRES Center, Bari Aldo Moro University
(Italy); 3BCAM -Basque Center for Applied Mathematics-Center, Bilbao,
Spain; 4Neuroradiology Unit, SS.Annunziata General Hospital, Taranto
(Italy); 5Physic Department, Bari Aldo Moro University , Bari (Italy)
Correspondence: Marina de Tommaso (marina.detommaso@uniba.it)
The Journal of Headache and Pain 2017, 18(Suppl 1):O4
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 137 of 151Background
Cortical spreading depression (SD) is thought to underlie migraine
aura but mechanisms of triggering SD and propagation in the
structurally normal cortex of migraine patients is still unknown. Some
studies showed that the sensory predominance of migraine aura is
likely due to a greater susceptibility of primary sensory cortex to CSD
probably for their structural complexity [1]. We used MRI imaging
registration in migraine with aura patients to elaborate a CSD
propagation logarithm that takes into account the morphology of
the various cortical areas involved.
Materials and methods
We process the data sets with the Freesurfer software to obtain the
geometry and labelling for the different brain regions (Desikan-Kiliani
Atlas or Brodman areas 1, 2, 3, 4, 44, 45, 17, 18) in five migraine with
aura patients. According to the map of the disturbed areas suggested
by the aura symptoms, we then initialize the region first affected in the
respective hemisphere. Starting the propagation of the CSD in this
region we recorded the arrival time in each point of the brain cortex.
Results
We obtained the different brain geometries and the Brodman areas
1, 2, 3, 4, 44, 45, 17 and 18 of the five subjects. In order to run a
simulation of the CSD propagating on the cortex we need to identify
an initial region as a starting point for the wave. We take a bearing
on the map of the disturbed regions provided along with the MRI
data from the patients. For the simulation of the CSD we started the
wave in these regions and recorded the propagation. In each point
we recorded the arrival time of the wave. We visualize the arrival
times of the wave in the Fig. 1. This was in accord with the reported
evolution of the clinical symptoms.
Conclusions
The way CSD propagates can change in relation to brain morphology.
The specific algorithm was able to provide for a simulation of the
electrical phenomenon, explaining the progressive evolution of clinical
symptoms. Further tests in larger series, could give an aid in
understanding the pathophysiological peculiarities of migraine-with-aura
brain.
References
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Spreading Depolarizations. J Neurosci. 2016 ;36(17):4733-43.Fig. 1 (abstract O4). Simulation of CSD progression in a single
patient with reported scotomas in the right visual hemifield,
followed by bilateral brachial paresthesia and speech disturbances.
The time of progressive cortical areas involvement in the simulation
model, was in accord with the reported clinical evolution of aura
symptoms.O5
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Interventional treatment is an important but underevaluated issue for
neurologist. However peripheral nerve blocks have been used for both
acute and preventive treatment of headaches for decades and are safe
and effective therapeutic options for many patients with headache
disorders. They can cause a long lasting (several weeks to months) pain
relief. This long lasting effect is thougt to be due to central pain
modulation. Nerve blocks may be an option for the patients who have
failed their home medications or who doesn’t want to use drugs.
Blocks may also be used to treat patients who need relief between
onabotulinum toxin A injections and in medication overuse headache
during their acute therapy. Nerve blocks are safe and can be
appropriate for children and pregnant patients, and also in patients
with kidney-liver diseases. In pregnancy, lidocaine is considered a cat-
egory B drug. Greater occipital nerve blockade is the most common
procedure in peripheral nerve blocks. But lesser occipital nerve block-
ades, sphenopalatine ganglion blockades, supratrochlear, auriculotem-
poral, supraorbital, infraorbital and mental nerve blockades, cervical
root blockades, their combinations can be used in patients with head-
ache disorders. Local anestetics and steroids are being used for nerve
blockades.
Botulinum toxin injections are also approved effective methods for
migraine all over the World. There is some other indications under
search and experineces increases the applications in every day.
We want to show the injection techniques and efficacy by sharing
our cases. Deepending on the time, after the presentation some
audience keep a chance to applicate tehmselves on the model
provided by authors.O6
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Background
A study was conducted to determine if galcanezumab (120 or 240
mg monthly), a humanized monoclonal antibody that selectively
binds to calcitonin gene-related peptide, was superior to placebo in
the prevention of chronic migraine.
Materials and methods
Eligible patients 18-65 years of age with chronic migraine (≥15 head-
ache days per month, of which at least 8 met criteria for migraine) were
randomized 2:1:1 to subcutaneous monthly injections of placebo
(N=558), galcanezumab 120 (N=278) or 240 mg (N=277). The primary
endpoint was the overall mean change-from-baseline in the number of
monthly migraine headache days (MHD) during the 3-month double-
blind treatment period. Key secondary measures included rates of
≥50%, ≥75%, and 100% reduction in monthly MHD, as well as the
changes in monthly MHD with acute migraine treatments, the Role
Function-Restrictive domain score of the Migraine-Specific Quality of
Life Questionnaire (MSQ-RFR), and the Patient Global Impression-
Severity of Illness (PGI-S).
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Baseline mean number of monthly MHD was 19.4. Both
galcanezumab doses demonstrated a statistically significant
difference (p<.001) compared with placebo in overall mean
reduction in number of monthly MHD during the treatment
period (placebo= -2.74; galcanezumab 120-mg= -4.83; galcanezu-
mab 240-mg= -4.62), with statistical separation from placebo
starting at Month 1. The rate of patients with ≥50% reduction
from baseline in MHD was significantly greater for both galcane-
zumab doses compared with placebo (both p<.001). Compared
with placebo, the 240-mg dose-group also had significantly
higher rates of ≥75% response (p<.001), greater reductions in
monthly MHD with acute migraine treatment (p<.001), and
greater improvement in the MSQ-RFR (p<.001) and PGI-S (p<.001).
There were no clinically meaningful differences between either
galcanezumab dose-group and placebo on any safety parameters
except for a higher incidence of injection site reaction (p<.05), in-
jection site erythema (p<.01), and sinusitis (p<.05) all in the 240-
mg dose-group relative to placebo.
Conclusions
Both doses of galcanezumab were superior to placebo in the
reduction of monthly MHD, with significantly more patients reducing
their monthly MHD by ≥50%. The 240-mg dose was also superior to
placebo on most other key secondary measures. Both galcanezumab
doses appeared to be efficacious, safe, and well-tolerated for the pre-
ventive treatment of chronic migraine.
Acknowledgements
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Background
The differential diagnosis between migraine with aura (MA) and
transient ischemic attacks (TIA) is difficult. Misclassification occurs often
and has grave consequences for the patients. In the International
classification of headache disorders 3rd edition beta (ICHD-3beta) this
was recognized and appendix criteria were given in the hope that they
might better discriminate between these diseases. Conversely,
misclassifications occur often in TIA clinics because of a lack of explicit
diagnostic criteria for TIA.
Methods
We prospectively included 120 patients with TIA who were
diagnosed according to the tissue based TIA definition and 1390
Danish patients and 152 Russian patients with MA. TIA was defined
as new neurologic deterioration lasting less than 24 hours with no
infarction in the relevant area on neuroimaging [1]. All received
extensive semi structured face to face interviews about relevant
clinical characteristics. Eligible patients with TIA had focal brain or
retinal ischemia with resolution of symptoms without presence of
new infarction on magnetic resonance imaging with diffusion
weighted imaging (n=112) or computed tomography (n=8). We
then tested main body and appendix criteria for MA for specificity
against TIA patients and for sensitivity against the migraine
materials. We developed explicit diagnostic criteria for TIA and
tested them for sensitivity in the TIA patients and for specificity in
the MA patients.Results
The appendix criteria for MA had specificity versus TIA of 0.91 while
the main body criteria were much less specific: 0.73. There was no
major difference in sensitivity and we therefore recommend that the
appendix criteria should replace the current main body criteria for
MA. Our proposed explicit diagnostic criteria for TIA had a sensitivity
of 1.0 which means that all 120 TIA patients fulfilled the criteria. The
specificity of the TIA criteria tested against the Danish material of MA
was 95% and tested against the Russian material it was 96%.
Conclusion
The field testing has led to preference for the appendix criteria for
MA. We were able to design explicit diagnostic criteria for TIA with
a very high sensitivity and specificity. We strongly recommend
implementation of these criteria in migraine and cerebrovascular
clinics.
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Background
Primary headache disorders are classified as rare when their
prevalence in the general population is below 1%. The criteria for the
diagnosis of rare primary headaches are detailed in Chapter 3 and
Chapter 4 of part one of the International Classification of Headache
Disorders, 3rd edition (ICHD-3) [1]. For the majority of rare headaches,
prevalence and incidence have been estimated by case reports or
underpowered observational studies. This paucity of evidence also
concerns the Italian population. Our study aims to estimate specific
and overall prevalence and incidence of rare headaches, according
to ICHD-3, in patients referred to tertiary Headache Centres in a 3-
year period.
Material and method
Data regarding patients referred to tertiary Headache Centres from
April 30, 2017 to May 1, 2014 were retrospectively collected, by means
of a web-based open source platform (SurveyMonkey.org). Each partici-
pating Centre received the approval of the competent Ethics Commit-
tee before commencing any study procedures. Patients were asked to
give their consent according to Italian law. Patients were identified
through Italian Health System unique identifier, in order to avoid dupli-
cations of patients referred to more than one Centre.
Results
Eleven Headache Centres were asked to participate and 10 participated
in the study as data can be easily retrieved from electronic sources
used for clinical practice. To date, data from 6 centres have been
collected. In the study period, a total of 15847 patients referred to the
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 139 of 151Centres, and 724 (4.5%) of them had a diagnosis (prevalence) of rare
headaches. Headache disorders with higher prevalence were cluster
headache, either episodic or chronic (n=393, 2.4%), primary stabbing
headache (n=49, 0.3%) and new daily persistent headache (n=26,0.2%).
Three hundred-ninety four (2.5%) patients received their first diagnosis
of a rare headache in the same period.
Conclusions
Data collected in participating Headache Centres allow to initially
depict rare headaches epidemiology. Retrospective data will be
integrated by prospective data collected in a registry that has been
started by participating Centres. These epidemiologic data will serve
for investigations about clinical features, diagnostic and therapeutic
management of rare, often neglected, primary headaches in Italy.
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Background
The safety, tolerability, and preliminary efficacy of non-invasive vagus
nerve stimulation (nVNS; gammaCore®) have been demonstrated in
clinical practice and pilot studies of acute migraine treatment [1,2].
The ease of use, flexibility, and favourable adverse event profile of
nVNS make it an attractive option for patients. The aim of this study
was to explore the efficacy, safety, and tolerability of nVNS for the
acute treatment of migraine.
Methods
This multicentre, double-blind, randomised, controlled trial (RCT) in-
cluded 248 patients with episodic migraine with or without aura
from 10 Italian tertiary headache centres. Entry criteria and efficacy
end points were consistent with existing guidelines and those of pre-
vious nVNS studies. Within 20 minutes from migraine pain onset, pa-
tients self-administered bilateral 120-second stimulations to the right
and left sides of the neck. Patients were instructed to repeat both
stimulations if pain did not improve by 15 minutes. Patients adminis-
tered an optional additional set of stimulations at 120 minutes if not
pain-free. Rescue medication use before 120 minutes was considered
treatment failure. Up to 5 migraine attacks were treated in the
double-blind period.
Results
Acute nVNS treatment (n=120) led to significantly higher pain-free
rates than sham (n=123) for the first treated migraine attack at 30
minutes (12.7% vs 4.2%; P=0.012) and 60 minutes (21.0% vs 10.0%;
P=0.023) but not at 120 minutes (30.4% vs 19.7%; P=0.067; primary
end point; sensitivity analysis). To address the inconsistency between
the 120-minute finding and the 2 earlier findings, a post hocrepeated-measures test confirmed that nVNS was superior to sham
through 120 minutes (odds ratio: 2.3; 95% CI: 1.2, 4.4; P=0.012).
Superiority of nVNS over sham was also seen for the rate of mild/no
pain at 120 minutes (40.8% vs 27.6%; P=0.030) and ≥50% responder
rates for no pain (32.4% vs 18.2%; P=0.020) and mild/no pain (47.6%
vs 32.3%; P=0.026). Adverse event incidences were low, and most
were mild and transient.
Conclusions
This RCT demonstrates that nVNS is rapidly effective, extremely well
tolerated, and practical for the acute treatment of episodic migraine
with or without aura. Significant benefits of nVNS versus sham were
observed for pain freedom at 30 and 60 minutes but not at 120
minutes (primary end point). A repeated-measures test validated the
primary end point, indicating the superiority of nVNS over sham
through 120 minutes. Findings provide a clinical rationale for acute
nVNS treatment in episodic migraine.
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Background
Several studies indicated that migraine patients have tract-specific al-
terations in several white-matter tracts as compared to controls [1-
12]. We investigated differences in white-matter tracts between epi-
sodic migraine (EM) patients and chronic migraine (CM) patients.
Materials and methods
We included consecutive eligible patients with EM or CM and referring
to a tertiary headache center. We selected Caucasian women aged
from 30 to 60 years. EM and CM patients were matched by age ±1.
Imaging was conducted on a single 3-Tesla magnetic resonance im-
aging (MRI) scanner. Diffusion tensor data (DTI) data were processed
using TRActs Constrained by Underlying Anatomy (TRACULA) for auto-
matic reconstruction of a set of major white-matter pathways from
diffusion-weighted MRI.
Results
We included 20 EM patients (mean age±SD 43.2±6.9) and 20 CM
patients (mean age±SD 43.8±6.9). Years lived with migraine were
similar in EM (mean±SD 14.3±7.0) and CM (mean±SD 18.6±9.0)
patients (P=0.118). Mean±SD number of days with headache per
month was 3.3±1.8 for EM; 9 (45%) CM patients had drug abuse.
We found differences in mean diffusivity (MD) between EM and CM
patients in the left superior longitudinal fasciculus temporal (Table 1).
We found differences in mean fractional anisotropy (FA) between EM
and CM patients bilaterally in the right inferior longitudinal fasciculus
and in the left superior longitudinal fasciculus temporal (Table 1).
EM patients showed a negative age-adjusted correlation between
years lived with migraine and FA in the uncinate fasciculus (r=-.501;
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tween years lived with migraine and MD in the corpus callosum for-
ceps major (r=.500; P=.049) and in the right anterior thalamic
radiation (r=.492; P=.050). We did not find any correlation between
frequency of migraine attacks and MD or FA nor in the EM nor in the
CM group.
Conclusions
We found differences in white matter tracts between EM and CM
patients. Our results also indicate that the longer the years lived with
migraine the greater is the impairment in selected white-matter
tracts. In summary, our data suggest that migraine type and number
of years with migraine affects white-matter tract status.
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To explore whether subjects exposed to head injury more often
developed a new headache or experienced exacerbation of previously
reported headache compared to non-exposed.
Methods
This population-based historical cohort study included headache
data from two large epidemiological surveys performed with an 11-
year interval. This was linked with data from hospital records on ex-
posure to head injury occurring between the health surveys. Partici-
pants in the surveys who had not been hospitalized because of a
head injury comprised the control group. The head injuries were
classified according to the Head Injury Severity Scale (HISS). Multi-
nomial logistic regression was performed to investigate the associ-
ation between head injury and new headache or exacerbation of
pre-existing headache in a population with known pre-injury head-
ache status, controlling for potential confounders.
Results
The exposed group consisted of 294 individuals and the control
group of 25,662 individuals. In multivariate analyses, adjusting for
age, sex, anxiety, depression, education level, smoking and alcohol
use, mild head injury increased the risk of new onset headache
suffering (OR 1.74, 95% CI 1.05 – 2.87), stable headache suffering (OR
1.70, 95% CI 1.15 – 2.50) and exacerbation of previously reported
headache (OR 1.93, 95% CI 1.24 – 3.02). The reference category was
participants without headache in both surveys.
Conclusion
Individuals exposed to a head injury were more likely to have
new onset and worsening of pre-existing headache and persistent
headache, compared to the surrounding general population. The
results support the entity of the ICHD-3 beta diagnosis “persistent
headache attributed to traumatic injury to the head”.
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Background
Few neuroimaging studies have explored brain morphometry in
patients affected by chronic migraine (CM). Most of these studies
were performed in patients with medication overuse. Here, we
performed voxel-based morphometry (VBM) analysis to investigate
the grey matter (GM) density of the whole brain in patients affected
by CM without medication overuse. Our aim was to investigate
whether there are fluctuations in the GM densities in relation to the
patients’ clinical features.
Materials and methods
Twenty untreated CM patients without a past medical history of
medication overuse underwent 3T MRI scans and were compared to
a group of 20 healthy volunteers (HV). SPM12 and CAT12 toolbox
were used to process MRI data and to perform VBM analysis of
structural T1-weighted MRI scans. The patients’ versus HV relative
GM density was assessed with an uncorrected threshold of p < 0.005.
To check for possible correlations, patients’ clinical features and GM
maps were regressed.
Results
Compared to HV, CM patients presented 4 clusters of significantly
lower GM densities: I) right cerebellar lobules (VIIIa, CrusII), II) the
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 141 of 151left occipital areas (BA17/BA18), III) the left middle temporal
gyrus, and IV) the left temporal pole /amygdala /pallidum
/orbitofrontal cortex. The GM density of cerebellar hemispheres
correlated negatively with the years of headache disease, and
positively with the number of tablets intake per month.
Conclusions
To summarize, CM is associated with lower GM density in
several brain areas known to be involved in antinociception,
multisensory integration, and analgesic dependence. The GM
density within the cerebellum was significantly related to longer
duration of headache disease and to higher consumption of
acute headache medications. We hypothesize that this
morphological pattern we identified may be considered as a
predisposing ground on which to develop medication overuse
headache.Fig. 1 (abstract O13). EM and CM respondents self-reporting (SR) an
assessed symptom or a physician diagnosis (SR-PD) of a conditionO13
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Background
Migraine is comorbid with various conditions, many with a greater
relative frequency in chronic migraine (CM) versus episodic migraine
(EM). The objective of this study was to replicate and extend work
on the comorbidity of pain, psychiatric, and endocrine/neurological
symptoms and conditions in a systematically recruited sample of
people with EM and CM.
Materials and Methods
Data from the prospective web-based baseline survey of the
Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
were used to identify people, recruited from an online panel
using quota sampling, with EM and CM based on criteria modified
from the International Classification of Headache Disorders, third
edition, beta version. Participants completed a Comorbidities/
Endophenotypes module that assessed 64 symptoms (e.g., neck
pain) and conditions (e.g., rheumatoid arthritis). Respondents were
asked (1) if they ever had a specific symptom (“Self-Reported
[SR]”) and, if present, (2) if the SR symptom or condition had
been confirmed/diagnosed by a “doctor” (“SR-physician diagnosis
[SR-PD]”). Chi-square analysis was used to compare the relative
frequency of symptoms and conditions in respondents with EM
versus CM. This report presents data on symptoms and conditions
from the Pain, Psychiatric, and Endocrine/Neurological comorbidity
categories.
Results
Available CaMEO respondents with migraine (16,763) were sent the
Comorbidities/Endophenotype module and 12,810 (76.4%: EM,
11,699; CM, 1,111) provided valid responses. Compared with the EM
group, the CM group had a similar mean age (EM, 41.3 years; CM,
41.9 years), was more likely to be female (EM, 74.2%; CM, 81.5%;
P<0.001) and white (EM, 84.0%; CM, 88.7%; P<0.001), and had a
mean higher body mass index (EM, 27.7 kg/m2; CM, 28.7 kg/m2;
P<0.001). The relative frequencies were significantly higher for 24
(85.7%) of the 28 SR symptoms and SR-PD conditions assessed (Fig.
1). 5 of these conditions had relative frequencies >10% higher in
CM than EM: chronic back pain (EM, 22.5%; CM, 37.6%), chronic
pain (EM, 7.4%; CM, 22.2%), neck pain (EM, 38.1%; CM, 55.3%), anx-
iety (EM, 25.7%; CM, 42.2%), and depression (EM, 28.1%; CM,
45.6%).Conclusions
Overall, significantly more respondents with CM versus EM
reported having specific symptoms or conditions. Mechanisms
explaining this association might include direct causality (e.g., CM
causes the comorbidity), reverse causality (e.g., the condition
increases CM risk), and shared genetic or environmental risk
factors. Confounding, or detection bias (i.e., “Berkson’s Bias”)
could also contribute.
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Background
Human pharmacological imaging has been used with great
success to study the cerebrovascular effects of headache-
inducing substances, including calcitonin gene-related peptide
(CGRP) and sildenafil. The role of the glutamate alterations in
the deep brain structures pons and thalamus is of emerging
interest but to date, methods to non-invasively study the
pharmacologically induced biochemical effects in these areas
have not been validated.
Materials and methods
We applied an optimized in vivo human pharmacological proton
(1H) magnetic resonance spectroscopy (MRS) protocol in a
randomized, placebo-controlled, double-blinded, double-dummy,
three-way cross-over design, using the headache-inducing sub-
stances calcitonin gene-related peptide (CGRP) and sildenafil,
with peripheral and central modes of action on the nervous sys-
tem respectively. Seventeen healthy volunteers were scanned
with our optimized 1H-MRS protocol to investigate the CGRP-
and sildenafil-induced glutamate+glutamine (Glx) changes in
both pons and thalamus. In addition, we systematically investi-
gated the Glx reproducibility and variability in pons and thal-
amus, based on repeated measurements on the same day and
three separate days, in order to validate our method.
Results
We found that spectral quality was good for measurements in
pons and thalamus with relatively low spectral line widths and
high signal-noise-ratio. The Glx measurement variation was
overall low in both pons and thalamus. The Glx level increased
in pons at 40 – 70 min after sildenafil administration, when
compared to placebo (5.6%, P=0.037). We found no sildenafil-
induced Glx changes in thalamus, and no CGRP-induced Glx
changes in pons or thalamus.
Conclusions
Our findings demonstrate that Glx measurements can be
reliably obtained from pons and thalamus. The sildenafil-
induced changes in pons likely reflect increased excitability of
the pontine neurons. CGRP did not induce pontine or thalamic
metabolic changes, indicating that it does not modify the neur-
onal excitability in these central deep brain structures, but ra-
ther exerts its effects on the peripheral nervous system and/or
the trigeminal ganglion.O15
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Background
Calcitonin gene-related peptide (CGRP) and sildenafil are vasoactive
substances that induce migraine attacks in patients. The intradural
arteries are thought to be involved, but these have never been ex-
amined in vivo. Furthermore, sildenafil is the only migraine inducing
compound, where cephalic dilation is not reported. Here, we investi-
gate the effect of CGRP and sildenafil on the extracranial and intra-
dural parts of the middle meningeal artery (MMA).
Methods
In a double-blind, randomized, three-way crossover, placebo-controlled
head-to-head comparison of CGRP and sildenafil, MR-angiography was
recorded in healthy volunteers at baseline and twice after study drug
administration. Circumferences of extracranial and intradural MMA seg-
ments were measured using semi-automated analysis software. The
area under the curve (AUC) for circumference change was compared
using paired t-tests between study days.
Results
Twelve healthy volunteers completed the study. The AUCBaseline-120min
was significantly larger on both the CGRP and sildenafil days in the
extracranial MMA (CGRP, p=0.0003; sildenafil, p=0.021) and the intradural
MMA (CGRP, p=0.013; sildenafil, p=0.027) compared to placebo.
Peak dilation of the extracranial MMA after CGRP was 15.7% (95% CI
[11.2-20.1]) and 18.9% (95% CI [12.8-24.9]) after sildenafil. Peak
intradural MMA dilation was 12.5% (95% CI [8.1-16.8]) after CGRP and
9.9% (95% CI [2.9-16.9]) after sildenafil.
Conclusion
An important novel finding of the present study is that both CGRP
and sildenafil dilate intradural arteries, supporting the notion that all
pharmacological migraine triggers, so far, do indeed dilate cephalic
vessels. We suggest that intradural artery dilation is associated with
headache induced by CGRP and sildenafil.
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Fig. 1 (abstract O16). Significant differences between CM and EM
groups expressed in log10p and following the application of the
False Discovery Rate (FDR) model
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Chronic migraine (CM) may be associated to specific cortical and
subcortical volumetric changes [1-4]. However, it is not clear whether
there is a causal relationship between these changes and the clinical
course of migraine or whether they are rather an epiphenomenon. The
objective of this study was to identify the main structural changes
associated with CM and the relationship with the disease duration.
Materials and methods
We included consecutive eligible patients with episodic migraine (EM)
or CM referring to a tertiary headache center. We selected Caucasian
women aged from 30 to 60 years. EM and CM patients were matched
by age ±1. The assessment was performed through a single 3-Tesla
magnetic resonance imaging (MRI) acquisition followed by a morfovo-
lumetric analysis through the Freesurfer software [5-7]. Groups analyses
were performed through the QDec software for cortical volumes (level
of significance fixed at p 0.01) and through the SPSS V22.0 software for
subcortical volumes (level of significance fixed at p 0.05).
Results
We included 17 EM patients (mean age±SD 42.4±6.1) and 17 CM
patients (mean age±SD 43.1±6.4). Years lived with migraine were not
significantly different in EM (mean±SD 18.2±10.6) as compared to
CM (mean±SD 21.4±11.6) patients (p=0.749).
CM patients showed a selective cortical volume loss involving the
insular cortex (p<0.005), the medial (p<0.005) and lateral (p<0.001)
orbitofrontal cortex, the posterior cingulate cortex (p<0.001) and the
inferior temporal cortex (p<0.005) in the right hemisphere, and the
lateral orbitofrontal cortex (p<0.001), the posterior cingulate cortex
(p<0.001) and the caudal anterior cingulate cortex (p<0.001) in the
left hemisphere. At subcortical level volume differences involved the
left and the right cerebellar cortex (p<0.05) and the medium and
posterior portion of the corpus callosum (p<0.05).
With respect to disease duration, a negative age-adjusted correlation
between years lived with migraine and volumetric reduction was
found in right (p<0.001) and left (p<0.005) middle temporal cortex in
EM patients and in the right superior frontal cortex (p<0.001), cuneus
(p<0.005) and lingual cortex (p<0.005), and left superior frontal cor-
tex (p<0.001) in CM patients. No correlations between disease dur-
ation and subcortical changes were found in the two groups.
Conclusions
Regions showing a volumetric reduction might represent crucial hubs
in migraine activity and pathophysiology. A better understanding of
their role in the basal disease as well as in the process of chronification
can provide a model to improve treatment options in patients with
migraine [8].
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We aimed to investigate the prevalence of headache in General
Population (adults 18-70 years old) in Greece. A quantitative study,
using the form of computer-assisted telephone interviews (C.A.T.I.)
was designed. A draft questionnaire consisting of 37 questions was
delivered in 145 headache sufferers in a pre-study work to evaluate
the diagnosis of the primary headache disorder according to ICH-
3beta diagnostic criteria. After the analysis of this questionnaire the
specific 37-item questionnaire was decided. In total, N=10,008 inter-
views, representative of the population of Greece in terms of gender,
age, and area, based on the most recent census (ELSTAT, 2011) were
performed using the structured evaluated questionnaire. Based on
the above contacts, n=1,197 respondents (12% of the sample) were
found to suffer from headaches that reduce their performance. The
one-year prevalence of Migraine that reduces activity was 8.2%
(n=0.6m population) of Tension-Type Headache (TTH) 3.8% (n=0.28m
of population) and of Cluster Headache 0.01% (n=0.74K of popula-
tion). Chronic migraine one-year prevalence was 1% (n=0.7K of popu-
lation). Females tend to suffer more from migraines and TTH as well
as ages 35-54. The average patients has been suffering from head-
aches for 12 years. Headaches typically occur once a month or more
frequently, 8 days per month on average. Although patients rarely
misss work due to headaches, they do report headache-induced re-
ductions in performance around 3 days per month. Slighly less than
half patients have felt bad/ humiliated because of headaches, while
social/family obligations are affected 3 days per month on average.
About one fifth of patients seek professional treatment for head-
aches, most of them in the private sector. The most popular specialty
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 144 of 151for headache treatment is neurologist, followed by internist. Regard-
ing both prophylactic and acute treatment, patients prefer oral medi-
cation to injection, even if the former is administered more
frequently. They also prefer oral medication/ injection to a stimula-
tion device. The stimulation device seems to be more attractive to
males. Painkillers also are by far the most common acute treatment
for headaches and the vast majority of patients have never taken
prophylaxis for headaches. Only a small fraction have stopped taking
a prophylactic treatment due to adverse effects. Interstingly, patients
would be willing to spend 20€ on average per month for headache
treatment, on average.
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Objective
Galcanezumab, a humanized monoclonal antibody that selectively
binds to the calcitonin gene-related peptide, was investigated in two
Phase 3 studies (EVOLVE-1 and EVOLVE-2) to determine superiority
to placebo in the prevention of migraine headache.
Methods
EVOLVE-1 and EVOLVE-2 were double-blind, 6-month studies in pa-
tients with episodic migraine (4 to 14 monthly migraine headache days
[MHD]) conducted in North America and globally, respectively. Patients
were randomized 2:1:1 to monthly subcutaneous injections of placebo,
galcanezumab 120 mg or 240 mg. Primary endpoint was overall mean
change from baseline in the number of monthly MHD during Months
1-6. Key secondary measures included rates of ≥50%, ≥75%, and 100%
reduction in monthly MHD and overall mean change from baseline in
monthly MHD with acute migraine treatments, and mean change from
baseline over Months 4-6 on the Role Function-Restrictive domain
score of the Migraine-Specific Quality of Life Questionnaire (MSQ-RFR)
and Patient Global Impression-Severity of Illness (PGI-S).
Results
Baseline mean number of monthly MHD was 9.1 for both studies.
Both galcanezumab doses demonstrated a statistically significant
improvement compared with placebo (both studies p<.001) for
overall mean change in monthly MHD (EVOLVE-1: placebo=-2.81;
GMB 120 mg=-4.73; GMB 240 mg=-4.57; EVOLVE-2: placebo=-2.28;
GMB 120 mg=-4.29; GMB 240 mg=-4.18). Percentage of patients with
MHD reductions of ≥50%, ≥75%, or 100% were significantly higher
for each galcanezumab dose compared with placebo (both studies
p<.001). Patients had a significantly greater overall mean reduction
of monthly number of MHD with acute migraine treatment for both
galcanezumab doses relative to placebo (both studies p<.001). Mean
change in MSQ-RFR and PGI-S ratings were statistically significant for
each galcanezumab dose versus placebo (MSQ-RFR: p<.001 and PGI-
S: p<.05, in both studies). There were no statistically significant differ-
ences between galcanezumab and placebo on the most common
treatment-emergent adverse events except for a greater incidence of
injection-site pruritus (both studies/doses p<.01) and injection-site re-
action (both studies/doses p<.05), and injection-site erythema (p<.05,
galcanezumab 240 mg) in EVOLVE-2.
Conclusions
Both doses of galcanezumab met the primary and all key secondary
objectives, after adjusting for multiplicity. Treatment effects were
similar across galcanezumab doses for efficacy, and safety; however,
there was a higher rate of injection-site pruritus and reaction ingalcanezumab-treated patients in both studies. EVOLVE-1 and
EVOLVE-2 demonstrated that galcanezumab, at either 120 mg or 240
mg monthly, provided clinical benefit and improved function in pa-
tients with episodic migraine.
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Background
The REPOSE Study, a European, multicenter, prospective, non-
interventional study, investigated the effectiveness and safety of real-life
use of onabotulinumtoxinA for chronic migraine (CM).
Materials and Methods
Adults prescribed onabotulinumtoxinA for CM were enrolled.
Patients received onabotulinumtoxinA approximately every 12
weeks according to their physician’s usual practice, guided by the
Summary of Product Characteristics. OnabotulinumtoxinA injection
practices, safety, headache-day frequency, and Migraine Specific
Quality of Life Questionnaire (MSQ) were collected at baseline and
follow-up visits.
Results
Among 644 patients enrolled, 633 patients received ≥1
onabotulinumtoxinA dose for a total of 3499 onabotulinumtoxinA
treatments. Patients had a mean (SD) age of 45.4 (12) years, were
typically women (85.3%) and had a mean of 20.6 headache days/
month. The median dose and median number of injection sites of
onabotulinumtoxinA per session (baseline up to follow-up session
8) was 155 U and 31 sites, respectively. Through follow-up session
8, patient-reported estimates of headache days/month (≥4 hours)
were significantly reduced from baseline (P<0.001 at each follow-
up session, Fig. 1). The MSQ domain scores (Role Restrictive, Pre-
ventive, and Emotional) were significantly reduced from baseline at
each follow-up session. Adverse drug reactions, typically of mild to
moderate severity, were reported by 18.3% of patients; eyelid pto-
sis (5.4%), neck pain (3.0%), and musculoskeletal stiffness (2.7%)
were most frequently reported.
Conclusion
Preventive treatment of CM with onabotulinumtoxinA in a
longer-term (24-month) real-world setting sustains a reduction
in the frequency of headache days and significantly improves
quality of life relative to baseline. No new safety concerns were
identified.
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Fig. 1 (abstract O19). Headache-day frequency calculated using the
patient-reported estimate of number of days in a month with head-
ache. Wilcoxon signed-rank test for change versus baseline (level of
significance: 5%). The number of patients in follow-up (FU) sessions 9-
12 were: FU9, n=67; FU10, n=38; FU11, n=21; FU12, n=16. The mean
change from baseline for FU sessions 9-12 were each significant
(*P<0.001)
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Objectives: sound induced flash illusion (SIFI) is an illusory cross
modal(audio-visual) phenomenon critically dependent upon
excitability of visual cortex [1]. A recent study with SIFI confirmed
hyperexcitability of visual cortex in migraine [2]; patients with
migraine show abnormality of chromatic perception with a more
relevant dysfunction in the wave-range of blu(S cones) [3]. Aims of
the study were explore the relationship between peripheral chro-
matic and central visual dysfunction evaluating also the presence of
functional receptor impairment in patients with migraine, with and
without aura examined interictally.
Subjects: 15 migraine patients with aura (MWA) and 15 without
aura(MWoA) were compared with 12 healthy controls with no
familiarity for migraine, and no significant age and sex differences
between groups.
Materials: all subjects underwent the following examinations:
1. SIFI text consisting of presentation of flashes and beeps in different
combinations to generate illusions of ‘fission’ (one flash with 2 beeps
perceived as 2 flashes) or ‘fusion’ (2 flashes with one beep perceived as
1 flash); SIFI has been employed to study excitability of visual cortex as
such illusory phenomena critically depend upon visual cortical
excitability (more active visual cortex–> less illusions). 2. colorimetric
test to explore dysfunction in color perception. 3. Multifocal
electroretinogram(mfERG) to evaluate the functional contribution of
retinal receptor in different retinal areas.
Results: according to previous report, MWA and MWoA patients
showed significantly reduced SIFI of fission with respect to
controls(p<.01). 8 MWA and 9 MWoA patients presented dysfunction
of color perception. In these patients SIFI were significantly more
reduced with respect to those showing no abnormality in chromatic
perception(p<.05). No significant changes emerged in mfERG when
comparing patients vs control; MWA vs MWoA, patients with and
without chromatic perception dysfunctions.
Discussion: results confirmed increased excitability of visual cortex in
MWA and MWoA patients [2]. Moreover, greater excitability levels are
found in patients with chromatic perception abnormalities suggesting
a potential pathophysiological relationship between peripheral and
central visual dysfunction in these patients. However, results of nornal
mfERG response seem to exclude direct dysfunctional involvement of
visual receptors, making likely abnormalities at different retinal levels of
the neural pathway (bipolar cells?)Conclusion: peripheral and central abnormalities of visual can be
found in migraine. They could be causally linked or follow to a
common basic abnormality. Further study are needed to define
the precise mechanism of such dysfunction together with their
potential interrelationship and their role in the pathophysiology
of the disease.
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Background
Perturbation of neuronal excitability contributes to migraine.
Neurosteroids, i.e., allopregnanolone (AP), epiallopregnanolone (EP),
dehydroepiandrosterone (DHEA) and deydroepiandrosterone sulfate
(DHEAS), rapidly modulate neuronal firing rate and might be involved
in the pathogenesis of migraine [1]. We sought to determine the
relationship between plasma levels of neurosteroids in patients with
migraine and cluster headache.
Materials and Methods
Patients with episodic migraine (EM, n=19), chronic migraine and
medication overuse headache (CM, n=51), and cluster headache (CH,
n=18) were studied. Sex- and age-matched subjects were also eva-
lueted (i.e., 31F and 16M). Patients were clinically characterized by
using validated questionnaires (BDI, MIDAS, HIT-6, SAS, as appropri-
ate). Menopausal status was also recorded. Plasma levels of AP, EAP,
DHEA and DHEAS were measured using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) [2]. Whether sampling was
concurrent with migraine/cluster attack was registered. Data have
been statistically analysed using Student’s t-test and Spearman’s cor-
relation. Data are presented as mean±SD.
Results
AP levels were consistently and significantly higher in EM (1.3±0.5
ng/mL) and CM (1.1±0.3 ng/mL) than in controls (0.6±0.3 ng/mL). In
contrast, AP levels were significantly reduced in CH patients vs
controls (0.3±0.1 vs 0.7±0.2 ng/mL, respectively; p<0.01). DHEA levels
were significantly reduced in EM (2.9±1.5 ng/mL) and CM (1.6±1.1
ng/mL) compared to controls (5.1±3.8 ng/mL; p<0.05). The profiles of
DHEAS and EAP across groups were inconsistent, being significantly
reduced in CM, but not different from controls in EM and CH. In CM
patients, the ratio AP/EAP was significantly higher than in controls
(3.0±1.7 vs 1.8±1.2, respectively; p<0.01).
Discussion
Changes of circulating levels of neurosteroids are associated to the
presence of migraine. The GABAA receptor agonist, AP, and the NMDA
receptor agonist, DHEA, were higher and lower than controls, respectively.
This suggests an attempt to modulate neuronal hyperexcitability in
migraine patients. Changes of neurosteroids concentrations in CH patients
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 146 of 151were significant only for AP, which may contribute to the more severe
clinical features of CH vs CM and EM. For the first time, we provide
evidence for a role of neurosteroids in the pathogenesis of migraine.
Novel and more effective therapies may now be devised by targeting
neurosteroid-related pathways.
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Objective
To compare efficacy on headache pain and the patient-centric meas-
ure of most bothersome symptom (MBS; nausea, phonophobia, or
photophobia) at 2 hours post dose, time course of migraine re-
sponse, rescue, and safety following treatment with lasmiditan 200
mg or 100 mg or placebo.
Materials and methods
In this randomized, double-blind, placebo-controlled study, subjects
with at least moderate disability (Migraine Disability Assessment
Score [MIDAS] ≥11) were randomized 1:1:1 to a first dose of lasmidi-
tan treatment (200 mg or 100 mg) or placebo within 4 hours of on-
set of a migraine attack (moderate severity or worse and not
improving). Subjects took a randomly assigned second dose of either
their previously assigned lasmiditan dose or placebo for rescue or re-
currence of migraine if needed (2 to 24 hours post initial dose); sub-
jects randomized to placebo received placebo as the second dose.
The primary measures were comparison of the proportions of sub-
jects (modified intent-to-treat population [mITT]) in the lasmiditan
200 mg and placebo groups who, at 2 hours post first dose, were
headache pain free and MBS free. Comparisons were made via logis-
tic regression with terms for treatment group and background mi-
graine preventative use. Lasmiditan 100 mg and placebo were also
compared and safety parameters assessed.
Results
At baseline, 1545 subjects assigned to lasmiditan 200 mg (n=518), 100
mg (n=503), or placebo (n=524) had a mean MIDAS score of 31.3 and
82% had ≥1 cardiovascular (CV) risk factors (in addition to migraine). At
2 hours, greater proportions were: headache pain free with lasmiditan
200 mg (32.2%) and 100 mg (28.2%) than placebo (15.3%; P<.001); MBS
free with lasmiditan 200 mg (40.7%) or 100 mg (40.9%) than placebo
(29.5%; both P<.001); and, had headache relief with lasmiditan (59%
each group) than placebo (42.2%; P<.001). In the lasmiditan 200 mg,
100 mg, and placebo groups, 29%, 36%, and 58%, respectively, took a
second dose for rescue. The most frequently reported adverse events
(AE) with lasmiditan were dizziness, fatigue, lethargy, nausea,
paresthesia, and somnolence. No notable increase in CV AEs occurred
in either lasmiditan group even among subjects with ≥1 CV risk factors
(eg hypertension).
Conclusions
Lasmiditan treatment provided more patients freedom from and
reduction of headache pain and MBS at 2 hours compared with
placebo. This patient population with severe disability associated with
migraine, tolerated lasmiditan treatment.
Trial registration
ClinicalTrials.gov Identifier NCT02439320.O23
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Objective
To investigate the mechanism of post-ictal headache.
Background
Seizures affect 50 million people worldwide and are followed by
headache in up to 50% of patients. These headaches are called Post-
Ictal Headaches (PIH), they are commonly migraineous in nature, can
last many hours, be very painful and since they strikes repetitively,
they drive patients to endure a significant hardship. Given that sei-
zures occur in the cortex, we hypothesized that PIH are intracranial
at origin and accordingly, aimed in this study to determine whether
and how seizures (both generalized and focal) activate peripheral
and central neurons of the meningeal sensory pathway.
Methods
Single-unit electrophysiological techniques were used to study the
physiological properties and response profile of C- and Aδ meningeal
nociceptors and high-threshold (HT) and wide-dynamic range (WDR)
neurons in the spinal trigeminal nucleus – in response to occurrence of
seizure underneath their dural receptive fields. Cortical electrodes were
used to trace the magnitude, extent and progression of epileptiform
seizure.
Results
The induction of seizure triggered prolonged activation in both
meningeal nociceptors and central trigeminovascular neurons. In the
ganglion, activity began to increase minutes after the seizure
reached their receptive fields and remained elevated for as long the
seizure activity continued. In the medullary dorsal horn, neurons
exhibited a biphasic response following seizure onset that consisted
of an initial inhibition of the spontaneous activity followed by a
gradual increase in activity that remained above baseline for at least
2 hours after seizure onset. In separate experiments, we created a
focal seizure that was restricted to either the parietal or occipital
cortex. Induction of focal seizure in the parietal cortex did not
produce any changes in neuronal activity, but induction of focal
seizure in the occipital cortex produced the same neuronal changes
that we observed with the generalized seizure.
Conclusions
This study provides evidence for activation of the trigeminovascular
pathway by generalized and focal seizures. The importance of this
study is that it uses a model of abnormal cortical activity to which
there are ample of evidence in human subjects suffering epilepsy
(and PIH), and thus, it bypass the bitter debate over the validity of
studying the headache phase of migraine using the controversial
cortical spreading depression model – to which evidence for actual
occurrence in humans are scarce.
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In recent years, an increased attention has been devoted to the
potential association between migraine and thyroid function, with
conflicting results. A few studies found that migraine may be
associated with an increased risk for the development of both overt
and subclinical hypothyroidism (SH). On the contrary, the risk of
developing migraine in patients with hypothyroidism has been
scarcely investigated. Therefore, the main purpose of our study was
to investigate the association between subclinical hypothyroidism
and migraine in adults, using a case-control strategy.
Materials and methods
151 consecutive patients with SH (24 men and 127 women, mean
age 48.36± 15.86 years) and 150 controls (37 men and 113 women,
mean age 50.86± 9.19 years) were recruited for the study. In all
subjects, migraine characteristics were collected through a direct
face-to-face interview, using a structured questionnaire. Moreover,
clinical characteristics and thyroid parameters (TSH, fT3, fT4, anti-
thyroglobulin and anti-peroxidase antibodies) were compared be-
tween SH patients with comorbid migraine and SH patients without
migraine.
Results
The prevalence of lifetime migraine was significantly higher in SH
patients in comparison with controls (46% vs 13%, p< 0.001; OR 5.80;
95% CI= 3.35-10.34). Both migraine without aura and migraine with
aura were significantly higher in SH patients than controls (38% vs. 9%,
p< 0.001; and 8% vs. 4%, p= 0.01, respectively). Thyroid hormones and
antibodies levels were not different between SH patients with migraine
and those SH patients without migraine. Finally, a higher comorbidity
for autoimmune diseases was found in SH patients with migraine
respect to SH patients without migraine.
Conclusions
Our data suggest that migraine is significantly more frequent in
patients with subclinical hypothyroidism respect to controls. Additional
studies are needed in order to corroborate this association and to
explore the underlying biological mechanisms.SISC ORAL PRESENTATIONS
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Background
Cystic fibrosis (CF) is autosomal recessive genetic disease caused by
mutation in the transmembrane conductance regulator (CFTR) that is
involved in Cl- ions transport. Coexistence of cystic fibrosis and
sporadic hemiplegic migraine (SHM) has been reported in only two
cases in literature so far [1]. Their co-occurrence may be due to more
than a simple chance. CFTR is widely expressed in the brain and
seems to be important in regulating other channels, suggesting that
some shared genetic channel mutation might cause the two diseases
at the same time.
Case report
A 32-y.o. caucasian male was diagnosed with CF at birth. He pre-
sented CFTR heterozygosis with a typical CFTR delta F508 mutation
in one allele and an unknown mutation on the other allele. He also
had patent foramen ovale that was surgically closed when he was
26-y.o.
The patient reported occasional cough bouts, triggering hemiplegic
migraine attacks
In March 2017 a such cough bout, lasting 48 hours, led to a severe
hemoptysis and followed by a 15-minutes long loss of consciousness.
The patient was transported to emergency rooms (ER) and intubated.
An arterial-blood gas test showed severe hypoxia with hypercapnia.The patient recovered in few days. A brain MRI+MRA, performed in
ER showed diffuse DWI alterations, affecting left frontal-parietal-
occipital areas, which later resolved, except for a persistent small
damage in the frontal region. Both large vessel diseases and embolic
sources as well were excluded by carotid duplex sonography, trans-
cranial doppler examination and transthoracic echocardiography.
In April, he was visited in our Headache Clinic. The neurological
examination showed a mild right hemiparesis with asymmetrical
increased tendon reflexes and upward plantar reflex on the right.
Conclusions
The ischemic damage, presented by the patient, suggests a migrainous
infarction, since it followed the migraine aura symtpoms and occurred
in the brain regions implied in HM. Then, it may be argued that
migrainous infarction was caused by the development of CSD in a
brain tissue, suffering from hypoxia due to cough bout and
hemoptysis.
In fact, cerebral infarction, with prompt expansion of the core infarct,
following mild hypoxia, is associated to mutation in CACNA1 gene in
both mice and humans, possibly related to neural excitability and the
following vasoconstrictive vascular coupling in the penumbra [2-3].
In conclusion, in CF patients there is the chance of SHM comorbidity,
due to a genetic overlap with a higher risk of developing migrainous
infarction.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Objectives: Chronic migraine (CM), Chronic tension-type headache
(CTTH) and new daily persistent headache (NDPH) are the main forms
of CPH reported in the ICHD-III beta version. Medication-overuse head-
ache (MOH) is classified among secondary headache but it generally af-
fects patients with a pre-existing primary headache. CPH have been
well described in adults and their diagnostic criteria were designed
based on the clinical characteristics in the adult population. However,
CPH are not a rare condition in children and adolescence with negative
impact on their quality of life.
Our aim was to investigate the clinical features of CPH in a cohort of
pediatric patients.
Methods: We retrospectively reviewed the charts of patients attending
the Headache Centre of Bambino Gesú Children and Insubria University
Hospital. The ICHD-III criteria were used for diagnosis. Statistical analysis
was conducted by SPPS version 22.0 and χ2 test was used to study pos-
sible correlations between: - CPH and population features (age and
sex); - CPH and headache qualitative features; - CPH and risk of MOH;
-CPH and response to prophylactic therapies.
Results: We included 377 patients with CPH (66.4% female, 33.6%
male, age between 0 and 18 years). The most frequent CPH type was
CM (73.5%), followed by CCTH (13.5%) and NDPH (13%). MOH was
detected in 10.9% of total patients. CPH are less frequent under 6 years
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 148 of 151of age (0.8%; p <0.05); significant greater frequency in females than in
males was found in the age group between 0-6 years (23/31 F, 8/31 M)
and between 15-18 years (41/51 F, 10/51 M) (p<0.05). No correlations
between age/sex and different CPH types were detected. We found a
more frequent incidence of vegetative symptoms (photo/phonophobia
and vertigo) in female sex (p< 0.05). Nausea and vertigo are the two
most frequent vegetative symptoms under 10 years of age (p<0.05)
while photo/phonophobia are more frequently in patients older than
15 years (p<0.05). Possible development of MOH has been found corre-
lated with CM types (p<0.05) and age above 15 years (p<0.05).
Our results show that 272 (72.1%) out of 377 CPH patients received a
prophylactic therapy. Among them, 190 patients received amitriptyline,
29 patients topiramate, 15 patients L-5 hydroxytryptophan, and 8 pa-
tients flunarizine. Thirty patient performed two or more drugs. Positive
response to therapy (reduction of attacks by at least 50% in a month)
was detected in 54% of patients, while no outcome data were obtained
from 29.4% of cases. Amitriptyline and topiramate had the highest effi-
cacy (p<0.05). We found that 59.2% of patients who received amitriptyl-
ine showed significant reduction in the attack frequency, while 48.4%
patients receiving topiramate improved their headache attack fre-
quency (p>0.05). However, for both drugs more than 30% of patients
did not have follow up data.
Conclusion: Our results showed that CPH presented a correlation
with patients’ age and sex. No significant differences were found
between CPH types and population/pain features. Development of
MOH was related with CM onset and adolescent age. Amitriptyline
and topiramate had the best effectiveness. However, it is to be
underlined that follow up data could not be issued from a moderate
percentage of patients. It will be useful in the future to reduce the
number of missing patients by improving patients’compliance and
promoting the concept of migraine as a disease that can cause
relevant disability.
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Background
Chronic migraine (CM) is a disabling neurologic condition that affects
2-3% of the general population, and is the first reason of consult-
ation in many tertiary headache centres. Nevertheless, comprehen-
sive descriptions of CM clinical features, risk factors and comorbidity
in large case series are very scarce. Aim of this study is to depict the
characteristics of CM in a large cohort of patients referred to several
tertiary headache centres throughout Italy.
Patients and methods
Patients with the diagnosis of CM according to ICHD-3 beta, consecu-
tively referred to 16 major Italian headache centres during the period
1st October 2016 – 31th March 2017 entered the study, having
expressed an informed consent. An especially prepared web-based
electronic medical record was filled in with anonymized patients data.
Results
Eight hundred and thirty-eight patients (female 86.3%; mean age
48.5±13.08 years) were included. CM mean duration was 10.7 years;
mean frequency of headache days was 22.7±6.11/month. Mean
headache duration was 10.5±6.81 hours; mean headache severity on
a 1-10 scale was 7.7±1.56. ICHD-3 beta CM diagnostic criterion C was
satisfied by having ≥8 days per month with migraine without aura
by the overwhelming majority of patients (95.5%), while a not negli-
gible percentage had migraine with aura (9.1%) or headache relieved
by a triptan (9.7%). Criteria for medication-overuse headache were
fulfilled in 71.4% of the cases. Most overused drugs were simple an-
algesics (40.6%), followed by triptans (35.1%), and combinationanalgesics (15.8%). Beyond medication overuse, the most frequent
risk factors for CM were: high baseline headache frequency (39.1%),
anxiety (30.3%), sleep disorders (26.0%), depression (22.2%), cutane-
ous allodynia (14.1%), life events (11.5%), excessive caffeine intake
(10.4%), sleep bruxism (9.1%), panic disorder (7.2%), and obesity
(6.2%). Most represented comorbid disorders were: anxiety (32.3%),
sleep disorders (32.2%), depression (25.4%), hypertension (20.5%), ir-
ritable bowel (8.4%), and fibromyalgia (6.6%). CM was highly disab-
ling in our population: mean MIDAS score was 66.6 and mean HIT-6
score 63.7. Mean monthly number of symptomatic drugs was 28.8
(range 0-270). Refractory chronic migraine (no MOH, unsuccessful
use of at least 3 preventive drugs) was present in 11.3% of the
patients.
Conclusions
The study of a large case series of patients with CM allows a precise
picture of this debilitating condition, of its main clinical features,
transformation to CM risk factors and comorbid disorders.
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Background: There are no prospective studies on prolonged auras
(PAs). i.e. an aura that includes at least one symptom lasting for
>1hr.
Objectives: We aimed to evaluate the prevalence of PAs and
compare their phenotype with NON-PAs in a prospective diary-aided
study.
Methods: We recruited 224 consecutive patients affected by
migraine aura attending the Headache Centers of Pavia and
Trondheim. Patients were asked to report on an ad hoc diary, during
three consecutive migraine with aura attacks, quality of each aura
symptom (AS), headache features and to insert the time of onset/
end of each AS and of the painful phase and describe the features of
headache.
Results: 72 patients completed the diaries during three consecutive
auras for a cumulative number of 216 auras recorded. Out of 216
auras, 38 (17%) were PAs. Out of 72 patients, 19 (26%) have at least
one PA. When comparing PAs with non-PAs (n=178) with respect to
20 features collected, PAs were characterized by a higher total num-
ber of symptoms (p<0.001), a higher frequency of sensory symptoms
(p<0.001) and a higher frequency of dysphasic symptoms (p<0.001).
No other differences were found.
We performed the same analysis comparing auras including at least
one symptom lasting for >2 hrs (PA>2, n=23) with the remaining
ones (n=193) and auras including at least one symptom lasting for
>4 hrs (PA>4, n=14) with the remaining ones (n=202). In the first
comparison, the only differences were a higher frequency of sensory
symptoms and a higher number of AS in PA>2 (p=0.001 and
p=0.005, respectively) and in the second comparison the only
difference was a higher number of AS in PA>4 (p=0.043).
Conclusion: PA is quite common (17% of all auras, occurring at least
once in 26% of patients) and phenotypically differs from the other
auras only for a higher number of non-visual symptoms (non-
VSs). This latter finding is not surprising if we consider that an
AS with a longer duration is likely related to a cortical spreading
depression (CSD) that proceeds along a longer path on the
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 149 of 151respective brain area. Such CSD therefore is more likely to in-
volve other adjacent brain areas, thus conferring a higher number
of non-VSs to PA. The substantial phenotypical similarities be-
tween PAs and the other auras is maintained also when we in-
crease the limit of duration to 2 and/or 4 hrs. This finding should
lead to a discussion about the term “prolonged aura” and how
long its duration should be.
O29
Microvascular vasospasm of cerebral cortex in “prolonged” aura
migraine
Stefano Viola1*, Paolo Viola2, Maria. P. Buongarzone1, Luisa Fiorelli1,
Mafalda Cipulli1, Pasqualino Litterio1
1Department of Neurology, Headache Center, via C. De Lellis 66054
Vasto (CH), Italy; 2Emergency Medical Service, Atessa, Lama dei Peligni
(CH), Italy
Correspondence: Paolo Viola
The Journal of Headache and Pain 2017, 18(Suppl 1):O29
Background: Many studies support the presence of endothelial
dysfunction in migraineurs. In a recent work, the authors have found
a coronary microvascular endothelial dysfunction (CMED) in migraine
patients compared with control group suggesting that there would
be a common pathophysiological pathway of impaired coronary and
cerebral endothelial function in migraine. CMED may lead to a
coronary microvascular vasospasm.
Aim: The aim was to verify the presence of a microvascular vasospasm
of cerebral cortex in “prolonged” aura migraine.
Methods: We studied the microcirculation of cerebral cortex by Near
Infrared Spectroscopy
(NIRS) and cerebral macrocirculation by transcranial Doppler (TCD) in
8 subjects (3 M and 5 F, age range 21-41 years) during spontaneous
“prolonged” migraine aura in according to ICHD criteria and com-
pared the results with the headache-free periods. Duration of aura
symptoms: between 2 and 8 hours.
Results: During aura NIRS showed a significant decrease of the
Arterial Pulse Wave of Cerebral Microcirculation amplitude (-33 % ±
5.7), p<0.001 contralateral to the symptoms of aura compared with
the headache-free periods; TCD showed a significant increase of Pul-
satility Index (+36.5 % ± 6.5), p<0.001 and a significant decrease of
the diastolic velocity in the posterior and middle cerebral artery
contralateral to the symptoms of aura compared with the headache-
free periods.
Conclusions: In conclusion during “prolonged” migraine aura we find
cortical areas of microvascular vasospasm corresponding to the
topography of aura symptoms and suggesting the presence of a
microvascular endothelial dysfunction.
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Background: A wide range of medications is now available for
migraine prophylaxis but some patients don’t show a significant
improvement also with the best tailored drug and some other
patients discontinue therapy because of side effects. The interest of
clinicians and patients toward nutraceutical medicine is expandingworldwide but limited evidence is to date available in favour of and
against their use in migraine prophylaxis [1,2].
Objectives: To compare efficacy and tolerability of a nutraceutical
formulation containing Magnesium 185 mg + Tanacetum parthenium
150 mg + Griffonia 100 mg/die (MTG) vs Amitriptyline 25 mg/die
(AMI) for 3 months, as prophylactic migraine therapy in a sample of
adult outpatients.
Patients and Methods: This is a retrospective study conducted by
reviewing the medical records of all patients consecutively referred
to the Headache Centre from January 2017 to June 2017. 62 patients
(52 females and 10 males), who received the diagnosis of migraine
with or without aura and were submitted to a 3 months prophylactic
therapy with AMI (33 cases) or with MTG (29 cases) were recruited.
Primary efficacy parameters were: attack frequency and aura
frequency reduction. Secondary efficacy parameters were pain
intensity, pain duration and aura duration reduction. Tolerability was
evaluated by means of reported side effects.
Results: A significant reduction of headache frequency, pain
intensity, pain duration, aura frequency and aura duration was found
in the whole sample after a 3 months prophylactic therapy. No
difference was found between MTG group and AMI group in attack
frequency reduction (4,90+6,37 vs 8,30±8,09, p=0,21) and in aura
frequency reduction (3,00+4,84 vs 2,34+2,89, p=0,72). Six patients in
AMI group reported side effects (weight gain 3 cases, somnolence 1
case, weight gain and somnolence in 2 cases). One patient in MTG
group reported both hands paresthesias.
Conclusions: The results of this study suggest that the nutraceutical
formulation containing Magnesium 185 mg+ Tanacetum parthenium
150 mg+ Griffonia 100 mg, could be a valid therapeutic option with
lower occurrence of side effects than Amitriptyline. The strength of
evidence of this study is low because of both the retrospective
design and the little sample. Double-blind randomized larger studies
are needed to correctly estimate the impact of the placebo effect in
this promising therapy.
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Background
Some epidemiological studies report many comorbidities in
migraine, mostly identified through questionnaires and based on
self-reported diagnosis. However, the prevalence of comorbidities
should be better performed by a clinical evaluation.
Materials and methods
We have evaluated prospectively the prevalence of some
comorbidities in the first 1000 migraine patients (aged 15-65 years),
afferent to Headache Center in the 2011-2013 years and resident in
the district of Empoli Health Authority, classified with a diagnosis of
migraine without aura (MO), migraine with aura (MA), and chronic
migraine (CM) that also includes patients with medication overuse
headache who had episodic MO before, according to the revised
ICHD-2R classification. The specialist visits were performed by a sin-
gle physician (A.P.). In addition to a detailed semistructured face to
The Journal of Headache and Pain 2017, 18(Suppl 1):111 Page 150 of 151face interview, health information was researched in the database of
specialist visits, hospital recovery or emergency department.
Results
Our clinical survey consisted of 1000 patients aged 15-64 years
(mean age 39.5), 780 females (mean age 39.9) and 220 males
(mean age 38.2). This population included 866 patients with epi-
sodic migraine (EM) (666 ♀ and 200 ♂, mean age 38.2) and 134
with CM (114 ♀ and 20 ♂, mean age 48.0). Out of 866 patients
with EM, 767 had MO (mean age 38.4) and 99 had MA (mean
age 36.7).
The prevalence of treated chronic conditions (CC) was: depression 5.6
%, hypertension, 9.3 %, diabetes 1.2 %, asthma 3.3 %, hypothyroidism
6.4 %, hypercholesterolemia 0.5 %.
Out of 56 patients assuming antidepressants only 4 assumed
amitriptyline. Out of 93 patients treated for hypertension, 42 used beta-
blockers (18 atenolol, 13 nebivolol, 6 propranolol, 3 bisoprolol, 1 meto-
prolol, 1 carvedilol).
Patients who assumed thyroid hormones were 64: they referred
thyroiditis (28), thyroidectomy (13), other (primitive, post-
hyperthyroidism, etc) hypothyroidisms (16), goitre in euthyroidism (7).
Patients with asthma were 65: 33 in current treatment and 32 in the
past. Migraine patients suffering of allergies were 198: 132 rhinitis, 42
drugs allergy and 19 food allergy.
Other somatic CC were: gallstones (5.4%), kidney stones (5.7%),
inflammatory bowel disease (0.5%) including Crohn disease (3 patients)
and ulcerative colitis (2 patients), celiac disease (0.5%, all females),
endometriosis (1.0%), psoriasis (0.7%), cardiac diseases (1.0%),
rheumatic/autoimmune diseases (0.7%) including lupus (0.2%), Behcet
disease, mixed connective disease, rheumatoid arthritis, scleroderma,
and Sjogren syndrome (0.1%).Vitiligo (0.2%), endometrial/breast cancer
(0.5%), meningioma (0.2%), hyperthyroidism (0.3%), restless legs
syndrome (0.3%), fibromyalgia (0.2%), were also detected. Other CC
whit a prevalence of 0.1% are not reported.
Hypothyroidism was more frequent in females (OR 0.163, p < 0.001),
and hypertension in CM compared to EM (OR 0.307, p < 0.001) but
EM patients were 10 years younger than CM patients (Table 1).
Conclusions
The percentages of treated CC in migraine patients in our survey, in
particular those involved in cardiovascular risk, were not higher
than those estimated through the analysis of prescription rate of
marker drugs in the general population in the same district [1,2]. In
this comparison, the higher prevalence of hypothyroidism was not
statistically significant when migraine patients were considered by
gender (♀ p = 0.067, ♂ p = 0.38), while epilepsy, diabetes,
hypercholesterolemia and asthma, on the contrary, were less
frequently reported (p<0.001).
Our data are in substantial agreement to a large general practitioner’s
database [see 2].
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Background
There is an increasing use of Alternative and Complementary
Medicine (CAM) for prophylaxis of pediatric primary headaches
[1,2,3,4].
Materials and methods
We carried out a search for clinical trials in PubMed of patients aged
0-18 years with primary headaches treated with nutraceuticals or
phytotherapeutic compounds.
Results
A) Nutraceuticals
The following evidences are available in the literature:
– Magnesium: significant reduction in attacks, consumption of
analgesics and disability in cases with Migraine (M) [5] and
Tension-Type Headache (TTH) [6]
– Riboflavin (vitamin b2): higher efficacy than placebo in the
treatment of TTH [7]. In M: effective compared to baseline [8]
but not superior to placebo [7, 9]
– Coenzyme Q10: in CoQ10-deficient patients, CoQ10 supplemen-
tation obtained a reduction of attacks’ frequency and disability
degree [10]. A trial showed no efficacy versus placebo [11]
– Alpha lipoic acid: no study available
– Melatonin: significant reduction in frequency and duration of M
or chronic TTH attacks [12]. In another study: reduction of
frequency, intensity, duration of M attacks and PedMIDAS score
[13]
– 5-hydroxytryptophan: no significant differences vs placebo in M
(Santucci M,1986).
B) Phytotherapeutic products
The following evidences are available in the literature:
– Petasites hibridus: 50% reduction of attacks in 77% of cases
with M in an open-label multicentre study [14]. Long term ef-
fects better than placebo in another study [15]
– Tanacetum parthenium: no study available
– Ginkgo biloba combined to Coenzyme Q10/Vitamin B2/
Magnesium: reduction of the M frequency and the use of
symptomatic medication in a open-label study [16]; reduction
of the M frequency in another open-label study[17]; reductions
of M frequency, duration, intensity, PedMIDAS score, behav-
ioural reactions to M were significantly greater in the Ginkgo-
lide group than in the group received L-tryptophan/5-
hydroxytryptophan (from Griffonia simplicifolia)/vitamin PP and
B6[18].
C) Italian experience in specialized juvenile headache Centers
In a multicentre study of 637 young M and TTH patients,
supplements and melatonin were used respectively by 205 (32%)
and 61 (10%) patients with a good/excellent efficacy in 68% and
75% of cases respectively, without differences between the two
headache types[19].
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Nutraceuticals and phytotherapeutics showed some positive effects
on M and TTH in pediatric patients in open label studies and in
some controlled studies with placebo. Further studies are needed to
better address therapeutic choices in primary pediatric headaches.
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